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Abstract 
 
This thesis details the design and implementation of novel chemical routes towards a series of 
highly propitious 7-azaindolyl derivatives of the indolocarbazole (ICZ) and 
bisindolylmaleimide (BIM) families, with subsequent evaluation for use as cancer 
chemotherapeutic agents. 
A robust synthetic strategy was devised to allow the introduction of a 7-azaindolyl moiety into 
our molecular template. This approach allowed access to a range of β-keto ester and β-keto 
nitrile intermediates from simple starting materials such as succinonitrile and ethyl formate. 
Critical analysis identified F-ring modulation as a major theme towards the advancement of 
ICZ and BIM derivatives in drug therapy. Thus, the employment of cyclocondensation 
methodology furnished a number of novel aminopyrazole, isoxazolone, pyrazolone and 
pyrimidinone analogues, considerably widening the scope of the prevalent maleimide 
functionality. 
Photochemical cyclisation provided for the first reported aza ICZ containing a six-membered 
F-ring, though similar application to other aza BIM derivatives had limited success. A second, 
more durable method towards achieving the aza ICZ core involved use of a Perkin-type 
condensation approach, with chemical elaboration of the headgroup instigated after rather than 
prior to aromatisation. The subsequent use of a modified Lossen rearrangement allowed 
access to further analogues containing a six-membered F-ring. 
Extensive screening of the novel aza ICZ and BIM derivatives was carried out against the 
NCI-60 cancer cell array, with nine prospective candidates selected for further biological 
evaluation. From the resulting five-dose assays, a number of compounds were shown to 
inhibit cancer cell growth at concentrations of below 10 nM. Indeed, the most active aza ICZ 
tested is currently under assessment by the Biological Evaluation Committee of the NCI due 
to excellent antiproliferative activity demonstrated across the panel of cell lines, with a mean 
GI50 of 34 nM, a mean total growth inhibition (TGI) of 4.6 µM and a mean cytotoxicity (LC50) 
of 63.1 µM.  
  
   
 
vii 
Correlation to known topoisomerase I (topo I) inhibitors was revealed by COMPARE 
analysis, and the resulting topo I-mediated DNA cleavage assays showed inhibitory activity 
below 1 µM for several derivatives. On completion of this work, it is evident that there exists 
enormous potential within the aza ICZ family for the development of novel anticancer agents. 
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1.0 Biological Introduction 
1.1 Cancer 
One of the major causes of death in the world, cancer is estimated to be responsible for one 
out of every four deaths in the United States alone.
1
 There is significant regional variability in 
the incident and mortality rates of different cancers, partly reflected by differences in lifestyle, 
prevalence and distribution of the major risk factors, detection practices and the availability 
and use of treatment services. For example, incident rates for breast cancer are highest in 
Western Europe but relatively low in sub-Saharan Africa and Asia, while half of the total 
number of cases and deaths worldwide due to liver cancer are estimated to occur in China.
2 
 
Fig. 1.1 Estimated worldwide cumulative incidence (%) for all cancers, excluding                                    
non-melanoma skin cancer
3 
In a European context, Ireland was ranked second behind Denmark in 2008 in terms of cancer 
incidence, but was much closer to the average with regard to cancer mortality rates across the 
countries surveyed (Figure 1.2).
4 
Depending on the type of cancer, prognostic estimates can 
differ quite significantly in this country. For example, five year survival rates for testicular 
and prostate cancer have been determined to be 97% and 88% respectively, while cancers of 
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the pancreas, lung, brain and stomach have survival rates of below 25% over the same time 
period.
5
   
 
Fig. 1.2 Estimated cancer incidence and mortality rates in Europe
5 
Whilst commonly and most frequently referred to as an ailment in a singular sense, cancer is 
in fact a collection of different diseases that have a number of common features, with the most 
prominent being the uncontrolled growth and spread within the body of abnormal forms of the 
body’s own cells. The actual term “cancer” refers to a malignant neoplasm, i.e. new growth. It 
can be quite difficult to classify and account for cancers as a particular group due to the fact 
that if a generalisation is made for this collection of diseases, there will always be an 
exception to disprove the rule. Despite this, it is possible to broadly define cancer as a set of 
diseases characterised by unregulated cell growth, leading to invasion of surrounding tissues 
and metastasis to other parts of the body.
6 
Though surgery is a primary method of treating cancer, it can only be effective if the cancer 
has not already undergone metastasis to other sites within the body. Other forms of treatment 
for cancer such as immunotherapy, chemotherapy and irradiation are thought to mediate their 
effects via induction of apoptosis in cancer cells.
7
 In order to achieve the successful treatment 
of the vast majority of cancers, it has become apparent that only combinations of therapeutic 
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agents chosen for the highest possible individual activity against a specific type of cancer will 
effect a desirable outcome.
8
 As a result, there is an even greater need for the development of 
novel drug templates with which to pursue targeted cancer therapies. 
 
1.2 Indolocarbazole alkaloids 
1.2.1 Discovery of staurosporine 
The indolo[2,3-a]carbazole alkaloids, with a core pentacyclic structure 1,  represent a family 
of compounds upon which much research has been focused in recent years. Within the 
indolocarbazole class of compounds, four other isomeric ring systems are possible due to 
different orientations of the indolyl unit fused to one of the benzenoid rings of carbazole 
moiety. However, nearly all of the indolocarbazoles that have been isolated from nature 
contain an indolo[2,3-a]carbazole core, and as a whole, most scientific focus has been paid to 
this isomeric class.
9
 While the first synthesis of an indolo[2,3-a]carbazole (ICZ) was reported 
by Tomlinson et al. in 1956, little attention was actually paid to this class of compounds until 
1977, when the first isolation of an ICZ from nature was reported by Omura and co-
workers.
10,11
 Discovered in the course of screening extracts of the bacterium Streptomyces 
staurosporeus, this alkaloid was initially called AM-2282, but was subsequently renamed 
staurosporine (STA) 2. 
 
Fig. 1.3 Indolo[2,3-a]carbazole 1 and STA 2 structures 
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Early biological studies were to show that staurosporine 2 exhibited inhibitory activity toward 
fungi and also possessed strong hypotensive activity. The realisation of the potential of 
staurosporine 2 as a lead compound in anti-cancer treatment was to follow in 1986, when it 
was shown to be an extraordinarily potent inhibitor of protein kinase C (PKC) (IC50 = 2.7 nM) 
and was strongly cytotoxic towards cancer cells.
12
 Unfortunately, STA 2 ultimately proved 
unsuitable to be brought forward as a pharmaceutical candidate due the wide variety of 
biological activities brandished by the compound, such as its ability to inhibit many more 
protein kinases in the low nanomolar range.
13 
1.2.2 Isolation of indolocarbazoles from natural sources 
The isolation of further indolocarbazoles displaying intriguing biological profiles served to 
propagate the potential use of this class of compounds as anti-cancer agents. In 1985, 
rebeccamycin (REB) 3, named after the daughter of the scientist who isolated the compound, 
was reported from cultures of the microorganism Nocardia aerocolonigenes.
14
 Containing just 
one N-glycosidic bond instead of two as in the case of STA 2, REB 3 was later shown to be 
active against leukemia and melanoma in mice, and to inhibit the growth of human lung 
adenocarcinoma cells, producing single-strand breaks in the DNA of these cells.
15
    
 
Fig. 1.4 REB 3, UCN-01 4, 11-hydroxy STA 5 and 3,11-dihydroxy STA 6 structures 
Isolated from Streptomyces sp. N-71, UCN-01 4, also known as 7-hydroxystaurosporine, was 
found to be a potent inhibitor of PKC and to exhibit significant in vivo antitumour activity.
16
 
Kinnel and Scheuer reported the isolation of 11-hydroxystaurosporine 5 and 3,11-
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dihydroxystaurosporine 6 from the Pohnpei tunicate Eudistoma sp. in 1992, the first examples 
of naturally occurring indolocarbazoles from a marine organism. Both 11-hydroxy STA 5 and 
3,11-dihydroxy STA 6 were shown to be active against cancer cell lines, with 5 proving to be 
a more potent PKC inhibitor than STA 2.
17 
Many aglycone ICZ derivatives have also been identified from natural sources, such as 
arcyriaflavin A 7, arcyriaflavin B 8 and arcyriaflavin C 9 which were reported to be contained 
in Arcyria denudata and Arcyria nutans slime moulds by Steglich et al.
18
 Interestingly, in the 
same course of work, a series of bisindolylmaleimides, arcyriarubin A 10, arcyriarubin B 11 
and arcyriarubin C 12, which are biosynthetically related to the ICZ class, were also isolated 
from  the same moulds. Due to the close structural and biosynthetic relationship that is shared 
by both classes,  bisindolylmaleimides are generally considered to be part of the broader ICZ 
family of compounds, despite their relative overall lack of planarity.
9
 The aglycone of STA 2 
itself, K252c 13, was reported to be isolated from a different actinomycete strain, 
Nocardiopsis sp. K-290, by Nakanishi and co-workers in 1985.
19
 However, since that time, 
both STA 2 and K252c 13 have been identified as coming from the same strains of 
microorganisms on a number of occasions, indicating that a complimentary biosynthetic 
pathway is involved.
20,21
  
 
Fig. 1.5 Arcyriaflavins A, B and C (7, 8, 9), arcyriarubins A, B and C (10, 11, 12)                    
and K252c 13 structures 
Though not possessing a sugar moiety, as in the case of STA 2 and REB 3 for example, the 
arcyriaflavins and arcyriarubins were still shown to mediate significant biological activity. 
Arcyriaflavin A 7 displays micromolar and submicromolar inhibition against a number of 
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PKC isoforms and strongly inhibits the proliferation of non-small cell lung cancer A549 and 
murine leukemia P388 cell lines.
22
 Arcyriarubin A 10, while being the simplest 
bisindolylmaleimide structure, is a relatively effective nanomolar inhibitor of PKC (IC50 = 87 
nM), along with the STA 2 aglycone, K252c 13 (IC50 = 110 nM).
19,23
  
Ultimately, a wide variety of indolocarbazoles have been isolated from many different 
organisms over the past 35 years, including bacteria, fungi and marine invertebrates. 
Screening programmes to isolate further indolocarbazoles from natural sources have 
continued unabated, due to the potent antiproliferative activity and other biological responses 
mediated by numerous members within the compound class. Much focus has also been paid to 
the total syntheses of these natural products, as well as the development of synthetic ICZ 
analogues - a number of which are currently undergoing clinical trials.
24
  
1.2.3 Biosynthesis of indolocarbazoles 
With the isolation of indolocarbazoles from natural sources leading to the discovery of an 
extensive array of novel compounds with immense therapeutic potential, much work has also 
been carried out towards the elucidation of ICZ biosynthesis. From a biotechnology 
standpoint, the identification of genes involved in the biosynthesis of the naturally occurring 
members of this class, as well as the disclosure of their metabolic precursors and 
intermediates, has resulted in significant breakthroughs in the past 25 years.
9
  
The biosyntheses of some of the more prominent members of the ICZ family have been 
widely studied, resulting in the identification of a number of similar key metabolic precursors 
(Scheme 1.1). The utilisation of isotope-labelled precursors in the fermentation of 
Streptomyces staurosporeus, the microorganism producer of STA 2, and Nocardia 
aerocolonigenes, the producer of REB 3, has led to the discovery that the core 
indolocarbazole structure is derived from two tryptophan 14 units.
25,26
 Concomitantly, glucose 
15 and methionine 16 were found to be the precursors responsible for the derivation of the 
sugar moiety in each case. However, it was not possible to determine the origin of the nitrogen 
of the lactam unit in STA 2 and maleimide unit in REB 3 in the course of these studies. 
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Scheme 1.1 Metabolic precursors of STA 2 and REB 3 
By examining and testing the biosynthetic mechanics involved in ICZ production in the 
natural world, it has been possible to develop a number of new ICZ analogues via the use of 
altered precursors and also by varying the fermentation conditions of the microorganisms 
involved. For example, the use of potassium bromide in the fermentation of Nocardia 
aerocolonigenes lead to the production of 1,11-dibromorebeccamycin 17, while the use of 7-
azatryptophan in the cultivation of strain NPS012745 was shown to result in the production of 
3-indolyl-4-(7-azaindolyl)pyrrole analogue 18.
27,28
      
 
Fig. 1.6 1,11-Dibromo REB 17 and 3-(indolyl)-4-(7-azaindolyl)pyrrole 18 structures 
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1.3 Biological mechanisms of indolocarbazoles 
A significant number of both synthetic and naturally occurring indolo[2,3-a]carbazoles have 
demonstrated excellent antitumour activity, and are thought to contribute their 
antiproliferative effects via protein kinase inhibition, as in the case of STA 2, or by 
topoisomerase I inhibition, such as with derivatives of REB 3.
29-31
  
1.3.1 Protein kinases 
Protein kinases represent one of the largest families of proteins in humans, and sequencing of 
the human genome has revealed there to be over 500 distinct kinases that can be grouped into 
about 20 known families on the basis of structural similarity.
32
 Kinase enzymes catalyse the 
phosphorylation of amino acid residues, i.e. the transfer of the terminal phosphate residue of 
adenosine triphosphate (ATP) to the hydroxyl group of serine, threonine or tyrosine residues 
(Scheme 1.2).  
 
Scheme 1.2 Phosphorylation of serine/threonine/tyrosine residues 
Research into protein kinases originated in 1955, when Fischer and Krebs perceived ATP-
dependent enzymatic activity, leading to the discovery of the serine/threonine kinase 
phosphorylase b kinase.
33,34
 Since then, kinase enzymes have played a central role in the 
elucidation of signal transduction pathways, and have been found to be involved in almost all 
critical cellular functions, such as growth, development and homeostasis.
35 
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In 1991, Knighton and co-workers solved the first crystal structure of a protein kinase 
catalytic domain, cAMP-dependent protein kinase (PKA) co-crystallised with a bound, high-
affinity inhibitor peptide, and since that time, about 1500 structures of around 200 unique 
kinases have been lodged on the Protein Data Bank (PDB).
36,37
 The catalytic domain is 
relatively conserved in both sequence and structure across all members of the kinase family, 
with most small molecule kinase inhibitors binding to this site and competing with ATP.
38
 
This approach of ATP antagonism can be limited in terms of selectivity due to the similarity 
between the catalytic domains in different kinases.
39 
1.3.1.1 Structural features of kinase catalytic domain 
The protein kinase catalytic domain consists of two major subdomains: a smaller N-terminal 
“lobe” and a larger C-terminal “lobe”. The N-terminus comprises five β-strands with one 
critical α-helix (αC-helix), while the C-terminus is primarily α-helical (Figure 1.7). 
 
Fig. 1.7 Phosphorylase kinase (PhK) complexed with ATP (PDB code 2PHK)
40,41
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Connecting the two domains is a peptide strand, which forms the hinge region (Figure 1.7). 
The active site of the catalytic domain is then formed by the cleft situated between the two 
subdomains and the hinge region. This cleft has a front pocket containing the residues which 
are directly involved in catalysis or the binding of ATP, while towards the back of the cleft, a 
hydrophobic pocket supports regulatory functions.
42
   
The adenine ring system of ATP binds to the amide backbone of the hinge region in the front 
pocket of the cleft of the domain (Figure 1.8). The orientation of the αC-helix within the N-
terminus, in part, regulates enzymatic activation, i.e. in active state, it is oriented towards the 
active site. This αC-helix frequently interacts with the C-terminal activation loop to alter the 
alignment of key catalytic residues. The activation loop of the C-terminus contains a number 
of elements which are vital for effective enzyme function. For example, it contains a Mg
2+
 
orienting loop which is critical for catalysis, mainly due to the fact that an aspartate residue 
binds directly to the magnesium ion cofactor (highlighted in green) orientating the γ-
phosphate of ATP for transfer. 
 
Fig. 1.8 Molecular contacts between ATP and conserved active site residues and cofactors 
Phosphorylation sites essential to the regulation of catalytic activity are contained on the 
activation loop. A network of strong hydrogen bonds is created by the incorporation of a 
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phosphate group on an activation loop residue, thus facilitating the organisation of catalytic 
active site residues and the phosphorylation residue binding site. The conserved lysine residue 
(highlighted in orange) which helps to orient ATP for catalysis is not in a flexible loop, unlike 
many of the essential catalytic residues, and is held in a more rigid conformation. This 
conserved lysine residue, along with another “gatekeeper” residue, control access to the 
hydrophobic pocket that contains kinase regulatory elements. The gatekeeper residue can have 
either a large amino acid side chain (e.g. phenylalanine in CDK2) which blocks ligand access 
to the back pocket, or a small side chain (e.g. threonine in EGFR) which allows access.
42
  
1.3.1.2 Deregulation of kinases and disease: attractive biological targets 
In 1980, it was first reported that protein kinases played a crucial role in oncogenesis and the 
progression of tumours.
43 
Since then, the development and advancement of such tools as 
genetic modulation, RNAi technology and bioinformatics, has implicated the deregulation of 
kinases in almost all human diseases, including diabetes, cardiovascular disease and 
neurological disease, as well as cancer.
44
 As a result, the targeted inhibition of kinases has 
become an attractive therapeutic strategy in the treatment of relevant diseases. They are 
considered to be the second most important group of drug targets after G-protein coupled 
receptors.
45
  
 
Fig. 1.9 Structures of erlotinib 19 and sunitinib 20 
Currently, there are 14 kinase inhibitors approved by the FDA, including erlotinib 19, which is 
marketed as a non-small cell lung cancer inhibitor, and sunitinib 20, which is marketed for the 
treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumour.
46,47
 It 
has been estimated that the global market for kinase-directed therapies is estimated to be 
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US$35 billion in 2013.
39
 A number of ICZ derivatives are currently undergoing clinical trials, 
including UCN-01 4, which is currently being examined for the treatment of cancer.
48
  
1.3.1.3 Staurosporine: a non-selective kinase inhibitor 
Ever since the disclosure of low nanomolar activity against PKC (IC50 = 2.7 nM), STA 2 has 
become a lead compound for the development of potential anticancer agents.
12
 Due to the 
wide biological profile with which STA 2 operates, in particular its lack of specificity as a 
kinase inhibitor, progression of this natural product towards clinical trials was not possible. 
Although there was some initial debate due to aberrant kinetic data, STA 2 was found to 
effectuate kinase inhibition due to competition with respect to ATP.
13
 This was later proven 
when crystal structures of the ICZ alkaloid in complex with the ATP-binding sites of cyclin-
dependent kinase 2 (CDK2) and PKA were resolved.
49,50
         
 
Fig. 1.10 STA 2 in complex with CDK2 (PDB code 1AQ1)
40,51 
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To date, coordinate sets of roughly 40 kinase catalytic domains co-crystallised with STA 2 
have been deposited with the PDB, for example in Figure 1.10. These structures demonstrate 
the existence of an almost universal common binding mode of STA 2 to these ATP-binding 
sites. In a similar manner to the binding of the adenine ring to the hinge region of the kinase 
catalytic domain (Figure 1.8), the lactam moiety of STA 2 forms two conserved hydrogen 
bonds to two amino acid residues in order to anchor the inhibitor inside the ATP-binding site. 
Shown in Figure 1.11 is STA 2 bound to the active site of phosphoinositide-dependent kinase 
1 (PDK1), clearly illustrating the hydrogen bond formed between the NH of the lactam ring 
and the backbone carbonyl of Ser-160, and also the bond formed between the lactam carbonyl 
and the backbone NH of the Ala-162 residue of the hinge. Another hydrogen bond also exists 
between the methylamino group of the STA 2 carbohydrate moiety and a backbone carbonyl 
group of a glutamate residue, Glu-209, which also helps to anchor the ATP-competitive 
inhibitor to the active site.     
            
Fig. 1.11 STA 2 in complex with PDK1 (PDB code 1OKYO)
52,53
 
While the relatively conserved nature of the kinase catalytic domain across the kinome can 
help to account for the lack of specificity of STA 2 and a number of other inhibitors across the 
kinome, there exists the potential to exploit subtle differences within the active site to generate 
a narrower selectivity profile for kinase inhibitors. For example, hydrophobic interactions are 
dominated by side-chain interactions which involve residues that are less conserved, such as 
the Leu-88, Leu-212 and Thr-222 residues of PDK1 (Figure 1.11). The residues involved in 
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these hydrophobic interactions are also subject to induced fit structural rearrangements on 
ligand binding. Overall, the exploitation of discreet differences in active site residues and 
conformations can help to confer or induce selectivity throughout the pan-kinase domain.
48
 
1.3.1.4 ICZs as protein kinase inhibitors 
Though the wide-ranging biological mode of action of STA 2 rendered it unsuitable as a 
clinical candidate, many other ICZ derivatives have since been investigated for their potential 
use as anticancer agents and in other diseases. UCN-01 4 is currently undergoing clinical trials 
due to its highly potent antiproliferative activity, and as an inhibitor of PKC (IC50 = 10 nM) is 
comparable to STA 2 (IC50 = 2.7 nM).
54
 UCN-01 4 is also a strong inhibitor of CHK1 (Ki = 
5.6 nM), PDK1 (IC50 = 5.0 nM), and other isoforms of PKC (IC50 ≤ 1 µM), and is unique in 
being the only naturally occurring ICZ analogue being evaluated for clinical use at 
present.
53,55
 Greater success has been seen with regard to synthetic ICZ derivatisation 
programmes, leading to the development of a number of highly promising chemotherapeutic 
candidates with the potential to widen the relatively narrow field of established kinase 
inhibitors on the market. To date, structural modifications to the STA 2 pharmacophore have 
included: (i) derivatisation of the lactam heterocycle, (ii) substitutions on aromatic rings A or 
E and (iii) structural variation of the sugar moiety (Figure 1.12). 
 
Fig. 1.12 Derivatisation of STA 2 pharmacophore; structure of UCN-01 4 
Replacement of the substituted pyranose sugar of STA 2 with a reduced furan ring, and the 
lactam group with a maleimide functionality furnished SB-218078 21, which proved to be a 
far more selective kinase inhibitor. SB-218078 21 demonstrated a 15-fold selectivity for 
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CHK1 (IC50 = 15 nM) compared to CDK1 (IC50 = 250 nM), and a 65-fold selectivity against 
PKC (IC50 = 1000 nM).
56
 This contrasts with STA 2, which inhibits the same kinases in a 
narrow IC50 range of 2.7 to 8 nM. Similarly, CEP-1347 22 retains the lactam moiety of STA 2, 
but contains a substituted furan ring instead of the glycoside functionality and two 
ethylthiomethyl substituents on aromatic rings A and E. ICZ derivative 22 was shown to 
exhibit potent inhibitory activity against MLK kinases, which are key participants in the 
activation of the JNK signalling cascade.
57
 The JNK signalling cascade has been of particular 
therapeutic interest in the treatment of the effects of Parkinson’s disease, as it has been 
implicated in the governing of neuronal dysfunction and subsequent death. This approach 
towards treating the disease offers an attractive alternative to existing remedies, helping 
prevent disease progression by targeting the mechanisms involved in the pathogenesis of the 
ailment.
58
  
 
Fig. 1.13 Structures of SB-218078 21 and CEP-1347 22 
Other highly promising pharmaceutical candidates arising from the derivatisation of the STA 
2 pharmacophore include midostaurin 23, a potent, non-specific inhibitor of a number of 
different kinases, including PKC, VEGFR2 and FLT3. Midostaurin 23 is currently under 
examination for treatment of acute myeloid leukemia (AML), as well as a number of different 
cancer types.
59
 Suppression of tumour growth by ICZ 23 is thought to occur by inhibition of 
tumour angiogenesis, in addition to directly inhibiting cancer cell proliferation.
60
 One of the 
main kinases targeted by 23, FLT3, is a receptor tyrosine kinase which is activated by 
mutation in approximately a third of AML patients. 
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Lestaurtinib 24 has also entered trials for treatment of acute myeloid leukemia, as well as for 
treatment of myelofibrosis and prostate cancer.
61
 While 24 has been shown to inhibit 
autophosphorylation and signalling of neurotrophin-specific Trk receptors, and to display 
potent antitumour activity, it has also been demonstrated to act on epidermal growth factor 
receptor, FLT3, RET and a number of other kinases.
62 
 
Fig. 1.14 Midostaurin 23 and lestaurtinib 24 structures 
1.3.1.5 Bisindolylmaleimides: non-planar ICZ derivatives 
Biosynthetically related and often used as synthetic precursors to ICZs, bisindolylmaleimides 
have proven to be worthy of much research focus in their own right, again due to the wide 
variety of biological activities modulated by this class, particularly as kinase inhibitors. 
Bisindolylmaleimide GF109203X 25 was originally proposed by Toullec et al. to be a 
selective inhibitor of PKC, though this was later discounted due to its inhibition of a number 
of other kinases.
63,64
 It was also found to target a number of other unexpected proteins, such as 
P-glycoprotein and 5-hydroxytryptamine3 (5-HT3) receptor.
65,66
  
Further elaboration of the bisindolylmaleimide template has since resulted in the development 
of ruboxistaurin 26, a specific inhibitor of the PKC isoforms, PKCβ1 (IC50 =4.7 nM) and 
PKCβ2 (IC50 = 5.9 nM). This BIM derivative 26 displays a high degree of selectivity 
compared with other protein kinases and PKC isoforms, such as PKCα (IC50 = 360 nM), 
PKCγ (IC50 = 300 nM), PKCε (IC50 = 600 nM) and PDK1 (IC50 = 750 nM).
67,68
 Due to the 
long-chain linker between the two indolic nitrogen atoms, macrocycle 26 has reduced 
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conformational freedom relative to other bisindolylmaleimides such as GF109203X 25, but 
without the planarity of its ICZ analogues. At present used to treat diabetic peripheral 
retinopathy, ruboxistaurin 26 is the first chemotherapeutic agent used in the treatment of this 
serious complication of diabetes.
69 
 
Fig. 1.15 Structures of GF109203X 25 and ruboxistaurin 26 
Another modified bisindolylmaleimide, enzastaurin 27, was found to be a highly potent 
inhibitor of PKCβ (IC50 = 6 nM) and the AKT/PI3 pathway, and is currently under clinical 
evaluation for such cancers as glioblastoma, non-small cell lung cancer and colorectal cancer. 
It displays significant selectivity over other isoforms of PKC, including PKCα (IC50 = 39 nM), 
PKCγ (IC50 = 83 nM) and PKCε (IC50 = 110 nM). With the activation of PKC, particularly 
PKCβ, implicated in tumour initiation and progression, orally administered BIM 27 induces 
apoptosis in a number of cancer cell lines and also inhibits VEGF-mediated angiogenesis.
70
  
 
Fig. 1.16 Structures of enzastaurin 27, BIM 28, and aza BIM derivatives 29 and 30 
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The bioisosteric replacement of 7-azaindolyl subunits instead of either indolyl moiety in the 
BIM series has also been shown to mediate significant kinase inhibitory activity. In 2003, Kuo 
and co-workers reported the synthesis of a series of macrocyclic BIM derivatives, such as 
BIM 28 and azaindolylmaleimide analogues 29 and 30, as potent inhibitors of glycogen 
synthase kinase-3 (GSK-3).
71
 Inhibition of GSK-3 has previously been shown to attenuate 
apoptotic signals, leading to the potential use of inhibitors of this kinase in the treatment of 
Alzheimer’s disease and other conditions.72,73  
Kinase Assay 28 29 30 
GSK-3β 0.022 0.017 0.034 
CDK1 1.251 4.428 > 10 
CDK2 0.922 2.439 > 10 
VEGFR 1.450 3.560 > 10 
PKCα 0.086 0.673 > 10 
PKCβII 0.006 0.046 1.163 
PKCθ 0.065 0.835 > 10 
PKA > 10 > 10 > 10 
 
Table 1.1 IC50 (µM) of kinase assays for BIM derivatives 28, 29 and 30
71 
It was found that the kinase selectivity profiles of the macrocyclic BIM derivatives, illustrated 
in Table 1.1, were dramatically altered by the incorporation of one and especially two 7-
azaindolyl functionalities. Aza BIM analogue 30 displayed excellent ATP-competitive activity 
against the GSK-3β isoform (IC50 = 34 nM), while simultaneously showing very weak 
inhibition against almost every member of a panel of 50 kinases, such as PKCα, PKA and 
CDK1 (IC50 > 10 µM for all three). Conversely, BIM analogue 28, while also observed to 
have excellent activity against GSK-3β, was shown to strongly inhibit a number of other 
kinases such as PKCα (IC50 = 86 nM), PKCβII (IC50 = 6 nM) and PKCθ (IC50 = 65 nM). 
Molecular modelling studies suggested that concomitant to the conserved hydrogen-bonding 
between the backbone residues of GSK-3β and the maleimide ring of macrocycle 30, a 
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significant hydrogen-bonding interaction also occurs between one of the azaindolic nitrogen 
atoms of 30 and a guanidine functionality of a side chain Arg-141 residue (Figure 1.17). It 
was posited that this particular hydrogen bond with Arg-141 is unique to GSK-3β, thus 
helping to explain the degree of selectivity observed for this series of 7-
azaindolylmaleimides.
71 
 
Fig. 1.17 Binding mode of aza BIM analogue 30 in GSK-3β active site71 
1.3.1.6 Heteroaryl ICZ analogues as kinase inhibitors 
Further diversification of the ICZ pharmacophore, with the appropriation of heteroaryl 
subunits, has served to potentiate kinase inhibitory activity in a number of reported instances.   
 
Fig. 1.18 Structures of ruthenium complex 31 and VEGFR inhibitor 32 
Chapter 1 | Biological Introduction 
 
 
[23] 
 
In 2005, Meggers et al. described the synthesis of a series of ICZ derivatives (containing a 
pyridine ring in place of an indolyl unit) bound in a ruthenium complex.
74
 These 
cyclometalated compounds were found to be highly efficacious inhibitors of the GSK-3α 
isoform of glycogen synthase kinase 3 (GSK-3), such as with complex 31 (IC50 = 0.3 nM), 
which is regarded as one of the most potent inhibitors of this kinase yet to be discovered. 
In 2008, Peifer and co-workers described the synthesis of a series of BIM analogues 
containing a 3,4,5-trimethoxyphenyl moiety, such as derivative 32, as potent inhibitors of 
vascular endothelial growth factor receptor (VEGFR).
75
 The VEGFR family of kinases play 
pivotal roles in the mediation of the effects of hypoxia-induced VEGFs on angiogenesis such 
as in pancreatic, gastric and colorectal carcinomas.
76
 Heteroaryl BIM/Combretastatin analogue 
32 was found to be a potent inhibitor of the isoforms VEGFR-2 (IC50 = 31 nM) and VEGFR-3 
(IC50 = 37 nM), while also blocking angiogenesis in an endothelial cell sprouting assay at a 
concentration of 1.3 µM using human lung-derived microvascular endothelial cells 
(HLMEC).
75 
 
Fig. 1.19 Structures of 3-(7-azaindolyl)-4-heteroaryl BIM derivatives 33 and 34 
Elaborating on previous work featuring macrocyclic BIM derivatives (Section 1.3.1.5), Kuo et 
al. achieved similar GSK-3β inhibitory activity and selectivity with the development of a 
panel of 7-azaindolyl-heteroarylmaleimides. Dispensing with a long-chain linker, and utilising 
an entire series of heteroaryl units instead of one of the 7-azaindolyl moieties, a number of 
potent GSK-3β inhibitors were developed, including derivatives 33 (Ki = 25 nM) and 34 (Ki = 
48 nM), both of which were shown to display good selectivity against a panel of 80 kinases.
77
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1.3.1.7 Kinase inhibitors containing a 7-azaindolyl nucleus 
Despite constituting a key component of a number of potent kinase inhibitors described in the 
previous section, the 7-azaindolyl functionality has been found to occur in a very limited 
number of natural products.
78
 In one such instance, structural elucidation of the variolins, a 
series of alkaloids isolated from the rare Antarctic sponge Kirkpatricka varialosa, revealed a 
common pyrido[3,2:4,5]pyrrolo[1,2-c]pyrimidine skeleton.
79
 A member of the class, variolin 
B 35, was found to be a potent inhibitor of the CDK and GSK-3 kinases, and to display 
cytotoxicity against a number of human cancer cell lines.
80 
 
Fig. 1.20 Structures of variolin B 35 and meriolin 3 36 
Synthetic derivatisation of the variolin B 35 structure subsequently led to the development of 
the meriolin series of compounds, such as meriolin 3 36, with enhanced potency and 
selectivity towards the CDK kinases, along with increased antiproliferative and proapoptotic 
properties.
81
 While displaying potent inhibition against CDKs such as CDK9 (IC50 = 6 nM), 
meriolin 3 36 was found to be less efficacious against other kinases such as GSK-3 (IC50 = 
230 nM) compared with variolin B 35 (IC50 = 70 nM).   
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1.3.2 Topoisomerase I 
Topoisomerase I (topo I) is a ubiquitous enzyme found in all mammals and plays an essential 
role in many important cellular functions such as replication and transcription. In 1985, 
Sternglanz and co-workers detailed experimentally, using topo I gene mutants, how the 
enzyme was not a prerequisite for cell growth in yeast.
82
 However, further genetic studies of 
topo I gene mutants showed that the enzyme was vital for the growth and development of the 
fruit fly, Drosophila melanogaster.
83
 This led to the inference that topo I played an essential 
role in more complex eukaryotic cells. Morham et al. illustrated this by later demonstrating 
how the inactivation of the topo I gene caused the death of mice early in embryogenesis.
84
    
 
Fig. 1.21 Topo I cleavage complex with human DNA (PDB code 1A36)
40,85 
In the human genome, there are four genes which encode for topo I: the nuclear topo I and 
mitochondrial topo I genes, along with the topo IIIα and topo IIIβ genes. The cellular function 
of topo I is to produce a transient single strand break in DNA, thus relaxing the torsional strain 
built up from the unwinding process, and allowing the DNA to be effectively transcribed and 
replicated. The single strand break is then religated, resulting in the restoration of the DNA 
double strand. A cleavage complex is formed when topo I binds to and cuts the phosphate 
backbone of DNA, with the enzyme encircling the DNA tightly like a clamp (Figure 1.21).
86
  
Chapter 1 | Biological Introduction 
 
 
[26] 
 
 
Scheme 1.3 Nucleophilic attack from tyrosyl residue of topo I to DNA phosphodiester bond 
The mechanism by which topo I induces a single strand break in DNA, called the nicking step, 
results from the nucleophilic attack of the phenolic oxygen of an active site tyrosine residue 
(Tyr-723 in human topo I) on a DNA phosphodiester bond (Scheme 1.3). Topo I then forms a 
covalent linkage to the 3’-end of the broken DNA strand, while generating a 5’-hydroxyl 
group at the other end of the break.
87
 Controlled rotation of the 5’-hydroxyl end of the broken 
strand around the intact DNA strand allows for the relaxation of the DNA (Scheme 1.4).  
 
 
Scheme 1.4 Single strand DNA break allows for controlled rotation of 5’-hydroxyl end 
1.3.2.1 Topo I as a chemotherapeutic target 
There has been widespread research interest in the development of topo I-directed 
chemotherapeutic drugs over the past few decades, with levels of topo I catalytic activity 
shown to be significantly elevated in a number of different cancers, such as colon, prostate 
and ovarian carcinomas.
88,89
 Wall et al. reported the isolation of a potent anticancer alkaloid, 
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camptothecin (CPT) 37, from the Chinese tree Camptotheca acuminata in 1966, which was 
later found to inhibit topo I by interacting with the topo I-DNA cleavage complex.
90,91
  
 
Fig. 1.22 Structures of camptothecin 37 and topotecan 38 
Topo I is reported to be the sole cellular target of CPT 37, and trapping the enzyme-DNA 
complex prevents religation of the broken strand of DNA. In acting as a topo I poison, CPT 37 
converts topo I into a DNA-damaging agent, resulting in cellular cytotoxicity and apoptosis. 
Though trials of CPT 37 were discontinued due to its harmful side-effects, derivatives such as 
topotecan 38 have since been developed and brought into clinical use.
92 
 
Fig. 1.23 Intercalation of topotecan 38 into the topo I-DNA cleavage complex                      
(PDB code 1K4T)
40,93 
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Topo I poisons, such as topotecan 38, act as uncompetitive inhibitors by specifically binding 
to the enzyme-substrate complex. Topotecan 38 mimics a DNA base pair and binds at the site 
of DNA cleavage by intercalating between the upstream and downstream base pairs (Figure 
1.23). The downstream DNA is displaced due to the intercalation, which prevents religation of 
the cleaved strand.
93
 Topotecan hydrochloride is marketed under the registered trademark 
Hycamtin, and is commonly used to treat ovarian, cervical and non-small cell lung carcinomas 
amongst others, and was the first topoisomerase I inhibitor approved for oral use.
94 
1.3.2.2 ICZ Topo I Inhibitors 
Though CPT 37 derivatives, such as topotecan 38, have shown highly significant promise as 
anticancer agents, they still suffer drawbacks such as low tumour response rates and dose-
limiting toxicity.
95
 As a result of these problems, and due to the excellent potential shown by 
topo I poisons for the treatment of cancer, significant efforts have been made to identify non-
CPT inhibitors of this enzyme. It is in this effort that ICZ derivatives have displayed a 
burgeoning proficiency. 
After the isolation of rebeccamycin 3, the exact mechanism of its potent antitumour action 
was initially unclear, but subsequent studies identified that REB 3 was able to induce in vitro 
DNA cleavage mediated by the topo I enzyme.
14
 In the same assay, two other ICZ derivatives, 
KT6006 39 and KT6528 40, exhibited even more potent activity.  
 
Fig. 1.24 Structures of REB 3, KT6006 39 and KT6528 40 
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In a similar manner seen for topotecan 38, KT6006 39 and KT6528 40 stabilised the topo I-
DNA cleavage complex and prevented religation, and furthermore, in the absence of the topo I 
enzyme, KT6528 40 behaved as a DNA intercalator.
96 
The aglycone indolocarbazole, BE-13793C 41, was reported to be isolated from 
Streptoverticillium mobaraense BA13793 by Kojiri and co-workers in 1991.
97
 While ICZ 41 
was shown to be an effective inhibitor of topo I and to have remarkable activity in Ehrlich 
ascites carcinoma (EAC) cells, its low aqueous solubility prevented further biological 
evaluation.
98
 The synthesis of a glycosidic analogue, ED-110 42, increased the water 
solubility of aglycone 41, while retaining significant inhibition of topo I and highly potent 
antitumour activity, including against cell lines resistant to established chemotherapeutic 
agents, vincristine and doxorubicin.
98 
 
Fig. 1.25 BE-13793C 41 and ED-110 42 structures 
Further chemical elaboration from the aglycone core 41, with the incorporation of a N-
formylamino substituent, yielded NB-506 43, another ICZ displaying excellent anticancer 
potential.
99
 NB-506 43 inhibits the kinase activity and DNA-relaxing activity of topo I, as well 
as acting as a DNA-binding agent in its own right.
100
 Despite entering clinical trials for the 
treatment of solid tumours in 1994, NB-506 43 has since been discontinued from evaluation 
for use as a chemotherapeutic agent.
101 
Numerous derivatives of REB 3 and NB-506 43 have been synthesised and evaluated, 
providing vital information for structure-activity relationship (SAR) studies. Using NB-506 43 
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as an example, the ICZ pharmacophore can be divided into three distinct regions on the basis 
of topo I inhibitory activity (Figure 1.26). The planar ICZ core (rings A – E) partially 
intercalates between two consecutive DNA base pairs, as seen also for topotecan 38, while the 
glycosidic moiety was proposed to project into a groove of the DNA double helix. The 
substituent attached to the F-ring imide nitrogen then protrudes toward the opposite groove, 
where it interacts with residues of the catalytic domain of topo I.
102
    
 
Fig. 1.26 SAR of NB-506 43 and structure of edotecarin 44 
Progressive modification of the NB-506 43 structural framework led Ohkubo et al. to what 
remains to date one of the most promising ICZ chemotherapeutic candidates, edotecarin 44.
103
 
The formyl unit on the F-ring was replaced with a more polar 1,3-dihydroxypropane group, 
while the two hydroxyl substituents on the A- and E-rings were shifted from the C1 and C11 
positions to the C2 and C10 positions. These discrete changes increased the overall aqueous 
solubility and plasma stability of the molecule, while retaining topo I activity and increasing 
cytotoxicity.
104
 In fact, ICZ derivative 44 induces single-strand DNA cleavage more 
effectively and also gives rise to more stable topo I-DNA complexes than CPT 37 or NB-506 
43. Edotecarin 44 is at present being trialled in the clinic for the treatment of amongst others, 
breast cancer, glioblastoma multiforme and gastric cancer.
105
  
The crystal structure of the indolocarbazole SA315F 45 bound to the human topo I-DNA 
covalent complex was reported by Burgin et al. in 2005, highlighting a similar intercalative 
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binding mode to that seen for topotecan 38 and other topo I inhibitors.
106
 The indole ring with 
the glycosidic substituent was shown to stack with bases on the intact strand side of the duplex 
DNA, with the other indole stacked with bases on the cleaved strand side. The maleimide ring 
of ICZ 45 is placed on the minor groove side of the intercalation binding pocket, with the 
glucose moiety positioned in the major groove of the ternary complex (Figure 1.27). 
   
Fig. 1.27 Structure of SA315F 45 and bound to topo I-DNA complex (PDB code 1SEU)
40,106 
1.3.2.3 7-Azarebeccamycin derivatives: greater selectivity than parent ICZs 
The incorporation of 7-azaindole subunits into the REB 3 pharmacophore has been shown to 
confer highly significant selectivity profiles towards tumour cell lines. Prudhomme et al. 
demonstrated that replacing indole units in REB 3 analogues with 7-azaindolyl bioisosteres, 
i.e. azaindolocarbazole derivatives 46 and 47, conferred relatively significant differences to 
their cytotoxicity profiles in comparison with their parent ICZs.
107
  
While both were found to exert considerable topo I inhibition, 7-aza ICZ derivative 47 was 
shown to be more potent than its isomeric analogue 46. This was found to correlate with its 
higher DNA affinity and greater cytotoxicity against a series of tumour cell lines. The most 
intriguing aspect to the biological evaluation of 7-aza ICZ derivatives 46 and 47 was that they 
demonstrated a relatively high degree of selectivity for some tumour lines, resulting in 
markedly different cytotoxicity profiles to their parent ICZs. For example, derivative 46 
displayed considerable selectivity for SK-N-MC neuroblastoma (IC50 = 59 nM) and NCI-H69 
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non-small cell lung cancer (IC50 = 10 nM) cell lines relative to IGROV1 ovarian cancer (IC50 
= 68.8 µM) and HT29 colon carcinoma (IC50 = >100 µM) lines. This starkly contrasted with 
its parent ICZ, which was found to be highly cytotoxic across all cell lines tested.
107
 Thus, in 
altering just one atom, it is possible to significantly modulate biological activity. 
 
Fig. 1.28 Structures of 7-aza REB 3 derivatives 46 and 47 
Prudhomme et al. further demonstrated that aza ICZ 48, containing two 7-azaindolyl moieties, 
was more cytotoxic against a number of cancer cell lines, such as L1210 leukemia (IC50 = 
0.067 µM) and HT29 non-small cell lung cancer (IC50 = 0.57 µM) lines, compared to REB 3 
(IC50 = 0.14 and 0.3 µM respectively).
108
 In comparison, N-methyl derivative 49 was found to 
be about ten times less potent against L1210 cells (IC50 = 0.58 µM) and inactive against HT29 
cells (IC50 = 97 µM), indicating that a free imide nitrogen is highly important for activity. 
 
Fig. 1.29 Structures of REB 3 analogues bearing two 7-azaindole moieties 
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1.4 Conclusion 
The ICZ alkaloids represent a privileged scaffold with which to explore the development of 
novel chemotherapeutic drugs due to the wide range of biological activities mediated by 
members of the class. Two main modes of action exist within the paradigm of ICZ derivatives 
as anticancer agents: inhibition of protein kinases and the topoisomerase I enzyme. For 
example, candidates such as lestaurtinib 24 and enzastaurin 27, which are both currently 
undergoing clinical trials, have been shown to demonstrate excellent kinase activity (Sections 
1.3.1.4 and 1.3.1.5), while other derivatives such as edotecarin 42 act primarily as 
topoisomerase I inhibitors (Section 1.3.2.2).
65,73,105 
Of the various synthetic derivatisations that have been described and documented, one of the 
most interesting developments has been seen with the bioisosteric assimilation of 7-azaindolyl 
subunits into the ICZ core. In these instances, the replacement of just one or two atoms has 
often resulted in the conferring of remarkable selectivity profiles relative to their parent ICZs 
(Sections 1.3.1.5 and 1.3.2.3).
74,108
         
 
    
 
 
 
 
 
 
 
 
Chapter 1 | Biological Introduction 
 
 
[34] 
 
1.5 References 
1. Siegel, R.; Ward, E.; Brawley, O.; Ahmedin, J. CA Cancer J. Clin. 2011, 61, 212-
236 
2. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. CA Cancer J. 
Clin. 2011, 61, 69-90 
3. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. 
GLOBOCAN 2008 v2.0, Cancer Incidence and  Mortality Worldwide: IARC 
CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on 
Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 12/2/2012 
4. Rang, H.P.; Dale, M.M.; Ritter, J.M. Pharmacology 1999, 4th Edition, Churchill 
Livingstone 
5. Ferlay, J.; Parkin, D.; Stelianova-Foucher, E. Eur. J. Cancer 2010, 46, 765-781 
6. Cancer in Ireland National Cancer Institute Ireland 2011, Annual Statistical 
Report 
7. Fulda, S.; Debatin, K.-M. Oncogene 2006, 25, 4798-4811 
8. Kummar, S.; Chen, H.X.; Wright, J.; Holbeck, S.; Davis Millin, M.; 
Tomaszewski, J.; Zweibel, J.; Collins, J.; Doroshow, J.H. Nat. Rev. Drug 
Discovery 2010, 9, 843-856 
9. Sánchez, C.; Méndez, C.; Salas, J.A. Nat. Prod. Rep. 2006, 23, 1007-1045 
10. Brunton, R.J.; Drayson, F.K.; Plant, S.G.P.; Tomlinson, M.L. J. Chem. Soc. 1956, 
4783-4785 
11. Omura, S.; Iwai, Y.; Hirano, A.; Nakagawa, A.; Awaya, J.; Tsuchiya, Y.; 
Takahashi, Y.; Masuma, R. J. Antibiot. 1977, 30, 275-282 
12. Tamaoki, T.; Nomoto, H.; Takahashi, I.; Kato, Y.; Morimoto, M.; Tomita, F. 
Biochem. Biophys. Res. Commun. 1986, 135, 397-402 
13. Omura, S.; Sasaki, Y.; Iwai, Y.; Takeshima, H. J. Antibiot. 1995, 48, 535-548 
14. Nettleton, D.E.; Doyle, T.W.; Krishnan, B.; Matsumoto, G.K.; Clardy, J. Tet. Lett. 
1985, 26, 4011-4014 
15. Bush, J.A.; Long, B.H.; Catino, J.J.; Bradner, W.T.; Tomita, K. J. Antibiot. 1987, 
40, 668-678 
16. Takahashi, I.; Kobayashi, E.; Asano, K.; Yoshida, M.; Nakano, H. J. Antibiot. 
1987, 40, 1782-1784 
17. Kinnel, R.B.; Scheuer, P.J. J. Org. Chem. 1992, 57, 6327-6329 
18. Steglich, W.; Steffan, B.; Kopanski, L.; Eckhardt, G. Angew. Chem. Int. Ed. Engl. 
1980, 19, 459-460 
19. Nakanishi, S.; Matsuda, Y.; Iwahashi, K.; Kase, H. J. Antibiot. 1986, 39, 1066-
1071 
20. Takahashi, H.; Osada, H.; Uramoto, M.; Isono, K. J. Antibiot. 1990, 43, 168-173 
21. Osada, H.; Takahashi, H.; Tsunoda, K.; Kusakabe, H.; Isono, K. J. Antibiot. 1990, 
43, 163-167 
22. Horton, P.A.; Longley, R.E.; McConnell, O.J.; Ballas, L.M. Cell. Mol. Life Sci. 
1994, 50, 843-845 
Chapter 1 | Biological Introduction 
 
 
[35] 
 
23. McCombie, S.W.; Bishop, R.W.; Carr, D.; Dobek, E.; Kirkup, M.P.; Kirschmeier, 
P.; Lin, S.-I.; Petrin, J.; Rosinski, K.; Shankar, B.B.; Wilson, O. Bioorg. Med. 
Chem. Lett. 1993, 3, 1537-1542 
24. Butler, M.S. Nat. Prod. Rep. 2005, 22, 162-195 
25. Yang, S.W.; Lin, L.J.; Cordell, G.A.; Wang, P.; Corley, D.G. J. Nat. Prod. 1999, 
62, 1551-1553 
26. Lam, K.S.; Forenza, S.; Doyle, T.W.; Pearce, C.J. J. Ind. Microbiol. 1990, 6, 291-
294 
27. Lam, K.S.; Schroeder, D.R.; Veitch, J.M.; Matson, J.A.; Forenza, S. J. Antibiot. 
1991, 44, 934-939 
28. Gullo, V.P.; McAlpine, J.; Lam, K.S.; Baker, D.; Petersen, F. J. Ind. Microbiol. 
Biotechnol. 2006, 33, 523-531 
29. Gray, N.; Détivaud, L.; Doerig, C.; Meijer, L. Curr. Med. Chem. 1999, 6, 859-875 
30. Prudhomme, M. Curr. Med. Chem. 2000, 7, 1189-1212 
31. Schupp, P.; Eder, C.; Proksch, P.; Wray, V.; Schneider, B.; Herderich, M., Paul, 
V. J. Nat. Prod. 1999, 62, 959-962 
32. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sudarsanam, S. Science 
2002, 298, 1912-1934 
33. Fischer, E.H.; Krebs, E.G. J. Biol. Chem. 1955, 216, 121-132 
34. Krebs, E.G.; Kent, A.B.; Fischer, E.H. J. Biol. Chem. 1958, 231, 73-83 
35. Liu, J.; Hu, Y.; Waller, D.L.; Wang, J.; Liu, Q. Nat. Prod. Rep. 2012 
36. Knighton, D.R.; Zheng, J.H.; Ten Eyck, L.F.; Ashford, V.A.; Xuong, N.H.; 
Taylor, S.S.; Sowadski, J.M. Science 1991, 253, 407-414 
37. Schwartz, P.A.; Murray, B.W. Bioorg. Chem. 2011, 39, 192-210 
38. McGregor, M.J. J. Chem. Info. Model. 2007, 47, 2374-2382 
39. Fischer, P.M. Curr. Med. Chem. 2004, 11, 1563-1583 
40. ArgusLab 4.0.1; Thompson, M.A. Planaria Software LLC, Seattle, WA, USA 
http://www.arguslab.com, accessed on 26/1/2012 
41. Lowe, E.D.; Noble, M.E.M.; Skamnaki, V.T.; Oikonomakos, N.G.; Owen, D.J.; 
Johnson, L.N. EMBO J. 1997, 16, 6646-6658 
42. Kornev, A.P.; Taylor, S.S. Biochim. Biophys. Acta 2009, 1804, 440-444 
43. Sefton, B.M.; Hunter, T.; Beemon, K.; Eckhart, W. Cell 1980, 20, 807-816 
44. Liao, J.J.-L. J. Med. Chem. 2007, 50, 409-424 
45. Weinmann, H.; Metternich, R. ChemBioChem 2005, 6, 455-459 
46. Chandregowda, V; Venkateswara Rao, G.; Chandrasekara Reddy, G. Org. Process 
Res. Dev. 2007, 11, 813-816  
47. Goodman, V.L.; Rock, E.P.; Dagher, R.; Ramchandani, R.P.; Abraham, S.; 
Gobburu, J.V.S.; Booth, B.P.; Verbois, S.L.; Morse, D.E.; Liang, C.Y.; 
Chidambaram, N.; Jiang, J.X.; Tang, S.; Mahjoob, K.; Justice, R.; Pazdur, R. Clin. 
Cancer Res. 2007, 13,1367-1373 
48. Gani, O.; Engh, R. Nat. Prod. Rep. 2010, 27, 489-498 
49. Toledo, L.M.; Lydon, N.B. Structure 1997, 5, 1551-1556 
50. Prade, L.; Engh, R.A.; Girod, A.; Kinzel, V.; Huber, R.; Bossemeyer, D. Structure 
1997, 5, 1627-1637 
51. Lawrie, A.M.; Noble, M.E.; Tunnah, P.; Brown, N.R.; Johnson, L.N.; Endicott, 
J.A. Nat. Struct. Biol. 1997, 4, 796-801 
Chapter 1 | Biological Introduction 
 
 
[36] 
 
52. Cerius2 Modeling Environment, 2007. San Diego: Molecular Simulations Inc., 
2000   
53. Komander, D.; Kular, G.S.; Bain, J.; Elliott, M.; Alessi, D.R.; Van Aalten, D.M. 
Biochem. J. 2003, 375, 255-262 
54. Jiang, X.; Zhao, B.; Britton, R.; Lim, L.Y.; Leong, D.; Sanghera, J.S.; Zhou, B.B.; 
Piers, E.; Andersen, R.J.; Roberge, M. Mol. Cancer Ther. 2004, 3, 1221-1227 
55. Zhao, B.; Bower, M.J.; McDevitt, P.J.; Zhao, H.; Davis, S.T.; Johanson, K.O.; 
Green, S.M.; Concha, N.O.; Zhou, B.B. J. Biol. Chem. 2002, 277, 46609-46615 
56. Jackson, J.R.; Gilmartin, A.; Imburgia, C.; Winkler, J.D.; Marshall, L.A.; Roshak, 
A. Cancer Res. 2000, 60, 566-572 
57. Mucke, H.A. IDrugs 2003, 6, 377-383 
58. Parkinson Study Group Neurology 2004, 62, 330-332 
59. Butler, M.S. Nat. Prod. Rep. 2005, 22, 162-195 
60. Stone, R.M.; Deangelo, D.J.; Klimek, V.; Galinsky, I.; Estey, E.; Nimer, S.D.; 
Grandin, W.; Lebwohl, D.; Wang, Y.; Cohen, P.; Fox, E.A.; Neuberg, D.; Clark, 
J.; Gilliland, D.G.; Griffin, J.D. Blood 2005, 105, 54-60 
61. Smith, B.D.; Levis, M.; Beran, M.; Giles, F.; Kantarjian, H.; Berg, K.; Murphy, 
K.M.; Dauses, T.; Allebach, J.; Small, D. Blood 2004, 103, 3669-3676 
62. Strock, C.J.; Park, J.I.; Rosen, D.M.; Dionne, C.; Ruggeri, B.; Jones-Bolin, S.; 
Denmeade, S.R.; Ball, D.W.; Nelkin, B.D. Cancer Res. 2003, 63, 5559-5563 
63. Toullec, D.; Pianetti, P.; Coste, H.; Bellevergue, P.; Grand-Perret, T.; Ajakane, 
M.; Baudet, V.; Boissin, P.; Boursier, E.; Loriolle, F.; Duhamel, L.; Charon, D.; 
Kirilovsky, J. J. Biol. Chem. 1991, 266, 15771-15781 
64. Davies, S.P.; Reddy, H.; Caivano, M.; Cohen, P. Biochem. J. 2000, 351, 95-105 
65. Conseil, G.; Perez-Victoria, J.M.; Jault, J.M.; Gamarro, F.; Goffeau, A.; Hofmann, 
J.; Di Petro, A. Biochemistry 2001, 40, 2564-2571 
66. Coultrap, S.J.; Sun, H.; Tenner Jr., T.E.; Machu, T.K. J. Pharmacol. Exp. Ther. 
1999, 290, 76-82 
67. Jirousek, M.R.; Gillig, J.R.; Gonzalez, C.M.; Heath, W.F.; McDonald III, J.H.; 
Neel, D.A.; Rito, C.J.; Singh, U.; Stramm, L.E.; Melikian-Badalian, A.; Baevsky, 
M.; Ballas, L.M.; Hall, S.E.; Winneroski, L.L.; Faul, M.M. J. Med. Chem. 1996, 
39, 2664-2671 
68. Komander, D.; Kular, G.S.; Schüttelkopf, A.W.; Deak, M.; Prakash, K.R.C.; Bain, 
J.; Elliott, M.; Garrido-Franco, M.; Kozikowski, A.P.; Alessi, D.R.; Van Aalten, 
D.M.F. Structure 2004, 12, 215-226 
69. Gálvez, M.I. Curr. Phar. Biotechnol. 2011, 12, 386-391 
70. Graff, J.R.; McNulty, A.M.; Ross Hanna, K.; Konicek, B.W.; Lynch, R.L.; Bailey, 
S.N.; Banks, C.; Capen, A.; Goode, R.; Lewis, J.E.; Sams, L.; Huss, K.L.; 
Campbell, R.M.; Iversen, P.W.; Lee Neubauer, B.; Brown, T.J.; Musib, L.; 
Geeganage, S.; Thornton, D. Cancer Res. 2005, 65, 7462-7469 
71. Kuo, G.-H.; Prouty, C.; DeAngelis, A.; Shen, L.; O’Neill, D.J.; Shah, C.; 
Connolly, P.J.; Murray, W.V.; Conway, B.R.; Cheung, P.; Westover, L.; Xu, J.Z.; 
Look, R.A.; Demarest, K.T.; Emanuel, S.; Middleton, S.A.; Jolliffe, L.; Beavers, 
M.P.; Chen, X. J. Med. Chem. 2003, 46, 4021-4031 
72. Cross, D.; Cubert, A.A.; Chalmers, K.A.; Facci, L.; Skaper, S.D.; Reith, A.D. J. 
Neurochem. 2001, 77, 94-102 
Chapter 1 | Biological Introduction 
 
 
[37] 
 
73. Castro, A.; Martinez, A. Expert Opin. Ther. Pat. 2000, 10, 1519-1527 
74. Bregman, H.; Williams, D.S.; Meggers, E. Synthesis 2005, 9, 1521-1527 
75. Peifer, C.; Selig, R.; Kinkel, K.; Ott, D.; Totzke, F.; Schӓchtele, C.; Heidenreich, 
R.; Rӧcken, M.; Schollmeyer, D.; Laufer, S. J. Med. Chem. 2008, 51, 3814-3824 
76. Kiselyov, A.; Balakin, K.V.; Tkachenko, S.E. Expert Opin. Invest. Drugs 2007, 
16, 83-107 
77. O’Neill, D.J.; Shen, L.; Prouty, C.; Conway, B.R.; Westover, L.; Xu, J.Z.; Zhang, 
H.-C.; Maryanoff, B.E.; Murray, W.V.; Demarest, K.T.; Kuo, G.-H. Bioorg. Med. 
Chem. 2004, 12, 3167-3185 
78. Popowycz, F.; Routier, S.; Joseph, B.; Mérour, J.-Y. Tetrahedron 2007, 63, 1031-
1064 
79. Perry, N. B.; Ettouati, L.; Litaudon, M.; Blunt, J. W.; Munro, M. H. G.; Parkin, S.; 
Hope, H. Tetrahedron 1994, 50, 3987–3992 
80. Simone, M.; Erba, E.; Damia, G.; Vikhanskaya, F.; Di Francesco, A.M.; Riccardi, 
R.; Bailly, C.; Cuevas, C.; Sousa-Faro, J.M.F.; D’Incalci, M. Eur. J. Cancer 2005, 
41, 2366-2377  
81.  chalier, A.; Bettaye , K.; Ferandin,  .; Lozach, O.; Cl ment, M.; Valette, A.; 
Liger, F.; Marquet, B.; Morris, J.C.; Endicott, J.A.; Joseph, B.; Meijer, L. J. Med. 
Chem. 2008, 51, 737-751 
82. Thrash, C.; Bankier, A.T.; Barrell, B.G.; Sternglanz, R. Proc. Natl. Acad. Sci. USA 
1985, 82, 4374-4378 
83. Lee, M.P.; Brown, S.D.; Chen, A.; Hsieh, T.-S. Proc. Natl. Acad. Sci. USA 1993, 
90, 6656-6660 
84. Morham, S.G.; Kluckman, K.D.; Voulomanos, N.; Smithies, O. Mol. Cell. Biol. 
1996, 16, 6804-6809 
85. Stewart, L.; Redinbo, M.R.; Qiu, X.; Hol, W.G.; Champoux, J.J. Science 1998, 
279, 1534-1541 
86. Pommier, Y. Nat. Rev. Cancer 2006, 6, 789-802 
87. Tse-Dinh, Y.-C.; Kirkegaard, K.; Wang, J.C. J. Biol. Chem. 1980, 255, 5560-5565 
88. Van der Zee, A.G.J.; Hollema, H.; Jong, S.; Boonstra, H.; Gouw, A.; Willemse, 
P.H.B.; Zijlstra, J.G.; Varies, E.G.E. Cancer Res. 1991, 51, 5915-5920 
89. Husain, I.; Mohler, J.L.; Seigler, H.F.; Besterman, J.M. Cancer Res. 1994, 54, 
539-546 
90. Wall, M.E.; Wani, M.C.; Cooke, C.E.; Palmer, K.H.; McPhail, A.T.; Slim, G.A. J. 
Am. Chem. Soc. 1966, 88, 3888-3890 
91. Hsiang, Y.H.; Hertzberg, R.; Hecht, S.; Liu, L.F. J. Biol. Chem. 1985, 260, 14873-
14878 
92. Staker, B.L.; Feese, M.D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, 
L.; Burgin, A.B. J. Med. Chem. 2005, 48, 2336-2345 
93. Staker, B.L.; Hjerrild, K.; Feese, M.D.; Behnke, C.A.; Burgin Jr., A.B.; Stewart, 
L. Biochemistry 2002, 99, 15387-15392 
94. Pommier, Y. Chem. Rev. 2009, 109, 2894-2902 
95. Ulukan, H.; Swaan, P.W. Drugs 2002, 62, 2039-2057 
96. Yamashita, Y.; Fujii, N.; Murakata, C.; Ashizawa, T.; Okabe, M.; Nakano, H. 
Biochemistry 1992, 31, 12069-12075 
Chapter 1 | Biological Introduction 
 
 
[38] 
 
97. Kojiri, K.; Kondo, H.; Yoshinari, T.; Arakawa, H.; Nakajima, S.; Satoh, F.; 
Kawamura, K.; Okura, A.; Suda, H.; Okanishi, M. J. Antibiot. 1991, 44, 723-728 
98. Yoshinari, T.; Yamada, A.; Uemura, D.; Nomura, K.; Arakawa, H.; Kojiri, K.; 
Yoshida, E.; Suda, H.; Okura, A. Cancer Res. 1993, 53, 490-494 
99. Ohkubo, M.; Nishimura, T.; Jona, H.; Honma, T.; Ito, S.; Morishima, H. 
Tetrahedron 1997, 53, 5937-5950 
100. Yoshinari, T.; Matsumoto, M.; Arakawa, H.; Okada, H.; Noguchi, K.; Suda, H.; 
Okura, A.; Nishimura, S. Cancer Res. 1995, 55, 1310-1315 
101. Arakawa, H.; Iguchi. T.; Yoshinari, T.; Kojiri, K.; Suda, H.; Okura, A. Cancer 
Res. 1995, 55, 1316-1320 
102. Bailly, C.; Qu, X.; Chaires, J.B.; Colson, P.; Houssier, C.; Ohkubo, M.; 
Nishimura, S.; Yoshinari, T. J. Med. Chem. 1999, 42, 2927-2935 
103. Ohkubo, M.; Nishimura, T.; Kawamoto, H.; Nakano, M.; Honma, T.; Yoshinari, 
T.; Arakawa, H.; Suda, H.; Morishima, H.; Nishimura, S. Bioorg. Med. Chem. 
Lett. 2000, 10, 419-422 
104. Goossens, J.F.; Kluza, J.; Vezin, H.; Kouach, M.; Briand, G.; Baldeyrou, B.; 
Wattez, N.; Bailly, C. Biochem. Pharmacol. 2003, 65, 25-34 
105. Sheng, C.; Miao, Z.; Zhang, W. Curr. Med. Chem. 2011, 18, 4389-4409 
106. Staker, B.L.; Feese, M.D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, 
L.; Burgin, A.B. J. Med. Chem. 2005, 48, 2336-2345 
107. Marminon, C.; Pierré, A.; Pfeiffer, B.; Pérez, V.; Léonce, S.; Joubert, A.; Bailly, 
C.; Renard, P.; Hickman, J.; Prudhomme, M. J. Med. Chem. 2003, 46, 609-622 
108. Marminon, C.; Pierré, A.; Pfeiffer, B.; Pérez, V.; Léonce, S.; Renard, P.; 
Prudhomme, M. Bioorg. Med. Chem. 2003, 11, 679-687 
 
  
 
 
 
 
 
Chapter 2 
 
Chemical Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 2 | Chemical Introduction 
 
 
[41] 
 
Contents 
 
2.1  Synthetic routes to indolo[2,3-a]carbazoles 
2.1.1   Fischer indolisation towards ICZs 
2.1.2   Accessing ICZs: aromatisation of bisindolyl precursors 
2.1.2.1    Utilisation of bisindolyl lactam precursors 
2.1.2.2    Cyclisation of bisindolylmaleimides 
2.1.2.3    Synthesis of ICZs via 2,2’-bisindole derivatives 
2.1.2.4    Utilisation of 3,3’-bisindolyl precursors towards unsymmetrical ICZs 
2.1.3   Formation of ICZ core via nitrene insertion 
2.1.4   Palladium(0)-catalysed polyannulation 
 
43 
44 
45 
45 
46 
50 
51 
56 
58 
 
2.2  Synthetic routes towards azaindolocarbazoles 
2.2.1   First reported synthesis of aza ICZs 
2.2.2   Synthesis of 7-azarebeccamycin analogues 
2.2.3   Routes to bridged 7-azarebeccamycin derivatives 
2.2.4   Synthesis of 5-azaindolocarbazoles 
 
59 
59 
60 
62 
64 
2.3  Targeted synthesis of bisindolylmaleimide analogues 
2.3.1   Synthesis of macrocyclic BIM: ruboxistaurin 26  
2.3.2   Route towards N-(azacycloalkyl) BIM: enzastaurin 27 
2.3.3   Accessing bisazaindolylmaleimide derivatives 
2.3.4   Synthesis of 4-azaindolyl-indolylmaleimides 
 
66 
66 
67 
67 
69 
2.4  Routes towards heteroaryl ICZ analogues 
2.4.1   Cyclometalation of ICZ analogues 
2.4.2   Aza derivatives of isogranulatimide 211  
2.4.3   Synthesis of 3,4-diaryl-2H-pyrrole-2-ones 
70 
70 
71 
72 
Chapter 2 | Chemical Introduction 
 
 
[42] 
 
2.4.4   Synthesis of 7-azaindolyl-heteroarylmaleimides 
 
73 
2.5  Conclusion 
 
74 
2.6  References 
 
76 
 
Chapter 2 | Chemical Introduction 
 
 
[43] 
 
2.0 Chemical Introduction 
2.1 Synthetic routes to indolo[2,3-a]carbazoles 
The first natural product found to contain the indolocarbazole core, staurosporine 2, was 
isolated from nature in 1977, with members of this structural class previously garnering little 
attention aside from purely synthetic interest.
1
 Of the five different isomeric ring systems 
available to the ICZ family of compounds, it is the indolo[2,3-a]carbazole 1 class that has 
been the subject of the greatest research interest, as it is this structural framework that has 
been found to be the main constituent of many natural products with a diverse range of potent 
biological activities. 
 
Fig. 2.1 Indolo[2,3-a]carbazole structural core 1 
Numerous diverse routes have been reported in reference to the formation of ICZs since the 
first synthetic protocol towards these polycyclic ring systems was described in 1956.
2
 For 
review purposes we have broadly classified an overview of the chemical techniques involved 
on the basis of the final step to yield the ICZ core, namely Fischer indole synthesis (Section 
2.1.1), aromatisation of bisindole precursors (Section 2.1.2), nitrene insertion (Section 2.1.3) 
and palladium(0)-catalysed polyannulation (Section 2.1.4).  
Initial synthetic efforts carried out in this field in the 1950’s were relatively sparse and limited 
in scope, predominantly involving variations of the Fischer indolisation. Once the potent 
biological activities of a number of ICZ alkaloids were realised in the late 1970’s and early 
1980’s, great emphasis was placed in the medicinal chemistry field on both the total syntheses 
of natural products from this series and on synthetic derivatisation programmes in order to 
develop new clinical candidates. Although perhaps by far the most heavily utilised means of 
access has involved the aromatisation of bisindolyl precursors, an ever expanding level of 
endeavour has meant that many other methodologies have been employed and developed.  
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2.1.1 Fischer indolisation towards ICZs 
As part of a wider synthetic effort towards the development of carbazole chemistry, 
Tomlinson et al. reported the first formation of an indolo[2,3-a]carbazole (ICZ) ring system in 
1956 as an N-methyl derivative 52 (Scheme 2.1).
2
 This ICZ 52 was accessed through the 
condensation of 8-amino-1,2,3,4-tetrahydro-9-methyl-9H-carbazole 50 with 2-
hydroxycyclohexanone 51, followed by dehydrogenation. Unfortunately, attempts to utilise 
this method to form parent ICZ 1 met with little success. 
 
Scheme 2.1 Synthesis of N-methyl ICZ derivative 52 
However, the successful synthesis of ICZ 1 was reported in 1958 by Willcox et al., utilising 
the methodology of a Fischer indolisation of 2-hydroxycyclohexanone 51 with 
phenylhydrazine 53 (Scheme 2.2).
3
  
 
Scheme 2.2 Synthesis of parent ICZ 1 
In recent years, Hu and Chen reported a series of ICZs from a neat one-pot reaction by means 
of Fischer indolisation, starting from substituted 2-aminocyclohexanone derivatives and a 
number of hydrazine hydrochlorides.
4
 One such representative reaction (illustrated in Scheme 
2.3) involves the synthesis of ICZ 56 from 2-amino-4-phenylcyclohexanone hydrochloride 54 
and (4-chlorophenyl)hydrazine hydrochloride 55 in a mixture of acetic acid and trifluoroacetic 
acid. The authors noted the simple efficiency and robust nature of the novel procedure, which 
is insensitive to air and moisture, with a panel of 16 ICZs being formed using this 
methodology.  
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Scheme 2.3 Accessing ICZs via one-pot Fischer indolisation 
2.1.2 Accessing ICZs: aromatisation of bisindolyl precursors 
Perhaps due to ease of access and the provision of significant scope for elaboration, the 
primary means reported in the literature towards the formation of the pentacyclic ICZ core 
involves the cyclisation of bisindolyl precursors. Methods employed include the aromatisation 
of bisindolyl lactams (Section 2.1.2.1) and bisindolylmaleimides (Section 2.1.2.2), Diels-
Alder and metathesis reactions of 2,2’-bisindoles (Section 2.1.2.3), and the cyclisation of 
unsymmetrical 3,3’-bisindole derivatives (Section 2.1.2.4).    
2.1.2.1 Utilisation of bisindolyl lactam precursors 
The first synthesis of the STA 2 aglycone K252c 13 was described by Winterfeldt and 
Sarstedt in 1983, three years before it was first reported to be isolated from a natural source.
5
 
 
Scheme 2.4 The first reported synthesis of K252c 13 
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Oxidation of amide 57, itself derived from tryptamine and indolyl-3-acetyl chloride, with 
DDQ in a mixture of THF and water provided diketone 58, which was then selectively 
reduced to hydroxy ketone 59 using sodium borohydride (Scheme 2.4). Cyclisation of 
hydroxy ketone 59 towards acetylated derivative 60 was effectuated using acetic anhydride 
and a base catalyst, which was subsequently reduced and deacetylated using TiCl3 in aqueous 
acetone followed by sodium bicarbonate in methanol respectively, yielding bisindolyl lactam 
61. The final oxidative ring closing step was accomplished by irradiation of lactam 61 in 
methanol, resulting in the formation of K252c 13. 
A novel synthesis of K252c was reported by Mahboobi et al. in 1999, where an intermolecular 
Michael addition of 1-(indol-3-yl)-2-nitroethene 62 to methyl 2-(indol-3-yl)acetate 63 initially 
yielded methyl 2,3-bis(indol-3-yl)-4-nitrobutanoate 64.
6
 Catalytic hydrogenation and 
cyclisation of nitrobutanoate 64 afforded lactam 65 in high yield of 87%, with subsequent 
oxidative cyclisation using DDQ and p-TSA then yielding K252c 13 (Scheme 2.5)  
 
Scheme 2.5 Synthesis of K252c 13 described by Mahboobi et al.
6
 
2.1.2.2 Cyclisation of bisindolylmaleimides 
In 1980, Steglich et al. described the neat synthesis of a bisindolylmaleimide for the first time, 
derivative 68, which would later lead to the development of relatively efficient synthetic 
routes towards ICZs.
7
 The condensation of indolylmagnesium iodide 67 with N-methyl 
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dibromomaleimide 66 in benzene at room temperature with a catalytic amount of HMPA 
afforded BIM 68 in a good yield of 60% (Scheme 2.6).        
 
Scheme 2.6 Synthesis of BIM 68 
Employing a variation of Steglich’s approach, Weinreb and co-workers reported the synthesis 
of N-benzyl K252c 73 in 1984.
8
 The initial formation of benzylated BIM 71 was achieved via 
the reaction of N-benzyl dibromomaleimide 70 with indolylmagnesium bromide 69. Oxidative 
cyclisation of BIM 71 with p-TSA and DDQ afforded ICZ 72, which was then reduced under 
Clemmensen conditions to give N-benzyl K252c 73 (Scheme 2.7).   
 
Scheme 2.7 Synthesis of N-benzyl K252c 73 
In 1993, Hill and co-workers reported the synthesis of K252c 13 via two other naturally 
occurring ICZ derivatives, arcyriarubin A 10 and arcyriaflavin A 7 (Scheme 2.8).
9
 Natural 
product 10 was afforded by reaction of dibromomaleimide 74 with indolylmagnesium 
bromide 69 in benzene. Oxidative cyclisation of bisindolylmaleimide 10 using palladium(II) 
acetate in acetic acid then formed the ICZ arcyriaflavin A 7. The subsequent reduction of ICZ 
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7 using lithium aluminium hydride yielded hydroxy lactam 75, with a hydrogenolysis in the 
presence of 10% Pd/C yielding K252c 13 in quite an efficient synthesis, with an overall yield 
of 14% from dibromomaleimide 74.  
 
Scheme 2.8 Synthesis of K252c 13 via arcyriarubin A 10 and arcyriaflavin A 7 
A higher yielding route to K252c 13 was described by Xie and Lown in 1994, incorporating 
the same benzylated BIM 71 as that first reported by Weinreb et al, though with a slightly 
modified coupling reaction (Scheme 2.9).
8,10
  
 
Scheme 2.9 Synthesis of K252c 13 by Xie and Lown
10 
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N-Benzyl dibromomaleimide 70, synthesised from dibromomaleimide 74 in 92% yield, was 
condensed with indolylmagnesium bromide 69 under reflux conditions to give BIM 71 
(Scheme 2.9). Base-induced conversion to maleic anhydride 76 was followed by 
photocyclisation to yield ICZ 77. Reaction of anhydride 77 with ammonium acetate then gave 
arcyriaflavin A 7, with consequent reduction to K252c 13 accomplished with zinc amalgam, 
with an overall yield from dibromomaleimide 74 of 25%. 
Ohkubo and co-workers disclosed the synthesis of a number of the arcyriaflavins in 1996, 
starting from dibromo-N-methylmaleimide 66 and 6-benzyloxyindole 78 (Scheme 2.10).
11 
 
Scheme 2.10 Route towards arcyriaflavin C 9 
Maleimide 66 and indole 78 were initially coupled using lithium hexamethyldisilazide as base, 
resulting in the formation of a monoindole derivative, with the subsequent Boc-protection of 
the indolic nitrogen giving 79 (Scheme 2.10). Further base-induced coupling of 6-
benzyloxyindole 78 with intermediate 79 led to bisindolyl system 80. Deprotection of the Boc 
group of bisindole 80 using methylamine, followed by oxidative cyclisation using DDQ and 
then subsequent debenzylation to give ICZ 81 was achieved in a high yield of 81% over three 
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steps. Maleic anhydride 82 was accessed by treatment of N-methyl maleimide 81 with a 
solution of aqueous potassium hydroxide, with consequent conversion to arcyriaflavin C 9 
allowed using ammonium acetate. Ohkubo et al. were to later apply the same synthetic 
methodology to the synthesis of topo I inhibitors ED-110 42 and NB-506 43.
12 
A novel route to arcyriarubin A 10 was reported by Faul et al. in 1998, where initially, 
following the reaction of indole 83 with oxalyl chloride, treatment of the glyoxyl chloride 
intermediate with sodium methoxide resulted in the formation of glyoxylate 84 (Scheme 
2.11).
13
 Arcyriarubin A 10 was then formed in a quantitative fashion by means of an 
intermolecular Perkin-type condensation of glyoxylate 84 with acetamide 85 in the presence 
of a 1 M solution of potassium tert-butoxide in THF. Despite requiring a step more than that 
described by Hill et al. (Scheme 2.8), the overall yield was significantly improved at 93%. 
 
Scheme 2.11 Synthesis of arcyriarubin A 10 reported by Faul et al.
13 
Having established a new and efficient route towards BIMs such as arcyriarubin A 10, Faul et 
al. subsequently applied their condensation method approach towards the total synthesis of 
rebeccamycin 3 and other ICZs.
14
 Deprotonation of acetamide 86 with sodium hydride in 
acetonitrile, followed by treatment with α-1,2-anhydrosugar 87 resulted in the formation of β-
N-glycoside 88, which then underwent an intermolecular Perkin-type condensation (similar to 
that seen previously in Scheme 2.11) with glyoxylate 89 to form the hydroxyimide 90 
(Scheme 2.12). The ensuing in situ treatment of reaction intermediate 90 with concentrated 
aqueous HCl under reflux conditions afforded bisindolylmaleimide 91. Oxidative cyclisation 
of BIM 91 to form the ICZ core was then accomplished using palladium(II) triflate in DMF, 
with subsequent debenzylation of the glycosidic moiety by means of Pearlman’s catalyst 
ultimately resulting in the formation of REB 3. 
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Scheme 2.12 Total synthesis of rebeccamycin 3 by Faul et al.
14 
2.1.2.3 Synthesis of ICZs via 2,2’-bisindole derivatives 
Many routes to ICZs have been described using 2,2’-bisindole derivatives as precursors, with 
aromatisation to the pentacyclic core achieved by a variety of different methods. The synthesis 
of phenylarcyriaflavin A 96 was reported by Somei and Kodama in 1992, utilising the 
approach of a Diels-Alder cycloaddition.
15
 Lithiation of 1-methoxyindole 92 was first of all 
carried out by treatment with n-butyl lithium, forming 2-lithio-1-methoxyindole, which then 
underwent oxidative coupling using anhydrous copper(II) sulfate and ultrasound stirring under 
an oxygen atmosphere to yield 2,2’-bis(1-methoxyindole) 93 in a yield of 54% (Scheme 2.13). 
Catalytic hydrogenation of the methoxy functionalities  then gave 2,2’-bisindole 94, which 
was subjected to Diels-Alder cycloaddition with N-phenylmaleimide 95 in the presence of 
catalytic 10% palladium on carbon in o-dichlorobenzene under reflux conditions to give 
phenylarcyriaflavin A 96 in 30% yield. Without the presence of 10% Pd/C, the yield of ICZ 
96 was almost halved to 17%.  
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Scheme 2.13 Synthesis of phenylarcyriaflavin A 96 via 2,2’-bisindole 93 
In 1995, Pindur and co-workers also reported the synthesis of an ICZ using a 2,2’-bisindole 
intermediate, 6-benzyl-12,13-dimethylarcyriaflavin A 102, employing a different method to 
that used by Somei and Kodama.
14,16
 Two units of N-methyl indole 97 were initially 
oxidatively coupled using copper(II) chloride, having previously been lithiated by means of n-
butyl lithium, to afford 2,2’-bis(1-methylindole) 98 (Scheme 2.14). 
 
Scheme 2.14 Synthesis of 6-benzyl-12,13-dimethylarcyriaflavin A 102 
2,2’-Bisindole 98 was then reacted with dimethyl acetylenedicarboxylate 99 in the presence of 
aluminium trichloride in bromobenzene, furnishing 2,2’-bisindol-3-yl dimethyl maleate 100. 
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Following photochemical cyclisation of dimethyl maleate 100, treatment with benzylamine 
101 resulted in the formation of 6-benzyl-12,13-dimethylarcyriaflavin A 102 (Scheme 2.14). 
Wood et al. described the synthesis of K252c 13 and a whole range of other ICZs in 1997 
from the coupling 2,2’-bisindole 94 with different α-diazo-β-keto-γ-lactams.17 A mixture of 
bisindole 94 and diazolactam 103 in degassed pinacolone was treated with rhodium(II) acetate 
in a sealed tube at 120 
o
C, resulting in the formation of K252c 13, with the annulation posited 
to proceed via intermediates 104 and 105 (Scheme 2.15). The choice of degassed pinacolone, 
which is quite compatible with carbenoid chemistry, as solvent had a significant effect on the 
yield of ICZ aglycon 13, as when the reaction had been carried out in benzene, a yield of only 
3% was recorded.   
 
Scheme 2.15 Synthesis of K252c 13 from 2,2’-bisindole 94 
In 2005, de Koning and co-workers described the novel use of a metathesis reaction to fashion 
an ICZ core 109 starting from precursor 2,2’-bisindole 94 (Scheme 2.16).18 Standard 
Vilsmeier-Haack conditions on bisindole 94, followed by Boc-protection led to dialdehyde 
106. Wittig olefination of dialdehyde 106 then lead to the required dialkene precursor 107 for 
the subsequent use of metathesis. Exposure of dialkene 107 to Grubbs’ second generation 
catalyst 108 resulted in aromatisation to ICZ 109.    
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Scheme 2.16 Formation of ICZ 109 via metathesis reaction 
Another novel route towards ICZ alkaloids featuring 2,2’-bisindole precursors was divulged 
when Snieckus and Cai reported the use of a Stille cross-coupling strategy in the synthesis of 
ICZ 115 (Scheme 2.17).
19
 Initial attempts to fashion a 2,2’-bisindolyl bond between 
differentially N-protected 3-substituted indole coupling partners using Suzuki-Miyaura cross-
coupling protocol had proven to be unsuccessful prior to the use of the corresponding Stille 
tactic. 
 
Scheme 2.17 Route to ICZ 115 via metalation-cross coupling sequence 
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The Stille coupling of 2-bromo indolo-3-carboxamide 110 with 2-stannylated N-
carboxyindole 111 provided 2,2’-bisindole 112 in good yield, which upon treatment with 
Eschenmoser’s salt afforded 2-substituted gramine 113. The sequential reaction of bisindole 
113 with methyl iodide and potassium cyanide/18-crown-6 resulted in the formation of 
acetonitrile 114. Base-mediated cyclisation of intermediate 114, followed by the immediate 
methylation of the relatively unstable phenol gave ICZ 115. 
2.1.2.4 Utilisation of 3,3’-bisindolyl precursors towards unsymmetrical ICZs 
Orito et al. announced the availability of a new route towards the formation of unsymmetrical 
ICZs in 2007 when describing the synthesis of a series of N-protected ICZ aglycones.
20
 
Gramine methiodide 117 was initially coupled with 2-(1-benzyl-1H-indol-3-yl)acetonitrile 
116 using t-BuLi to afford bisindole precursor 118 in excellent yield of 96% (Scheme 2.18).   
 
Scheme 2.18 Route to N-benzylated ICZ 122 
Subsequent cyclisation of bisindole 118 by treatment with trifluoroacetic acid, followed by 
DDQ oxidation of the resulting cyclisation product gave ICZ 119, again in a high yield of 
93%. Reduction and condensation of ICZ 119 with 2,4,6-trimethoxybenzaldehyde 120, 
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followed by a second reduction using sodium borohydride resulted in the formation of N-
(2,4,6-trimethoxy)benzylamine 121. Carbonylation of benzylamine 121 was then carried out 
using palladium(II) acetate and copper(II) acetate in DMSO under a carbon monoxide 
atmosphere to give lactam 122. With each of the three nitrogen atoms of ICZ 122 bearing a 
different substituent, it has been postulated that this route could be prove useful in potential 
application to the synthesis of staurosporine 2 and related glycosidic ICZs. 
2.1.3 Formation of ICZ core via nitrene insertion 
The use of nitrene insertions to form the pentacyclic ICZ core has also been frequently 
documented in the literature. In one of the earliest examples, Raphael et al. described the 
synthesis of arcyriaflavin B 8 in 1983 by means of nitrene insertion following an initial Diels-
Alder cycloaddition (Scheme 2.19).
21
 2-Nitrocinnamaldehyde 123 was initially condensed 
with a Wittig reagent obtained from 4-methoxy-2-nitrobenzylbromide 124 to give 1,4-
diarylbutadiene 125. The neat thermal cycloaddition of butadiene 125 with maleimide 126 
was followed by oxidation with DDQ to give terphenyl imide 127. A double nitrene insertion 
of imide 127 allowed for the formation of the ICZ core, with ether cleavage by heating in 
molten pyridine hydrochloride subsequently yielding arcyriaflavin B 8. 
 
Scheme 2.19 Route towards arcyriaflavin B 8 via Diels-Alder cycloaddition 
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A new strategy towards ICZ ring systems was described in 2000, when Tomé and co-workers 
reported the synthesis of arcyriaflavin A 7 starting from commercially available 2-
nitrobenzaldehyde 128.
22
 Ketone 130 was initially formed by the Wittig reaction of aldehyde 
128 with corresponding keto-ylide 129, which was then treated with TBDMS triflate in the 
presence of triethylamine to afford diene 131. Diels-Alder cycloaddition of diene 131 with 
maleimide 126, followed by silyl ether hydrolysis, gave solely endo-cycloadduct 132 in 
quantitative yield (Scheme 2.20). 
 
Scheme 2.20 Synthesis of arcyriaflavin A 7 via Fischer indolisation 
Fischer indolisation of trione 132 with phenylhydrazine 133 subsequently yielded 
regioisomers 134 and 135 in a ratio of 2.2:1. After chromatographic separation of the 
regioisomers, aromatisation of major isomer 134 was effected using DDQ, with the final ring 
closure carried out via formal nitrene insertion using triethyl phosphite to give arcyriaflavin A 
7 (Scheme 2.20). 
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2.1.4 Palladium(0)-catalysed polyannulation 
In a relatively unique departure from the standard methodology of forming ICZs, a novel 
synthesis of N-benzyl arcyriaflavin A 72 featuring a palladium(0)-catalysed polyannulation 
was disclosed by Saulnier et al. in 1995.
23
 Treatment of diacetylene 136 with trifluoroacetic 
anhydride resulted in the formation of the corresponding bistrifluoroacetanilide 137 in high 
yield of 96% (Scheme 2.21).  
 
Scheme 2.21 Synthesis of ICZ 72 via palladium(0)-catalysed polyannulation 
The reaction of the generated acetanilide 137 with N-benzyldibromomaleimide 70 and 
anhydrous potassium carbonate in the presence of tetrakis(triphenylphosphine)-palladium(0) 
in dry acetonitrile led to the formation of N-benzyl arcyriaflavin A 72. In the synthesis of ICZ 
72, this highly interesting novel polyannulation reaction generates four bonds and three rings 
in a straightforward one-pot process.  
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2.2 Synthetic routes towards azaindolocarbazoles 
The incorporation of azaindolyl moieties into the ICZ pharmacophore represents a relatively 
new development in medicinal chemistry, with the first reported synthesis of an 
azaindolocarbazole (aza ICZ) detailed in 2002.
24
 As a result, there exists only a limited 
number of routes detailed in the literature towards these ICZ bioisosteres, meaning that further 
advancement of the synthetic accessibility of aza ICZs represents a privileged field to further 
explore the possibility of new chemotherapeutic agents.    
2.2.1 First reported synthesis of aza ICZs 
Routier et al. described the first synthesis of symmetrical and non-symmetrical 
azaindolocarbazole derivatives in 2002, invoking methodology that had its origins in 
Steglich’s first approach towards the BIM template (Section 2.1.2.2).7,24 Initially, the reaction 
of 7-azaindole 139 with N-methyl dibromomaleimide 66, using ethyl magnesium bromide in a 
mixture of toluene and DCM, resulted in the formation of C-3 alkylated derivative 140 
(Scheme 2.22). Previous utilisation of LiHMDS instead of the Grignard reagent had 
culminated only in substitution on the indolic nitrogen of 7-azaindole 139.  
 
Scheme 2.22 First described route to azaindolocarbazole 144 
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Following N-phenylsulphonyl protection of 3-substituted azaindole 140, reaction of 
intermediate 141 with the lithium salt of 7-azaindole 139 then generated 
bisazaindolylmaleimide 142 in moderate yield of 64%. Boc-protection of the free indolic 
nitrogen of BIM analogue 142, followed by the selective cleavage of the phenylsulphonyl 
group, afforded another bisazaindolylmaleimide 143. Oxidative photocyclisation of mono-Boc 
substituted 143 was carried out in the presence of molecular iodine, with a final deprotection 
step performed using formic acid then ultimately leading to aza arcyriaflavin A derivative 
144. The choice of protecting group for the photocyclisation step was seemingly crucial, with 
decomposition of starting materials observed when other substituents had been employed 
(Scheme 2.22). 
A similar approach was exercised in the synthesis of unsymmetrical aza ICZ 147, with the 
bioisosteric replacement of just one of the indole units of the ICZ pharmacophore with a 7-
azaindolyl moiety (Scheme 2.23).
24
 The lithio derivative of 7-azaindole 139 was coupled with 
2-bromo-3-(N-Boc-indol-3-yl)-1-methylmaleimide 145 to form maleimide 146 in 67% yield. 
Photocyclisation of maleimide 146, accompanied by Boc-deprotection using TBAF in THF 
under reflux conditions, effectuated the formation of monoaza arcyriaflavin A derivative 147. 
 
Scheme 2.23 Synthesis of first unsymmetrical aza ICZ 147 
2.2.2 Synthesis of 7-azarebeccamycin analogues 
In the wake of the work carried out by Routier et al., Prudhomme and co-workers 
implemented further progression of the azaindolocarbazole core towards the development of a 
series of azarebeccamycin derivatives which were to display biological properties of 
considerable interest.
24,25
 At first, beginning from previously synthesised precursors such as 
maleimide 146, Prudhomme et al. focused on N-glycosylation (Scheme 2.24).   
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N-Glycosylation of maleimide precursor 146 was carried out by means of a Mitsunobu 
reaction using 2,3,4,6-tetra-O-acetyl-α-D-glucopyranose 148 in the presence of DEAD and 
triphenylphosphine, yielding β-N-glycoside 149 (Scheme 2.24). Subsequent Boc-deprotection 
to afford glycosidic BIM analogue 150 was only achieved using formic acid, as the attempted 
use of tetrabutylammonium fluoride resulted in concomitant deacetylation of the sugar 
functionality and the formation of a sparingly soluble compound unsuitable for further 
elaboration. Oxidative photocyclisation of BIM analogue 150 and sequential cleavage of the 
acetate moieties using aqueous ammonium hydroxide in methanol finally furnished 
azarebeccamycin analogue 151.
25
  
 
Scheme 2.24 Route to azarebeccamycin derivative 151 
Substitution on the imide nitrogen of BIM analogue 150 was made possible via conversion to 
maleic anhydride intermediate 152 (Scheme 2.25). This was accomplished by the initial 
treatment of N-methyl maleimide 150 with aqueous sodium hydroxide in THF, followed by 
photochemical aromatisation to yield anhydride 152. Reaction of anhydride 152 with a range 
of amines, in this case hydrazine hydrate, allowed for the formation of a series of N-
substituted derivatives, such as N-amino maleimide 153.
26
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Scheme 2.25 Formation of N-amino maleimide aza-ICZ 153 
In order to fashion azarebeccamycin analogues containing two 7-azaindolyl units, Prudhomme 
et al. synthesised a series of bisazaindolylmaleimide precursors, such as N-benzyloxymethyl 
derivative 154, using similar methodology to that established previously by Routier et al.
24,27
 
Aromatisation of maleimide 154 under photochemical conditions lead to ICZ 155, with 
deprotection then carried out in two steps to give 7-aza REB analogue 156 (Scheme 2.26).
27 
 
Scheme 2.26 Synthesis of azarebeccamycin derivative 156 containing two azaindolyl units 
2.2.3 Routes to bridged 7-azarebeccamycin derivatives 
Prudhomme and co-workers found that bridged azarebeccamycin derivatives were relatively 
accessible from aza ICZs such as aglycone 147.
28
 The initial glycosidic linkage was formed by 
means of the coupling of 1-chloro-2-O-tosyl-3,4,6-tri-O-benzyl-α-D-glucopyranose 157 with 
aza ICZ 147 in the presence of potassium hydroxide and the phase transfer catalyst tris(2-(2-
methoxyethoxy)ethyl)amine (TDA-1) in acetonitrile (Scheme 2.27).    
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Scheme 2.27 Synthesis of 7-aza REB analogue 159 
Formation of the second N-glycosyl bond, affording bridged derivative 158, was achieved by 
subsequent treatment with sodium azide in DMF, though the yield was quite low at 12% over 
two steps. Debenzylation of the sugar group was carried out using boron tribromide in DCM, 
which gave bridged 7-aza REB analogue 159 in 90% yield (Scheme 2.27). 
 
Scheme 2.28 Route to bridged 7-aza REB analogue 165 
Using a similar but more efficient strategy, Prudhomme et al. later focused on forming the 
first N-glycosyl bond prior to the photochemical aromatisation of the aza ICZ (Scheme 
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2.28).
29
 A Mitsunobu coupling of maleimide 160 and 1-hydroxy-2-O-tosyl-3,4,6-tri-O-benzyl-
α-D-glucopyranose 161 led to the formation of N-glycoside 162 in high yield of 88%. 
Deprotection of the phenylsulphonyl group, followed by oxidative photocyclisation afforded 
aza ICZ 163. Bridging of the sugar moiety to the second indolic nitrogen was then carried out 
by reaction of aza ICZ 163 with sodium azide, with debenzylation consequently occurring by 
treatment with Pearlman’s catalyst, giving bridged glycoside 164. Finally, aminolysis using 
aqueous ammonium hydroxide in methanol allowed the formation of bridged 7-aza REB 
analogue 165.
29 
2.3.4 Synthesis of 5-azaindolocarbazoles 
A synthetic route towards 5-azaindolocarbazoles was reported for the first time by Coudert et 
al. in 2008, whereby a series of 5-aza ICZ derivatives were fashioned using two key steps: a 
Stille reaction and photochemical cyclisation (Scheme 2.29).
30 
 
Scheme 2.29 Synthesis of 5-aza ICZs 169 and 171 
Monobromoindolylmaleimide 166 was initially engaged in a Stille coupling reaction with 1-
Boc-3-trimethylstannyl-5-azaindole 167 to yield the 5-aza BIM analogue 168 in high yield of 
92%. Oxidative cyclisation of 5-aza BIM 168 in the presence of a tenfold excess of iodine led 
to the formation of 5-azaindolocarbazole 169, with the cleavage of the Boc group occurring 
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during workup of the reaction. The treatment of 5-aza ICZ 169 with dimethylaminoethylamine 
170 under reflux conditions subsequently furnished N-amino 5-aza ICZ 171 in 70% yield 
(Scheme 2.29).
30
  
 
Scheme 2.30 Route to glycosidic 5-aza ICZ 175 
The synthesis of glycosylated 5-aza ICZs was also examined, beginning with 5-aza BIM 168 
(Scheme 2.30). Glycosidic 5-aza BIM 173 was prepared by the initial Mitsunobu reaction of 
5-aza BIM 168 with tetrabenzyl-D-glucopyranose 172, followed by deprotection of the Boc 
group using formic acid at room temperature. Following photochemical cyclisation to yield 
the pentacyclic 5-aza ICZ core, debenzylation of 5-aza ICZ 174 using boron tribromide 
resulted in the formation of derivative 175, which bore an unexpected quaternary pyridine 
nitrogen atom.
30
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2.3 Targeted synthesis of bisindolylmaleimide analogues 
While extremely useful as precursors in the synthesis of ICZs, bisindolylmaleimide 
derivatives have served as target compounds in their own right as a result of excellent 
biological activities exhibited by some members of the class. The development of a number of 
BIM analogues as clinical candidates has meant that the synthetic elaboration of this family of 
compounds continues to be of major interest to medicinal chemists.  
2.3.1 Synthesis of macrocyclic BIM: ruboxistaurin 26 
The synthesis of a series of macrocyclic BIM analogues was disclosed by Jirousek et al. in 
1996, which would ultimately lead to the development of one member, ruboxistaurin 26, for 
clinical use in the treatment of diabetic peripheral retinopathy, as a specific inhibitor of PKC 
isoforms PKCβ1 and PKCβ2.
31
  
 
Scheme 2.31 Route towards ruboxistaurin 26 
Reaction of N-methyl-2,3-bisindolylmaleimide 68 with bisiodide 176 gave a mixture of 
macrocyclic products comprising of silyl ether 177 and alcohol 178 with a combined yield of 
78% (Scheme 2.31). Partial loss of the silyl protecting group during the reaction was deemed 
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inconsequential in terms of the overall synthesis as it was intended to be removed in the 
ensuing step. Base hydrolysis followed by an acidic work-up and subsequent treatment with 
1,1,3,3-hexamethyldisilazane resulted in the formation of bisindolylmaleimide macrocycle 
179. Mesylation of the alcohol moiety of BIM 179 was carried out using methanesulfonic 
anhydride, affording a mesylate intermediate which then underwent displacement with 
dimethylamine to give ruboxistaurin 26.
31
   
2.3.2 Route towards N-(azacycloalkyl) BIM: enzastaurin 27 
Further derivatisation of the BIM pharmacophore led to the discovery of another selective 
inhibitor of PKCβ, enzastaurin 27, which is currently undergoing clinical trials as a 
chemotherapeutic agent.
32
  
 
Scheme 2.32 Synthesis of enzastaurin 27 
Faul and co-workers initially carried out the in situ treatment of the hydrochloride salt of N-(1-
pyridin-2-yl methyl-piperidin-4-yl) indole 180 with oxalyl chloride and methanol to furnish 
glyoxylate 181 (Scheme 2.32). Utilising the same intermolecular Perkin-type condensation 
methodology previously developed within their group (Section 2.1.2.2), glyoxylate 181 was 
reacted with acetamide 182  to form BIM derivative enzastaurin 27.
13,32 
2.3.3 Accessing bisazaindolylmaleimide derivatives 
In incorporating 7-azaindolyl functionalities into the BIM pharmacophore, Kuo et al. 
synthesised a series of macrocyclic bisazaindolylmaleimides, such as derivative 30, from an 
N-methyl-2,3-dichloromaleimide unit 185 (Scheme 2.33).
33
 Trimethylstannane 184 was 
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formed from treatment of iodide 183 with trimethyltin chloride and n-BuLi in THF at -78 
o
C. 
A palladium cross-coupling reaction of stannane 184 with maleimide 185 then gave 
deprotected bisazaindolylmaleimide 186 in 41% yield. Subsequent alkylation of BIM 
analogue 186 with bismesylate 187 afforded N-methyl macrocycle 188, with further 
hydrolysis and aminolysis yielding macrocyclic bisazaindolylmaleimide 30.
33
   
 
Scheme 2.33 Synthesis of macrocyclic bisazaindolylmaleimide 30 
A route was also devised by Kuo and co-workers towards acyclic bisazaindolylmaleimides, 
beginning from 7-azaindole 139 (Scheme 2.34).
34
 The Grignard of precursor 139 was initially 
formed using ethylmagnesium bromide, which upon treatment with methyl oxalyl chloride 
afforded methyl 7-azaindole-3-glyoxylate 189. N-Alkylation of the indolic nitrogen of 
glyoxylate 189 with 3-(tert-butyldimethylsilyloxy)propyl bromide was then carried out in the 
presence of caesium carbonate in DMF, forming α-keto ester 190. Utilisation of standard 
Perkin-type conditions allowed for maleimide formation, in which ester 190 was condensed 
with 2-(N-ethyl-7-azaindolyl)acetamide 191 using potassium tert-butoxide in THF at 0 
o
C. 
Application of concentrated aqueous HCl resulted in cleavage of the silyl protecting group, 
yielding acyclic bisazaindolylmaleimide 192.
34
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Scheme 2.34 Route towards acyclic bisazaindolylmaleimide 192 
2.3.4 Synthesis of 4-azaindolyl-indolylmaleimides 
In 2009, Hu and co-workers, in the search for novel GSK-3β inhibitors, reported the synthesis 
of a series of BIM analogues bearing a 4-azaindolyl moiety.
35
 The reported compounds 
contained a maleimide ring substituted either at the azaindolic nitrogen (as seen for derivative 
196) or at the 3-position of the 4-azaindolyl unit (e.g. analogue 200). Reaction of indolyl-3-
maleimide intermediate 193 with 4-azaindole 194 in the presence of LDA in THF furnished 
protected BIM analogue 195 (Scheme 2.35). Respective treatment with TBAF and ammonium 
acetate then afforded desired 4-azaindolyl-indolylmaleimide 196. 
 
Scheme 2.35 Synthesis of 4-azaindolyl-indolylmaleimide 196 
To achieve the formation of 4-aza BIM analogue 200, N-methyl-4-azaindole 197 was initially 
reacted with aluminium trichloride and ethyl oxalyl monochloride, resulting in glyoxylate 198 
(Scheme 2.36). Employing similar methodology to Faul and co-workers (Section 2.1.2.2), 
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condensation of acetamide 199 with glyoxylate 198, followed by removal of the silyl ether 
using TBAF, afforded the formation of 4-azaindolyl-indolylmaleimide 200 in a poor yield of 
12%.
13,35
   
 
Scheme 2.36 Intermolecular Perkin-type condensation towards 4-aza BIM analogue 200  
 
2.4 Routes towards heteroaryl ICZ analogues 
Diversification of the ICZ pharmacophore has not just been limited to the bioisosteric 
replacement of indole units with azaindole moieties (Section 2.2) or the development of 
bisindolylmaleimides as clinical candidates (Section 2.3). Continued efforts to potentiate the 
biological effects of ICZ analogues has seen the incorporation of a wide range of aryl subunits 
in place of one of the indole functionalities, thus helping to broaden our knowledge of the 
associated structure-activity relationships. 
2.4.1 Cyclometalation of ICZ analogues 
The use of ICZ derivatives as organometallic enzyme inhibitors has been explored by 
Meggers et al. in the synthesis of a series of pyrido[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-
diones as constituents of half-sandwich ruthenium complexes (e.g. complex 210).
36
 Reaction 
of 2-acetylpyridine 201 and 4-methoxyphenylhydrazine hydrochloride 202 lead to the 
formation of hydrazone 203, which then underwent Fischer indolisation using trimethylsilyl 
polyphosphate as Lewis acid (Scheme 2.37). Demethylation in the presence of boron 
tribromide led to the formation of 5-hydroxypyridoindole 204. Following TBDMS protection, 
lithiation and subsequent reaction with dibromomaleimide 206 afforded monobromo 
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intermediate 207, which was then subjected to photochemical cyclisation to yield carbazole 
208. Cyclometalation of TBDMS-protected ligand 208 was achieved upon reaction with 
ruthenium precursor 209 in the presence of potassium carbonate. Finally, TBAF-induced silyl 
deprotection resulted in the formation of carbazole ruthenium complex 210.
36 
 
Scheme 2.37 Synthesis of carbazole ruthenium complex 210 
2.4.2 Aza derivatives of isogranulatimide 211 
The synthetic access to a series of analogues of the natural product isogranulatimide 211 
bearing an azaindolyl moiety instead of an indolyl subunit was described by Prudhomme et al. 
in 2007.
37
 One of the routes reported involved the treatment of 3-substituted azaindole 212 
with imidazole magnesium bromide to yield diaryl maleimide adduct 213, with concomitant 
loss of the carbamate protecting group (Scheme 2.38). Following another Boc-protection, 
owing to the insolubility of maleimide 213, cyclisation under photochemical conditions led to 
products 214 and 215, which were separated by chromatography. Further oxidation of both 
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derivatives using manganese dioxide, followed by Boc-deprotection using formic acid, 
afforded aza analogues 216 and 217 of isogranulatimide 211 respectively.
37
  
 
Scheme 2.38 Accessing 7-azaindolyl derivatives 216 and 217 of isogranulatimide 211 
2.4.3 Synthesis of 3,4-diaryl-2H-pyrrole-2-ones 
In a bid for the rational design and synthesis of novel vascular endothelial growth factor 
receptor (VEGFR) inhibitors, Peifer and co-workers reported a series of 3,4-diaryl-2H-
pyrrole-2-ones in 2008, based on a previously synthesised lead compound.
38,39
 For example, 
the fashioning of 3-(3,4,5-trimethoxyphenyl)-4-(indolyl)-2H-pyrrole-2-one 220 was described 
from precursor 218 in an adaptation of Faul’s Perkin-type condensation methodology 
(Scheme 2.39).
13
 The cyclisation of precursor 218 to yield pyrrolone 219 was carried out 
under thermodynamic Knoevenagel reaction conditions, with the 2-
(trimethylsilyl)ethoxymethyl (SEM) protecting group on the indolic nitrogen deemed crucial 
towards formation of the desired product. It was discovered that as a consequence of having 
no protecting group in place, deprotonation of the indolic nitrogen led to anionic 
delocalisation, therefore resulting in deactivation of carbonyl activity necessary for the 
condensation to occur. The removal of the SEM protecting group to yield target compound 
220 subsequently proved to be much more difficult than expected. For example, the 
application of commonly-used deprotecting agent TBAF resulted in the oxidation of the 
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pyrrolone ring to a pyrrole-2,5-dione group. Reaction of SEM-protected 219 with HCl in tert-
butyl alcohol ultimately resulted in the formation of desired pyrrolone 220 (albeit in low yield 
of 10%), as well as hemiaminal 221. Following separation and isolation, it was possible to 
convert byproduct 221 to target compound 220 by treatment with sodium methoxide in 
methanol (Scheme 2.39).
39 
 
Scheme 2.39 Synthesis of 3-(3,4,5-trimethoxyphenyl)-4-(indolyl)-2H-pyrrole-2-one 220 
2.4.5 Synthesis of 7-azaindolyl-heteroarylmaleimides 
Expanding on the syntheses of acyclic and macrocyclic bisazindolylmaleimides (Section 
2.3.3), Kuo et al. reported the development of a series of 7-azaindolyl heteroarylmaleimides, 
effecting the replacement of one of the 7-azaindolyl units with a diverse range of aryl 
cogeners.
40
 One of the approaches described involved the initial oxidation and N-alkylation of 
7-azaindole-3-acetonitrile 222 to afford acetamide 223 (Scheme 2.40). The reaction of 
acetamide 223 with diethyl oxalate in the presence of potassium tert-butoxide then gave 4-
hydroxy maleimide 224, which was then treated with oxalyl chloride to yield key intermediate 
225, from which a range of 7-azaindolyl-heteroarylmaleimide derivatives could be fashioned. 
For example, the Stille coupling of chloride 225 with 2-tributylstannylpyrazine 226 was 
effectuated in the presence of Pd(P(t-Bu)3)2. Removal of the silyl protecting group using 
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TBAF subsequently led to desired 3-(1-(3-hydroxypropyl)-7-azaindolyl)-4-pyrazin-2-yl-
pyrrole-2,5-dione 227.
40 
 
Scheme 2.40 Route to 3-(7-azaindolyl)-4-pyrazin-2-yl-maleimide 227 
 
2.5 Conclusion 
Much progress has been observed in the development of synthetic routes to indolo[2,3-
a]carbazole derivatives over the past thirty years. Initial efforts were focused mainly on the 
use of Fischer indolisation methodology to achieve the pentacyclic ICZ core, however many 
limitations arise from this approach, such as regiochemical constraints or the sensitivity of 
reaction intermediates to acidic conditions employed. Burgeoning scientific interest in these 
alkaloids has meant that a number of novel conduits, such the palladium(0)-catalysed 
polyannulation method proffered by Saulnier and co-workers (Section 2.1.4), were uncovered 
and detailed in the literature. The most widely utilised techniques remain firmly rooted in the 
cyclisation of bisindolyl congeners towards the central benzenoid ring of the ICZ template, 
due to the fundamental accessibility of the precursors, and the well-established precedence of 
a variety of coupling modes extended by Steglich and Faul, amongst others (Section 2.1.2). 
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In contrast, the advancement of strategies towards bioisosteric azaindolocarbazole derivatives 
has been far more limited and underdeveloped. Of the relatively few approaches detailed, 
Prudhomme and Routier devised means of access to azaindolylmaleimide progenitors via an 
adaptation of Steglich’s substitution procedure of indolyl subunits with halogenated 
maleimides, with subsequent aromatisation to aza-ICZ systems (Section 2.2). Kuo and co-
workers, with specific interest in bisazaindolylmaleimides, examined the usage of Stille 
coupling reactions and Perkin-type condensation techniques enroute to the progression of a 
series of novel BIM analogues (Section 2.3.3). 
Given the highly appealing biological modes of action attributed to a number of aza ICZ 
derivatives, and the conferring of unique selectivity profiles relative to analogous ICZs 
(Sections 1.3.1.5 and 1.3.2.3), the exploration of new synthetic routes to this chemical family 
is of paramount interest to the further enhancement of this area of medicinal chemistry.   
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3.0 Aims and Objectives 
3.1 Overview of project 
The isolation of staurosporine 2 in 1977 proved to be a significant milestone in the field of 
medicinal chemistry, with ensuing research yielding a number of indolocarbazole derivatives 
as clinical candidates for the treatment of cancer and other diseases.
1
 In terms of synthetic 
elaboration, the incorporation of 7-azaindolyl subunits into the ICZ pharmacophore represents 
a highly appealing and incipient paradigm with which to pursue the development of novel 
chemotherapeutic agents. Contrary to the abundance of indolyl congeners, the 1H-pyrrolo[2,3-
b]pyridine nucleus is considerably less abundant in natural products. One such compound, 
variolin B 35, has been reported to display excellent antiproliferative properties in human 
tumour cell cultures, along with a synthetic analogue meriolin 3 36 (Section 1.3.1.7).
2,3
 
 
3.2 Biological significance of 7-azaindole in ICZ template       
 
Figure 3.1 Structures of meriolin 3 36, bisazaindolylmaleimide 30 and aza REB derivative 46 
Appropriation of 7-azaindolyl subunits into the framework of ICZ derivatives has previously 
been shown to significantly alter the pharmacological properties of these compounds. In 2003, 
Kuo et al. discovered that the introduction of 7-azaindolyl functionalities into macrocyclic 
bisindolylmaleimide structures (such as 30) conferred a dramatic increase in selectivity for 
glycogen synthase kinase-3 (GSK-3) due to additional discrete H-bonding (Section 1.3.1.5).
4
 
Also in 2003, Prudhomme and co-workers reported greater cytotoxic selectivity of a series of 
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azarebeccamycin derivatives (e.g. aza ICZ 46) for a number of cancer cell lines relative to 
their indolyl analogues (Section 1.3.2.3).
5
 Remarkably, given the scope for potential 
enhancement of biological profiles, there have been no aza analogues of STA 2 or UCN-01 4 
reported to date. 
    
3.3 Development of synthetic targets 
The incorporation of 7-azaindolyl subunits and novel F-ring constituents into the ICZ template 
forms the central tenet of our program of fragment-based drug discovery. Thus, the key aim in 
our synthetic strategy is to develop novel routes towards these alkaloid derivatives and to 
synthesise new analogues of biological significance.   
Our initial focus assumes the chemical elaboration of bisindolylmaleimide scaffold 10, a key 
bioactive precursor to the ICZ core, due to the prodigious chemotherapeutic potential 
exhibited by members of the class.
6
 Previous endeavour within this area has primarily 
examined N-alkylation of the indolic nitrogens or heteroaryl derivatisation, shown in Figure 
3.2. For example, the use of benzofuranyl functionalities by Kozikowski et al. led to the 
synthesis of a series of BIM analogues, such as compound 228, which display high selectivity 
for GSK-3β.7 
 
Fig. 3.2 Structures of arcyriarubin A 10 and benzofuranyl analogue 228 
Expanding on the theme of heteroaryl derivatisation of BIM derivatives steered Peifer et al. to 
3,4,5-trimethoxyphenyl analogues 32 and 230 from lead molecule 229, a potent VEGFR 
inhibitor (Figure 3.3).
8
 Modification of the maleimide moiety of 229 towards these isomeric 
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lactam derivatives produced strikingly different biological profiles. Though derivative 32 was 
found to potently inhibit VEGFR, its isomer 230 displayed significantly weaker activity, thus 
illustrating the importance of the orientation of the F-ring hydrogen bonding units within the 
active site.   
 
Fig. 3.3 Structures of 3,4,5-trimethoxyphenyl BIM derivatives 229, 32 and 230 
Previous work within our research group has examined novel F-ring modification of the ICZ 
template towards 6-membered heterocyclic congeners such as bisindolylpyrimidinone 231.
9
 
This attractive approach towards the development of new clinical candidates offers the 
possibility of enhancing existing physicochemical properties, such as the solubility and 
bioavailability of ICZs containing maleimide moieties. In extending this purpose towards the 
inclusion of 7-azaindolyl bioisosteres, as with general structure 232, modulation of the ICZ F-
ring can also be used as a vehicle by which to diversify H-bonding networks in ligand-target 
complexes. 
 
Fig. 3.4 Structures of bisindolylpyrimidinone 231 and general azaindole scaffold 232 
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3.4 Synthetic focus and application 
The initial phase of diversity-oriented synthesis towards novel aza ICZ derivatives shall 
undertake to expand the VEGFR inhibitor template 32 towards novel isomeric congeners 233 
and 234, incorporating a 7-azaindolyl moiety and F-ring modulation. Concomitant to 
possessing the ability to mimic the conformation of the key lactam functionality, 
derivatisation of the aminopyrazole ring of 233 and 234 provides an excellent platform with 
which to probe active site interactions. Comparison of the biological profiles of both sets of 
isomers should afford an excellent basis for SAR study, given the different F-ring orientations 
within the binding pocket. 
 
Fig. 3.5 7-Azaindolyl analogues 233 and 234 of VEGFR inhibitors 32 and 229 
Further F-ring modification of the BIM pharmacophore should proffer a useful mechanism by 
which to further explore the essential protein-ligand interactions necessary for biological 
activity. We propose that accessing analogues such as aminopyrazole 235 and isoxazolone 
236 shall result in a promising diversification of existing H-bonding networks within this 
structural class of compounds. 
 
Figure 3.6 Structures of aminopyrazole 235 and isoxazolone 236 BIM derivatives 
Chapter 3 | Aims and Objectives 
 
 
[85] 
 
The ultimate goal of this work lies in the accomplishment of new routes towards novel 
azaindolocarbazoles of general structure 237, as there is a significant paucity in the literature 
with regard to these alkaloids in comparison to ICZs. 
 
Fig. 3.7 Structure of K252c 13, REB 3 and general aza ICZ 237 
Little work has been carried out in this field with regard to alteration of the F-ring throughout 
the ICZ family, such as for K252c 13 and rebeccamycin 3. It is envisaged that such 
modification of aza ICZ 237, with the retention of an amide functionality, has the potential to 
confer more favourable pharmacological properties, such as increased bioavailability, greater 
stabilisation of the topo I-DNA complex and the exploitation of discrete differences in the 
kinase active site. Adaptation of the F-ring in order to encompass six-membered heterocycles, 
such as derivative 238, represents a synthetic strategy carried out for the first time within this 
research group.
10,11
 Given the rationale for use of 7-azaindolyl moieties in the ICZ template, 
the synthesis of aza analogues, such as 239, is of primary interest in this body of work.    
 
Fig. 3.8 Structures of novel ICZs 238 and 239 containing 6-membered F-rings 
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4.0 Chemical Results and Discussion 
4.1 Initial strategy towards novel azaindolocarbazole derivatives 
The inceptive aim of our project was to establish a route to novel BIM analogues containing a 
7-azaindolyl moiety, such as 232 and 240, replacing the maleimide ring with other 
heterocyclic congeners. Retrosynthetic analysis allowed the identification of key versatile 
intermediates β-keto ester 241 and β-keto nitrile 242, from which it would be possible to 
access a range of BIM derivatives (Scheme 4.1). It was further theorised that intermediates 
241 and 242 could be reached by the coupling of acyl chloride precursor 243 with either 
nitrile 244 or ester 245. 
 
Scheme 4.1 Retrosynthetic analysis to access aza BIM derivatives 232 and 240 
The basis of this formative strategy had its origins in work concomitantly carried out by Braňa 
et al. and our research group towards derivatives of the BIM template.
1-3
 In 2006, Braňa and 
co-workers described the synthesis of β-keto ester 248, which was initially obtained from the 
coupling of acyl chloride 246 and ester 247 in the presence of LDA (Scheme 4.2). A series of 
pyrazolones, such as derivative 249, were fashioned from intermediate 248 following 
treatment with the appropriate hydrazine in the presence of camphoric acid.
1
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Scheme 4.2 Route towards pyrazolone 249 described by Braňa et al.1 
Contemporary work within our research group, which was focused on the realisation of 
bisindolyl ICZ derivatives, utilised methyl ester 250 in place of ethyl ester 247 (Scheme 
4.3).
2,3
 Subsequent optimisation of reaction conditions led to the formation of β-keto ester 251 
in a high yield of 80%. Illustrating the versatility of these key intermediates, 
cyclocondensation of oxopropanoate 251 with guanidine led to bisindolylpyrimidinone 231, 
with subsequent photochemical cyclisation affording ICZ 238. 
 
Scheme 4.3 Synthesis of ICZ 238 via bisindolylpyrimidinone 231
2,3 
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In keeping with our goal of developing novel aza ICZ derivatives, we sought to develop 
innovative synthetic routes to better exploit the outstanding clinical potential proffered by 
members of this class of compounds. Initially, we focused on a strategic modification of the 
route used within our laboratory to access β-keto ester 251 (Scheme 4.3), whereby the 
inclusion of a 7-azaindolyl moiety would allow access to a range of intermediates such as 241 
and 242. Such an approach would differ from previously documented syntheses of aza ICZ 
derivatives, which have primarily employed methods such as Grignard or Stille coupling at 
the 3-position of 7-azaindolyl subunits (Sections 2.2, 2.3.3 and 2.3.4).
4,5
 A program of 
diversity oriented synthesis from these intermediates would extend our knowledge of the F-
ring binding motifs associated with ICZ and BIM derivatives. The accessibility of novel 
heterocyclic congeners of the ICZ pharmacophore is key to the exploration of new H-bonding 
contacts within targeted enzymatic active sites. 
  
4.2 Routes to azaindolyl precursors and key intermediates 
While a number of azaindolyl subunits are freely available to purchase commercially, there 
are relatively high costs associated with these molecular building blocks compared to their 
indolyl analogues. Therefore, a cost-effective synthetic route to these precursors was 
necessary for the significant undertaking involved with this project.  
4.2.1 Synthesis of 7-azaindolyl precursors 
In order to achieve β-keto ester intermediate 241, it was first of all necessary to obtain the 
precursor 7-azaindolyl-3-carboxylic acid 252 (Scheme 4.4). 
 
Scheme 4.4 7-Azaindolyl precursor 252 of β-keto ester 241 
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In 2003, enroute to the industrial scale synthesis of an antitussive drug, Allegretti et al. 
reported the fashioning of 7-azaindolyl-3-carboxylic acid 255 over five steps from the 
inexpensive starting materials of succinonitrile 253 and ethyl formate 254 (Scheme 4.5).
6
 It 
was subsequently decided to adapt this route to the laboratory scale required for our needs. 
 
Scheme 4.5 Route towards 7-azaindolyl-3-carboxylic acid 255 reported by Allegretti et al.
6 
The first step in this synthesis was the condensation of succinonitrile 253 and ethyl formate 
254 under a nitrogen atmosphere in the presence of sodium methoxide in toluene to yield the 
corresponding salt of 2-(hydroxymethylene)succinonitrile 256 (Scheme 4.6). The cream-
coloured mixture was treated in situ with t-butyl amine and acetic acid and subsequently 
heated to reflux, resulting in the formation of enaminonitrile 257 as a brown solid in 81% 
yield. Base-catalysed intramolecular condensation of intermediate 257 was then carried out 
using potassium hydroxide in ethanol to give pyrrole 258 as a light brown crystalline material 
in a yield of 65%. Use of the t-butyl protecting group was noted to be unusual, as it is not 
normally utilised as protecting group for indolic or pyrrolic nitrogens.
6 
 
Scheme 4.6 Synthesis of pyrrole 258 from succinonitrile 253 and ethyl formate 254 
Completion of the pyridine functionality of the 7-azaindolyl nucleus was afforded by the 
reaction of pyrrole 258 with 1,1,3,3-tetramethoxypropane in the presence of a catalytic 
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amount of p-toluenesulfonic acid, with the driving force for the completion of the reaction 
being the azeotropic removal of the methanol by-product (Scheme 4.7). Deprotection of 
azaindole 259 was achieved using three equivalents of the Lewis acid, aluminium trichloride, 
in chlorobenzene under reflux conditions, forming 3-cyano-7-azaindole 260 as an off-white 
solid in 81% yield. Previous use of benzyl protecting groups had been described by the 
authors to be fruitless when deprotection was required.
6
  
 
Scheme 4.7 Synthesis of 3-cyano-7-azaindole 260 
The pyridine functionality of a 7-azaindolyl subunit gives rise to a characteristic set of signals 
in 
1
H NMR spectra, corresponding to the three adjacent aromatic protons. The C-H5 proton is 
almost always the most shielded of the three, and is observed by a doublet of doublets at 7.22 
ppm in the case of azaindole 259 (Figure 4.1).  
 
Fig. 4.1 Aromatic region of 
1
H NMR spectrum of azaindole 259 (CDCl3, 300 MHz)  
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While the other two aromatic protons are also split into distinct doublets of doublets, they are 
easily distinguishable by their coupling constants, with that of the C-H4 proton being almost 
twice that of the C-H6 (8.0 and 4.7 Hz respectively in the case of azaindole 259). 
Depending on the reaction conditions, 3-cyano-7-azaindole 260 could either be hydrolysed to 
7-azaindolyl-3-carboxylic acid 255 or converted to 7-azaindole 139, another useful precursor 
(Scheme 4.8). Treatment of nitrile 260 with concentrated aqueous hydrochloric acid at a 
controlled temperature of 70 
o
C led to the formation of carboxylic acid 255 as a white solid in 
91% yield. The use of harsher reaction conditions, i.e. heating to reflux for 48 hours, led to the 
formation of 7-azaindole 139 in 62% yield via intermediate decarboxylation of acid 255. 
 
Scheme 4.8 Synthesis of 7-azaindole 139 and 7-azaindolyl-3-carboxylic acid 255 
4.2.2 Initial routes towards β-keto ester intermediates 
The use of 7-azaindolyl-3-carboxylic acid 255 as a precursor towards the formation of β-keto 
ester 263 was attempted via a number of base-mediated coupling methods with indolyl ester 
250 (Scheme 4.9). 
4.2.2.1 Attempted base-mediated condensation 
Initially, esterification of commercially available indole-3-acetic acid 261 was achieved 
following treatment with dimethyl carbonate (serving as methylating agent) in the presence of 
potassium carbonate, affording N-methyl ester 250 as a golden oil in 84% yield (Scheme 
4.9).
7
 7-Azaindolyl acyl chloride 262 was then generated in quantitative yield as a yellow 
solid following stirring of acid 255 in excess thionyl chloride with a few drops of DMF at 
room temperature. Employing the same base-mediated methodology described by Braňa et al. 
and previously utilised within our research group, the coupling of ester 250 with acyl chloride 
262 to form β-keto ester 263 was attempted.1-3 A solution of N-methyl ester 250 was added to 
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a vessel containing 2.2 equivalents of LDA in dry THF at -78 
o
C under a nitrogen atmosphere, 
with the resulting mixture maintained at this temperature for one hour. A suspension of acyl 
chloride 262 in THF was then added to the reaction vessel, containing the corresponding α-
anion of ester 250, in a dropwise manner. 
 
Scheme 4.9 Attempted synthesis of β-keto ester 263 
Upon completion of the additions, the dark mixture was allowed to warm to room temperature 
over a period of 14 hours. Following workup, analysis of the crude product revealed that β-
keto ester 263 had not formed, with starting material primarily identified. Systematic variation 
of the reaction conditions, such as using different equivalents of base and acyl chloride 262, 
similarly did not result in the desired outcome. 
4.2.2.2 Utilisation of N-protected acyl chloride 
Having been unable to access β-keto ester 263, the next attempted route involved the use of N-
protected acyl chloride 266 towards the synthesis of β-keto ester 267 (Scheme 4.10). 
Methylation of 3-cyano-7-azaindole 260 using sodium hydride and iodomethane in DMF at 0 
o
C gave N-methyl-3-cyano-7-azaindole 264 in 68% yield, which was then hydrolysed to 
carboxylic acid 265 using concentrated aqueous HCl. Treatment of acid 265 with oxalyl 
chloride in DCM led to the formation of acyl chloride 266 as a white solid in quantitative 
yield. Using a similar procedure to that described in Section 4.2.2.1, acyl chloride 266 was 
added to the anion of indolyl ester 250 at -78 
o
C under an inert atmosphere, with the resulting 
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mixture being allowed to warm to room temperature overnight. However, analysis of the 
crude product revealed that the desired β-keto ester 267 had not been formed. 
In fact, limited formation of the self-condensation product 268 of ester 250 was detected by 
spectroscopic analysis of the crude mixture, illustrating the lack of reactivity of azaindolic 
electrophile 266. 
 
Scheme 4.10 Attempted route towards β-keto ester 267 
4.2.2.3 Claisen condensation approach 
An approach to β-keto ester 267 using Claisen condensation conditions was next to be 
implemented (Scheme 4.11).  
 
Scheme 4.11 Attempted Claisen condensation approach towards β-keto ester 267  
Conversion of carboxylic acid 255 to N-methyl methyl ester 269 was achieved in 74% yield 
following treatment with dimethyl carbonate and potassium carbonate in DMF. Subsequent to 
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the deprotonation of ester 250 using sodium methoxide in methanol, a solution containing 
azaindolic ester 269 was slowly added, with the resulting reaction mixture then allowed to stir 
at room temperature for four hours. Once more however, the desired β-keto ester 267 was not 
formed, with only the presence of starting materials detected in analysis of the crude product 
mixture. Modification of the experimental conditions, such as varying the equivalents of 
starting materials and increasing the reaction temperature to reflux, again could not effect a 
desirable outcome. 
4.2.2.4 Activation of acid 265 using 1,1’-carbonyldiimidazole 
The use of a CDI-activated carboxylic acid instead of an acyl chloride was next to be 
examined in the coupling step towards β-keto ester 267 (Scheme 4.12). 1,1’-
Carbonyldiimidazole (CDI) was added to a solution of acid 265 in DMF, with the resulting 
mixture heated to 50 
o
C for 1.5 hours before then being cooled to -10 
o
C. Indolyl ester 250 
was subsequently added, followed by sodium hydride in a portionwise manner over a 20 
minute period. The reaction mixture was then stirred at -10 
o
C for 30 minutes before being 
allowed to warm to room temperature over 3 hours. Upon workup, analysis of the crude 
product showed that the desired β-keto ester 267 had not formed and that once more, the self-
condensation product 268 of ester 250 was present along with unreacted starting material.  
 
Scheme 4.12 Activation of carboxylic acid 265 using CDI 
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4.2.3 N-Benzyl protecting group on 7-azaindolyl moiety 
It was clear that the problem with the coupling reactions lay with the 7-azaindolyl 
functionality, as the employment of analogous indolyl electrophiles had previously proven to 
be successful (Section 4.1).
1-3
 As evidence of the self-condensation of indolyl ester 250 
demonstrated the suitable nucleophilicity of the anion, our focus turned towards the solubility 
of the 7-azaindolyl subunit. Thus, instead of a methyl protecting group, the use of an N-benzyl 
group was pursued as a means to bestow greater organic solubility (Scheme 4.13). 
Benzylation of 3-cyano-7-azaindole 260 was carried out using sodium hydride and benzyl 
bromide in DMF, forming the N-protected product 270 as an off-white solid in 72% yield. 
Hydrolysis of the nitrile functionality of azaindole 270 using concentrated aqueous HCl then 
afforded carboxylic acid 271 in high yield of 94%. Treatment of a suspension of acid 271 in 
DCM with 2.1 equivalents of oxalyl chloride at room temperature led to the formation of acyl 
chloride 272 as a white solid in quantitative yield. It was observed that the characteristic IR 
carbonyl stretch shifted from 1689 cm
-1
 in acid 271 to 1739 cm
-1
 in acyl chloride 272. 
 
Scheme 4.13 Route towards successful formation of β-keto ester 273 
Employing the methodology of Braňa et al., a partial suspension of acyl chloride 272 in THF 
was added to the anion of ester 250 in THF at -78 
o
C under a nitrogen atmosphere, with the 
resulting mixture then allowed to warm to room temperature overnight.
1
 Following workup, 
spectroscopic analysis of the crude residue revealed that the desired β-keto ester 273 had been 
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formed, with purification by flash column chromatography affording the pure product 273 as 
an orange/brown crystalline solid in 37% yield. 
The two benzylic CH2 protons of β-keto ester 273 are nonequivalent, leading to an AB system 
in the 
1
H NMR spectrum (Figure 4.2). The two doublets arising from the geminal coupling (J 
= 15.0 and 15.1 Hz respectively) display a classic distortion of peak heights associated with 
AB systems, i.e. an increase in intensity of the inner peaks. This contrasts with the 
1
H spectra 
of nitrile 270 and carboxylic acid 271, in which the same protons, HA and HB, give rise to a 
singlet in each case. The lone Hα proton of ester 273 displays a chemical shift of 5.62 ppm, 
which is seen to be characteristic across similar β-keto esters. Interesting to note also is the 
effect of the β-keto ester functionality on the 7-azaindolyl aromatic protons in 273 relative to 
the carboxylic acid of precursor 271. The C-H2’ proton becomes more shielded, moving from 
a multiplet between 8.33-8.37 ppm to 7.88 ppm in ester 273, while in contrast, C-H4’ becomes 
more deshielded, shifting to 8.65 ppm. No significant change was observed for the C-H5’ and 
C-H6’ protons.  
 
Fig. 4.2 Expansion of aromatic region: 
1
H NMR spectrum of β-keto ester 273               
(CDCl3, 300 MHz)  
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4.2.4 Temperature studies with N-methyl acyl chloride 266 
Given the successful formation of β-keto ester 273 (Section 4.2.3), it was concluded that the 
original problems encountered with the coupling step had resulted not from the lack of 
reactivity of the 7-azaindolyl subunit, but rather as a result of solubility. Calculation of the 
partition coefficient (ClogP) of acid chlorides used within the group indicated that N-methyl 
acyl chloride 266 was considerably more polar than the other acid chlorides utilised (Figure 
4.3).    
 
Fig. 4.3 Structures and calculated partition coefficients of acyl chlorides 246, 266 and 272 
While indolyl acyl chloride 246 had previously been employed within our laboratory in the 
proficient synthesis of analogous β-keto esters (Section 4.1), utilisation of 7-azaindolyl acyl 
chloride 266 under similar conditions could not effectuate a successful outcome, despite 
numerous attempts. The introduction of a benzyl protecting group, seen for acyl chloride 272, 
finally led to the successful attainment of a viable β-keto ester 273 containing a 7-azaindolyl 
moiety. Ultimately, after much examination of experimental parameters, it was found that 
increasing the reaction temperature immediately after the addition of acyl chloride 266 
resulted in the successful formation of desired oxopropanoate 267 (Scheme 4.14).  
 
Scheme 4.14 Synthesis of β-keto ester 267 
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Subsequent optimisation afforded β-keto ester 267 in a yield of 42% as a yellow crystalline 
solid when the reaction vessel temperature was increased from -78 
o
C to 35 
o
C after the final 
addition of acyl chloride 266. The development of this methodology was to prove vital in the  
synthesis of a number of other key aza ICZ precursors (Sections 4.2.5, 4.2.6, 4.2.8 and 4.2.9).  
4.2.5 Synthesis of β-keto nitrile intermediate 276 
Having successfully accessed β-keto esters 267 and 273 containing 7-azaindolyl 
functionalities, the attainment of other useful intermediates was examined. Accessing β-keto 
nitrile 276 represented one such judicious route (Scheme 4.15). Reaction of commercially 
available indole-3-acetonitrile 274 with sodium hydride and iodomethane in DMF at 0 
o
C led 
to the formation of N-methyl indole-3-acetonitrile 275 as an off-white solid in 84% yield. 
After stirring acetonitrile 275 in a solution of LDA in THF at -78 
o
C for 1 hour under a 
nitrogen atmosphere, a suspension of acyl chloride 266 in THF was added in a dropwise 
manner. 
 
Scheme 4.15 Route towards β-keto nitrile 276 
The temperature of the vessel was then raised to 35 
o
C upon completion of the addition, with 
the reaction subsequently allowed to stir at this temperature overnight. Following quenching 
of the reaction and workup, purification of the crude brown residue by flash column 
chromatography led to the isolation of oxopropanenitrile 276 as a reddish/brown solid in 54% 
yield. 
4.2.6 Synthesis of bis-7-azaindolyl oxopropanoate 281 
Bis-7-azaindolyl oxopropanoate 281 was the next target intermediate, beginning from 7-
azaindole 139 (Scheme 4.16). Methylation of azaindole 139 was achieved under standard 
sodium hydride/methyl iodide conditions, affording N-protected 7-azaindole 277 as a green oil 
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in 94% yield. The dropwise addition of oxalyl choride to a solution of azaindole 277 in diethyl 
ether allowed for intermediary glyoxyl chloride formation, which was subsequently treated 
with potassium hydroxide in a mixture of water and acetone to give glyoxylate 278 as a white 
solid in 47% yield following acidic workup.    
The Wolff-Kishner reduction of oxoacetic acid 278 towards acetic acid 279 was carried out in 
a one-pot procedure involving the heating of a mixture of acid 278, hydrazine hydrate and 
sodium methoxide in ethylene glycol to 150 
o
C for 3 hours, allowing the solvent to 
concentrate down to roughly half the volume in that time. Acidic workup led to the 
precipitation of acetic acid 279 as a pure white solid in 84% yield, following copious water 
washes to remove all traces of remaining ethylene glycol. 
 
Scheme 4.16 Route to bis-7-azaindolyl oxopropanoate 281 
The highly efficient conversion of acetic acid 279 to ester 280 was carried out by treatment of 
a solution of 279 in methanol with neat sulfuric acid, with the resulting mixture allowed to stir 
for 2 hours at room temperature. After the pH of the acidic solution was carefully adjusted to 
9 using saturated aqueous sodium bicarbonate, extraction with ethyl acetate allowed for the 
isolation of ester 280 as a yellow oil in 97% yield. The LDA-mediated condensation of ester 
280 with acyl chloride 266 subsequently resulted in the formation of bis-7-azaindolyl 
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oxopropanoate 281 as a golden crystalline solid in 38% yield (Scheme 4.16), with a 
characteristic signal corresponding to the C-Hα proton observed at 5.63 ppm in the 1H NMR 
spectrum. 
4.2.7 Route towards oxopropanenitrile 287 
The next step in our synthetic strategy of fragment-based drug discovery was to incorporate a 
3,4,5-trimethoxyphenyl functionality into our template for aza BIM derivatives. 
Bisindolylmaleimide analogues containing this aryl subunit had previously been shown by 
Peifer and co-workers to elicit potent VEGFR inhibitory activity.
8
 To this end, it was initially 
necessary to fashion 7-azaindolyl-3-acetonitrile 283 to allow access to β-keto nitrile 
intermediate 287. The Mannich reaction of diethylamine hydrochloride and formaldehyde 
with 7-azaindole 139 led to gramine 282 as an orange solid in excellent yield of 88% (Scheme 
4.17). However, all subsequent endeavour to convert diethyl gramine 282 to acetonitrile 283 
was met with failure. As well as attempting to protonate the gramine moiety of 282 under 
acidic conditions followed by nucleophilic attack of a cyanide anion, a strategy of alkylating 
the same functional group using dimethyl sulfate was also pursued, but to no avail.   
 
Scheme 4.17 Attempted synthesis of 7-azaindolyl-3-acetonitrile 283 
This problem was later overcome when it was found that dimethyl gramine analogue 284, also 
prepared in excellent yield from 7-azaindole 139, could readily undergo cyanolysis to form 
nitrile 283 as a white crystalline material in 52% yield (Scheme 4.18). Given that the 
conversion to acetonitrile 283 proved unsuccessful under similar reaction conditions using 
diethyl gramine 282, it suggests that perhaps difficulties arise with substitution of the cyanide 
anion on the corresponding quaternary salt of 282. Further examination of this reaction could 
provide a topic for future work. 
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Reaction of acetonitrile 283 with sodium hydride and iodomethane resulted in N-methyl 
derivative 285, albeit in relatively low yield of 46%. Formation of a dimethylated by-product, 
arising as a consequence of the highly acidic nature of the protons adjacent to the nitrile, 
accounted for the comparatively low yield of desired product 285. 
 
Scheme 4.18 Route to β-keto nitrile 287 
The base-catalysed condensation of acetonitrile 285 with acyl chloride 286, generated 
quantitatively from the reflux of 3,4,5-trimethoxybenzoic acid in chloroform and excess 
thionyl chloride, afforded β-keto nitrile 287 as a yellow solid in 49% yield. Due to negligible 
solubility issues with acyl chloride 286, there was no need for immediate adjustment of 
temperature upon completion of additions. 
4.2.8 Synthesis of oxopropanenitrile 289 
Synthesis of the regioisomer of β-keto nitrile 287, oxopropanenitrile 289, proved to be 
relatively straightforward, given the previous establishment of methodology involving the use 
of acyl chloride 266 (Section 4.2.4). The anion of commercially available 3,4,5-
trimethoxyphenyl acetonitrile 288 was initially generated at -78 
o
C using a solution of LDA in 
THF under a nitrogen atmosphere (Scheme 4.19).  
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Scheme 4.19 Synthesis of oxopropanenitrile 289 
A suspension of acyl chloride 266 in THF was then added to the mixture, at which point the 
reaction vessel was warmed to 35 
oC and left to stir overnight. Following workup, the β-keto 
nitrile 289 product was isolated as a yellow solid in 46% yield by flash column 
chromatography, employing an ethyl acetate/hexane (70:30) eluent system. 
4.2.9  Synthesis of oxopropanoate 292 
Oxopropanoate 292 was synthesised in two steps from 3,4,5-trimethoxyphenyl acetic acid 290 
via ester 291 (Scheme 4.20). Initial attempts to effect the esterification of acid 290 using 
oxalyl chloride with a drop of anhydrous DMF in THF followed by stirring in methanol, 
resulted in only a moderate yield of 28%. 
 
Scheme 4.20 Route to β-keto ester 292 
However, treatment of acid 290 with potassium carbonate and dimethyl carbonate in DMF 
under reflux conditions for 16 hours resulted in a significant improvement in the yield of ester 
291 to 87%, which was isolated as a colourless oil after column chromatography. Reaction of 
acyl chloride 266 with the anion of ester 291 under similar conditions to that seen previously 
(Section 4.2.4) led to the formation of oxopropanoate 292 in 51% yield as a pale yellow solid 
following chromatographic purification. 
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4.3 Cyclocondensation reactions: accessing aza BIM derivatives 
With the successful establishment of a viable methodology to allow access to a series of 
oxopropanoate and oxopropanenitrile intermediates (Section 4.2), it was now possible to 
proceed with the next stage of our synthetic strategy. To achieve our goal of developing novel 
aza BIM and aza ICZ derivatives of biological interest, we next examined the 
cyclocondensation of these intermediates, and their subsequent elaboration.   
4.3.1 Synthesis and derivatisation of 5-aminopyrazole 293 
Reaction of β-keto nitrile 287 (Section 4.2.7) with hydrazine hydrate in the presence of 
hydrochloric acid led to the formation of 3-(3,4,5-trimethoxyphenyl)-4-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-5-amine 293, a highly promising heterocyclic 
bioisostere of the potent VEGFR inhibitor 229 (Scheme 4.21).
9
  
 
Scheme 4.21 Synthesis of 5-aminopyrazole 293 
Monitoring of the reaction by TLC revealed that no starting material remained after 20 hours 
under reflux, with the pure product 293 subsequently isolated by column chromatography 
(10% methanol in ethyl acetate) as a light brown solid in 70% yield. The use of camphoric 
acid instead of hydrochloric acid as catalyst for the transformation, as detailed by Braňa et al. 
in the synthesis of an analogous series of pyrazolones (Scheme 4.2), resulted in a significant 
reduction in yield to 28% over a similar reaction time. 
As well as acting as a useful congener to established kinase inhibitor 229, aminopyrazole 293 
offers an appealing template with which to pursue further synthetic diversification towards the 
potential enhancement of enzyme-inhibitor contacts.  
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Although structural confirmation of aminopyrazole 293 was provided for by 
1
H NMR and 
mass spectrometry data, the apparent absence of four quaternary carbon signals in the 75 MHz 
13
C NMR spectrum was problematic. A detailed comparison with the precursor, β-keto nitrile 
287, served to indicate that the missing signals belong to carbon atoms constituent of the 
aminopyrazole moiety, or those neighbouring the heterocyclic moiety.  
Subsequent analysis of aminopyrazole 293 on a more powerful 125 MHz instrument led to the 
discovery of four additional peaks of broad and weak intensity at 95.2, 126.9, 141.8 and 152.3 
ppm. To better understand the origin of these signals, a further series of 
13
C NMR experiments 
were carried out, initially focused on alternating the probe temperature and pulse frequency. 
Following the incremental variation of both parameters, best resolution of the four peaks was 
obtained with a pulse time delay of 7 seconds and with the probe temperature set to 315 K 
(Figure 4.3). 
 
Fig. 4.3 Expansion of 
13
C NMR spectrum of aminopyrazole 293                                         
(DMSO-d6, 150 MHz, 315 K, τ = 7 sec) 
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With the unambiguous assignment of all CH and CH3 carbon nuclei within the molecule 
provided for by the application of DEPT and 2D HSQC experiments, establishment of all 
quaternary carbons was then necessary in apportioning the identity of the four suppressed 
13
C 
peaks. Consequently, a 2D HMBC (heteronuclear multiple bond correlation) technique was 
employed, whereby correlation between protons and quaternary carbons is obtained via 
coupling over two or more bond lengths (Figure 4.4). For purposes of clarity, 
13
C NMR 
signals on the y-axis are labelled: (i) green for CH aromatic peaks, (ii) orange for quaternary 
carbon peaks of normal intensity and (iii) red for broad quaternary carbon peaks.   
 
Fig. 4.4 2D HMBC spectrum of aminopyrazole 293 (
13
C NMR on y axis, 
1
H NMR on x axis) 
Examining the quaternary signals (orange annotation) of normal intensity first, C(3’’) of 
aminopyrazole 293 shows distinct correlation to the C-H2’’ proton, and less so to C-H4’’, which 
is a further bond length away. The bridgehead carbon C(3a’’) at 119.5 ppm is seen to couple 
to C-H2’’ and C-H5’’ over three bond lengths, though correlation to the more proximal C-H4’’ is 
somewhat suppressed. The opposing bridgehead carbon C(7a’’) clearly correlates to the C-
H2’’, C-H4’’ and C-H6’’ protons, all of which are three bonds distant. The equivalent quaternary 
Chapter 4 | Chemical Results and Discussion 
 
 
[111] 
 
carbons of the trimethoxyphenyl moiety, C(3’) and C(5’), give rise to a single signal at 152.5 
ppm, with coupling seen to the corresponding equivalent protons of the ring, C-H2’ and C-H6’. 
Stronger correlation is shown to occur between the same two protons and the carbon at the 
para-position, C(4’), despite the further bond length. 
Eliminating the assigned quaternary carbons, it is possible to designate the four weak peaks 
(red annotation) in the 
13
C NMR spectrum as C(1’), C(3), C(4) and C(5), all of which lie in or 
adjacent to the aminopyrazole ring. Of these signals, two are more readily identifiable, with 
C(4) correlating to C-H2’’ and C(1’) coupling to the C-H2’ and C-H6’ protons. The remaining 
two quaternary signals are weaker again and definitive correlation is difficult to prove, 
complicating the spectroscopic analysis. However, it is possible to surmise that C(5) is the 
more deshielded of the two nuclei, as it is bonded to two heteroatoms as opposed to just one. 
From the series of 
13C NMR experiments conducted, it was found that the C(4) and C(1’) 
signals could be resolved by increasing the temperature of the probe. However, it was not 
possible to distinguish the even less pronounced C(3) and C(5) peaks until the delay time was 
also raised to 7 seconds, inferring a long spin-lattice relaxation of the 
13
C nuclei involved. It is 
an intrinsic property of carbon nuclei in any molecule to have either a short or long relaxation 
time, with quaternary carbons in fixed structures typically showing longer relaxation times, 
often longer than that provided for under standard conditions.
10 
Broadening of the four quaternary carbon signals could possibly arise due to annular 
tautomerism of the aminopyrazole moiety of 293, with interchange of the NH ring proton. 
Previous studies have noted a similar broadening of signals in the spectra of other 
aminopyrazoles.
11,12
 For example, in a study examining the structure and tautomerism of a 
series of monoaryl-substituted aminopyrazoles in both solid state and in solution, Puello and 
co-workers observed broad 
13
C NMR peaks corresponding to a coalescence of quaternary 
carbon signals from either tautomer.
11 
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4.3.1.1 Bicyclic derivatives of 5-aminopyrazole 293 
In the initial stage of this derivatisation study, it was possible to effect the formation of 
bicyclic systems 295 and 297 via reaction of 5-aminopyrazole 293 with respective bidentate 
electrophiles (Scheme 4.22). Treatment of a solution of 293 in DCM with two drops of 
triethylamine followed by N-chlorocarbonyl isocyanate 294 led to triazinedione 295 as a white 
precipitate in 56% yield, following quenching of the reaction by the addition of water. 
Confirmation of the formation of the barbiturate moiety was given by the appearance of a 
broad 2H singlet at 11.66 ppm in the 
1
H NMR spectrum of product 295, corresponding to the 
two free NH protons.  
Scheme 4.22 Routes to bicyclic analogues 295 and 297 
Treatment of aminopyrazole 293 with a 20-fold molar excess of hexafluoroacetylacetone 296 
in acetic acid at 80 
o
C over 20 hours led to the formation of pyrazolo[1,5-a]pyrimidine 295 as 
a orange solid in 54% yield.  
Interestingly, the coupling of fluorine to carbon is observed in the 
13
C NMR spectrum of 
pyrimidine 297 in the form of four quartets (Figure 4.5). Large coupling constants (JF-C = 
275.4 and 275.2 Hz respectively) were identified for the overlapping quartets of Cα and Cβ as 
a consequence of substitution with three fluorine atoms. The effect is also noticeable over a 
distance of two bonds from the site of fluorine substitution, namely for the quaternary carbons 
C5 and C7. However, the magnitude of coupling is significantly diminished with increased 
remoteness from the fluorine atoms at JF-C = 37.8 and 34.7 Hz respectively. No coupling was 
observed beyond two bond lengths. 
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Fig. 4.5 Expansion of 
13
C NMR spectrum of pyrimidine 297 (CDCl3, 125 MHz) 
4.3.1.2 Reaction of 5-aminopyrazole 293 with monodentate electrophiles 
Continuing with a synthetic derivatisation theme, the monosubstitution of 5-aminopyrazole 
293 with a number of electrophiles was next to be investigated.  
 
Scheme 4.23 Monosubstitution of 5-aminopyrazole 293 
Consequent to the formation of bicyclic systems 295 and 297 (Section 4.3.1.1), it was 
expected that the reaction of 293 with a given set of monodentate electrophiles would result in 
substitution on the exocyclic amine (Scheme 4.23). 
The expected substitution on the exocyclic nitrogen of 5-aminopyrazole 293 was found to 
occur upon reaction with trifluoroacetic anhydride 299 in acetonitrile, resulting in the 
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formation of acetylated product 300 as a pale yellow solid in 41% yield (Scheme 4.24). 
Structural confirmation of the product 300 was afforded by the appearance of two broad 
singlets at 11.23 and 13.52 ppm in the 
1
H NMR spectrum, corresponding to the acetamide NH 
and pyrazolic NH respectively. 
 
Scheme 4.24 Synthesis of monosubstituted aminopyrazole derivatives 300, 302 and 304 
It was therefore an unexpected result, when the treatment of aminopyrazole 293 with acetic 
anhydride 301 in acetonitrile at reflux temperature for 24 hours led to the formation of N-
acetyl 302, with the site of substitution lying at position 1 of the ring. Purification of the crude 
reaction residue by column chromatography (40% hexane in ethyl acetate) led to the isolation 
of acetylated derivative 302 as a pale yellow crystalline solid in good yield of 62%. The 
identification of a broad 2H singlet at 5.60 ppm in the 
1
H NMR spectrum, corresponding to 
the free exocyclic amine, served to ascertain the correct structure of the product. 
Reaction of aminopyrazole 293 with methyl isothiocyanate 303 led to the formation of 
carbothioamide 304 as a white solid in 47% yield, with substitution of the aminopyrazole 
again occurring on the nitrogen at position 1 of the pyrazole, in a similar fashion to acetylated 
analogue 302 (Scheme 4.24).  
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Fig. 4.6 
1
H NMR spectrum of carbothioamide 304 (DMSO-d6, 300 MHz) 
The mode of substitution of carbothioamide 304 is illustrated by analysis of the 
1
H NMR 
spectrum (Figure 4.6), with a broad 2H singlet at 7.14 ppm arising due to the free amino 
functionality of the aminopyrazole. Two characteristic signals are observed due to the 
presence of the thioamide substituent, with a broad 3H doublet at 3.16 ppm corresponding to 
the methyl group and a broad 1H doublet at 10.15 ppm as a result of the thioamide NH. 
Comparison of the 
13
C NMR spectra of monosubstituted aminopyrazoles 300, 302 and 304 
with that of their precursor 293 serves to illustrate an interesting trend. As in the case of parent 
aminopyrazole 293 (Section 4.3.1), a number of the quaternary carbon signals of 
trifluoroacetamide 300 appear as broad peaks, while all of the quaternary carbon signals in the 
13
C NMR spectra of acetylated aminopyrazole 302 and carbothioamide 304 are of similar, 
normal intensity. This can perhaps be explained by the fact that by substituting at the N(1) 
position of the aminopyrazole, as in the case of derivatives 302 and 304, there is no possibility 
of annular tautomerism, with the electronic configuration of the ring effectively “locked” in 
position. However, with trifluoroacetamide 300, interchange of the NH ring proton is still 
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possible, therefore potentially resulting in the peak broadening of neighbouring quaternary 
carbons in the 
13
C spectrum.  
Precedence for the difference in regioselectivity observed for the substitution of 
aminopyrazole 293 exists within the literature. It has been noted that the structural nature of 
the end product depends on the type of reagent and reaction conditions used.
13 
While using different electrophiles and reaction parameters, Nie and co-workers described the 
substitution of various 5-aminopyrazoles of general structure 305 with ethoxycarbonyl 
isothiocyanate 306, with the regioselectivity of the reaction dependant on both the conditions 
employed and the nature of the ring substituent at the C(4) position (Scheme 4.25).
14
  
 
Scheme 4.25 Reaction of aminopyrazole 305 with ethoxycarbonyl isothiocyanate 306
14
  
When the reaction was carried out in mixture of ethyl acetate and benzene at room 
temperature, with an electron-withdrawing group such as CN or Br at the C(4) position of 305, 
electrophilic substitution occurred solely at the N(1) position of the ring (general structure 
307). However, with an electron-donating group at the C(4) position, disubstitution occurred 
under the same reaction conditions (general structure 308). Nie et al. later found that when the 
reaction was carried out in ethyl acetate at reflux temperature, substitution occurred solely on 
the exocyclic amine (general structure 309), regardless of the nature of the ring substituent.
14
 
This suggests that while reaction at the N(1) position may be the more kinetically-favoured 
Chapter 4 | Chemical Results and Discussion 
 
 
[117] 
 
process, substitution on the amino functionality is more thermodynamically-favoured due to 
the thermal stability of the resulting products. 
Elnagdi et al. noted that heating a mixture of aminopyrazole 310 in neat acetic anhydride 301 
to reflux led to the formation of acetamide 311 in 90% yield, with substitution on the 
exocyclic amine (Scheme 4.26).
15
 Similar to that seen with Nie and co-workers (Scheme 
4.25), the formation of acetamide 311 appears to arise as a result of being the more 
thermodynamically-favoured product, mirroring the situation with the formation of 
trifluroacetamide 300 (Scheme 4.24). To add to the complexity, this contradicts the 
substitution pattern we observed under modified conditions, hence the need for future 
investigation. 
 
Scheme 4.26 Synthesis of acetamide 311 from aminopyrazole 310
15
     
4.3.2 Synthesis and derivatisation of 5-aminopyrazole 312 
In terms of biological mode of action, the spatial positioning of molecular functionalities can 
prove critical towards the exploitation of unique features in enzymatic binding pockets. Peifer 
and co-workers described how the regioisomer 230 of VEGFR inhibitor 32 was found to be 
completely inactive against the same kinase, simply with a different orientation of the lactam 
moiety (Figure 4.7).
8 
 
Fig. 4.7 VEGFR inhibitor template described by Peifer et al.
8
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Expanding our endeavour in the study of 5-aminopyrazoles (Section 4.3.1), our next aim was 
to fashion a series of regioisomers of our previous molecular template, realising the 
opportunity for the exploration of novel target-ligand binding motifs and SAR study. To this 
end, the synthesis and derivatisation of 3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrazol-5-amine 312 was undertaken, beginning from the previously 
formed oxopropanenitrile precursor 289 (Section 4.2.8). 
 
Scheme 4.27 Synthesis of 5-aminopyrazole 312 
Reaction of β-ketonitrile 289 with hydrazine hydrate, with hydrochloric acid acting as 
catalyst, in absolute ethanol at reflux temperature led to the formation of aminopyrazole 312 
as a brown solid in 62% yield (Scheme 4.27).  
Understandably, the 
1
H NMR spectrum of aminopyrazole 312 revealed a striking similarity in 
comparison to regioisomer 293 (Figure 4.8). The only major difference between the two 
spectra involves the signals arising from the C-H2 and C-H4 protons, which coalesce to form a 
broad singlet at 7.55 ppm in the case of aminopyrazole 312, whereas they resolve into 
separate, distinct peaks in the case of aminopyrazole 293. 
In the 
13
C NMR spectrum of aminopyrazole 312, four quaternary carbons appear as broad, 
weak signals at 105.3, 107.0, 125.4, and 151.8 ppm, indicating the potential effect of annular 
tautomerism, with the possibility of interchange of the NH ring proton leading to a 
suppression of the observed peaks. This corresponds to the spectroscopic analysis carried out 
for its regiosomer, aminopyrazole 293, which also contained four weak quaternary carbon 
signals.  
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Fig. 4.8 Comparison of 
1
H NMR spectra of 293 and 312 (DMSO-d6, 300 MHz) 
In analytical terms, the main feature to distinguish between the two regioisomers is by their 
melting point ranges, between which there is considerable difference. The melting point range 
of aminopyrazole 312 (135-137 
o
C) was found to be far lower than that of aminopyrazole 293 
(266-267 
o
C). The relatively large disparity between the melting points of the regioisomers 
could perhaps be due to additional intramolecular hydrogen bonding in 312 due to the 
positioning of the amino moiety. This leads to the suggestion that aminopyrazole 312 should 
have better physicochemical characteristics than its regioisomer 293. 
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4.3.2.1 Bicyclic derivatives of 5-aminopyrazole 312 
As in the case of analogue 293, derivatisation of aminopyrazole 312 can be effected in a 
straightforward manner as a result of its nucleophilic nature. Treatment of a cooled solution of 
aminopyrazole 312 and a few drops of triethylamine in DCM with N-chlorocarbonyl 
isocyanate 294 led to the formation of triazinedione 313 as a white solid in 45% yield 
(Scheme 4.28). Structural confirmation of the barbiturate moiety of triazinedione 313 is 
afforded by the two broad singlets arising from the NH protons at 11.59 and 11.74 ppm in the 
1
H NMR spectrum. 
 
Scheme 4.28 Synthesis of bicyclic derivatives 313 and 314 of aminopyrazole 312 
Condensation of aminopyrazole 312 with hexafluoroacetylacetone 296 in an acidic medium 
gave highly-conjugated pyrazolo[1,5-a]pyrimidine 314 as an orange/red solid in high yield of 
78%, following purification by flash column chromatography (40% ethyl acetate in hexane). 
4.3.2.2 Reaction of 5-aminopyrazole 312 with monodentate electrophiles 
It was interesting to note that aminopyrazole 312 exhibited similar regioselectivity towards 
monodentate electrophiles as with its analogue 293, despite the rearrangement of the 7-
azaindolyl and 3,4,5-trimethoxyphenyl rings at the C(3) and C(4) ring positions. Though the 
overall presence of these two large aryl units may have some influence on the substitution 
pattern observed, their position on the aminopyrazole ring cannot be said to directly affect 
regioselectivity.  
Reaction of aminopyrazole 312 with trifluoroacetic anhydride 299 afforded trifluoroacetamide 
315 as an off-white solid in 68% yield (Scheme 4.29). The presence of two broad singlets at 
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11.37 and 13.30 ppm in the 
1
H NMR spectrum confirm that substitution occurred on the 
exocyclic amino functionality rather than N(1) nitrogen. As observed for each of the other 
fluorinated aminopyrazole derivatives, fluorine-carbon coupling is evident in the 
13
C NMR 
spectrum of 315. Once more, a large coupling constant was recorded for the quartet arising 
from the trifluoromethyl carbon (J = 288.0 Hz), with the magnitude dropping significantly 
over a distance of two bond lengths to the carbonyl carbon (J = 36.2 Hz). 
 
Scheme 4.29 Monosubstitution of aminopyrazole 312 towards derivatives 315, 316 and 317 
Acetylated derivative 316 was synthesised as a greyish solid in a good yield of 71% following 
treatment of aminopyrazole 312 with acetic anhydride 301 in acetonitrile at reflux. The site of 
substitution was confirmed to be the N(1) position of the pyrazole due to the presence of a 2H 
broad singlet at 5.56 ppm in the 
1
H NMR spectrum, corresponding to the exocyclic amino 
functionality. 
Reaction of aminopyrazole 312 with methyl isothiocyanate 303 led to the formation of 
carbothioamide 317 as a white solid in 76% yield. Spectroscopic analysis again provided  
structural confirmation of substitution at the N(1) pyrazolic position.  
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The effect of the substituent on the N(1) position of carbothioamide 317 and acetylated 
aminopyrazole 316 is similar to that seen for their corresponding regioisomers (Section 
4.3.1.2), with the relative intensities of all quaternary carbon signals in the respective 
13
C 
NMR spectra all being broadly similar. However, in the 
13
C NMR spectrum of 
trifluoroacetamide 315, with no substitution on the N(1) position of the aminopyrazole, a 
number of the quaternary carbons give rise to broad, weak peaks.  
The monosubstitution yields of parent compound 312 were found to be considerably higher 
than those of its analogue 293, despite similar reaction times being employed – perhaps 
indicative of a more nucleophilic aminopyrazole moiety. 
4.3.3 Synthesis and derivatisation of 5-aminopyrazole 318   
The next step in our synthetic strategy was to synthesise and derivatise aminopyrazole 318 
from oxopropanenitrile 276 (Scheme 4.30). It was posited that aminopyrazole 318 could 
proffer an interesting novel bioisostere to acyriarubin A 10. 
 
Scheme 4.30 Synthesis of aminopyrazole 318 from oxopropanenitrile 276 
A similar synthetic methodology was employed to that previously used for the fashioning 
analogous aminopyrazoles 293 and 312 (Sections 4.3.1 and 4.3.2). Treatment of β-keto nitrile 
276 (Section 4.2.5) with five equivalents of hydrazine hydrate in the presence of hydrochloric 
acid under reflux conditions led to the formation of 3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrazol-5-amine 318 as a light brown crystalline material 
in 64% yield after purification via flash column chromatography (10% methanol in ethyl 
acetate). The use of acetic acid has also been described in the literature as catalyst for the 
successful synthesis of aminopyrazole heterocycles from β-keto nitrile intermediates.16 
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However, when employed as acid catalyst for the synthesis of 318 under similar reaction 
conditions, a lower yield of 48% was obtained.  
4.3.3.1 Bicyclic derivatives of 5-aminopyrazole 318 
Extending the derivatisation methodology previously employed for 3-(3,4,5-
trimethoxyphenyl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-5-amine 293 
(Section 4.3.1) and 3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-trimethoxyphenyl)-
1H-pyrazol-5-amine 312 (Section 4.3.2) towards the BIM analogue aminopyrazole 318 
proved to be relatively straightforward. 
Following dissolution in dry DCM containing four drops of triethylamine, treatment of 
aminopyrazole 318 with N-chlorocarbonyl isocyanate 294 led to the formation of 
triazinedione 319 as a grey solid in 66% yield following aqueous workup (Scheme 4.31). The 
highly deshielded NH protons of the barbiturate moiety of bicyclic derivative 319 were 
observed at 11.55 and 11.68 ppm in the 
1
H NMR spectrum. 
 
Scheme 4.31 Synthesis of bicyclic derivatives 319 and 320 from aminopyrazole 318 
Formation of bis(trifluoromethyl)pyrimidine 320 was achieved following the heating of a 
mixture of aminopyrazole 318 in acetic acid and a 20-fold molar excess of 
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hexafluoroacetylacetone 296 to 80 
o
C for 20 hours. Column chromatography (40% ethyl 
acetate in hexane) provided the pure bicyclic product 320 as a bright red solid in 47% yield. 
As in the case of analogous bicyclic pyrimidine derivatives 297 and 312, fluorine-carbon 
coupling is evident in the 
13
C NMR spectrum of 320. Two large quartets (JF-C = 275.2 and 
275.7 Hz respectively) arise due to the two trifluoromethyl carbon nuclei, with fluorine-
carbon coupling over a distance of three bond lengths to the adjacent quaternary carbons 
resulting in two smaller quartets (JF-C = 38.1 and 37.4 Hz respectively).  
4.3.3.2 Reaction of 5-aminopyrazole 318 with monodentate electrophiles 
No discernible difference in regioselectivity was observed for the reaction of aminopyrazole 
318 with a series of monodentate electrophiles than that seen previously for aminopyrazoles 
293 (Section 4.3.1.2) and 312 (Section 4.3.2.2).  
Following application of trifluoroacetic anhydride 299 to solution of aminopyrazole 318 in 
acetonitrile, followed by heating to reflux for 20 hours, trifluoroacetamide 321 was isolated as 
a white solid in 35% yield from the resulting crude brown residue by flash column 
chromatography (30% hexane in ethyl acetate) (Scheme 4.32). 
 
Scheme 4.32 Synthesis of mono-substituted aminopyrazole derivatives 321, 322 and 323 
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Treatment of aminopyrazole 318 with 1.2 equivalents of acetic anhydride 301 in acetonitrile 
under reflux conditions led to the formation of acetylated derivative 322 as a white crystalline 
solid in good yield of 70%. Substitution at the N(1) position of the aminopyrazole ring was 
confirmed by the appearance of a broad singlet at 5.44 ppm in the 
1
H NMR spectrum of 322 
integrating for two protons, corresponding to the NH2 exocyclic amino moiety. 
In a similar manner, treatment of a solution of aminopyrazole 318 in acetonitrile with methyl 
isothiocyanate 303 also resulted in substitution at the N(1) pyrazolic position. Carbothioamide 
323 was isolated as a white solid in 53% yield following purification by column 
chromatography, employing a 50:50 mixture of ethyl acetate and hexane as eluent. Once 
again, key to the discernment of the site of substitution was the appearance of a broad 2H 
singlet at 6.34 ppm in the 
1
H NMR spectrum due to the NH2 amino functionality, as well as 
the lack of any broad 1H singlet which could correspond to a highly deshielded NH ring 
proton. 
Having successfully completed the synthesis of three series of derivatised aminopyrazoles 
(Sections 4.3.1, 4.3.2 and 4.3.3), it was evident that the pattern of regioselectivity with regard 
to reaction of the parent aminopyrazoles with monodentate electrophiles was not dependent on 
the nature of the aryl substituents. In the case of reaction with methyl isothiocyanate and 
acetic anhydride, substitution occurred at the N(1) position of the aminopyrazole ring in each 
case, i.e. the kinetic product of the reaction was more favourable than the thermodynamic 
product.     
 
Fig. 4.9 Structures of trifluoroacetamide 321 and hypothetical trifluoroacetylated      
aminopyrazole 324 
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However, when treated under similar conditions with trifluoroacetic anhydride, the most 
reactive of the three monodentate electrophiles used, substitution occurred on the exocyclic 
amine of the aminopyrazole (such as with derivative 321), i.e. the thermodynamic product was 
the more favourable of the two. In this scenario, it is possible that the kinetic product of the 
reaction (e.g. hypothetical compound 324) was more unstable than the analogous 
carbothioamide and acetyl derivatives, due to the greater electron-withdrawing ability of the 
trifluoroacetyl moiety. Hence, substitution on the amino group may resulted in the more stable 
and favoured product 321. 
4.3.4 5-Membered heterocycles from oxopropanoate intermediates 
The use of oxopropanoate intermediates in the formation of novel 5-membered heterocyclic 
BIM bioisosteres was also examined as part of this overall project. In a manner analogous to 
that previously employed by Braňa and co-workers in the synthesis of bisindolylpyrazolones 
(Scheme 4.2), β-keto ester 267 (Section 4.2.4) was treated with hydrazine hydrate in the 
presence of camphoric acid (Scheme 4.33).
1
 However, it was not possible to isolate the 
desired pyrazolone 325 owing to a multitude of side-products formed, despite a number of 
attempts at purification by column chromatography. Spectroscopic analysis indicated that only 
a small proportion of the expected product 325 was formed, even after repeated attempts. 
 
Scheme 4.33 Synthesis of pyrazolone 325 and 326 from oxopropanoates 267 and 273 
In contrast, reaction of N-benzyl β-keto ester 273 with hydrazine hydrate under similar 
conditions resulted in the formation of an appreciable quantity of the expected pyrazolone 
product 326. However, purification was not a straightforward task, as it was necessary to 
employ a number of different chromatographic eluent systems before it was possible to isolate 
the pure product 326 as a brown solid in 52% yield (2% methanol in DCM). 
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Despite the problematic reaction of β-keto ester 267 with hydrazine hydrate, it was found to 
readily undergo cyclocondensation to form isoxazolone 327 following treatment with five 
equivalents of hydroxylammonium chloride in methanol under reflux conditions (Scheme 
4.34). Isoxazolone 327 was isolated in 64% yield as a light brown solid following flash 
column chromatography (5% methanol in ethyl acetate). Subsequent alkylation to N-methyl 
derivative 328 was achieved under standard conditions using sodium hydride and methyl 
iodide in DMF, with the product formed as an off-white solid in 88% yield.     
 
Scheme 4.34 Synthesis of isoxazolone 327 and conversion to N-methyl derivative 328 
 
4.4 Accessing of 6-membered heterocyclic BIM derivatives 
The synthesis of 6-membered heterocyclic derivatives of the BIM pharmacophore has 
previously been explored within our research group by Pierce and McCarthy (Scheme 4.35).
2,3
    
 
Scheme 4.35 Synthesis of 6-membered pyrimidinone BIM derivatives 231, 329, 330 and 331 
Utilising nucleophiles such as guanidine and thiourea, base-mediated cyclocondensation of 
bisindolyl β-keto ester 251 led to the fashioning of 2-aminopyrimidin-4-one 231 and thiouracil 
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329 respectively. Further elaboration of thiouracil 329 afforded desulfurised pyrimidinone 
analogue 330 and uracil 331. 
It was discovered that the successful synthesis of 6-membered BIM analogues from β-keto 
ester 251, such as pyrimidinone 231 and thiouracil 329, was highly dependent on the reactive 
nature of the nucleophile. For example, reaction of ester 251 with urea failed to directly 
produce uracil 331, which instead had to be accessed via thiouracil 329. Similarly, the use of 
other nucleophiles such as O-methyl isourea and N,N’-dimethyl thiourea failed to produce the 
desired 6-membered products, with only starting material identified. As a result of the reagent-
dependant nature of these cyclocondensation reactions involving precursor 251, the 
development of a library of 6-membered BIM derivatives was pursued by secondary 
modification of pyrimidinone 231 and thiouracil 329.
2,3
     
4.4.1 Routes towards monoaza 6-membered BIM derivatives 
Consequent to the previous synthetic effort towards bisindolyl derivatives such as 
pyrimidinone 231 (Scheme 4.35), accessing analogous systems containing 7-azaindolyl 
subunits represented a highly desirable endeavour in our program of fragment-based drug 
discovery, given the significant alteration of pharmacological properties that has occurred 
upon their inclusion in similar chemotherapeutic candidates (Sections 1.3.1.5 and 1.3.2.3). 
Initially, the reaction of β-keto ester 267 (Section 4.2.4) with guanidine under basic conditions 
was examined (Scheme 4.36).  
 
Scheme 4.36 Synthesis of pyrimidinone 332 from β-keto ester 267 
Following the liberation of guanidine from the corresponding carbonate salt by treatment with 
sodium methoxide, ester 267 underwent cyclocondensation to form pyrimidinone 332. The 
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crude product was isolated as a dark green precipitate following an acidic workup, with 
subsequent purification by column chromatography (10% methanol in ethyl acetate) 
furnishing the desired product 332 as a light brown solid in 42% yield. 
Employing similar conditions to that used for the synthesis of pyrimidinone 332 (Scheme 
4.36), the reaction of thiourea with β-keto ester 267 was next to be explored (Scheme 4.37). 
Once again, a crude precipitate was obtained following an acidic workup. While it was 
indicated by mass spectrometry that a very limited amount of desired thiouracil product 333 
had been formed, it was not possible to isolate a pure sample, with numerous other products in 
evidence by TLC and 
1
H NMR analysis. Varying the reaction conditions employed, 
significant effort was expended in an attempt to both increase the yield of desired thiouracil 
333 and also to limit side-product formation, to no avail. 
 
Scheme 4.37 Synthesis of thiouracil 333 from β-keto ester 267 
The formation of uracil 334 from the reaction of β-keto ester 267 with urea in the presence of 
excess sodium methoxide was also attempted (Scheme 4.38). However, even with a prolonged 
reaction time of 96 hours, none of desired product 334 was afforded and only starting material 
was detected. This confirmed work by Pierce regarding the lack of nucleophilicity of urea and 
similar reagents necessary for effective heterocyclic formation from β-keto ester precursors.2    
 
Scheme 4.38 Attempted synthesis of uracil 334 from β-keto ester 267 
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The use of β-keto ester 273, with an N-benzyl protecting group on the azaindolic moiety 
(Section 4.2.3), towards the synthesis of similar monoaza 6-membered BIM derivatives was 
also explored (Scheme 4.39). However, attempts to access pyrimidinone 335 and thiouracil 
336 via reaction of precursor 273 with guanidine and thiourea respectively proved 
unsuccessful. Degradation of the starting material was detected in each case, with no evidence 
of desired products 335 and 336 having formed. 
 
Scheme 4.39 Attempted synthesis of pyrimidinone 335 and thiouracil 336 
Therefore, replacing the N-methyl protecting group of ester 267 with a benzyl functionality in 
analogous intermediate 273 meant that it was not possible to effectuate cyclocondensation 
towards 6-membered heterocyclic bioisosteres of the BIM series. Further investigation is 
required in order to determine the impact of such functionalities on this particular reaction.  
4.4.2 Attempted syntheses of further 6-membered BIM derivatives 
Having previously experienced variable success in the synthesis of 6-membered heterocyclic 
BIM derivatives using precursors containing both indolyl and 7-azaindolyl substituents 
(Section 4.4.1), the use of other oxopropanoate intermediates was examined.  
 
Scheme 4.40 Attempted synthesis of pyrimidinone 337 and thiouracil 338 
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However, it was found that the respective base-mediated reactions of bis-7-azaindolyl β-keto 
ester 281 (Section 4.2.6) with guanidine and thiourea only resulted in the recovery of starting 
material, without formation of desired products 337 and 338 (Scheme 4.40). 
The unreliable nature of the cyclocondensation methodology towards these BIM analogues 
was further highlighted by the attempted syntheses of pyrimidinone 339 and thiouracil 340 
(Scheme 4.41), from the 3,4,5-trimethoxyphenyl substituent-bearing oxopropanoate 292 
(Section 4.2.9). As in the case of bis-7-azaindolyl β-keto ester 281 (Scheme 4.40), desired 
products 339 and 340 were not formed, with degradation of starting material in each case.  
 
Scheme 4.41 Attempted synthesis of pyrimidinone 339 and thiouracil 340 
As previously alluded to at the start of this section (Section 4.4), Pierce had noted that the 
reactivity of the nucleophile utilised was of paramount importance in the successful synthesis 
of analogous 6-membered BIM derivatives from bisindolyl β-keto ester 251 (Scheme 4.35).2 
Given the application of a similar methodology towards the formation of 6-membered aza 
BIM derivatives (Sections 4.4.1 and 4.4.2), it can be concluded that the success of this type of 
cyclocondensation reaction is also highly dependent on the nature of substituents of the 
oxopropanoate precursor. For instance, it was found that where two 7-azaindolyl substituents 
(Scheme 4.40) or a 3,4,5-trimethoxyphenyl and 7-azaindolyl substituent (Scheme 4.41) were 
employed in reaction with guanidine or thiourea, the corresponding pyrimidinone and 
thiouracil derivatives were not afforded. However, it was possible to fashion pyrimidinone 
232 from oxopropanoate 267, giving rise to optimism towards future elaboration of this 
synthetic route in the development of novel aza BIM and aza ICZ derivatives. 
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4.5 Synthetic routes towards novel azaindolocarbazoles 
Given the wealth of literature that exists in relation to the synthesis of ICZs, it is somewhat 
surprising that comparatively little focus has been paid towards azaindolocarbazoles, 
especially given how the replacement of one or more benzenoid rings with a pyridine moiety 
has been shown to confer unique biological selectivity in a number of cases (Section 
1.3.2.3).
17,18
  
 
Scheme 4.42 Aromatisation of aza BIM analogues of general structure 341 to aza ICZ 342 
Having previously accessed a wide number of aza BIM derivatives (Sections 4.3 and 4.4), our 
ultimate aim was to examine the formation of the central C-C bond towards novel aza ICZs of 
general structure 342 with both 5- and 6-membered heterocyclic headgroups, thus continuing 
the medicinal chemistry effort in the development of chemotherapeutic agents based on the 
lead compound in the class, staurosporine 2 (Scheme 4.42). It has been well documented 
within the literature that ICZs often display more potent biological activity than their 
bisindolyl precursors.
19
 For example, Sanchez-Martinez et al. detailed how a series of 
indolo[2,3-a]pyrrolo[3,4-c]carbazoles consistently showed greater inhibition towards CDK2 
and CDK4 compared with their corresponding BIMs.
20 
4.5.1 Accessing aza ICZs via 6-membered aza BIM derivatives 
The initial intention of our efforts in the synthesis of novel aza ICZs involved the 
aromatisation of 6-membered heterocyclic bioisosteres of the BIM pharmacophore by 
photocyclisation or other means (Scheme 4.43). However, as previously detailed (Section 
4.4), cyclocondensation methodology towards aza BIM derivatives of general structure 343 
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proved to be unreliable, with pyrimidinone 332 the only compound successfully synthesised 
and isolated in this class of compounds.   
 
Scheme 4.43 Envisaged route to aza ICZs with 6-membered F-rings 
Aromatisation of pyrimidinone 332 was completed by photochemical means with U.V. light 
and a catalytic amount of molecular iodine, thus forming the first aza ICZ with a 6-membered 
F-ring, derivative 239 (Scheme 4.44).  
 
Scheme 4.44 Synthesis of aza ICZ 239 from pyrimidinone 332 
Application of UV light to the stirred reaction mixture was achieved using a medium pressure 
mercury lamp. Optimisation of reaction conditions found that the highest yield of product was 
obtained by employing a solvent system of acetonitrile/methanol (3:2), with a high dilution 
factor of 0.08 g per 200 mL. The highly-conjugated aza ICZ product 239 was subsequently 
purified by flash column chromatography (1% methanol in ethyl acetate) as an off-white solid 
in a yield of 51%. 
The increase in conjugation upon aromatisation of pyrimidinone 332 to aza ICZ 239 is 
accompanied by a significant deshielding effect on the 
1
H NMR spectrum of 239. As can be 
seen by direct comparison in Table 4.1, all of the aromatic protons of aza ICZ 239 are more 
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deshielded than in precursor 332. The effect is most pronounced on the C-H4 and C-H4’ 
protons of pyrimidinone 332, which are shifted from a doublet at 7.48 ppm to 9.72 ppm and a 
doublet of doublets at 8.64 ppm to 9.27 ppm respectively, upon aromatisation to aza ICZ 239. 
Formation of the central C-C bond of the azaindolocarbazole structure is also confirmed by 
the disappearance of the C-H2 and C-H2’ proton signals in the spectrum of 239.      
 
 
332 
 
C-H4 
 
C-H4’ 
 
C-H5 
 
C-H5’ 
 
C-H6 
 
C-H6’ 
 
C-H7 
 7.48 
(1H, d) 
8.64 
(1H, dd) 
6.85-6.89 
(2H, m) 
7.02-7.15 
(3H, m) 
7.02-7.15 
(3H, m) 
8.24 
(1H, dd) 
7.02-7.15 
(3H, m) 
 
239 
 
C-H9 
 
C-H4 
 
C-H10 
 
C-H3 
 
C-H11 
 
C-H2 
 
C-H12 
 9.72 
(1H, d) 
9.27 
(1H, dd) 
7.23 
(1H, t) 
7.38 
(1H, q) 
7.50 
(1H, t) 
8.54 
(1H, dd) 
7.67 
(1H, d) 
 
Table 4.1 Comparison of aromatic 
1
H NMR chemical shifts (ppm) between pyrimidinone 33     
and aza ICZ 239 (DMSO-d6, 300 MHz) 
4.5.2 Attempted aromatisation of 5-membered aza BIM derivatives 
Having successfully effectuated the aromatisation of 6-membered aza BIM derivative 332 
towards aza ICZ 239 (Section 4.5.1), the synthesis of other novel aza ICZs from previously 
formed 5-membered aza BIM derivatives (Sections 4.3.3 and 4.3.4) was then examined. With 
aminopyrazole 318 proving more soluble than pyrimidinone 332, acetonitrile was the sole 
solvent initially employed in the attempted photocyclisation towards aza ICZ 345 (Scheme 
4.45). However, following application of UV light and the presence of a catalytic amount of 
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iodine, anticipated product 345 was not formed after 16 hours. The same solvent system 
(acetonitrile/methanol, 3:2) to that previously used in the synthesis of aza ICZ 239 (Section 
4.5.1) was then used under similar photochemical conditions, but once more the desired aza 
ICZ 345 was not afforded, even when the reaction time was extended to 36 hours. 
 
Scheme 4.45 Attempted synthesis of aza ICZ 345 from aminopyrazole 318 
Another method to effect the central C-C bond formation towards aza ICZ 345 was then 
attempted by means of Pd(II)-mediated oxidation (Scheme 4.45). Palladium(II) acetate, a 
well-known mediator of this type of reaction, was added to a stirred solution of aminopyrazole 
318 in anhydrous DMF, which was then heated to 110 
o
C for 20 hours. However, this 
alternative strategy once again failed to yield aza ICZ 345, with only starting material 
recovered from the reaction. 
 
Scheme 4.46 Attempted synthesis of aza ICZ 346 from isoxazolone 327 
Both photochemical cyclisation and Pd(II)-mediated oxidation methodology was also used in 
the attempted synthesis of aza ICZ 346 from isoxazolone 327 (Scheme 4.46). In the same 
manner as previously seen with aminopyrazole 318 (Scheme 4.45), the application of either 
chemical route once again failed to form desired aza ICZ 346, with only the presence of 
starting material detected in either case. This is not unexpected due to limited literature 
precedent in the case where both indolic nitrogens are alkylated, and as such, perhaps removal 
of the methyl groups is key to a more successful outcome. 
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4.5.3 Further routes to aza ICZ precursors: accessing azaindolylmaleimides 
Examining our effort towards the formation of novel aza ICZs, it was clear that accessibility 
was hindered in two key areas: (i) the cyclocondensation methodology used to synthesise 
these BIM derivatives proved too unreliable to allow for the establishment of a library of such 
compounds (Section 4.4), and (ii) the nature of the precursor’s headgroup/indolic substituent 
is essential for the formation of the central C-C bond, with heterocycles such as 
aminopyrazoles and isoxazolones proving ineffective in this regard (Section 4.5.2). As a 
result, a more robust synthetic strategy was required.   
It has previously been shown by both Prudhomme and Routier (and indeed in the general ICZ 
class) that aromatisation towards aza ICZs can be carried out using precursors containing a 
dione moiety, such as azaindolylmaleimide or azaindolylmaleic anhydrides.
21,22
 It was 
therefore posited that a series of aza ICZs of general structure 348 could be accessed from 
dione precursors 347, with subsequent F-ring modification allowing for the synthesis of a 
range of both 5- and 6-membered aza ICZs (Scheme 4.47). 
 
Scheme 4.47 Aromatisation of dione precursor 347 to aza ICZ 348 with                       
subsequent F-ring modification 
To date, the primary synthetic means utilised in this field of chemistry towards the formation 
of monoazaindolylmaleimide or bisazaindolylmaleimide precursors of aza ICZs has involved 
the coupling of 7-azaindoles with dibromomaleimide subunits, which can often lead to 
problems with regiospecificity (Section 2.2). As a result, we sought to examine a novel mode 
of accession towards aza ICZ precursors such as 347.   
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4.5.3.1 Synthesis of monoazaindolyl maleimide precursors 
The Perkin-type condensation of indolyl-3-acetic acids with indolyl-3-glyoxyl chlorides in the 
presence of base, such as triethylamine, has previously been documented in the attainment of 
bisindolylmaleic anhydrides, such as by Gribble et al. in the synthesis of ICZs such as 353 
(Scheme 4.48).
23
 Anhydride 351 is converted to maleimide 352 using hexamethyldisilazane, 
which then undergoes Pd(II)-mediated oxidative cyclisation towards ICZ 353, with the final 
transformation carried out in poor yield of 8% while requiring five equivalents of 
Pd(CF3CO2)2 catalyst. This again shows the apparent influence of indolic alkyl substituents on 
this transformation, and their role in hindering aromatisation.  
 
Scheme 4.48 Route to ICZ 353 via maleic anhydride 351 and maleimide 352
23 
The application of this Perkin-type condensation methodology towards the synthesis of novel 
maleic anhydride 355 proved to be a relatively straightforward accomplishment (Scheme 
4.49). Initially, N-methyl indole-3-acetic acid 350 was formed by treatment of indole-3-acetic 
acid 261 with sodium hydride and methyl iodide in THF, with acid 350 formed as a light 
brown solid in 84% yield. Separately, a stirred solution of N-methyl-7-azaindole 277 in 
diethyl ether at 0 
o
C was treated with oxalyl chloride. After stirring at room temperature over 
3 hours, glyoxyl chloride 354  was isolated as an off-white solid in quantitative yield 
following solvent evaporation under reduced pressure.  
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Scheme 4.49 Synthesis of maleic anhydride 355 via Perkin-type condensation 
Glyoxyl chloride 354 was then added to a stirred solution containing N-methyl indole-3-acetic 
acid 350 and triethylamine in DCM, with the resulting reaction mixture being allowed to stir 
for 14 hours at room temperature. Isolation of maleic anhydride 355 as a bright red solid in 
37% yield from the crude reaction residue was achieved by flash column chromatography 
(30% ethyl acetate in hexane) (Scheme 4.49). 
 
Scheme 4.50 Synthesis of N-hydroxy maleimide 356 and maleimide 357 
Treatment of a solution of maleic anhydride 355 in dry pyridine with hydroxylammonium 
chloride under reflux conditions led to the formation of N-hydroxyl maleimide 356 as a red 
solid in 71% yield, following purification by column chromatography (hexane/ethyl acetate, 
50:50) (Scheme 4.50). Conversion of maleic anhydride 355 to maleimide 357 occurred in 
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excellent yield of 88%. A solution of anhydride 355 in DMF was treated with 10 equivalents 
of hexamethyldisilazane, followed by 5 equivalents of methanol, with the resulting reaction 
mixture then being allowed to stir at room temperature for 24 hours. Following purification by 
column chromatography (hexane/ethyl acetate, 50:50), the highly-conjugated product, 
maleimide 357, was isolated as a brilliant red solid. 
4.5.3.2 Synthesis of bis(7-azaindol-3-yl)maleimide precursors 
The synthesis of bis(7-azaindol-3-yl)maleic anhydride 358 was attempted using a similar 
methodology to that used in the synthesis of maleic anhydride 355 (Scheme 4.49). Glyoxyl 
chloride 354 was added to a stirred solution of acetic acid 279 (Section 4.2.6) and 
triethylamine in DCM, with the resulting mixture then allowed to stir for 14 hours at room 
temperature (Scheme 4.51). However, anhydride 358 was not formed, with only starting 
material recovered from the crude reaction residue. Likewise, heating the reaction mixture did 
not result in desired product formation. This indicated the relatively unreactive nature of N-
methyl 7-azaindolyl-3-acetic acid 279 in comparison with its indolyl analogue 350. 
 
Scheme 4.51 Attempted synthesis of maleic anhydride 358 
A different variation of the Perkin-type reaction towards anhydride 358 was then employed 
(Scheme 4.52). A solution of glyoxylate 278 (Section 4.2.6) in ethanol was treated with one 
equivalent of potassium hydroxide, with the resulting mixture stirred at room temperature for 
4 hours. Following evaporation of the solvent and desiccation overnight at 50 
o
C, potassium 
salt 359 was isolated as a white solid in quantitative yield. A mixture of acetic acid 279 and 
potassium salt 359 in acetic anhydride was then heated to 130 
o
C for 4 hours. Pure maleic 
anhydride 358 was isolated by column chromatography (40% hexane in ethyl acetate) as a 
dark red solid in 45% yield. 
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Scheme 4.52 Route to anhydride 358 from glyoxylate 278 
Due to the symmetry of anhydride 358, only half the number of signals arises in both the 
1
H 
and 
13
C NMR spectra of the compound. For example, in the 
1
H NMR spectrum (Figure 4.10), 
both methyl groups give rise to one singlet at 3.90 ppm.  
 
Fig. 4.10 
1
H NMR spectrum of maleic anhydride 358 (CDCl3, 300 MHz) 
The C-H5 and C-H5’ protons display a single quartet at 6.68 ppm, while the C-H4 and C-H4’ 
protons give rise to a doublet of doublets at 7.09 ppm. One singlet at 7.87 ppm is seen for the 
C-H2 and C-H2’ protons, leaving a doublet of doublets for the C-H6 and C-H6’ protons at 8.20 
ppm (Figure 4.10). 
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Similar to its 3-(indol-3-yl)-4-(7-azaindol-3-yl) analogue 355 (Section 4.5.1.1), anhydride 358 
was readily converted to its N-hydroxy counterpart 360 by treatment with hydroxylammonium 
chloride in dry pyridine at reflux (Scheme 4.53). Following purification by column 
chromatography (30% hexane in ethyl acetate), N-hydroxy maleimide 360 was isolated as a 
red solid in 59% yield. 
 
Scheme 4.53 Synthesis of N-hydroxy maleimide 360 and maleimide 361 
Conversion of maleic anhydride 358 to maleimide 361 was achieved in excellent yield of 
92%, following treatment of a solution of anhydride 358 in DMF at room temperature with 
hexamethyldisilazane, followed by methanol. Purification by column chromatography (20% 
hexane in ethyl acetate) afforded the highly-conjugated product as an orange-red solid.  
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4.5.4 Aromatisation studies towards monoaza ICZs and F-ring modulation 
Initial attempts to effectuate the aromatisation of maleic anhydride 355 and N-hydroxy 
maleimide 356 (Section 4.5.3.1) towards the respective aza ICZs 362 and 363 proved 
problematic (Scheme 4.54). Only the presence of starting material was detected in either case 
when both UV light and palladium(II) trifluoroactetate were engaged to mediate the 
cyclisation.    
 
Scheme 4.54 Attempted aromatisation of maleic anhydride 355 and N-hydroxymaleimide 356 
However, in the ensuing application of photochemical conditions to a solution of maleimide 
357 and a catalytic amount of iodine in acetonitrile, it was found that formation of aza ICZ 
364 occurred readily (Scheme 4.55). Optimisation of reaction conditions later allowed for the 
isolation of fully-aromatised product 364 in 81% yield.    
 
Scheme 4.55 Cyclisation of maleimide 357 towards aza ICZ 364 
Prior to the elucidation of optimum reaction conditions, purification of aza ICZ 364 had 
proven extremely arduous, due to the co-elution of one or more side products under column 
chromatography, coupled with the sparing solubility of the compounds involved. Elimination 
of side product formation was subsequently achieved by increasing the dilution factor of the 
reaction mixture from 100 mg/150 mL of maleimide 357 in acetonitrile to 100 mg/300 mL. 
Addition of a saturated solution of aqueous sodium thiosulfate during workup resulted in the 
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precipitation of a brilliant yellow solid from the biphasic mixture. Following filtration, 
copious water washes and thorough desiccation, analysis of the solid revealed that aza ICZ 
364 had been formed in high purity (Figure 4.11). 
 
Fig. 4.11 
1
H NMR spectrum of aza ICZ 364 (DMSO-d6, 300 MHz)  
Upon complete characterisation of aza ICZ 364, it was possible to gain greater insight into the 
previous side product formation. As well as the expected molecular ion peak at 355 m/z 
appearing in mass spectra of the impure 364, a peak also arose at 357 m/z, potentially 
corresponding to the starting material, maleimide 357. However, from TLC analysis it was 
clear that no more starting material remained, which was further confirmed by NMR 
spectrometry. Although unable to isolate and definitively assign the side products formed 
within the reaction, a number of distinguishable peaks could be identified in the 
1
H NMR 
spectrum (Figure 4.12).  
Of the identifiable peaks within the spectrum, those which are worthy of immediate attention 
include the multiplet at 5.63 ppm and the two doublets at 6.62 and 6.64 ppm (J = 5.1 Hz for 
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both). That which initially appears to be a doublet at 2.73 ppm can actually be assigned as a 
pair of singlets at 2.72 and 2.74 ppm. 
 
Fig. 4.12 
1
H NMR spectrum of aza ICZ 364 with distinguishable signals of side product(s) 
highlighted in yellow (DMSO-d6, 300 MHz) 
Examining the aromatisation of maleimide 357, it is likely that the reaction proceeds through 
dihydro intermediate 365 before conversion to the final product, aza ICZ 364 (Scheme 4.56). 
However, it is unlikely that reaction intermediate 365 is the side product contained in the 
impure sample of 364, as there ought to be two distinct singlets in close proximity occurring 
near 4 ppm due to the two sets of methyl protons. Instead there is one singlet at 3.91 ppm, 
which integrates for the combined singlets at 2.72 and 2.74 ppm, leading to the conclusion 
that the protons for one of the methyl groups have become significantly more shielded.  
It is possible that the shielding effect experienced by one of the methyl groups occurs due to a 
loss of conjugation, brought about by a [1,5] sigmatropic shift of dihydro intermediate 365 to 
give cis 366 and trans 367 side products. Coupling between the cis and trans protons in either 
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of the two proposed side products 366 and 367 can then account for the multiplet 5.63 ppm 
and the two doublets at 6.62 and 6.64 ppm. 
 
Scheme 4.56 Formation of possible side products 366 and 367 of aza ICZ 364 
With insufficient dilution of the reaction mixture, precipitation of intermediary products such 
as 365 can occur, thus introducing the possibility of a [1,5] sigmatropic shift towards 
sideproducts 366 and 367. A doubling of the dilution factor ensured that no precipitation of 
reaction intermediates occurred under exposure to UV light, therefore allowing for the 
formation of aza ICZ 364 in high yield of 81%. 
 
Scheme 4.57 Formation of N-hydroxymaleimide 363 from maleimide 364                                  
via maleic anhydride 362 
The base-catalysed conversion of aza ICZ maleimide 364 to maleic anhydride 362 was carried 
out under reflux in a 2 M solution of aqueous sodium hydroxide for 14 hours (Scheme 4.57). 
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Once cooled to room temperature, dropwise treatment of the reaction mixture with an aqueous 
2 M HCl solution lead to the precipitation of anhydride 362 as a yellow solid in 84% yield, 
which was subsequently used without further purification. A considerable shift of the carbonyl 
stretch was noted in the IR spectrum of anhydride 362 (1747 cm
-1
) compared to maleimide 
precursor 364 (1719 cm
-1
).  
The synthesis of hydroxymaleimide 363 was afforded by the application of 
hydroxylammonium chloride to a mixture of anhydride 362 in pyridine under reflux 
conditions for 12 hours (Scheme 4.57). Recrystallisation from absolute ethanol gave 
hydroxymaleimide 363 as a yellow solid in 88% yield. 
 
Scheme 4.58 Alternative synthesis of N-hydroxymaleimide 363 via                                           
Boc-protected maleimide 368 
A more facile route towards hydroxymaleimide 363 was successfully undertaken via Boc-
protected maleimide 368 (Scheme 4.58). A suspension of maleimide 364 in acetonitrile was 
treated with 2.2 equivalents of di-tert-butyl-dicarbonate (Boc anhydride) and then 0.1 
equivalents of DMAP. After stirring at room temperature for 1 hour, removal of solvent under 
reduced pressure, followed by recrystallisation from ethanol, afforded Boc-protected 
maleimide 368 in excellent yield of 97%. In a similar manner to that previously seen (Scheme 
4.57), formation of hydroxymaleimide 363 was achieved in 94% yield by heating a mixture of 
368 and five equivalents of hydroxylammonium chloride in pyridine to 90 
o
C for 14 hours. 
Seeking to expand the theme of F-ring modulation towards the synthesis of 6-membered 
heterocycles, a modified Lossen rearrangement involving the tosyl derivative of 
hydroxymaleimide 363 and hydrazine was examined (Scheme 4.59). Initially, tosyl chloride 
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was added to a solution of aza ICZ 363 and DMAP in pyridine and DMSO, with the resulting 
mixture allowed to stir for 4 hours at room temperature. The tosyl derivative of 363, used 
without further purification, then underwent a modified Lossen rearrangement following 
reaction with hydrazine hydrate under reflux in ethanol. As a result, a mixture of regioisomers 
369 and 370 was obtained, which proved inseparable by flash column chromatography. 
Employing preparative HPLC, the distance between the peaks of the two regioisomers was 
small and it was not possible to achieve sufficient purification of either regioisomer. 
 
Scheme 4.59 Synthesis of aza ICZs 369 and 370 with 6-membered F-rings 
4.5.5 Aromatisation towards bisaza ICZ 373 and F-ring modulation 
Employment of a similar synthetic methodology towards the development of bisaza ICZs to 
that applied in the monoaza series (Section 4.5.4) proved highly successful (Scheme 4.60). 
 
Scheme 4.60 Synthesis of N-hydroxymaleimide aza ICZ 373 from maleimide 361 
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Aromatisation of maleimide 361 to bisaza ICZ 371 was achieved in 88% yield (Scheme 4.60), 
greater than that obtained for its monoaza analogue 364 (Scheme 4.55). Following protection 
of maleimide 371 to Boc-derivative 372 in excellent yield of 95%, transformation to 
hydroxymaleimide 373 was achieved by reaction with hydroxylammonium chloride in 
pyridine, forming the desired product as a bright yellow solid in 93% yield. 
Due to the symmetrical nature of hydroxymaleimide 373, it was possible to effectuate the 
synthesis of aza ICZ 374 without the occurrence of regioisomers (Scheme 4.61). Following 
tosylation of 373 by treatment with tosyl chloride in the presence of DMAP and pyridine, 
reaction with hydrazine hydrate afforded aza ICZ 374, containing a 6-membered F-ring, by 
means of a modified Lossen rearrangement. Purification by flash column chromatography 
(DCM/MeOH, 95:5) afforded aza ICZ 374 as an off-white solid in 44% yield. 
 
Scheme 4.61 Synthesis of aza ICZ 374 with 6-membered F-ring 
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4.6 Conclusion 
The indolocarbazoles and their derivatives, such as the bisindolylmaleimides, offer enormous 
scope for the development of novel anticancer agents due to the profound nature in which they 
interact on a cellular level. Many synthetic routes towards the ICZs and the BIMs have been 
documented, predominantly since the 1980’s. However, the azaindolocarbazole members of 
the ICZ family have been far less frequently researched - surprisingly so, given the excellent 
biological selectivity profiles that have been described for a number of derivatives. Hence, the 
aim of this project was to devise and implement novel synthetic routes towards aza ICZ and 
aza BIM derivatives, and to examine the paradigm of F-ring modulation as a means of 
potentiating anticancer activity. 
Retrosynthetic analysis identified a series of oxopropanoate and oxopropanenitrile derivatives 
as key intermediates towards the development of aza BIM, and ultimately aza ICZ, targets of 
clinical interest. To this end, initial difficulties were encountered in the synthesis of 
oxopropanoate 267, with only starting material or the self-condensation product 268 of ester 
250 recovered from the reaction. However, following thorough examination of the 
experimental parameters, it was found that increasing the reaction temperature to 35 
o
C upon 
final addition of acyl chloride 266 allowed for the successful formation of desired product 
267. Further application of this methodology allowed for the synthesis of a range of analogous 
oxopropanoate and oxopropanenitrile intermediates. 
Condensation of oxopropanenitrile intermediates 276, 287 and 289 with hydrazine resulted in 
the formation of a series of 5-aminopyrazoles. These heterocyclic targets were to show 
excellent promise both as novel bioisosteres of the BIM core and also for their versatility in 
subsequent derivatisation studies, thus propagating the theme of F-ring modulation. Reaction 
of 5-aminopyrazoles 293, 312 and 318 with bidentate electrophiles such as N-chlorocarbonyl 
isocyanate or hexafluoroacetylacetone afforded novel bicyclic triazinedione and pyrimidine 
systems respectively, while reaction with monodentate electrophiles led to a series of 
derivatives which were substituted either on the exocyclic amine or one of the ring 
nitrogens.
24 
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The synthesis of 6-membered BIM analogues from oxopropanoates 267, 273, 281 and 292 
was found to be significantly more challenging, with pyrimidinone 332 the only derivative to 
be successfully synthesised and purified. It is thought that the nature of the cyclocondensation 
reaction is dependent on the reactivity of nucleophiles such as guanidine and thiouracil, and 
also on the substituents of the oxopropanate electrophiles. 
Aromatisation of pyrimidinone 332 under photochemical conditions led to the successful 
synthesis of the first aza ICZ 239 with a 6-membered F-ring to be described in the literature.
25
 
Subsequent attempts to effectuate similar cyclisations of aminopyrazole 318 and isoxazolone 
327 did not achieve the desired result, perhaps due to the nature of the 5-membered F-rings or 
the alkyl substituents on the indolic nitrogens. Consequently, it was posited that greater 
success would be met in derivatisation of the F-ring after aromatisation had occurred. 
Maleimides 357 and 361 were found to readily undergo aromatisation towards derivatives 364 
and 371, and from these novel aza ICZs, it was possible to achieve desired F-ring modulation 
towards such highly promising candidates as hydroxymaleimides 363 and 373, as well as aza 
ICZ 374 containing a 6-membered F-ring. 
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5.0 Biological Results and Discussion 
The aim of this project was to synthesise and evaluate novel azaindolocarbazole (aza ICZ) 
derivatives, a highly promising and underexploited class of compounds in the field of 
anticancer chemotherapy. Having generated a chemical library containing over 50 novel 
compounds, the biological profiling of potential candidates was imperative in order to exploit 
molecular targets associated with anticancer mechanisms. Considering the diverse chemical 
nature of the indolocarbazole family and associated derivatives, it is unsurprising that a vast 
array of biological modes of action have been associated with different members within the 
class. For example, concomitant to its potent antitumour activity (Section 1.3.2.2), 
rebeccamycin 3 has also been shown to exert antibacterial activity.
1
 Antifungal activity has 
been demonstrated by a number of staurosporine 2 analogues, such as RK-286C 375, which is 
also a protein kinase C (PKC) inhibitor.
2
 The antiviral properties of a number of members of 
the class have also been noted within the literature, such as in the case of the bisindole pyrrole, 
lycogarubin C 376, which was shown in 1994 by Asakawa and co-workers to have moderate 
activity against the HSV-1 virus.
3
      
 
Fig. 5.1 Structures of REB 3, RK-286C 375 and lycogarubin C 376 
The anticancer action of ICZs, however, has been the most widely investigated and reported 
bioactive mechanism associated with this class of compounds.
4-7
 Potent cytotoxic and 
antitumour properties have been documented for numerous ICZ and BIM derivatives, 
primarily occurring via inhibition of eukaryotic DNA topoisomerase I (topo I) or by protein 
kinase inhibition (Section 1.3).
8
 Given the vast importance of cancer research in modern 
society (Section 1.1), it is upon this area that we will focus the evaluation of our panel of 
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novel aza ICZ derivatives. Aiming to realise and exploit suitable biological targets associated 
with such in vivo activity, initial testing involved screening against the NCI 60 cell panel, 
along with DNA topological assays. 
   
5.1 NCI-60 cell screen 
Potential candidates from our library of novel aza ICZ and aza BIM derivatives were initially 
tested against the US National Cancer Institute 60 human tumour cell line panel (NCI-60). 
Developed in the late 1980’s as an in vitro drug-discovery tool, it was intended that the NCI-
60 panel be used to identify compounds with growth-inhibitory or toxic effects on particular 
types of tumour.
9
 However, it quickly became clear that much additional biological 
information could be provided by this screening model. The formation of distinctive patterns 
corresponding to differential sensitivities of the cell lines to particular compounds was found 
to occur, which could then be correlated to similar mechanisms of cell growth inhibition. As a 
result of these observations, Paull and co-workers were able to develop the COMPARE 
algorithm, which can be used to help predict the biological mechanisms by which potential 
chemotherapeutic candidates exert their activity.
10 
Within the NCI-60 panel, the cell lines employed represent leukemia and melanoma, as well 
as cancers of the lung, colon, brain, ovary, breast, prostate and kidney. Compounds submitted 
to this screening process are initially tested at a single dose (10 µM) against the 60 cell line 
panel. Subsequent to this initial testing, compounds which satisfy threshold inhibition criteria 
in a minimum number of cell lines are progressed to a full five-dose assay. 
In the five-dose assay, the percentage growth is calculated at each of the five drug 
concentration levels using a series of absorbance measurements (time zero (Tz), control 
growth (C), and test growth in the presence of the drug at the five different levels (Ti)). The 
response parameters GI50 (concentration required for 50% inhibition of growth) and LC50 
(concentration required for 50% cell death) are extracted from concentration-response curves 
by linear interpolation, while TGI (total growth inhibition) is read as the x-axis intercept from 
the five different drug concentrations.
11 
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5.2 NCI-60 single-dose screen results 
The in vitro activity of each selected compound against the NCI-60 cell panel was displayed 
in the form of an overall mean graph (Appendix i to xxix), comprising a series of horizontal 
bar graphs representing units of nominal growth percent, deviating from the mean growth 
inhibition for the 60 cell line array, i.e. centre line or ‘0’ (a representative example is seen in 
Figure 5.2).  
                                                                                                            
Fig. 5.2 Structure of aminopyrazole 293 and corresponding single-dose NCI-60 cell array 
For each case against the overall mean growth of a compound, graphs which extend to the 
right (-) denote a relative cytotoxic or positive growth inhibitory effect on individual cell lines, 
while those which extend to the left (+) of centre line indicate a relative chemoprotective or 
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non-cytotoxic effect (Figure 5.2). From an early stage in the DTP program, it was recognised 
that identifiable trends across the NCI-60 cell array are characteristic of molecular 
mechanisms of action. 
5.2.1 Aza BIM derivatives containing a 3,4,5-trimethoxyphenyl moiety  
Single-dose mean graphs for parent aminopyrazoles 293 and 312, along with derivatives 295, 
297, 302, 304, 313, 314, 316 and 317 can be found in Appendices i to x. 
With a mean growth of 75%, aminopyrazole 293 did not satisfy the threshold inhibition 
criteria in order to proceed to the five-dose assay (Table 5.1). However, appreciable 
selectivity was shown towards HL-60(TB) and RMPI-8226 leukemia, SNB-75 CNS cancer 
and in particular HOP-92 non-small cell lung cancer lines. Although extension of the 
aminopyrazole moiety towards bicyclic systems 295 and 297 resulted in an increase in the 
mean growth percentage in both cases, greater selectivity was achieved towards the HOP-92 
cell line. This was particularly evident for pyrimidine 297 (Appendix iii), which completely 
arrests growth in this tumour cell line and even exhibits a degree of cytotoxicity after 48 hours 
incubation. 
The selectivity exhibited towards the HOP-92 line by aminopyrazole 293 and derivatives 295 
and 297 indicate the bioactive potential of this compound class, within which it is possible 
that interactions with various isoforms of PKC could have a role. COMPARE analysis has 
previously indicated that the HOP-92 line is one of the most responsive out of the NCI-60 
panel towards PKC modulators.
12
 Enzastaurin 27, which is a BIM analogue and a selective 
inhibitor of PKCβ, has shown strong antiproliferative activity in the low micromolar range 
against the HOP-92 cell line, amongst others within the panel.
13
 Hence, given the specificity 
exhibited by aminopyrazole 293 and its bicyclic derivatives towards HOP-92 cells, further 
biological evaluation could involve assays against the various isoforms of the PKC enzyme. 
While the introduction of an acetyl functionality (derivative 302) resulted in a significant loss 
of activity across the 60 cell line panel (Appendix iv), carbothioamide 304 displayed a lower 
mean growth (66.5%, Appendix v) to that of parent aminopyrazole 293. Retaining remarkably 
similar activity against RMPI-8226 and SNB-75 cell lines to that of its precursor 293, 
Chapter 5 | Biological Results and Discussion 
 
 
[160] 
 
thioamide substitution in 304 gave increased selectivity towards a number of other lines, 
notably in two renal carcinomas (CAKI-1 and UO-31). 
           
 
Table 5.1 Aminopyrazoles 293 and 312 and respective derivatives 
Examination of the single-dose data for aminopyrazole 312 and its derivatives serves to 
illustrate an interesting pattern of tumour chemoselectivity amongst these two isomeric 
classes. Parent aminopyrazole 312 (Appendix vi) and carbothioamide 317 (Appendix x) 
display similar growth inhibition against a number of cell lines including SNB-75, CAKI-1, 
UO-31 and UACC-62 (melanoma) lines, closely resembling the profiles obtained for their 
No. 
Substituents 
NSC 
No. 
Mean 
(%) 
Five 
Dose 
Selected Cells (% Growth) Regioisomer 
Correlation 
(COMPARE) 
R1 R2 HOP-92 SNB-75 CAKI-1 UO-31 
293 NH2 H 754616 75.1 x 30.9 38.1 50.0 51.7 0.791 
295 -NHCONHCO- 754617 104.3 x 53.5 99.7 118.4 94.8 0.366 
297 -NC(CF3)CHC(CF3)- 754618 94.0 x -3.1 67.2 - 73.7 0.632 
302 NH2 COCH3 763899 104.2 x 86.4 101.9 81.0 92.8 0.475 
304 NH2 CSNHCH3 763898 66.5 x - 39.7 18.2 25.3 0.805 
 R3 R4         
312 NH2 H 763892 79.8 x 47.9 34.4 48.9 49.6 0.791 
313 -NHCONHCO- 763893 101.5 x 87.7 67.2 89.8 94.2 0.366 
314 -NC(CF3)CHC(CF3)- 763894 95.4 x - 73.2 82.3 71.2 0.632 
316 NH2 COCH3 763896 76.6 x - 8.5 39.7 33.1 0.475 
317 NH2 CSNHCH3 763895 78.6 x - 26.5 34.1 35.9 0.805 
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isomers 293 and 304. Accordance of the regioisomers is borne out by the high correlations 
obtained using COMPARE analysis, with 0.791 for aminopyrazoles 293 and 312, and 0.805 
for carbothioamides 304 and 317, where 1 is an identical result (Table 5.1). 
In stark contrast to its relatively inactive isomer 302, acetylated aminopyrazole 316 (Appendix 
ix) exhibited significant growth inhibition against CAKI-1, UO-31 and especially SNB-75 cell 
lines, with correlation between the two regioisomers relatively modest at 0.475. Bicyclic 
derivatives 313 and 314 (Appendices vii and viii) displayed unremarkable growth inhibition 
across the NCI-60 cell panel. Unfortunately, pyrimidine 314 was not evaluated against the 
HOP-92 cell line, the line against which the isomeric pyrimidine system 297 had previously 
displayed excellent selective inhibition. Moderate correlation of 0.632 between the two 
pyrimidine systems across remaining lines within the NCI-60 panel indicate that the 
antiproliferative activity of derivative 314 against HOP-92 cells would be worthy of future 
assessment. 
Upon overall appraisal of both sets of regioisomers, close agreement in the single-dose data 
for a number of compounds from either class, especially parent aminopyrazoles 293 and 312, 
carbothioamides 304 and 317 and acetylated aminopyrazole 316, denotes the possibility of a 
common biological mode of action. On the other hand, the lack of activity observed for 
derivative 302 in comparison with its isomer 316, along with the poor correlation between 
triazinedione systems 295 and 313, suggests that there is room for more extensive SAR study.   
5.2.2 Derivatives of 5-aminopyrazole 318 
Single-dose mean graphs for aminopyrazole 318 and derivatives 319, 320, 322 and 323 can be 
found in Appendices xi to xv. 
While possible to distinguish a pattern of tumour chemoselectivity across a number of 
derivatives containing a 3,4,5-trimethoxyphenyl moiety (Sections 5.2.1 ), it was more difficult 
to do so across the NCI-60 profiles of aminopyrazole 318 and its derivatives, suggesting 
different biological targets (and hence molecular mechanisms of action) across the class. 
Thus, it appears that modulation of the F-ring leads to unique bioactivity profiles, a significant 
discovery in the BIM/ICZ field of research. Parent compound 318 (Appendix xi) displays 
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selective activity against a number of leukemia cell lines, especially the SR line, while being 
relatively nonactive across almost all melanoma, ovarian and prostate cell lines. Mean growth 
across the six leukemia lines was found to be 65.1%, while the least activity was seen for 
melanoma, with a mean growth of 95.4% across nine cell lines (Table 5.2). 
 
 
 
 
 
 
 
 
Table 5.2 Aminopyrazole 318 and derivatives 319, 320, 322 and 323 
Similar to its precursor 318, triazinedione 319 is most active against SR leukemia and MCF7 
cell lines, despite having the highest mean growth in this compound series (Appendix xii). In 
contrast, bicyclic congener, pyrimidine 320, displays insignificant growth inhibition against 
any of the leukemia cell lines (Appendix xiii). However, excellent activity is shown for a 
number of other lines, especially SNB-75 CNS cancer cells (Table 5.2). Acetylated derivative 
322 shows greatest growth inhibition against the SR leukemia cell line (Appendix xiv), 
mirroring the parent aminopyrazole 318. 
The trend in selectivity towards melanoma cell lines in this series makes for interesting 
comparative analysis, with parent aminopyrazole 318 initially displaying little activity in this 
regard. The introduction of a bicyclic system in the case of triazinedione 319 resulted in no 
improvement, however trifluoromethyl-substituted pyrimidine 320 induces significant growth 
No. 
Substituents NSC 
No. 
Mean 
(%) 
Five 
Dose 
Selected Cells (% Growth) 
R R’ SR SNB-75 M14 MDA-MB-435 
318 NH2 H 754612 82.0 X 18.4 54.7 119.6 84.6 
319 -NHCONHCO- 754613 94.6 X 61.4 73.4 117.4 104.9 
320 -NC(CF3)CHC(CF3)- 754614 76.9 X 86.3 9.1 12.8 85.5 
322 NH2 COCH3 762132 77.0 X 28.2 54.0 73.2 33.2 
323 NH2 CSNHCH3 754615 73.8 X 46.2 53.3 27.5 25.6 
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inhibition against M14 cells. Monosubstitution of the aminopyrazole in the case of acetylated 
derivative 322 gives good selectivity for the MDA-MB-435 line, and in the case of 
carbothioamide 323 the M14 and MDA-MB-435 lines. It is therefore seen that substitution on 
the F-ring induces different antiproliferative mechanisms in the cells tested, with the nature of 
the substituent leading to different selectivity profiles in the NCI-60 cell array. Worthy of 
further investigation, future work on this series could aim to look at increasing the potency of 
the aminopyrazole derivatives in order to better exploit the appealing bioactive characteristics 
observed. 
5.2.3 Various aza BIM derivatives 
Single-dose mean graphs for various aza BIM derivatives 326, 327, 328, 332, 356, 357 and 
361 can be found in Appendices xvi to xxii. 
 
 
Table 5.3 Aza BIM derivatives 326, 327, 328, 332, 356, 357 and 361 
No. 
Substituents 
X 
NSC 
No. 
Mean 
(%) 
Five 
Dose 
Selected Cells (% Growth) 
R R’ SR 
SF-
295 
SNB-
75 
MDA-MB-
435 
SK-
MEL-2 
A498 
326 -NHNHCO- Bn CH 762134 95.3 x 91.3 94.2 49.5 104.8 - 118.1 
327 -NHOCO- Me CH 762131 60.9  9.3 51.6 49.2 2.6 36.0 79.4 
328 -N(CH3)OCO- Me CH 762133 92.5 x 83.5 92.2 73.3 100.7 87.0 105.9 
332 -NC(NH2)NHCO- Me CH 754611 97.6 x 90.4 98.2 87.6 98.8 105.1 85.7 
356 -CON(OH)CO- Me CH 762130 97.8 x 53.1 93.1 79.8 104.9 109.8 113.1 
357 -CONHCO- Me CH 762129 28.8  12.1 9.5 10.4 12.9 -13.8 -19.9 
361 -CONHCO- Me N 763897 56.1  9.0 
-
14.1 
-12.1 67.1 94.5 -15.7 
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Due to the relative structural disparity between the various aza BIM derivatives featured in 
Table 5.3, little correlation in activity is seen across the NCI-60 panel. Pyrazolone 326 
displays insignificant inhibition against the majority of cell lines, with a mean growth of 
95.3% (Appendix xvi). The only exception was in the case of SNB-75 CNS cancer, which was 
the only cell line to have less than 50% growth after 48 hours incubation. 
Isoxazolone 327, with a mean growth of 60.9%, passed the threshold inhibition criteria in 
order to proceed to five-dose testing (Appendix xvii). Good selectivity is seen for a number of 
cell lines, with growth almost completely arrested in the case of M14 melanoma cells, and 
excellent activity also seen against SR leukemia, NCI-H522 lung cancer and HT29 colon 
cancer lines. The introduction of a methyl protecting group on the isoxazolone moiety for 
derivative 328 resulted in an almost complete loss of growth inhibitory activity (Appendix 
xviii). However, some selectivity is retained for UO-31 renal, MCF7 and MDA-MB-468 
breast cancer cells, against which parent isoxazolone 327 is also active. With a mean growth 
of 97.6%, six-membered pyrimidinone BIM derivative 332 was shown to have very little 
bioactivity across the NCI-60 panel, concomitant with relatively little selectivity evident for 
any particular cell lines (Appendix xix). The bisindolyl analogue of pyrimidinone 332, 
previously synthesised within our research group, had also exhibited little antiproliferative 
activity, with a mean growth of 101.9%.
14 
Both monoaza maleimide 357 (Appendix xxi) and bisaza maleimide 361 (Appendix xxii) were 
brought forward for five-dose testing, given the promising nature of the single-dose data for 
both compounds. Although monoaza maleimide 357 had a lower mean growth of 28.8% 
compared with bisaza analogue 361 (56.1%), greater selectivity was seen for bisaza 361, 
which displays a degree of cytotoxicity against SF-295 and SNB-75 CNS cancer, and A498 
renal cancer lines. Monoaza maleimide 357 also displays cytotoxic effects against a number of 
lines within the panel, including SF-539 CNS, SK-MEL-2 melanoma and A498 renal cells. 
The greater degree of selectivity seen for bisaza maleimide 361 mirrors work carried out by 
Kuo and co-workers (Section 1.3.1.5), who noted that a series of bisaza BIM derivatives were 
more selective inhibitors of glycogen synthase kinase-3 (GSK-3) than their monoaza 
analogues.
15
 However, this is not a direct correlation, as Kuo et al. utilised a kinase inhibition 
assay, whereas this data arises from cellular growth inhibition assays.   
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The role of the maleimide moiety in the bioactivity of 357 and 361 was highlighted in the 
single-dose data obtained for hydroxymaleimide 356 (Appendix xx). The introduction of an N-
hydroxy functionality to the maleimide ring for 356 resulted in a loss of activity across the 
NCI-60 array (mean growth 97.8%), with the only appreciable growth inhibition retained for 
the SR leukemia cell line (Table 5.3). 
5.2.4 Azaindolocarbazoles 
Single-dose mean graphs for aza ICZs 239, 364, 363, 368, 371, 372 and 373 can be found in 
Appendices xxiii to xxix. 
 
 
 
 
Table 5.4 Six-membered aza ICZ 239 
Pyrimidinone 239 was the first aza ICZ with a six-membered F-ring to be tested against the 
NCI-60 cell screen (Appendix xxiii). Although formation of the central carbazole ring resulted 
in greater bioactivity in comparison with its unaromatised analogue 332, aza ICZ did not meet 
the criteria for further analysis within the DTP program. Selectivity was observed against a 
number of cell lines, including NCI-H522 lung, UO-31 renal and MCF7 and T-47D breast 
carcinomas (Table 5.4). Using COMPARE analysis, it was shown that poor correlation of 
0.441 exists between aza ICZ 239 and its ICZ analogue 231, previously synthesised within 
this research group, and the introduction of an aza moiety resulted in a decrease in overall 
activity.
14
 Hence, the discrete change of a single atom results in a different biological profile, 
as was described previously by Prudhomme et al. with other aza ICZ derivatives (Section 
1.3.2.3).
16
  
No. NSC No. 
Mean 
(%) 
Five 
Dose 
Selected Cells (% Growth) 
NCI-H522 UO-31 MCF7 T-47D 
239 762128 79.5 x 35.1 39.4 45.7 48.7 
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In contrast, all of the aza ICZs containing a 5-membered F-ring to be tested against the NCI-
60 panel were found to be sufficiently active in order to proceed to the five-dose screen (Table 
5.5). Given the conserved structural nature of aza ICZs 364, 363, 368, 371, 372 and 373, it is 
unsurprising that similar trends of bioactivity are observed across the series. For example, the 
SR leukemia cell line is consistently targeted by each compound to varying degrees. In the 
cases of maleimide 364, hydroxymaleimide 363 and Boc-protected maleimides 368 and 372, 
growth of SR leukemia cells is almost completely arrested, while in the case of maleimide 371 
and hydroxymaleimide 373, significant cytotoxicity was observed.   
 
 
Table 5.5 Aza ICZs 364, 363, 368, 371, 372 and 373 containing 5-membered F-rings 
Bisaza maleimide 371 and bisaza hydroxymaleimide 373 were found to be more potent than 
their monoaza analogues 364 and 363, in contrast with the single-dose data obtained for 
unaromatised monoaza and bisaza maleimides 357 and 361 (Section 5.2.3). 
Hydroxymaleimide 373 was the most bioactive compound in the series against the NCI-60 
cell array, with the induction of cytotoxic effects against eight different cell lines after 48 
No. 
Substituent 
X 
NSC 
No. 
Mean 
(%) 
Five 
Dose 
Selected Cells (% Growth) 
R 
MOLT-
4 
SR 
SF-
295 
SNB-
75 
MCF7 
T-
47D 
MDA-MB-
468 
364 H CH 762125 63.1  61.5 10.2 69.5 61.2 15.9 34.9 20.5 
363 OH CH 762126 37.7  -8.6 3.3 18.2 -6.4 3.3 -7.7 41.5 
368 Boc CH 762127 50.7  61.0 5.9 52.3 28.9 4.4 -0.6 5.5 
371 H N 763889 55.9  -7.6 
-
30.2 
6.5 16.1 20.3 61.8 24.3 
372 Boc N 763890 61.2  -5.8 1.8 16.8 85.3 24.7 57.1 31.4 
373 OH N 763891 20.0  -33.0 
-
25.1 
-17.8 10.3 5.4 25.3 -14.9 
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hours of incubation, particularly in the case of MOLT-4 and SR leukemia and 786-0 renal 
cancer lines (Appendix xxix).  
5.2.5 Conclusion 
Of the twenty nine compounds submitted to the DTP for screening to date, nine were deemed 
to be sufficiently cytotoxic or have suitably interesting selectivity profiles to progress to five-
dose testing. Much useful information was obtained from the single-dose testing, with a 
number of promising leads for future work. A number of aza BIM derivatives containing a 
3,4,5-trimethoxyphenyl subunit displayed good selectivity towards the HOP-92 line (Section 
5.2.1), which would make it worthwhile to further investigate the biological pathways 
responsible for apoptosis in these cells, in particular PKC interaction. It was also clear that F-
ring modulation could profoundly impact on the anticancer activity of aza BIM derivatives 
(Section 5.2.2). For example, substitution of aminopyrazole 318 with either mono- or 
bidentate ligands resulted in different antiproliferative profiles and the conferring of good 
selectivity for a number of cancer cell lines, such as melanoma M14 or MDA-MB-435 lines.  
The changing of even one atom significantly impacted on the single-dose data obtained for 
different candidates. For example, a second 7-azaindolyl subunit instead of an indolyl moiety 
in maleimide 361 lead to greater selectivity for a number of cell lines, though with a higher 
overall mean growth than its monoaza analogue 357. Further exploitation of this paradigm 
could be of major benefit in future SAR studies. Interestingly, there is a complete drop off in 
activity between maleimide 357 to hydroxymaleimide 356, whereas significant 
antiproliferation is evident for both corresponding monoaza ICZ derivatives 364 and 363. 
Hence, it can be surmised that the maleimide functionality is of considerably greater 
importance towards antiproliferative activity in the unaromatised analogues compared to their 
corresponding planar aza ICZs.   
Although not as detailed as results obtained from the five-dose assay, the single-dose NCI-60 
screen allows for a higher throughput of compounds and is a valuable tool in the identification 
of potential leads for future chemotherapeutic candidates, and also for elucidating putative 
biological mechanisms of action.  
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5.3 NCI-60 five-dose screen results 
Compounds which were successfully brought forward for five-dose testing were tested against 
the NCI-60 cell panel at five different concentrations ranging from 100 µM to 10 nM. As a 
result of the data obtained, dose-response curves were generated for cell growth inhibition as a 
function of inhibitor concentration for each cell line. The three characteristic in vitro 
parameters, GI50, TGI and LC50, were calculated for each cell line in response to the presence 
of the different drug candidates. 
5.3.1 Five-dose data for isoxazolone 327 
Having shown sufficient promise in initial screening, isoxazolone 327 was subsequently tested 
at five different concentrations against the NCI-60 cell array. Inhibition across the panel was 
observed to occur in a dose-dependent manner (Figure 5.3), with GI50 values predominantly 
in the low micromolar range (Appendices xxx and xxxi).  
 
Fig. 5.3 Dose-response curves for isoxazolone 327 
It was of significant interest to note that the MDA-MB-435 melanoma line, which had the 
lowest percentage growth after 48 hours in the single-dose screen, also had the lowest GI50 
and TGI values (1.18 µM and 3.75 µM respectively) in response to isoxazolone 327 in the 
five-dose testing, illustrating a consistency in results. The lethal concentration required for the 
death of 50% of cell population (LC50) was >100 µM in almost all cases across the panel. The 
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only appreciable cytotoxicity was found for the COLO 205 colon carcinoma line, with an 
LC50 value of 58 µM (Figure 5.4). 
 
Fig. 5.4 Dose response curves of isoxazolone 327 against colon cancer and melanoma cells 
The antiproliferative activity recorded against the MDA-MB-435 line suggests the potential 
role of isoxazolone 327 as a mitogen-activated protein kinase (MAPK) inhibitor. In 2000, 
Roberts et al. described how p38 MAP kinase plays a role in the adhesive properties of human 
tumour cells, specifically MDA-MB-435 cells.
17
 Concomitantly, Laufer et al. demonstrated in 
2008 that a series of diaryl-substituted isoxazolones functioned as potent inhibitors of the p38 
MAP kinase enzyme.
18
 Hence, in order to investigate MAPK inhibition as a potential 
biological mechanism for 327, future investigation using the relevant enzyme assays is 
imperative. 
5.3.2 Five-dose data for maleimides 357 and 361 
With the second-lowest mean growth in the single-dose screen, monoazaindolyl maleimide 
357 was a clear candidate for further biological examination. Pronounced cytotoxic effects are 
observed across many cell lines at higher concentrations, however there is a discernible drop-
off in activity between the 10 µM and 100 nM levels (Appendices xxxii and xxxiii). 
 
Fig. 5.5 Structures of monoaza maleimide 357 and bisaza maleimide 361 
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As seen for isoxazolone 327 (Section 5.3.1), correlation between the two screens is quite 
noticeable in the case of maleimide 357. The A498 renal cancer cell line was observed to have 
the lowest TGI value (2.3 µM) out of the NCI-60 cell panel (Figure 5.6), thus complimenting 
the single-dose data for 357, in which the lowest growth percent (-19.9%) was also seen for 
the same line.  
 
Fig. 5.6 Dose-response curves for 357 against melanoma, renal and colon cancer cells 
Maleimide 357 is also seen to have cytotoxic effects across several cell lines, including COLO 
205 (LC50 = 8.1 µM) and KM12 (LC50 = 43.2 µM) colon, SF-539 (LC50 = 42.4 µM) CNS, 
M14 (LC50 = 58.8 µM) and SK-MEL-5 (LC50 = 21.8 µM) melanoma lines. An interesting 
parallel between isoxazolone 327 and maleimide 357 is revealed by the fact that the most 
pronounced cytotoxicity is observed against the COLO 205 cell line in both cases.  
Maleimide 361 displays a broadly similar dose-response curve to that of its monoaza analogue 
357 (Appendices xxxiv and xxxv). However, at lower concentrations, admirable selectivity is 
seen for A498 renal cancer cells in the NCI-60 array, with a submicromolar dosage (0.9 µM) 
of malemide 361 required to totally arrest growth, and a GI50 of 157 nM (Figure 5.7).
 
 
Fig. 5.7 Dose-response curves for bisazaindolyl maleimide 361 
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Bisaza maleimide 361 also displays considerable cytotoxicity against A498 cells with an LC50 
of 33.2 µM. Significantly, analogous BIM enzastaurin 27, which is most active against K562 
and MOLT-4 leukemia, HOP-92 lung and PC-3 prostate cancer cells, does not exert any 
antiproliferative activity on the A498 line.
13
 
As seen previously with isoxazolone 327 and monoaza maleimide 357, bisaza maleimide 361 
mediates anticancer activity primarily in a dose-dependent manner. Low TGI values are 
observed across a range of different cell lines, including MALME-3M (5.5 µM) and SK-
MEL-2 (7.4 µM) melanoma, SK-OV-3 (7.6 µM) ovarian, UO-31 (6.8 µM) renal and HOP-92 
(17.0 µM) cancer cell lines. 
5.3.3 Five-dose data for monoaza ICZs 
The dose-response curves for the aza ICZs with five-membered F-rings were found to be more 
atypical than those seen for isoxazolone 327 (Section 5.3.1) and maleimides 357 and 361 
(Section 5.3.2). For example, greater antiproliferative activity is seen across almost all cell 
lines at a concentration of 10 µM than at 100 µM for monoaza ICZ 364 (Appendices xxxvi and 
xxxvii, Figure 5.9). This may in part be due to the relatively insoluble nature of the 
compound, with reduced efficacy at higher concentration perhaps due to aggregation of the 
precipitated maleimide 364. 
Excellent activity at nanomolar concentrations is seen for 364 against a number of cell lines, 
highlighting its considerable potency. For example, low nanomolar activity is seen against SR 
leukemia cells (GI50 = <10 nM), and also against NCI-H460 lung (GI50 = 22.6 nM), MCF7 
(GI50 = 31.0 nM) and MDA-MB-468 breast (GI50 = 27.4 nM) cancer cells (Figure 5.8).
 
 
Fig. 5.8 Dose-response curve for aza ICZ 364 
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Though antiproliferative activity is quite potent even at lower concentrations for a number of 
cells, little cytotoxicity was seen for monoaza ICZ 364 across the panel. COMPARE analysis 
indicated a correlation of 0.679 with the mycotoxin, 5-methoxy sterigmatocystin (NSC 
S178249), which has previously been shown to have potent antitumour properties.
19
 
Introduction of a Boc protecting group on the maleimide moiety of monoaza ICZ 368 resulted 
in a large increase in the solubility of the compound (for instance, dissolution occurs much 
more readily in DMSO at higher concentrations). This is seen to translate into a more typical 
dose-response curve across the NCI-60 cell array (Figure 5.9), with higher concentrations 
generally corresponding to greater antiproliferative activity for 368.  
 
Fig. 5.9 Dose-response curves for maleimide 364 and Boc-protected maleimide 368 
As was the case for maleimide 364, greatest activity for 368 is seen against SR leukemia cells 
(GI50 = 15.4 nM), along with inhibition of several other lines in the nanomolar range, such as 
NCI-H460 lung (GI50 = 34.3 nM), ACHN (GI50 = 42.7 nM) and UO-31 (GI50 = 29.0 nM) 
renal, and MCF7 breast (GI50 = 36.2 nM) cancer cells (Appendices xl and xli, Figure 5.10).   
Boc-protected aza ICZ 370 exhibits cytotoxicity against several cell lines, such as HOP-62 
lung (LC50 = 9.6 µM), OVCAR-3 (LC50 = 8.2 µM) and OVCAR-4 ovarian (LC50 = 6.7 µM), 
and BT-549 breast (LC50 = 14.6 µM) cancer cells. This contrasts starkly with maleimide 364, 
which only shows discernible evidence of a cytotoxic effect against one cell line from the 
NCI-60 array, SNB-75 (LC50 = 61.2 µM). It is possible that the Boc functionality renders 368 
into a pro-drug for maleimide 364, resulting in greater solubility of the molecule and 
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increasing the ease with which it crosses the cell membrane. It is also possible that the Boc 
group could potentiate interactions with cellular targets. Using COMPARE, strong correlation 
of 0.811 is seen between Boc-protected maleimide 368 and maleimide 364, with moderate 
correlations also seen between 368 and a phenanthridine derivative (0.614, NSC S125552) 
and camptothecin (0.538, NSC S651012), a known topo I inhibitor (Section 1.3.2.1). 
 
Fig. 5.10 Dose-response curves for 368 against leukemia, lung, ovarian,                                 
renal and breast cancer cells 
Upon conversion of 368 to hydroxymaleimide 363, most cytotoxicity is lost (Appendices 
xxxviii and xxxix). However, greatest antiproliferative activity is once more seen against SR 
leukemia cells (GI50 = 35.3 nM), suggesting a common target (Figure 5.11).  
 
Fig. 5.11 Dose-response curve for aza ICZ 363 
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Useful bioactivity is also seen for 363 against a number of melanoma cell lines, such as M14 
(GI50 = 259 nM) and SK-MEL-5 (GI50 = 470 nM) (Figure 5.11). 
Further investigation using the COMPARE algorithm demonstrates a very high correlation 
between hydroxymaleimide 363 and a series of derivatives of camptothecin 37, such as 
anticancer agent topotecan 38 (Table 5.6). 
 
Correlation Compound NSC Number 
0.848 Camptothecin prodrug S374028 
0.836 Camptothecin conjugate (+ etoposide) S683556 
0.825 Deoxycamptothecin S105132 
0.819 Camptothecin lysinate S610457 
0.811 Topotecan 38 S609699 
 
Table 5.6 Correlation of aza ICZ 363 with derivatives of camptothecin 37 using COMPARE 
The strong correlation seen between aza ICZ 363 and the derivatives of camptothecin 37 
indicate the existence of a similar biological mode of action. As camptothecin 37 and its 
derivatives are renowned as topo I inhibitors, it suggests that aza ICZ 363 could interact with 
the same enzyme or perhaps with DNA itself. 
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5.3.4 Five-dose data for bisaza ICZs 
Having examined the chemotherapeutic potential of a series of monoazaindolyl ICZs (Section 
5.3.3), attention was subsequently focused on derivatives containing two 7-azaindolyl 
moieties. Maleimide 371 was found to have a similarly unusual dose-response profile 
(Appendices xlii and xliii) to that of its monoaza analogue 364, containing a general trend of 
increased bioactivity with decreasing concentration from 100 µM to 100 nM. Once more, poor 
solubility of maleimide 371 is thought to be a factor in this phenomenon. 
 
Fig. 5.12 Structures of aza ICZs 371 and 372 
It was found that the addition of the second azaindolyl subunit in 371 did not significantly 
enhance antiproliferative activity against the NCI-60 array relative to monoaza ICZ 364. Once 
more, however, excellent growth inhibition is seen against SR leukemia cells (GI50 = <10 
nM), which have been consistently targeted by any aza ICZs tested that contain a five-
membered F-ring (Figure 5.13).  
 
Fig. 5.13 Dose-response curves of maleimide 371 against leukemia and renal cancer cells 
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Due to the nature of the dose-response curves for bisaza ICZ 371, it was not possible to 
calculate GI50 values for a number of cell lines, and reassessment against the panel is currently 
ongoing in order to ascertain more accurate information. 
Protection of the maleimide moiety in 372 with a Boc group resulted in increased 
antiproliferative activity against a number of cell lines relative to its precursor 371, again 
raising the possibility of 372 functioning as a prodrug (Appendices xliv and xlv). Unlike with 
its monoaza analogue 368, however, a significant increase in cytotoxicity against a number of 
cell lines is not observed. 
 
Fig. 5.14 Dose-response curves for 372 against leukemia, colon and breast cancer cells 
As in the case of maleimide 371, the nature of the dose-response curves recorded for Boc-
protected 372 meant that GI50 values for a number of cell lines were unable to be calculated. 
However, amongst the figures that proved possible to obtain, considerable cytostatic effects 
are evident across a number of different cancer types, with only low nanomolar concentrations 
of 372 required to inhibit 50% of growth in many instances (Figure 5.14). As seen previously, 
a GI50 value of less than 10 nM is seen for the SR leukemia cell line, along with a number of 
other lines such as SW-620 colon, SF-295 CNS, ACHN and CAKI-1 renal cancers. 
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Fig. 5.15 Dose-response curves for bisaza ICZ 373 
Upon conversion of Boc-protected maleimide 372 to hydroxymaleimide 373, restoration of 
more typical dose-response curves were recorded, albeit with a large increase in cytotoxicity 
across most cell lines tested (Figure 5.15). Low nanomolar GI50 values of less than 10 nM 
were obtained for 373 against similar cell lines to those targeted by its precursor 372, such as 
SR leukemia, SW-620 colon, ACHN and CAKI-1 renal cancer cells (Figure 5.16).  
 
Fig. 5.16 Dose-response curves for 373 against leukemia, lung, melanoma,                            
renal and breast cancer cells 
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There were also nanomolar TGI figures obtained for hydroxymaleimide 373 against a number 
of cancer lines, including MOLT-4 leukemia (54.0 nM), SF-539 CNS (97.8 nM) and UACC-
62 melanoma (81.5 nM) cells. Unlike either of its bisazaindolyl analogues 371 and 372, aza 
ICZ 373 displays cytotoxic effects across many cancer cells, such as MDA-MB-468 breast 
(LC50 = 1.3 µM), SK-MEL-5 (LC50 = 0.8 µM) and UACC-62 melanoma (LC50 = 5.9 µM) 
lines (Appendices xlvi and xlvii). 
Utilisation of the COMPARE algorithm to help determine a putative biological mode of action 
for hydroxymaleimide 373 proved relatively successful, with strong correlation again seen for 
topotecan 38. As was the case with its monoaza analogue 363, strong correlation between 
hydroxymaleimide 373 and topotecan 38 was observed based on GI50 values (0.755). 
However, unlike with monoaza ICZ 363, this correlation between bisaza ICZ 373 and 
topotecan 38 was upheld on comparison of TGI (0.611) and LC50 (0.745) values. In fact, 375 
was found to have an identical potency to toptecan 38 in terms of mean cytotoxicity (LC50 = 
63 µM), further corroborating evidence of a common biological mechanism. Strong 
correlation, based on LC50 values, was also noted between bisaza ICZ 373 and the clinical 
standard anticancer agent cisplatin (0.757). 
Examination of the five-dose data for aza ICZs 363 and 373 illustrates that the 
hydroxymaleimide moiety is necessary for strong correlation to the bioactivity of topotecan 
38. Though both compounds exhibit excellent growth inhibition across many cell lines in the 
NCI-60 array, inclusion of the second azaindolyl functionality in 373 results in a large 
increase in cytotoxicity against a number of different cancer types, a fact which could prove 
very useful in future SAR work.    
The use of topotecan 38 and other topo I inhibitors (particularly camptothecin 37 derivatives) 
has been of immense importance in the field of cancer chemotherapeutics over the last twenty 
years.
20
 Due to an ever growing understanding of the role of topoisomerase I in the 
proliferation of different cancer types, new targets are constantly being uncovered. This year 
for example, using the Cancer Cell Line Encyclopaedia (CCLE), Barretina et al. predicted that 
expression of the SLFN11 gene was linked to sensitivity to topo I inhibitors.
21
 Examining over 
4,000 primary tumour samples spanning 39 lineages, it was found that Ewing’s sarcomas 
Chapter 5 | Biological Results and Discussion 
 
 
[179] 
 
exhibited the highest SLFN11 expression, suggesting that topo I inhibitors could potentially 
offer an effective treatment option for this cancer type (Figure 5.17). 
 
Figure 5.17 Expression of SLFN11 in 4,103 primary tumour samples
21 
Looking for markers which were predictive of response to several conventional 
chemotherapeutic agents, SLFN11 expression had emerged as the top correlate of sensitivity 
towards topotecan 38 and irinotecan 377, another camptothecin 37 derivative. These latest 
findings confirm the preliminary results of a number of clinical trials currently underway to 
examine the use of topotecan 38 and irinotecan 377 in combinatorial regimens towards the 
treatment of Ewing’s sarcoma.22 
 
Figure 5.18 Structure of irinotecan 377 
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5.3.5 Conclusion 
A vast amount of valuable information was obtained from the results of the five-dose assays 
on nine aza BIM and aza ICZ derivatives, which has lead to a number of potential leads for 
further biological evaluation. It was found that isoxazolone 323 exhibited good activity 
against the MDA-MB-435 cell line, suggesting a potential role as a MAPK inhibitor (Section 
5.3.1). Although maleimides 357 and 361 show good selectivity for a number of cancer cell 
lines within the NCI-60 array, there is a drop off in activity at lower concentrations (Section 
5.3.2). However, this issue with potency could be addressed in future SAR studies. 
In contrast to maleimides 357 and 361, most of the monoaza and bisaza ICZs exhibit excellent 
activity against a number of cell lines at lower concentrations (Sections 5.3.3 and 5.3.4). In 
particular, many of the candidates within this series show good selectivity for the SR leukemia 
cell line, warranting a need for further examination to establish the associated molecular 
targets. As evidenced by COMPARE analysis, there is a strong correlation between the 
biological profiles of hydroxymaleimides 363 and 373 and that of the known topoisomerase I 
inhibitor, topotecan 38. Hence, the next mode of investigation in the elucidation of the 
biological targets associated with these aza ICZs assumes the form of a series of topological 
assays. 
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5.4 Topoisomerase I-mediated DNA cleavage assay 
Results from the NCI-60 five dose screen had previously indicated a strong correlation 
between the bioactivities of several candidates from our aza ICZ panel and those of known 
topo I inhibitors, such as topotecan 38 (Sections 5.3.3 and 5.3.4). Initiating a series of DNA 
topological assays, selected derivatives were screened for their ability to inhibit topo I-
mediated DNA cleavage. Each aza ICZ was examined at a number of different concentrations, 
with the experimental protocol adapted from Marminon et al. (Section 7.2.1).
16
 By measuring 
the intensity of the nicked DNA in the lanes of each gel, it was possible to quantify the 
activity of each drug relative to the standard topo I inhibitor camptothecin 37. 
5.4.1 Monoaza ICZ assays 
In the first assay, maleimide 364 showed excellent activity against topo I, comparing very 
favourably against camptothecin 37 (Figure 5.19). 
       
 
Fig. 5.19 Topo I assay for maleimide 364 at different concentrations, with a graph of relative 
intensities of inhibition compared to CPT controls; A = positive control (DNA + topo I + 
water); B = negative control (DNA); C = camptothecin (20 µM); D = camptothecin (50 µM). 
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The topo I inhibition displayed by maleimide 364 was found to be relatively consistent 
regardless of dosage, with only a small decrease in observed activity corresponding to a 
lowering of the drug concentration (Figure 5.19). The inhibitory activity of maleimide 364 
was found to be almost identical to that shown by camptothecin 37, albeit slightly lower. The 
pattern of topo I inhibition mirrors the unusually flat dose-response curve obtained for 364 in 
the NCI-60 five dose screen (Section 5.3.3), and is perhaps a function of the relatively 
insoluble nature of the compound. 
The introduction of a Boc protecting group in aza ICZ 368 results in more typical 
concentration-dependent activity against topo I (Figure 5.20). However, despite the overall 
increase in solubility, Boc-protected 368 displays less inhibition than parent maleimide 364. 
       
 
Fig. 5.20 Topo I assay for Boc-protected maleimide 368 at different concentrations;               
A = positive control (DNA + topo I + water); B = negative control (DNA only);                     
C = camptothecin (20 µM); D = camptothecin (50 µM). 
The third derivative in the monoaza ICZ series, hydroxymaleimide 363, showed less topo I 
activity than maleimide 364, Boc-protected maleimide 368 or the camptothecin controls 
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(Figure 5.21). This was an unexpected result, as a high correlation had previously been 
recorded between the bioactivity of hydroxymaleimide 363 in the NCI-60 five dose screen and 
those of a series of camptothecin derivatives (Section 5.3.3). Given the measured intensities of 
nicked DNA across the different concentrations, it can be seen that topo I inhibition by aza 
ICZ 363 in this assay is independent of dose. 
       
 
Fig. 5.21 Topo I assay for hydroxymaleimide 363 at different concentrations;                         
A = positive control (DNA + topo I + water); B = negative control (DNA only);                                            
C = camptothecin (20 µM); D = camptothecin (50 µM). 
The disparity between the NCI-60 data and the cleavage assay for hydroxymaleimide 363 is 
perhaps indicative of a different inhibitory mechanism than that of the topo I “poisoning” 
effectuated by derivatives of camptothecin 37. It is possible that aza ICZ 363 instead acts as a 
topo I “suppressor”, whereby the drug directly inhibits the enzyme without stabilising the 
intermediary topo I-DNA covalent complex. Inhibition of topo I in this manner prevents any 
binding of the enzyme to the cleavage site, thus halting all subsequent steps in the catalytic 
cycle, such as religation of the broken DNA strands.
23
 As such, the interaction of 
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hydroxymaleimide 363 with topo I in this manner would not be illuminated in a cleavage 
assay, and could explain the low level of observed activity. 
5.4.2 Bisaza ICZ assays 
Maleimide 371, containing two azaindolyl moieties, retains an almost uniform level of 
inhibition across the range from 50 µM down to 1 µM, illustrating activity which is relatively 
independent of concentration at the dosages tested in this assay (Figure 5.22). 
       
 
Fig. 5.22 Topo I assay for maleimide 371 at different concentrations; A = positive control   
(DNA + topo I + water); B = negative control (DNA only); C = camptothecin (20 µM);             
D = camptothecin (50 µM). 
Much like the results of the cellular testing on the NCI-60 panel (Section 5.3.4), the 
incorporation of a second 7-azaindolyl subunit into the aza ICZ pharmacophore did not 
improve the efficacy of maleimide 371 compared with its monoaza analogue 364. Lower 
levels of inhibition were also observed for 371 compared to the camptothecin controls. 
0 
20000 
40000 
60000 
80000 
100000 
1
 µ
M
 
2
.5
 µ
M
 
5
 µ
M
 
1
0
 µ
M
 
2
0
 µ
M
 
5
0
 µ
M
 
2
0
 µ
M
 C
P
T 
5
0
 µ
M
 C
P
T 
ar
e
a
 
371 
Chapter 5 | Biological Results and Discussion 
 
 
[185] 
 
However, introduction of a Boc protecting group in aza ICZ 372 (lending a structural 
similarity to the topo I inhibitor NB-506 43) resulted in a significant increase in the level of 
interaction with the topo I-DNA covalent complex, as evidenced in Figure 5.23. Although the 
dose-response curve is not as typical as that recorded for monoaza analogue 368 (Section 
5.4.1), there is a clear drop off in activity at concentrations of 1 µM and 2.5 µM for aza ICZ 
372, a property not readily seen for the other aza ICZ derivatives tested. Unlike with parent 
maleimide 371, the inclusion of a second 7-azaindolyl functionality for Boc-protected 
derivative 372 resulted in an increase in topo I inhibition relative to its monoaza analogue 368, 
again consistent with data obtained from the NCI-60 five-dose screen (Section 5.3.4). 
       
 
Fig. 5.23 Topo I assay for Boc-protected maleimide 372 at different concentrations;                
A = positive control (DNA + topo I + water); B = negative control (DNA only);                      
C = camptothecin (20 µM);D = camptothecin (50 µM). 
Hydroxymaleimide 373 was the most promising candidate to emerge from the NCI-60 five-
dose screen, with excellent antiproliferative activity recorded across a range of different 
cancer cell lines, with a strong correlation to the bioactivity of topotecan 38 indicated by 
COMPARE analysis (Section 5.3.4). It was therefore of little surprise that hydroxymaleimide 
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373 displayed outstanding inhibitory activity in the topo I-mediated DNA cleavage assay 
(Figure 5.24). As in the case of Boc-protected maleimide 372, it would appear that a second 
7-azaindolyl subunit does much to increase the efficacy of aza ICZ 373 relative to its monoaza 
analogue 363. 
       
 
Fig. 5.24 Topo I assay for hydroxymaleimide 373 at different concentrations;                          
A = positive control (DNA + topo I + water); B = negative control (DNA only);                      
C = camptothecin (20 µM); D = camptothecin (50 µM). 
 
5.4.3 Conclusion 
The results of the assays indicate that significant interaction occurs between the tested aza ICZ 
candidates and the topo I-DNA covalent complex, a mode of action which could perhaps be at 
least partially responsible for the antiproliferative activities recorded in the NCI-60 screen. 
However, although hydroxymaleimide 373 was the most potent compound tested in the five 
dose screen, it did not display the greatest inhibition of topo I in the cleavage assay, indicating 
that perhaps there are other cellular targets or mechanisms involved. For example, it is 
possible that hydroxymaleimide 373 also acts as a topo I suppressor as well as a topo I poison. 
0 
5000 
10000 
15000 
20000 
25000 
1
 µ
M
 
2
.5
 µ
M
 
5
 µ
M
 
1
0
 µ
M
 
2
0
 µ
M
 
5
0
 µ
M
 
2
0
 µ
M
 C
P
T 
5
0
 µ
M
 C
P
T 
ar
e
a
 
373 
Chapter 5 | Biological Results and Discussion 
 
 
[187] 
 
Apart from Boc-protected maleimides 368 and 372, unusual dose-response profiles were 
observed for the other aza ICZs tested, with activity seemingly independent of the dosage 
range. In order to ascertain a lower limit of topo I inhibition for these derivatives, it is 
necessary that further assays be carried out at concentrations below the previous lowest 
dosage of 1 µM. 
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5.5 Topoisomerase II decatenation assay 
Furthering the examination of our library of novel aza BIM and aza ICZ derivatives against 
DNA topological assays, selected candidates were screened for their ability to inhibit 
topoisomerase II-mediated circular kinetoplast DNA (kDNA) decatenation. The standard 
topoisomerase II inhibitor, ellipticine 378, was used as a reference compound in this study. 
Topoisomerase II (topo II), which belongs to the same enzymatic family as topo I (Section 
1.3.2), helps to modulate DNA processes via transient double-strand breaks in the DNA 
helix.
24
 Topo II is involved in many vital cellular processes, such as replication, transcription, 
recombination and segregation, as well as cell proliferation.
25
 With higher expression of topo 
II in proliferating cells than inactive cells, this enzyme is a useful target for the induction of 
cytotoxic effects in many cancer types. A number of anticancer agents, such as etoposide and 
doxorubicin, target topo II and trap the enzyme in a covalently-bound complex with DNA, 
thus interfering with its catalytic activity and leading to DNA damage and cell death.
26
  
5.5.1 Topo II inhibition results 
The candidates selected for topo II testing are listed in Table 5.7 and Table 5.8. It was found 
that aza BIM derivatives 293, 295, 297, 300 and 304, all of which contain a 3,4,5-
trimethoxyphenyl moiety, exhibited no inhibitory activity against topo II. Partial inhibition 
was seen at 100 µM for barbiturate 319 and pyrazolopyrimidine 320.  
Structure Compound Activity 
 
 
293; R1=NH2, R2=H - 
295; -NHCONHCO- - 
297; -NC(CF3)CHC(CF3)- - 
300; R1=COCF3, R2=H - 
304; R1=H, R2=CSNHCH3 - 
 
Table 5.7 Topo II decatenation assay: (+*) partial inhibition at 100 µM;                                   
(+
ϯ
) partial inhibition at 100 µM, inactive at 1 and 10 µM 
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Structure Compound Activity 
 
 
319; -NHCONHCO- +* 
320; -NC(CF3)CHC(CF3)- +* 
 
 
327; -NHOCO +ϯ 
328; -N(CH3)OCO- - 
332; NC(NH2)NHCO- - 
 
Table 5.8 Topo II decatenation assay: (+*) partial inhibition at 100 µM;                                   
(+
ϯ
) partial inhibition at 100 µM, inactive at 1 and 10 µM 
 
Isoxazolone 327 is seen to partially inhibit topo II at a concentration of 100 μM, although at 
lower concentrations, however, of 10 μM and 1 μM, the level of inhibition drops off (Table 
5.8). It was found that alkylation of isoxazolone 327 to methylated derivative 328 resulted in a 
loss of enzymatic inhibitory activity, mirroring the single-dose data from the NCI-60 cell 
array, where a loss of antiproliferative activity was recorded from 327 to 328 (Section 5.2.3). 
Pyrimidinone 332, which was one of the least active compounds in the single-dose NCI-60 
screen, was similarly found to exhibit no inhibition towards topo II. 
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Fig. 5.25 Representative topo II decatenation assay of screening panel and structures of 
ellipticine 378 and maleimide 379; H = positive control (cDNA + ATP + topo II);                       
I = negative control (cDNA + ATP + topo II + 100 µM ellipticine 378)      
 
Lane No. A B C D E F G 
Compound No. 381 327 327 327 328 319 320 
Concentration 100 µM 100 µM 10 µM 1 µM 100 µM 100 µM 100 µM 
Topo II Inhibition - +* - - - +* +* 
 
Table 5.9 Results of representative topo II decatenation assay;                                           
inhibitory activity: (+*) = partial inhibition; (-) = not active against topo II 
 
5.5.2 Conclusion 
In the first phase of testing, partial inhibitory activity against topo II was seen for a number of 
candidates within the class of aza BIM derivatives. The lack of complete inhibition can 
perhaps be attributed to insufficient molecular planarity, which is required for efficient DNA 
intercalation, and is a key feature of many topo II inhibitors, such as ellipticine 378. Further 
assays are planned towards the inclusion of previously synthesised aza ICZ derivatives, within 
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which it is anticipated that greater bioactivity will be observed, owing to their more rigid 
structural nature. 
This key SAR feature can be further illustrated by the fact that none of the compounds 
containing an unrestricted 3,4,5-trimethoxyphenyl moiety exhibited any activity towards topo 
II. In comparison, it is likely that DNA intercalation is more easily achieved in the case of 
bicyclic systems 319 and 320 which contain greater conformational planarity, thus 
contributing to the partial topo II inhibition. 
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6.0 Current Perspectives 
6.1 Overview 
The definitive achievement of synthetic endeavour within this project involved successfully 
completing a panel of forty-one novel derivatives of the aza BIM 380 and aza ICZ 381 
templates. Considerable success was met in propagating the previously underexploited theme 
of F-ring modulation, leading to the development of key heterocyclic analogues, containing 
isoxazolone, aminopyrazole or pyrimidinone headgroups, for instance.   
 
Fig. 6.1 Key aza BIM 380 and aza ICZ 381 
Previous work in this field has focused on the coupling of azaindolyl moieties to 
dibromomaleimide subunits, a path which limits the scope of heteroaryl derivatisation within 
the resulting aza BIMs and aza ICZs. To this end, a series of β-keto ester and β-keto nitrile 
intermediates, initially identified via retrosynthetic analysis, were fashioned in order to 
advance our goal of diversity-oriented synthesis. The cyclocondensation of these 
intermediates with various nucleophiles such as hydrazine or guanidine, followed by several 
different modes of derivatisation, resulted in the formation of novel analogues of the BIM 
pharmacophore, later to prove of considerable biological interest. 
Aromatisation studies involving these aza BIM derivatives later resulted in the 
photochemically-induced synthesis of the first reported aza ICZ with a six-membered F-ring. 
Limitations to this approach informed the design and progression of a second route, whereby 
the aza ICZ template, and subsequent F-ring modulation, was accomplished from maleimide 
precursors following Perkin-type methodology. Two novel routes ultimately leading towards 
aza ICZs were therefore developed in this project.    
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Preliminary biological evaluation of candidates from the panel of aza BIM and aza ICZ 
derivatives was achieved in the form of the NCI-60 cell screen and a series of DNA 
topological assays. The identification of several lead compounds, along with the disclosure of 
excellent selectivity in the bioactive profiles of numerous derivatives, confirmed the 
pursuance of F-ring elaboration as a viable paradigm to the medicinal chemist. 
                        
 
 
                                    
        
  
 
Fig. 6.2 Novel aza BIM and aza ICZ derivatives with anticancer activity 
Mean growth = 94.0% 
NSC lung cancer selectivity 
(HOP-92: -3.1%) 
Mean growth = 73.8% 
Melanoma potency 
(M14 growth: 27.5%; 
MDA-MB-435: 25.6%) 
Mean growth = 60.9% 
Melanoma, leukemia potency 
(SR growth: 9.3%; 
MDA-MB-435: 2.6%) 
Topo I inhibitor (1 µM) 
Mean GI50 = 1.44 µM 
Topo I inhibitor (1 µM) 
Mean GI50 = 0.22 µM 
Topo I inhibitor (1 µM) 
Mean GI50 = 0.03 µM 
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The selectivity profiles revealed by a number of candidates in the NCI-60 single dose screen 
illustrated the potential that exists for unique molecular targets within this class of 
compounds. For example, pyrimidine 297 was shown to be highly selective for the HOP-92 
lung cancer cell line, with carbothioamide 323 targeting melanoma cell lines and isoxazolone 
displaying excellent activity against melanoma and leukemia cell lines (Figure 6.2).  
Of the twenty-nine compounds submitted to the NCI-60 cell screen, nine were selected for 
further screening, representing an excellent return. Utilisation of the COMPARE algorithm 
revealed a correlation between the five dose data for a number of derivatives within the panel 
and a series of camptothecin analogues, highlighting the possibility of topo I inhibition as a 
putative mechanism of action. This was borne out in topo I-mediated DNA cleavage assays, 
with aza ICZs such as maleimide 364, Boc-protected maleimide 372 and hydroxymaleimide 
373 showing low micromolar inhibitory activity. The most bioactive compound from the five 
dose screen, hydroxymaleimide 373, is currently being assessed by the Biological Evaluation 
Committee in the NCI, and is under consideration for further testing. 
                                                          
6.2 Future Work 
The incorporation of a 3,4,5-trimethoxyphenyl functionality into the aza BIM template 382 
was seen to confer admirable selectivity towards a number of cancer cell lines within the NCI-
60 cell array (Section 5.2.1). Identification of targets associated with these cell lines, followed 
by molecular modelling of ligand-enzyme interactions, shall allow further functionalisation of 
the aminopyrazole pharmacophore towards the achievement of potential clinical candidates. 
 
Fig. 6.3 General structures of aza BIM derivatives 
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As previously discussed, unique and specific bioactive profiles were obtained for more 
conventional aza BIM derivatives of general structure 383 (Sections 5.2.2, 5.3.3 and 6.1). 
Second-generation endeavour towards increasing both selectivity and potency will involve 
substitution on the azaindolic rings using hydroxyl or halogen functionalities, removal of alkyl 
protecting groups or replacement with solubilising chains, and also further F-ring modulation.  
It is proposed that isoxazolone 327 may be a potent inhibitor of mitogen-activated protein 
(MAP) kinase, given its activity against the MDA-MB-435 cell line and also that previous 
biological evaluation of compounds containing an isoxazolone heterocycle have been shown 
to exhibit good inhibition against p38 MAP kinase. Kinase and tubulin inhibition assays 
would form the next steps of biological evaluation for derivatives of 327.  
The most bioactive compounds within the library of aza BIM and aza ICZ derivatives proved 
to be the fully aromatised aza ICZs with 5-membered F-rings (Section 5.3.4), such as 
maleimide 364, with excellent activity seen for this compound class down to a low nanomolar 
concentration against a number of cell lines. Given the antiproliferative nature of these aza 
ICZs, it will be important to carry out flow cytometry studies in order to ascertain the point in 
the cell cycle at which growth is arrested. From this, it will be possible to probe potential 
interactions with, for instance, checkpoint kinases, thus advancing further towards a complete 
understanding of the associated biological mode of action.   
 
Fig. 6.4 Structures of proposed aza ICZs 384 and 385 
Solubility can be regarded as a significant issue towards the future development of aza ICZs 
as clinical candidates, as evidenced by the dose-response curves in the 5-dose assays. The 
introduction of a lipophilic Boc group on the maleimide ring did help in this regard, and 
further resolution of this problem could possibly be accomplished by the formation of 
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quaternary salts at the azaindolic nitrogen atoms (384), for example by reaction with alkyl 
halides or inorganic complexes containing ruthenium or platinum. The introduction of more 
water soluble moieties, such as N-formyl or 2-aminopropane-1,3-diol groups (385), by 
substitution on the nitrogen atom of the maleimide ring could also help improve solubility, as 
in the well-known ICZs, NB-506 43 and edotecarin 44 (Section 1.3.2.2). 
Given the excellent antiproliferative and topo I activity of hydroxymaleimide 373, it should 
function as a lead compound for future work. It is envisaged that further SAR study would 
examine the use of various hydroxyl or halogen atom substituents on the peripheral benzenoid 
rings or long-chain amines on the indolic nitrogens (R1 and R2 of 385). The synthesis of 
analogues containing 4-, 5- or 6-azaindolyl moieties also represents a worthy paradigm with 
which to investigate and pursue the development of novel anticancer chemotherapeutic agents. 
Much effort remains to be expended towards F-ring modulation in the field of ICZ chemistry, 
as the enormous potential remains for the exploitation of discrete differences in the active sites 
of protein kinases. For example, the synthesis of derivatives containing sulfomaleic anhydride 
387 or isothiazolone dioxide 389 headgroups could allow for the expansion of the hydrogen 
bonding networks in the ligand-enzyme complex.   
 
Fig. 6.5 Proposed syntheses of sulfomaleic anhydride 387 and isothiazolone 389 
Overall, this project has examined many different aspects of the aza ICZ pharmacophore 
towards their use against cancer. Given the scarcity of literature precedent towards these 
derivatives within the wide spectrum of the broader ICZ family, it is envisaged that this work 
will help to inform and encourage future work within this field. As evidenced by extensive 
NCI-60 and topo I inhibitory data obtained, enormous potential exists within aza ICZs to 
develop viable candidates for use in the clinic. On a personal level, I have gained invaluable 
insight into the multifaceted discipline of medicinal chemistry, and a huge respect for both its 
scope and the possibilities that exist there within. 
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7.0 Experimental 
7.1 General procedures 
Solvents were distilled prior to use as follows: dichloromethane was distilled from 
phosphorous pentoxide; ethyl acetate was distilled from potassium carbonate; ethanol and 
methanol were distilled from magnesium in the presence of iodine and stored over 3 Å 
molecular sieves; toluene was distilled from sodium and benzophenone and stored over 4 Å 
molecular sieves; hexane was distilled prior to use; tetrahydrofuran was freshly distilled from 
sodium and benzophenone. Diethyl ether was obtained pure from Riedel-de Haën. HPLC 
grade acetonitrile was obtained from Fluka. Molecular sieves were dried by heating to >100 
o
C at 0.2 mbar overnight or at 140 
o
C for 24 hours. Organic phases were dried using 
anhydrous magnesium sulfate. All commercial reagents were used without further purification 
unless otherwise stated.  
Melting points were measured in a uni-melt Thomas Hoover capillary melting point apparatus 
and are uncorrected. Thin layer chromatography was carried out on precoated silica gel plates 
(Merck 60 PF254), and visualisation was achieved by UV light detection (254 or 366 nm) or 
vanillin staining. Wet flash column chromatography was performed using Kieselgel silica gel 
60, 0.040 – 0.063 mm (Merck). 
Infrared spectra were recorded as a thin film on sodium chloride plates for liquids or a 
potassium bromide (KBr) disc for solids on a Perkin Elmer Spectrum 100 FT-IR spectrometer. 
Low resolution mass spectra were recorded on a Waters Quattro Micro triple quadrupole 
spectrometer (QAA102) in electrospray ionisation (ESI) mode using 50% acetonitrile – water 
containing 0.1% formic acid as eluent. High resolution mass spectra (HRMS) were recorded 
on a Waters LCT Premier Time of Flight spectrometer in electrospray ionisation (ESI) mode 
using 50% acetonitrile – water containing 0.1% formic acid as eluent. Samples (max. 1 mg) 
were dissolved in acetonitrile, methanol or a 1:1 acetonitrile/methanol mixture. 
1
H (300 MHz) and 
13
C (75 MHz) NMR spectra were recorded on a Bruker Avance 300 NMR 
spectrometer. 
1
H (400 MHz) NMR spectra were recorded on a Bruker Avance 400 NMR 
spectrometer. 
13
C (125 MHz) NMR spectra were recorded on a Bruker Avance 500 NMR 
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spectrometer. 
1
H (600 MHz) and
 13
C (150 MHz) NMR spectra were recorded on a Bruker 
Avance III 600 MHz NMR spectrometer equipped with a dual CH cryoprobe. Spectra were 
recorded at room temperature (~20 
o
C) unless otherwise stated, in deuterated chloroform 
(CDCl3) with tetramethylsilane (TMS) as an internal standard, deuterated dimethylsulfoxide 
(DMSO-d6), or deuterated methanol (CD3OD). Chemical shifts (δH and δC) are expressed in 
parts per million (ppm) relative to the reference peak. Coupling constants (J) are expressed in 
Hertz (Hz). Splitting patterns in 
1
H NMR spectra are designated as s (singlet), bs (broad 
singlet), d (doublet), bd (broad doublet), t (triplet), q (quartet), dd (doublet of doublets) and m 
(multiplet). 
13
C NMR spectra were assigned (CH, CH2, CH3) with the aid of DEPT 
(Distortionless Enhancement by Polarisation Transfer) experiments. 
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7.2 Chemical data 
7.2.1 Route towards 7-azaindolyl precursors 
2-(tert-Butylaminomethylene)succinonitrile (257)
1 
While stirring under a nitrogen atmosphere, sodium metal (4.720 g, 205 
mmol) was carefully added in a portionwise manner to methanol (100 mL), 
which was cooled to 0 
o
C in an ice bath. Once complete, the excess solvent 
was evaporated under reduced pressure, leaving sodium methoxide as a white 
solid (11.023 g, 204 mmol). Also under a nitrogen atmosphere, anhydrous toluene (100 mL) 
was added to the sodium methoxide, with the resulting suspension cooled to 5 
o
C. To this 
stirred suspension, a solution of ethyl formate 254 (18.3 mL, 227 mmol) and succinonitrile 
253 (15.026 g, 188 mmol) in anhydrous toluene (100 mL) was added dropwise over a 20 
minute period. Once the addition was complete, the mixture was allowed to stir at room 
temperature for 2.5 hours. To the reaction mixture was then added tert-butylamine (20.2 mL, 
192 mmol), followed by acetic acid (13.2 mL, 231 mmol), and the resulting mixture heated to 
reflux for 2.5 hours. Once cooled to room temperature, brine (50 mL) was added, and the two 
phases were separated. The aqueous layer was extracted with toluene (2 x 20 mL), before the 
combined organic extracts were washed with water (2 x 50 mL), dried over magnesium sulfate 
and evaporated under reduced pressure. The brown residue was desiccated overnight at 50 
o
C 
to yield 257 as a brown solid (24.875 g, 81 %) in a mixture of E and Z isomers (1:6): m.p. 
114-117 
o
C (lit.
1
 118-119 
o
C); vmax/cm
-1
 (KBr) 3319, 2977, 2191, 1638, 1227; δH (300 MHz, 
CDCl3) 1.30 [9H, s, C(CH3)3], 3.16 [2H, s, CH2CN], 5.21 [1H, bd, J 14.2, NH], 6.91 [1H, d, J 
14.2, C=CH (E isomer)], 7.01 [1H, d, J 14.5, C=CH (Z isomer)]; δC (75 MHz, CDCl3) 15.5 
(CH2, CH2CN), 30.1 (3CH3, C(CH3)3), 53.4 (C, C(CH3)3), 65.0 (C, C=CHNH), 116.3 (C, CN), 
122.1 (C, CN), 146.8 (CH, C=CHNH); m/z (ES+) 164.1 [M+H]
+
 (100%).  
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5-Amino-1-(tert-butyl)-1H-pyrrole-3-carbonitrile (258)
1 
Potassium hydroxide (17.862 g, 271 mmol) was dissolved in absolute ethanol 
(150 mL) at 50 
o
C, with the resulting solution then cooled to room 
temperature. To the latter, a solution of 2-(tert-
butylaminomethylene)succinonitrile 257 (24.004 g, 147 mmol) in absolute 
ethanol (40 mL) was added while stirring. The resulting mixture was stirred 
for 4 hours at room temperature before being concentrated under reduced pressure until a solid 
started to precipitate out. Water (120 mL) was then added and the mixture was stirred for 1 
hour. The precipitate was filtered, washed with water and desiccated overnight to yield 258 as 
a brown solid (15.571 g, 65 %): m.p. 111-112 
o
C (lit.
1
 112-113 
o
C); vmax/cm
-1
 (KBr) 3396, 
3335, 2972, 2212, 1633, 1526, 1213; δH (300 MHz, DMSO-d6) 1.53 [9H, s, C(CH3)3], 4.46 
[2H, bs, NH2], 5.55 [1H, d, J 2.2, C-H4], 7.15 [1H, d, J 2.3, C-H2]; δC (75 MHz, DMSO-d6) 
29.1 (3CH3, C(CH3)3), 56.5 (C, C(CH3)3), 87.0 (C, aromatic C), 95.4 (CH, aromatic CH), 
118.0 (C, CN), 121.0 (CH, aromatic CH), 139.6 (C, aromatic C); m/z (ES+) 164.1 [M+H]
+
 
(100%). 
 
1-(tert-Butyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (259)
1 
 
To a solution of 5-amino-1-(tert-butyl)-1H-pyrrole-3-carbonitrile 258             
(15.008 g, 92.4 mmol) in toluene (150 mL) was added 1,1,3,3-
tetramethoxypropane (16.9 mL, 102.6 mmol) and then p-toluenesulfonic acid 
monohydrate (1.863 g, 9.8 mmol). The reaction mixture was then slowly 
heated to reflux, utilising distillation apparatus to perform the azeotropic 
removal of methanol, a by-product of the reaction. After 1 hour, the reaction mixture was 
cooled to room temperature and the solvent evaporated under reduced pressure. Diethyl ether 
(100 mL) was added to residue, which was then heated to reflux for 20 minutes. Once cooled 
to room temperature, the latter mixture was filtered off, with the residue being washed with 
diethyl ether (20 mL). The combined organic layers were evaporated under reduced pressure, 
with the residue then being subjected to flash column chromatography (hexane/ethyl acetate, 
70:30) to yield the pure product 259 as an orange crystalline solid (14.047 g, 76%): m.p. 90-
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91 
o
C (lit.
1
 91-92
 o
C); vmax/cm
-1
 (KBr) 2972, 2215, 1602, 1522, 1210; δH (300 MHz, CDCl3) 
1.83 [9H, s, C(CH3)3], 7.22 [1H, dd, J 8.0, 4.7, C-H5], 7.87 [1H, s, C-H2], 8.04 [1H, dd, J 8.0, 
1.7, C-H4], 8.43 [1H, dd, J 4.7, 1.6, C-H6]; δC (75 MHz, CDCl3) 29.1 (3CH3, C(CH3)3), 58.5 
(C, C(CH3)3), 83.1 (C, aromatic C), 115.6 (C, CN), 117.6 (CH, aromatic CH), 121.4 (C, 
aromatic C), 127.9 (CH, aromatic CH), 133.1 (CH, aromatic CH), 144.1 (CH, aromatic CH), 
147.1 (C, aromatic C); m/z (ES+) 200.2 [M+H]
+
 (100%). 
 
1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile (260)
1 
Under a nitrogen atmosphere at room temperature, 1-(tert-butyl)-1H-
pyrrolo[2,3-b]pyridine-3-carbonitrile 259 (13.501 g, 67.8 mmol) was added 
portionwise to a stirred suspension of AlCl3 (28.026 g, 210.2 mmol) in 
chlorobenzene (120 mL) over 30 minutes. Once the additions were complete, 
the reaction mixture was heated to reflux for 8 hours. Once cooled to room temperature, 
precooled 2 M aqueous HCl (150 mL) was carefully added to the reaction mixture, which was 
then allowed to stir for 2 hours. Celite (10 g) was then added to the mixture, which was 
subsequently filtered. The phases were separated and the organic layer was washed with 2 M 
aqueous HCl (3 x 25 mL), following which the combined aqueous extracts were washed with 
a further portion of chlorobenzene (25 mL). The pH of the strongly acidic aqueous layer was 
adjusted to 2.5 using 50 wt.% aqueous NaOH. The precipitate formed was filtered, washed 
with water and desiccated at 50 
o
C to give 260 as an off-white solid (7.840 g, 81%): m.p. 254-
256 
o
C (lit.
1
 259-260 
o
C); vmax/cm
-1
 (KBr) 3021, 2837, 2220, 1583, 1418, 1287; δH (300 MHz, 
DMSO-d6) 7.29 [1H, dd, J 7.9, 4.7, C-H5], 8.12 [1H, dd, J 8.0, 1.5, C-H4], 8.41 [1H, dd, J 4.7, 
1.4, C-H6], 8.44 [1H, s, C-H2], 12.84 [1H, bs, NH]; δC (75 MHz, DMSO-d6) 83.2 (C, aromatic 
C), 115.6 (C, CN), 117.9 (CH, aromatic CH), 118.9 (C, aromatic C), 127.3 (CH, aromatic 
CH), 135.5 (CH, aromatic CH), 145.0 (CH, aromatic CH), 147.4 (C, aromatic C); m/z (ES+) 
144.1 [M+H]
+
 (100%). 
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1H-Pyrrolo[2,3-b]pyridine-3-carboxylic acid (255)
1 
1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile 260 (3.506 g, 24.5 mmol) was 
suspended in 12 M aqueous HCl (50 mL), and the resulting mixture was 
heated to 70 
o
C for 20 hours. Water (30 mL) and charcoal (0.4 g) were then 
added, and the mixture was stirred for 1 hour at 70 
o
C. Celite (0.4 g) was 
then added and the mixture was stirred for a further hour at 70 
o
C. The warm  
solution was then filtered, before being cooled to room temperature. The pH of the strongly 
acidic solution was adjusted to 2.5 using 50 wt.% aqueous NaOH, at which point a white 
precipitate formed. The suspension was then stirred for 2 hours at room temperature, before 
the precipitate was filtered off and washed with water, then desiccated overnight at 50 
o
C to 
yield carboxylic acid 255 as a white solid (3.616 g, 91%): m.p. 244-246 
o
C (lit.
1
 245-246
o
C); 
vmax/cm
-1
 (KBr) 3416, 3145, 2545, 1679, 1531, 1320, 1186; δH (300 MHz, DMSO-d6) 7.22 
[1H, dd, J 7.8, 4.8, C-H5], 8.14 [1H, s, C-H2], 8.30-8.34 [2H, m, C-H4,6], 12.46 [1H, bs, 
COOH]; δC (75 MHz, DMSO-d6) 106.3 (C, aromatic C), 117.4 (CH, aromatic CH), 118.3 (C, 
aromatic C), 128.8 (CH, aromatic CH), 132.6 (CH, aromatic CH), 143.7 (CH, aromatic CH), 
148.6 (C, aromatic C), 165.4 (C, C=O); m/z (ES+) 163.1 [M+H]
+
 (100%). 
 
1H-Pyrrolo[2,3-b]pyridine (139)
1 
A mixture of 1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 260 (3.450 g, 24.1 mmol) 
and 12 M aqueous HCl (40 mL) were heated to reflux for 24 hours. The reaction 
mixture was cooled to 70 
o
C and additional 12 M aqueous HCl (40 mL) was 
added. The mixture was then once again heated to reflux for 24 hours. Once the 
mixture was cooled to room temperature, water was added (50 mL) and was adjusted to pH 
2.5 using 50 wt.% aqueous NaOH. Charcoal (0.4 g) and celite (0.4 g) were added to the 
mixture, which was then stirred for 1 hour at room temperature and subsequently filtered. The 
filtrate was adjusted to pH 12 using 50 wt.% aqueous NaOH, after which it was extracted with 
DCM (4 x 20 mL). The combined organic extracts were dried over magnesium sulfate and 
evaporated to yield 139 as a white solid (1.776 g, 62%): m.p. 106-108 
o
C (lit.
1
 105-106 
o
C); 
vmax/cm
-1
 (KBr) 3067, 1600, 1584, 1422, 1279, 1107; δH (300 MHz, CDCl3) 6.51 [1H, d, J 3.5, 
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C-H3], 7.09 [1H, dd, J 7.9, 4.8, C-H5], 7.40 [1H, d, J 3.5, C-H2], 7.97 [1H, dd, J 7.9, 1.6, C-
H4], 8.35 [1H, dd, J, 4.8, 1.5, C-H6], 11.89 [1H, bs, NH]; δC (75 MHz, CDCl3) 100.5 (CH, 
aromatic CH), 115.7 (CH, aromatic CH), 120.6 (C, aromatic C), 125.4 (CH, aromatic CH), 
129.1 (CH, aromatic CH), 142.2 (CH, aromatic CH), 148.9 (C, aromatic C); m/z (ES+) 119.1 
[M+H]
+
 (100%). 
 
Methyl 1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (269)
 
To a solution of 1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid 255 (1.500 g, 
9.3 mmol) in DMF (40 mL) was added dimethyl carbonate (5.8 mL, 68.9 
mmol) and potassium carbonate (2.065 g, 14.9 mmol). The resulting mixture 
was heated to reflux for 14 hours. Once cooled to room temperature, water 
(50 mL) and ethyl acetate (50 mL) were added to the reaction mixture. The 
two phases were separated and the aqueous phase was further extracted with ethyl acetate (50 
mL). The combined organic extracts were then washed with water (4 x 50 mL) and brine (50 
mL), before being dried over magnesium sulfate and evaporated under reduced pressure. The 
crude residue was subjected to flash column chromatography to yield the product 269 as a 
white solid (1.307 g, 74%): m.p. 116-118 
o
C; vmax/cm
-1
 (KBr) 3123, 3012, 1712, 1599, 1359, 
1266; δH (300 MHz, CDCl3) 3.91 [3H, s, OCH3], 3.93 [3H, s, NCH3], 7.22 [1H, dd, J 7.8, 4.9, 
C-H5], 7.91 [1H, s, C-H2], 8.39 [1H, dd, J 4.9, 1.6, C-H6], 8.41 [1H, dd, J 7.8, 1.6, C-H4]; δC 
(75 MHz, CDCl3) 31.8 (CH3, NCH3), 51.1 (CH3, OCH3), 105.5 (C, aromatic C), 117.9 (CH, 
aromatic CH), 119.0 (C, aromatic C), 129.9 (CH, aromatic CH), 135.0 (CH, aromatic CH), 
144.0 (CH, aromatic CH), 148.0 (C, aromatic C), 164.9 (C, C=O); m/z (ES+) 191.3 [M+H]
+
 
(100%); HRMS (ES+): Exact mass calculated for C10H11N2O2 191.0821. Found 191.0812. 
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1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (264) 
1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile 260 (17.343 g, 121 mmol) was 
dissolved in DMF (150 mL), and the resulting solution was cooled to 0 
o
C in an 
ice bath. Sodium hydride (55 wt.% oil dispersion, 7.390 g, 169 mmol) was then 
added portionwise over 10 minutes, ensuring that the reaction did not become 
too vigorous. Once the addition was complete, the reaction mixture was stirred at     0 
o
C for a 
further 30 minutes. At this point, a solution of iodomethane (10.5 mL, 169 mmol) in DMF (40 
mL) was added in a dropwise manner. Upon completion, the reaction mixture was allowed to 
warm to room temperature and was stirred for 3 hours. Water (50 mL) was then carefully 
added to quench the reaction. The reaction mixture was extracted with ethyl acetate (3 x 100 
mL), and the combined organic extracts were then washed with water (5 x 100 mL) and brine 
(100 mL), dried over magnesium sulfate and evaporated under reduced pressure to yield the 
crude product as a reddish solid. This was then purified by flash column chromatography 
(hexane/ethyl acetate, 50:50) to yield the pure product 264 as an off-white solid (12.741 g, 
68%): m.p. 102-104 
o
C; vmax/cm
-1
 (KBr) 3117, 3053, 2221, 1602, 1574, 1533, 1450, 1412, 
1304, 1122; δH (300 MHz, CDCl3) 3.96 [3H, s, N-CH3], 7.26 [1H, dd, J 7.9, 4.7, C-H5], 7.75 
[1H, s, C-H2], 8.07 [1H, dd, J 7.9, 1.5, C-H4], 8.46 [1H, dd, J 4.7, 1.5, C-H6]; δC (75 MHz, 
CDCl3) 32.0 (CH3, NCH3), 84.2 (C, aromatic C), 115.1 (C, CN), 118.1 (CH, aromatic CH), 
120.0 (C, aromatic C), 128.2 (CH, aromatic CH), 135.9 (CH, aromatic CH), 145.3 (CH, 
aromatic CH), 146.8 (C, aromatic C); m/z (ES+) 158.2 [M+H]
+
 (100%); HRMS (ES+): Exact 
mass calculated for C9H8N3 158.0718. Found 158.0711. 
 
1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (265)
2 
1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 264 (12.624 g, 80 
mmol), was suspended in 12 M aqueous HCl (100 mL), and the suspension 
was heated to 70 
o
C to give a dark red homogenous solution, which was 
stirred at this temperature for 20 hours. At this point, the reaction mixture 
was diluted with water (100 mL) and charcoal (0.8 g) was added. The 
mixture was stirred at 70 
o
C for 30 minutes, before celite (0.8 g) was added, with the reaction 
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mixture then being stirred for a further 30 minutes. The warm solution was filtered and the 
filtrate was then allowed to cool to room temperature. The strongly acidic solution was 
carefully adjusted to pH 2.5 using 50 wt.% aqueous NaOH, at which point a white precipitate 
was formed. This suspension was stirred at room temperature for 2 hours before the 
precipitate was filtered off, washed with water and desiccated at 50 
o
C overnight to yield the 
pure product 265 as a white solid (11.628 g, 83%): m.p. 253-255 
o
C (lit.
2
 249-251 
o
C); 
vmax/cm
-1
 (KBr) 3488, 3109, 2922, 2498, 1674, 1599, 1538, 1466, 1268, 1135; δH (300 MHz, 
DMSO-d6) 3.87 [3H, s, N-CH3], 7.26 [1H, dd, J 7.9, 4.7, C-H5], 8.24 [1H, s, C-H2], 8.32 [1H, 
dd, J 7.9, 1.6, C-H4], 8.35 [1H, dd, J 4.7, 1.6, C-H6], 12.25 [1H, bs, COOH]; δC (75 MHz, 
DMSO-d6) 31.3 (CH3, NCH3), 104.9 (C, aromatic C), 117.6 (CH, aromatic CH), 118.6 (C, 
aromatic C), 129.0 (CH, aromatic CH), 136.2 (CH, aromatic CH), 143.5 (CH, aromatic CH), 
147.6 (C, aromatic C), 165.1 (C, C=O); m/z (ES+) 176.1 [M+H]
+
 (100%). 
 
7.2.2 Synthesis of key intermediates 
7.2.2.1 Routes towards oxopropanoates 
 Methyl 2-(1-methyl-1H-indol-3-yl)acetate (250)3 
To a solution of indole-3-acetic acid 261 (6.000 g, 34.2 mmol) in DMF (50 
mL) was added potassium carbonate (6.002 g, 43.4 mmol) and dimethyl 
carbonate (8.6 mL, 102.1 mmol). The resulting mixture was heated to 
reflux for 16 hrs. The reaction mixture was cooled to room temperature, 
then water (80 mL) and ethyl acetate (60 mL) were added. Following 
separation of the two layers, the aqueous layer was extracted with ethyl acetate (2 x 40 mL). 
The combined organic extracts were then washed with water (4 x 50 mL), followed by brine 
(50 mL) and then dried over magnesium sulfate. The solvent was evaporated under reduced 
pressure to yield the crude product as a dark red oil. This was then subjected to flash column 
chromatography (hexane/ethyl acetate, 75:25), isolating 250 as a golden oil which was used 
without further purification (5.866 g, 84%): vmax/cm
-1
 (NaCl) 2951, 1736, 1617, 1475, 1332, 
1163; δH (300 MHz, CDCl3) 3.66 [3H, s, OCH3], 3.67 [3H, s, NCH3], 3.74 [2H, s, 
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CH2COOCH3], 6.97 [1H, s, C-H2], 7.11 [1H, t, J 7.8, C-H5], 7.21 [1H, t, J 7.9, C-H6], 7.25 
[1H, d, J 7.9, C-H7], 7.58 [1H, d, J 8.0, C-H4]; δC (75 MHz, CDCl3) 31.1 (CH2, 
CH2COOCH3), 32.7 (CH3, NCH3), 52.0 (CH3, OCH3), 106.8 (C, aromatic C), 109.4 (CH, 
aromatic CH), 119.0 (CH, aromatic CH), 119.3 (CH, aromatic CH), 121.8 (CH, aromatic CH), 
127.7 (C, aromatic C), 127.8 (CH, aromatic CH), 137.0 (C, aromatic C) 172.7 (C, C=O); m/z 
(ES+) 204.4 [M+H]
+
 (100%). 
 
1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl chloride (266) 
1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid 265 (4.301 g, 24.4 
mmol) was ground into a fine powder, then suspended in DCM (80 mL) 
under an inert atmosphere. While cooling in an ice bath, oxalyl chloride (4.5 
mL, 51.2 mmol) was added in a dropwise fashion. Once the addition was 
complete, the reaction mixture was stirred for 16 hours at room temperature. 
The solvent and excess oxalyl chloride was removed under reduced pressure, to yield acyl 
chloride 266 in quantitative yield as a white solid, which was subsequently used without 
further purification: vmax/cm
-1
 (KBr) 2916, 2553, 1695, 1641, 1551, 1273, 1124. 
 
Methyl 2-(1-methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-
oxopropanoate (267) 
Method A: 
A solution of LDA (1.8 M, 33.3 mL, 59.9 mmol) in THF (30 
mL) was cooled to -78 
o
C under a nitrogen atmosphere. A 
second solution of methyl 2-(1-methyl-1H-indol-3-yl)acetate 
250 (4.512 g, 22.2 mmol) in THF (10 mL) was then added in a 
dropwise manner, with the resulting mixture being stirred for 1 
hour at         -78 
o
C. A suspension of 1-methyl-1H-pyrrolo[2,3-
b]pyridine-3-carbonyl chloride 266 (4.735 g, 24.3 mmol) in THF (40 mL) was slowly added 
Chapter 7 | Experimental 
 
 
[215] 
 
to the reaction mixture over a 20 minute period. Once the addition was complete, the reaction 
mixture was warmed to 35 
o
C and left to stir for 12 hours. The solvent was removed under 
reduced pressure and the residue was dissolved in ethyl acetate (80 mL) and washed 
successively with a saturated aqueous sodium bicarbonate solution (50 mL), water (50 mL) 
and then brine (50 mL), before being dried over magnesium sulfate. Removal of the organic 
solvent under reduced pressure yielded the crude product as a brown solid, which was then 
subjected to column chromatography (hexane/ethyl acetate, 50:50) to yield 267 as a yellow 
crystalline solid (3.360 g, 42%): m.p. 101-103 
o
C; vmax/cm
-1
 (KBr) 2951, 1737, 1651, 1533, 
1449, 1375; δH (300 MHz, CDCl3) 3.77 [3H, s, OCH3], 3.77 [3H, s, NCH3], 3.87 [3H, s, 
NCH3], 5.69 [1H, s, CHα], 7.13 [1H, dd, J 7.9, 4.7, C-H5’], 7.14-7.32 [4H, m, C-H2,5,6,7], 7.67 
[1H, d, J 7.7, C-H4], 7.92 [1H, s, C-H2’], 8.38 [1H, dd, J 4.7, 1.6, C-H6’], 8.65 [1H, dd, J 7.9, 
1.6, C-H4’]; δC (75 MHz, CDCl3) 32.0 (CH3, NCH3), 32.9 (CH3, NCH3), 52.7 (CH3, OCH3), 
53.0 (CH, CHCOOCH3), 107.1 (C, aromatic C), 109.6 (CH, aromatic CH), 113.4 (C, aromatic 
C), 118.3 (CH, aromatic CH), 118.8 (CH, aromatic CH), 119.3 (C, aromatic C), 119.7 (CH, 
aromatic CH), 121.9 (CH, aromatic CH), 127.1 (C, aromatic C), 128.9 (CH, aromatic CH), 
131.2 (CH, aromatic CH), 135.7 (CH, aromatic CH), 136.7 (C, aromatic C), 144.8 (CH, 
aromatic CH), 148.3 (C, aromatic C), 170.0 (C, C=O), 188.1 (C, C=O); m/z (ES+) 362.2 
[M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C21H20N3O3 362.1505. Found 
362.1509. 
Method B:  
To a solution of LDA (1.8 M, 6.1 mL, 3.39 mmol) in THF (15 mL) under a nitrogen 
atmosphere at -78 
o
C was added, in a dropwise manner, a solution of methyl 2-(1-methyl-1H-
indol-3-yl)acetate 250 (1.005 g, 4.9 mmol) in THF (5 mL). Following stirring at -78 
o
C for 1 
hour, a suspension of 1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl chloride 266 (1.054 g, 
5.4 mmol) in THF (10 mL) was added over a period of 20 minutes. Once the addition was 
complete, the reaction mixture was allowed to warm to room temperature under stirring over 
14 hours. The solvent was evaporated under reduced pressure and the residue was dissolved in 
ethyl acetate (40 mL), before being washed with saturated aqueous sodium bicarbonate 
solution (30 mL), water (30 mL) and brine (30 mL), before being dried over magnesium 
sulfate. The solvent was removed under reduced pressure, and the crude residue was 
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subsequently subjected to flash column chromatography (hexane/ethyl acetate, 50:50). 
However, the desired product was not formed, with only the self-condensation product 268 of 
ester 250 identified: δH (300 MHz, CDCl3) 3.68 [2H, s, 
CH2COCH], 3.68 [3H, s, OCH3], 3.73 [3H, s, NCH3], 3.90 
[3H, s, NCH3], 5.16 [1H, s, CHα], 6.82 [1H, d, J 11.7, C-H5], 
6.98-7.31 [7H, m, C-H2,2’,5’,6,6’,7,7’], 7.34 [1H, d, J 8.2, C-H4], 
7.41 [1H, d, J 7.9, C-H4’]; m/z (ES+) 375.1 [M+H]
+
 (100%). 
 
1-Benzyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (270) 
A stirred solution of 1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 260 (1.010 
g, 7.1 mmol) in anhydrous DMF (10 mL) was cooled to 0 
o
C. Sodium 
hydride (60 wt.% oil dispersion, 0.426 g, 10.7 mmol) was carefully 
added to the mixture in a portionwise manner, which was then left to stir 
for 30 minutes at 0 
o
C. Benzyl bromide (1.0 mL, 8.5 mmol) was 
subsequently added dropwise to the reaction mixture, which was then allowed to warm to 
room temperature and stirred for 3 hours. Water (20 mL) was carefully added to quench the 
reaction, and the resulting mixture was extracted with ethyl acetate (3 x 20 mL). The 
combined organic extracts were washed with water (4 x 50 mL) and brine (50 mL), then dried 
over magnesium sulfate. The solvent was removed under reduced pressure and the crude 
residue was subjected to flash column chromatography (hexane/ethyl acetate, 80:20) to yield 
270 as an off-white solid (1.188 g, 72%): m.p. 94-95 
o
C; vmax/cm
-1
 (KBr) 3106, 2215, 1573, 
1528, 1424, 1306, 1177; δH (300 MHz, CDCl3) 5.52 [2H, s, CH2Bn], 7.25-7.39 [6H, m, C-
H5,2’-6’], 7.68 [1H, s, C-H2], 8.08 [1H, dd, J 7.9, 1.5, C-H4], 8.48 [1H, dd, J 4.7, 1.5, C-H6]; δC 
(75 MHz, CDCl3) 48.7 (CH2, CH2Bn), 85.0 (C, aromatic C), 115.0 (C, CN), 118.4 (CH, 
aromatic CH), 120.0 (C, aromatic C), 127.9 (2CH,   2 x aromatic CH), 128.3 (CH, aromatic 
CH), 128.5 (CH, aromatic CH), 129.1 (2CH, 2 x aromatic CH), 134.8 (CH, aromatic CH), 
135.7 (C, aromatic C), 145.5 (CH, aromatic CH), 146.7 (C, aromatic C); m/z (ES+) 234.4 
[M+H]
+
 (100%). HRMS (ES+): Exact mass calculated for C15H12N3 234.1031. Found 
234.1020.  
Chapter 7 | Experimental 
 
 
[217] 
 
1-Benzyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (271) 
1-Benzyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 270 (1.005 g, 4.3 
mmol) was suspended in 12 M aqueous HCl (30 mL), with the resulting 
mixture then being heated to 70 
o
C for 28 hours. Water (15 mL) and 
charcoal (0.1 g) were then added, and the reaction mixture was allowed 
to stir for 1 hour at 70 
o
C. Celite (0.1 g) was added to the mixture, which 
was allowed to stir for a further hour at 70 
o
C. The warm solution was 
then filtered, and allowed to cool to room temperature. Through the cautious addition of 50 
wt.% aqueous NaOH, the strongly acidic solution was adjusted to pH 2.5, at which point a 
white precipitate formed. The mixture was allowed to stir for 2 hours at room temperature 
before the precipitate was filtered off, washed with copious water, then desiccated overnight at 
50 
o
C to yield the pure product 271 as a white solid (0.984 g, 94%): m.p. 188-190 
o
C; vmax/cm
-
1
 (KBr) 2921, 2573, 1689, 1534, 1432, 1261; δH (300 MHz, DMSO-d6) 5.55 [2H, s, CH2], 
7.28 [1H, dd, J 7.9, 4.7, C-H5], 7.31-7.33 [5H, m, C-H2’-6’], 8.33-8.37 [3H, m, C-H2,4,6], 12.29 
[1H, bs, COOH]; δC (75 MHz, DMSO-d6) 66.3 (CH2, CH2Bn), 105.7 (C, aromatic C), 117.9 
(CH, aromatic CH), 118.7 (C, aromatic C), 127.5 (2CH, 2 x aromatic CH), 127.6 (CH, 
aromatic CH), 128.6 (2CH, 2 x aromatic CH), 129.2 (CH, aromatic CH), 135.2 (CH, aromatic 
CH), 137.5 (C, aromatic C), 143.7 (CH, aromatic CH), 147.3 (C, aromatic C), 165.1 (C, 
C=O); m/z (ES+) 253.3 [M+H]
+
 (100%). HRMS (ES+): Exact mass calculated for 
C15H13N2O2 253.0977. Found 253.0977. 
 
1-Benzyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl chloride (272) 
1-Benzyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid 271 (0.902 g, 3.6 
mmol) was ground into a fine powder, then suspended in DCM (25 mL) 
under an inert atmosphere. While cooling in an ice bath, oxalyl chloride 
(0.64 mL, 7.5 mmol) was added in a dropwise fashion. Once complete, 
the reaction mixture was stirred for 12 hours at room temperature. The 
solvent and excess oxalyl chloride was removed under reduced pressure, 
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to yield acyl chloride 272 in quantitative yield as a white solid, which was subsequently used 
without further purification: vmax/cm
-1
 (KBr) 3090, 3033, 2531, 1739, 1636, 1525, 1393, 1171. 
 
Methyl 3-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-(1-methyl-1H-indol-3-yl)-3-
oxopropanoate (273) 
A solution of LDA (1.8 M, 3.24 mL, 5.8 mmol) in THF (10 
mL) was cooled to -78 
o
C under a nitrogen atmosphere. A 
second solution of methyl 2-(1-methyl-1H-indol-3-yl)acetate 
250 (0.535 g, 2.6 mmol) in THF (3 mL) was then added in a 
dropwise manner, with the reaction mixture being stirred for 1 
hour at -78 
o
C. A suspension of acyl chloride 272 (0.862 g, 3.2 
mmol) in THF (5 mL) was then added to the reaction mixture 
in a dropwise manner over a 15 minute period, which was 
subsequently allowed to slowly warm to room temperature and left to stir for 14 hours. The 
solvent was removed under reduced pressure, with the resulting reddish brown residue being 
dissolved in ethyl acetate (40 mL), then washed with a saturated aqueous sodium bicarbonate 
solution (30 mL), water (30 mL) and brine (30 mL), before being dried over magnesium 
sulfate. The solvent was removed under reduced pressure and the crude residue was subjected 
to flash column chromatography (hexane/ethyl acetate, 65:35) to yield the pure product 273 as 
a light orange/brown crystalline solid (0.424 g, 37%): m.p. 89-91 
o
C; vmax/cm
-1
 (KBr) 2949, 
1748, 1652, 1527, 1425, 1393, 1187; δH (300 MHz, CDCl3) 3.71 [3H, s, NCH3], 3.73 [3H, s, 
OCH3], 5.34 [1H, d, HA of AB, J 15.0, CH2Ph], 5.46 [1H, d, HB of AB, J 15.1, CH2Ph], 5.62 
[1H, s, C-Hα], 7.09-7.31 [10H, m, C-H2,5,6,7,5’,2’’-6’’], 7.57 [1H, d, J 8.0, C-H4], 7.88 [1H, s, C-
H2’], 8.38 [1H, dd, J 4.7, 1.6, C-H6’], 8.65 [1H, dd, J 7.9, 1.6, C-H4’]; δC (75 MHz, CDCl3) 
32.9 (CH3, NCH3), 48.4 (CH2, CH2Ph), 52.7 (CH3, OCH3), 53.0 (CH, CHCOOCH3), 107.0 (C, 
aromatic C), 109.6 (CH, aromatic CH), 113.8 (C, aromatic C), 118.3 (CH, aromatic CH), 
119.0 (CH, aromatic CH), 119.3 (C, aromatic C), 119.7 (CH, aromatic CH), 121.9 (CH, 
aromatic CH), 127.0 (C, aromatic C), 127.9 (2CH, 2 x aromatic CH), 128.2 (CH, aromatic 
CH), 128.9 (CH, aromatic CH), 129.0 (2CH, 2 x aromatic CH), 131.2 (CH, aromatic CH), 
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134.6 (CH, aromatic CH), 135.9 (C, aromatic C), 136.7 (C, aromatic C), 144.9 (CH, aromatic 
CH), 148.1 (C, aromatic C), 170.0 (C, C=O), 188.3 (C, C=O); m/z (ES+) 438.1 [M+H]
+
 
(100%); HRMS (ES+): Exact mass calculated for C27H24N3O3 438.1802. Found 438.1818. 
 
1-Methyl-1H-pyrrolo[2,3-b]pyridine (277)
4 
A solution of 7-azaindole 139 (4.002 g, 33.9 mmol) in DMF (60 mL) was 
cooled to 0 
o
C in an ice bath. Sodium hydride (60 wt.% oil dispersion, 2.033 g, 
50.8 mmol) was then added in a portionwise manner. The resultant mixture was 
then allowed to stir at 0
o
C for 30 minutes. A solution of methyl iodide (2.53 mL, 40.6 mmol) 
in DMF (20 mL) was then added in a dropwise manner, after which the reaction mixture was 
allowed to warm to room temperature and stirred for 3 hours. Water (80 mL) was carefully 
added to quench the reaction. The aqueous layer was extracted with ethyl acetate (3 x 60 mL), 
and then the combined organic extracts were washed with water (4 x 100 mL) and brine (100 
mL), before being dried over magnesium sulfate and evaporated under reduced pressure to 
yield the crude product as a brown oil. The crude product was subjected to flash column 
chromatography (hexane/ethyl acetate, 75:25) to yield N-methyl product 277 as a green oil 
which was used without further purification (4.229 g, 94%): vmax/cm
-1
 (NaCl) 3053, 2941, 
1595, 1570, 1516, 1439, 1409, 1297; δH (300 MHz, CDCl3) 3.88 [3H, s, NCH3], 6.44 [1H, d, J 
3.5, C-H3], 7.04 [1H, dd, J 7.8, 4.7, C-H5], 7.15 [1H, d, J 3.5, C-H2], 7.90 [1H, dd, J 7.8, 1.5, 
C-H4], 8.33 [1H, dd, J 4.7, 1.4, C-H6]; δC (75 MHz, CDCl3) 31.3 (CH3, NCH3), 99.3 (C, 
aromatic CH), 115.5 (C, aromatic CH), 120.7 (C, aromatic C), 128.9 (C, aromatic CH), 129.1 
(C, aromatic CH), 142.6 (C, aromatic CH), 147.6 (C, aromatic C); m/z (ES+) 133.3 [M+H]
+
 
(100%). 
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2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-oxoacetic acid (278) 
A solution of 1-methyl-1H-pyrrolo[2,3-b]pyridine 277 (4.002 g, 30.3 
mmol) in diethyl ether (60 mL) was cooled to 0 
o
C using an ice bath. 
Oxalyl chloride (3.07 mL, 36.3 mmol) was then added in a dropwise 
manner over a period of 20 minutes. Once the addition was complete, the 
resulting mixture was allowed to slowly warm to room temperature over 3 
hours. The solvent and excess oxalyl chloride was then removed by evaporation under 
reduced pressure. The solid residue was then suspended in acetone (80 mL), with the resulting 
mixture then being treated with a solution of potassium hydroxide (6.813 g, 121.4 mmol) in 
water (80 mL) before being left to stir at room temperature for 14 hours. The ensuing deep 
brown solution was acidified to pH 2 using 2M aqueous HCl, with the subsequent precipitate 
being filtered, washed with water and to dried to give oxoacetic acid 278 as a white solid 
(2.891 g, 47%): m.p. 266-267 
o
C; vmax/cm
-1
 (KBr) 3130, 2408, 1709, 1654, 1591, 1522, 1365, 
1277; δH (300 MHz, DMSO-d6) 3.93 [3H, s, NCH3], 7.37 [1H, dd, J 7.8, 4.8, C-H5], 8.44 [1H, 
dd, J 4.7, 1.4, C-H6], 8.49 [1H, dd, J 7.8, 1.4, C-H4], 8.69 [1H, s, C-H2], 13.92 [1H, bs, 
COOH]; δC (75 MHz, DMSO-d6) 31.7 (CH3, NCH3), 109.7 (C, aromatic C), 118.3 (C, 
aromatic C), 119.1 (CH, aromatic CH), 129.7 (CH, aromatic CH), 141.4 (CH, aromatic CH), 
144.7 (CH, aromatic CH), 148.1 (C, aromatic C), 164.6 (C, C=O), 180.3 (C, C=O); m/z (ES+) 
205.2 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C10H9N2O3 205.0613. Found 
205.0604. 
 
2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (279) 
A solution of 2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-oxoacetic acid 
278 (1.763 g, 8.6 mmol) in ethylene glycol (20 mL) was treated with 
hydrazine hydrate (2.71 mL, 43.2 mmol), and the resulting mixture was 
heated to 60 
o
C. Sodium methoxide (4.989 g, 92.4 mmol) was then added in 
a portionwise manner, following which the reaction mixture was slowly 
heated to 150 
o
C. The mixture was stirred at 150 
o
C for 3 hours, allowing the solvent to 
concentrate to roughly half the original volume, before being cooled to room temperature and 
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then carefully diluted with water (100 mL). Using an ice bath, the resulting solution was 
cooled to 0 
o
C and then acidified to pH 2 using 12 M aqueous hydrochloric acid. The 
precipitate formed was filtered, washed with water and dried to yield pure acetic acid 279 as a 
white solid (1.382 g, 84%): m.p. 235-236 
o
C; vmax/cm
-1
 (KBr) 2933, 2475, 1704, 1585, 1542, 
1359, 1294; δH (300 MHz, DMSO-d6) 3.61 [2H, s, CH2COOH], 3.72 [3H, s, NCH3], 7.01 [1H, 
dd, J 7.8, 4.7, C-H5], 7.34 [1H, s, C-H2], 7.87 [1H, dd, J 7.8, 1.6, C-H4], 8.19 [1H, dd, J 4.7, 
1.5, C-H6], 12.23 [1H, bs, COOH]; δC (75 MHz, DMSO-d6) 30.5 (CH3, NCH3), 30.7 (CH2, 
CH2COOH), 105.8 (C, aromatic C), 114.9 (CH, aromatic CH), 119.7 (C, aromatic C), 127.2 
(CH, aromatic CH), 128.3 (CH, aromatic CH), 142.3 (CH, aromatic CH), 147.3 (C, aromatic 
C), 172.8 (C, C=O); m/z (ES+) 191.2 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated 
for C10H11N2O2 191.0821. Found 191.0814. 
 
Methyl 2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetate (280) 
 2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid 279 (0.701 g, 3.7 
mmol) was dissolved in methanol (25 mL), and the resulting solution was 
carefully treated with neat sulphuric acid (1 mL). This mixture was then 
stirred at room temperature for 2 hours. Saturated aqueous sodium 
bicarbonate solution was added to the reaction mixture in a portionwise 
manner until pH 9 was reached. The resulting alkaline solution was extracted with ethyl 
acetate (3 x 15 mL), and the combined organic extracts were washed with water (20 mL) and 
brine (20 mL), before being dried over magnesium sulfate. The solvent was removed under 
reduced pressure to yield the ester product 280 as a yellow oil which was used without further 
purification (0.734 g, 97%): vmax/cm
-1
 (NaCl) 2951, 1736, 1617, 1475, 1332, 1163; δH (300 
MHz, CDCl3) 3.68 [3H, s, NCH3], 3.72 [2H, s, CH2COOCH3], 3.82 [3H, s, OCH3], 7.03 [1H, 
dd, J 7.9, 4.7, C-H5], 7.12 [1H, s, C-H2], 7.88 [1H, dd, J 7.9, 1.5, C-H4], 8.33 [1H, dd, J 4.7, 
1.4, C-H6]; δC (75 MHz, CDCl3) 30.0 (CH3, NCH3), 30.1 (CH2, CH2COOCH3), 52.0 (CH3, 
OCH3), 105.3 (C, aromatic C), 115.3 (CH, aromatic CH), 120.0 (C, aromatic C), 127.2 (CH, 
aromatic CH), 127.7 (CH, aromatic CH), 143.0 (CH, aromatic CH), 147.8 (C, aromatic C), 
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172.1 (C, C=O); m/z (ES+) 205.2 [M+H]
+
 (20%), 100.1 (100%); HRMS (ES+): Exact mass 
calculated for C11H13N2O2 205.0977. Found 205.0967. 
 
Methyl 2,3-bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-oxopropanoate (281) 
A solution of LDA (1.8 M, 1.54 mL, 2.8 mmol) in THF (20 
mL) was cooled to -78 
o
C under a nitrogen atmosphere. A 
second solution of methyl 2-(1-methyl-1H-pyrrolo[2,3-
b]pyridin-3-yl)acetate 280 (0.257 g, 1.3 mmol) in THF (5 mL) 
was then added in a dropwise manner, with the resulting 
mixture being stirred for 1 hour at -78 
o
C. A suspension of 1-
methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl chloride 266 (0.294 g, 1.5 mmol) in THF (10 
mL) was added in a dropwise manner to the reaction mixture over a 15 minute period. Once 
the addition was complete, the mixture was warmed to 35 
o
C and left to stir under a nitrogen 
atmosphere for 14 hours. The solvent was then evaporated under reduced pressure, and the 
crude residue dissolved in ethyl acetate (40 mL). The organic phase was extracted with 
saturated aqueous sodium bicarbonate solution (30 mL), water (30 mL) and brine (30 mL), 
before being dried over magnesium sulfate. The solvent was removed under reduced pressure 
and the crude product was purified by flash column chromatography (hexane/ethyl acetate, 
20:80) to yield 281 as a golden crystalline solid (0.178 g, 38%): m.p. 94-95 
o
C; vmax/cm
-1
 
(KBr) 2950, 1747, 1651, 1598, 1533, 1448, 1302; δH (300 MHz, CDCl3) 3.78 [3H, s, NCH3], 
3.88 [3H, s, NCH3], 3.91 [3H, s, OCH3], 5.63 [1H, s, C-Hα], 7.09 [1H, dd, J 7.9, 4.7, C-H5’], 
7.25 [1H, dd, J 7.9, 4.7, C-H5], 7.43 [1H, s, C-H2], 7.95 [1H, s, C-H2’], 8.02 [1H, dd, J 7.9, 
1.5, C-H4], 8.34 [1H, dd, J 4.7, 1.5, C-H6], 8.40 [1H, dd, J 4.8, 1.6, C-H6’], 8.65 [1H, dd, J 7.9, 
1.6, C-H4’]; δC (75 MHz, CDCl3) 31.4 (CH3, NCH3), 32.1 (CH3, NCH3), 52.9 (CH3, OCH3), 
53.4 (CH, CHCOOCH3), 105.7 (C, aromatic C), 113.3 (C, aromatic C), 115.8 (CH, aromatic 
CH), 118.9 (CH, aromatic CH), 119.2 (C, aromatic C), 119.5 (C, aromatic C), 127.5 (CH, 
aromatic CH), 128.8 (CH, aromatic CH), 131.2 (CH, aromatic CH), 135.7 (CH, aromatic CH), 
143.3 (CH, aromatic CH), 144.9 (CH, aromatic CH), 147.7 (C, aromatic C), 148.3 (C, 
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aromatic C), 169.7 (C, C=O), 187.5 (C, C=O); m/z (ES+) 363.1 [M+H]
+
 (100%); HRMS 
(ES+): Exact mass calculated for C20H19N4O3 363.1457. Found 363.1453. 
 
Methyl 2-(3,4,5-trimethoxyphenyl)acetate (291)
5 
A solution of 3,4,5-trimethoxyphenyl acetic acid 290 (1.503 g, 6.6 mmol) in 
DMF (30 mL) was treated with potassium carbonate (1.100 g, 8.0 mmol) and 
dimethyl carbonate (1.1 mL, 13.3 mmol). The resulting mixture was heated to 
reflux for 16 hours before being cooled to room temperature. Water (50 mL) 
was added to the reaction mixture, which was then extracted with ethyl acetate 
(3 x 30 mL). The combined organic extracts were washed with water (4 x 50 
mL) and brine (50 mL), before being dried over magnesium sulfate. The solvent was removed 
under reduced pressure, and the crude red residue was subjected to flash column 
chromatography (hexane/ethyl acetate, 80:20), yielding ester 291 as a clear oil which was used 
without further purification (1.394 g, 87%): vmax/cm
-1
 (NaCl) 2948, 2840, 1737, 1592, 1508, 
1127; H (300 MHz, CDCl3) 3.57 [2H, s, CH2COOCH3], 3.71 [3H, s, p-OCH3], 3.83 [3H, s, 
NCH3], 3.86 [6H, s, 2 x m-OCH3], 6.50 [2H, s, C-H2,6]; δC (75 MHz, CDCl3) 41.4 (CH2, 
CH2COOCH3), 52.1 (CH3, COOCH3), 56.1 (2CH3, 2 x m-OCH3), 60.8 (CH3, p-OCH3), 106.2 
(2CH, 2 x aromatic CH), 129.5 (C, aromatic C), 137.0 (C, aromatic C), 153.2 (2C, 2 x 
aromatic C), 172.0 (C, C=O); m/z (ES+) 241.1 [M+H]
+
 (100%). 
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Methyl 3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-oxo-2-(3,4,5-
trimethoxyphenyl)propanoate (292)
 
Under a nitrogen atmosphere, a solution of methyl 2-(3,4,5-
trimethoxyphenyl)acetate 291 (0.737 g, 3.1 mmol) in THF (5 mL) 
was added to a stirred solution of LDA (3.8 mL, 6.8 mmol) in THF 
(20 mL), which had previously been cooled to -78 
o
C. The 
resulting mixture was maintained at -78 
o
C and stirred for 1 hour. 
A suspension of 1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl 
chloride 266 (0.722 g, 3.7 mmol) in THF (10 mL) was added to the 
reaction mixture in a dropwise manner over a period of 20 minutes. Once complete, the 
reaction mixture was warmed to 35 
o
C and stirred for 14 hours, still under an inert 
atmosphere. The solvent was evaporated under reduced pressure, and the resulting residue was 
dissolved in ethyl acetate (50 mL), before being washed with saturated aqueous sodium 
bicarbonate solution (40 mL), water (40 mL) and then brine (40 mL). Upon drying over 
magnesium sulfate, the solvent was removed under reduced pressure, affording the crude 
product as a brown solid. Purification via flash column chromatography (hexane/ethyl acetate, 
30:70) gave oxopropanoate 292 as a yellow crystalline solid (0.622 g, 51%): m.p. 108-110 
o
C; 
vmax/cm
-1
 (KBr) 2938, 2839, 1716, 1650, 1593, 1449, 1128; δH (300 MHz, CDCl3) 3.79 [3H, s, 
COOCH3], 3.83 [3H, s, p-OCH3], 3.87 [6H, s, 2 x m-OCH3], 3.93 [3H, s, NCH3], 5.32 [1H, s, 
CHα], 6.71 [2H, s, C-H2’,6’], 7.26 [1H, dd, J 7.8, 4.8, C-H5], 7.82 [1H, s, C-H2], 8.41 [1H, dd, J 
4.8, 1.6, C-H6], 8.65 [1H, dd, J 7.9, 1.6, C-H4]; δC (75 MHz, CDCl3) 32.1 (CH3, NCH3), 52.8 
(CH3, COOCH3), 56.3 (2CH3, 2 x m-OCH3), 60.8 (CH3, p-OCH3), 61.5 (CH, CHCOOCH3), 
106.6 (2CH, 2 x aromatic CH), 113.6 (C, aromatic C), 119.0 (CH, aromatic CH), 119.2 (C, 
aromatic C), 129.2 (C, aromatic C), 131.2 (CH, aromatic CH), 135.7 (CH, aromatic CH), 
137.9 (C, aromatic C), 145.0 (CH, aromatic CH), 153.4 (2C, 2 x aromatic C), 169.4 (C, C=O), 
187.4 (C, C=O); m/z (ES+) 399.2 [M+H]
+
 (100%); HRMS (ES+): HRMS (ES+): Exact mass 
calculated for C21H23N2O6 399.1556. Found 399.1546. 
 
 
Chapter 7 | Experimental 
 
 
[225] 
 
7.2.2.2 Routes towards oxopropanenitriles  
2-(1-Methyl-1H-indol-3-yl)acetonitrile (275)
6
 
Indole-3-acetonitrile 274 (6.005 g, 38.4 mmol) was dissolved in DMF (80 
mL), with the resulting solution being cooled to 0 
o
C. Sodium hydride (55 
wt.% oil dispersion, 2.524 g, 57.6 mmol) was then added slowly in a 
portionwise manner. The reaction mixture was stirred for 30 minutes, with 
the temperature maintained at 0 
o
C. A solution of iodomethane (3.6 mL, 57.6 
mmol) in DMF (10 mL) was then added dropwise to the reaction mixture, which was 
subsequently allowed to warm to room temperature and stirred for 2 hours. Water (50 mL) 
was cautiously added to quench the reaction, which was then extracted with ethyl acetate (3 x 
60 mL). The combined organic extracts were washed with water (4 x 100 mL) and brine (100 
mL), and then dried over magnesium sulfate. The solvent was removed under reduced 
pressure and the crude reddish residue was purified by flash column chromatography 
(hexane/ethyl acetate, 75:25), yielding the product 275 as an off-white crystalline material 
(5.503 g, 84%): m.p. 57-59 
o
C (lit.
6
 59-60 
o
C) vmax/cm
-1
 (KBr) 2954, 2247, 1657, 1553, 1464, 
1377; H (400 MHz, CDCl3) 3.78 [3H, s, NCH3], 3.82 [2H, s, CH2CN], 7.09 [1H, s, C-H2], 
7.17 [1H, t, J 7.5, C-H5], 7.25-7.34 [2H, m, C-H6,7], 7.57 [1H, d, J 7.9, C-H4]; δC (75 MHz, 
CDCl3) 14.2 (CH2, CH2CN), 32.8 (CH3, NCH3), 103.0 (C, aromatic C), 109.8 (CH, aromatic 
CH), 118.3 (CH, aromatic CH), 118.6 (C, C≡N), 119.8 (CH, aromatic CH), 122.4 (CH, 
aromatic CH), 126.5 (C, aromatic C), 127.5 (CH, aromatic CH), 137.3 (C, aromatic C); m/z 
(ES+) 171.1 [M+H]
+
 (100%). 
 
2-(1-Methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-
oxopropanenitrile (276) 
A solution of LDA (1.8 M, 29.0 mL, 52.1 mmol) in THF (100 
mL) was cooled to -78 
o
C under a nitrogen atmosphere. A 
second solution of 2-(1-methyl-1H-indol-3-yl)acetonitrile 275 
(4.029 g, 23.7 mmol) in THF (15 mL) was then added in a 
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dropwise fashion, with the resulting mixture being stirred for 1 hour at -78 
o
C. 1-Methyl-1H-
pyrrolo[2,3-b]pyridine-3-carbonyl chloride 266 (5.533 g, 28.4 mmol) was suspended in THF 
(60 mL) and slowly added to the reaction mixture over a 20 minute period. Once the addition 
was complete, the reaction mixture was warmed to 35 
o
C and left to stir under a nitrogen 
atmosphere for 12 hours. The solvent was removed under reduced pressure and the residue 
was dissolved in ethyl acetate (150 mL), and then washed successively with a saturated 
aqueous sodium bicarbonate solution (120 mL), water (120 mL) and then brine (120 mL). 
Removal of the organic solvent under reduced pressure yielded the crude product as a brown 
solid, which was then subjected to flash column chromatography (hexane/ethyl acetate, 30:70) 
to yield the pure oxopropanenitrile 276 as a reddish crystalline solid (4.218 g, 54%): m.p. 96-
98 
o
C; vmax/cm
-1
 (KBr) 3053, 2920, 2243, 1652, 1597, 1533, 1448, 1368; H (300 MHz, 
CDCl3) 3.75 [3H, s, NCH3], 3.87 [3H, s, NCH3], 5.55 [1H, s, CHα], 7.16-7.33 [5H, m, C-
H2,5,5’,6,7], 7.71 [1H, d, J 7.6, C-H4], 7.96 [1H, s, C-H2’], 8.38 [1H, dd, J 4.7, 1.6, C-H6’], 8.58 
[1H, dd, J 7.9, 1.6, C-H4’]; δC (75 MHz, CDCl3) 32.2 (CH3, NCH3), 33.0 (CH3, NCH3), 39.6 
(CH, CHCN), 104.8 (C, aromatic C), 109.9 (CH, aromatic CH), 111.3 (C, aromatic C), 117.6 
(C, aromatic C), 118.6 (CH, aromatic CH), 119.1 (CH, aromatic CH), 119.3 (C, C≡N), 120.4 
(CH, aromatic CH), 122.7 (CH, aromatic CH), 125.7 (C, aromatic C), 128.1 (CH, aromatic 
CH), 131.1 (CH, aromatic CH), 136.0 (CH, aromatic CH), 137.1 (C, aromatic C), 145.1 (CH, 
aromatic CH), 148.2 (C, aromatic C), 183.3 (C, C=O); m/z (ES+) 327.2 [M-H]
-
 (100%); 
HRMS (ES+): Exact mass calculated for C20H17N4O 329.1402. Found 329.1407. 
 
N,N-Diethyl-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)methanamine (282) 
A solution of diethylamine hydrochloride (0.604 g, 5.5 mmol) and water 
(5 mL) was cooled in an ice bath to 0 
o
C. This was treated with 37 wt.% 
aqueous formaldehyde (0.36 mL, 4.8 mmol) and stirred for 30 minutes. A 
solution of 7-azaindole 139 (0.500 g, 4.2 mmol) in ethanol (10 mL) was 
then added, with the resulting mixture maintained at 0 
o
C for 30 minutes, 
before being heated to reflux for 20 hours. Once cooled to room temperature, the reaction 
mixture was diluted with water (20 mL), then adjusted to pH 11 using 50 wt.% aqueous 
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NaOH. Extraction with dichloromethane (3 x 20 mL) was then performed, and the combined 
organic extracts were dried over magnesium sulfate, filtered and evaporated under reduced 
pressure to yield a yellow/orange residue. The crude product was purified by flash column 
chromatography (ethyl acetate/methanol, 80:20), giving amine 282 as a light orange solid 
(0.755 g, 88%): m.p. 62-64 
o
C; max/cm
-1
 (KBr) 3142, 2970, 2931, 2787, 1583, 1544, 1454, 
1421, 1298, 1048; δH (300 MHz, DMSO-d6) 0.98 [6H, t, J 7.1, 2 x NCH2CH3], 2.43 [4H, q, J 
7.1, 2 x NCH2CH3], 3.66 [2H, s, CH2], 7.01 [1H, dd, J 7.8, 4.7, C-H5], 7.32 [1H, s, C-H2], 
7.99 [1H, dd, J 7.8, 1.2, C-H4], 8.18 [1H, dd, J 4.6, 1.4, C-H6], 11.44 [1H, bs, NH]; δC (75 
MHz, DMSO-d6) 11.8 (CH3, 2 x NCH2CH3), 45.9 (CH2, 2 x NCH2CH3), 48.1 (CH2, 
CH2N(CH2CH3)2), 110.9 (C, aromatic C), 114.8 (CH, aromatic CH), 119.7 (C, aromatic C), 
124.5 (CH, aromatic CH), 127.3 (CH, aromatic CH), 142.3 (CH, aromatic CH), 148.8 (C, 
aromatic C); m/z (ES+) 204.1 [M+H]
+
 (100%). HRMS (ES+) Exact mass calculated for 
C12H18N3 [M+H]
+
, 204.1501. Found 204.1498. 
 
N,N-Dimethyl-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanamine (284)
7
 
A mixture of dimethylamine (33 wt.% in ethanol, 9.8 mL, 55.2 mmol), 
acetic acid (2.7 mL, 48 mmol) and water (10 mL) was cooled in an ice bath 
to 0 
o
C. The resulting solution was subsequently treated with 37 wt.% 
aqueous formaldehyde (3.6 mL, 48.1 mmol) and stirred for 30 minutes. 7-
Azaindole 139 (5.004 g, 42.4 mmol) in ethanol (20 mL) was then added, 
with the resulting solution stirred at 0 
o
C for 30 minutes, before being heated to 100 
o
C for 18 
hours. At this point, TLC analysis showed complete consumption of starting material, and the 
reaction mixture was cooled to room temperature. The solution was diluted with water (40 
mL) and adjusted to pH 11 using 50 wt.% aqueous NaOH. After extraction with 
dichloromethane (3 x 30 mL), the organic extracts were dried over magnesium sulfate, filtered 
and evaporated under reduced pressure to give the crude product as a pale yellow solid. 
Purification was carried out by flash column chromatography (ethyl acetate/methanol, 80:20) 
to yield amine 284 as a white crystalline solid (6.052 g, 82%): m.p. 157-158 
o
C (lit.
7
 144-152 
o
C); vmax/cm
-1
 (KBr) 3079, 2947, 2775, 1604, 1528, 1412, 1334, 1002; δH (300 MHz, DMSO-
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d6) 2.13 [6H, s, N(CH3)2], 3.51 [2H, s, CH2N(CH3)2], 7.02 [1H, dd, J 7.9, 4.7, C-H5], 7.33 
[1H, s, C-H2], 7.98 [1H, dd, J 7.9, 1.5, C-H4], 8.19 [1H, dd, J 4.7, 1.5, C-H6], 11.46 [1H, bs, 
NH]; δC (75 MHz, DMSO-d6) 44.8 (CH3, 2 x NCH3), 54.4 (CH2, CH2N(CH3)2), 110.6 (C, 
aromatic C), 114.9 (CH, aromatic CH), 119.7 (C, aromatic C), 124.7 (CH, aromatic CH), 
127.2 (CH, aromatic CH), 142.4 (CH, aromatic CH), 148.7 (C, aromatic C); m/z (ES+) 176.1 
[M+H]
+
 (100%). 
 
2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)acetonitrile (283)
8
 
To a solution of N,N-dimethyl-1-(1H-pyrrolo[2,3-b]pyridin-3-
yl)methanamine 284 (5.603 g, 32.0 mmol) in DMF (20 mL) was added a 
solution of sodium cyanide (2.35 g, 48.2 mmol) in water (16 mL). Acetic 
acid (5 mL) was then added in a dropwise manner, and the resulting solution 
was heated to 110 
o
C for 8 hours. After cooling to room temperature, the solution was diluted 
with saturated aqueous potassium carbonate (30 mL), then extracted with ethyl acetate (3 x 40 
mL). The organic extracts were dried over magnesium sulfate, filtered and evaporated under 
reduced pressure to yield the crude product. Purification by flash column chromatography 
(hexane/ethyl acetate, 40:60) gave acetonitrile 283 as a white crystalline solid (2.589 g, 52%), 
m.p. 135-137 
o
C (lit.
8
 136-138 
o
C); vmax/cm
-1
 (KBr) 3089, 2888, 2248, 1611, 1585, 1538, 
1420, 1337; δH (300 MHz, CDCl3) 3.85 [2H, s, CH2], 7.16 [1H, dd, J 7.9, 4.8, C-H5], 7.40 
[1H, s, C-H2], 7.99 [1H, dd, J 7.9, 1.5, C-H4], 8.38 [1H, dd, J 4.8, 1.5, C-H6], 11.92 [1H, bs, 
NH]; δC (75 MHz, CDCl3) 14.6 (CH2, CH2CN), 102.8 (C, aromatic C), 116.0 (CH, aromatic 
CH), 117.8 (C, CN), 119.0 (C, aromatic C), 124.0 (CH, aromatic CH), 127.1 (CH, aromatic 
CH), 143.1 (CH, aromatic CH), 148.9 (C, aromatic C); m/z (ES+) 158.0 [M+H]
+
 (100%). 
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2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetonitrile (285)
9
 
2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)acetonitrile 283 (2.106 g, 13.4 mmol) was 
dissolved in anhydrous DMF (30 mL) and the resulting solution was cooled 
to 0 
o
C in an ice bath. Sodium hydride (55 wt.% oil dispersion, 0.585 g, 13.4 
mmol) was added slowly in a portionwise manner. Once the addition was 
complete, the resulting mixture was allowed to stir at 0 
o
C for 20 minutes. At this point, a 
solution of iodomethane (0.83 mL, 13.4 mmol) in DMF (5 mL) was added in a dropwise 
fashion. The reaction mixture was then allowed to warm to room temperature, with stirring, 
over 2 hours. Water (20 mL) was cautiously added to quench to reaction. Following extraction 
with ethyl acetate (3 x 30 mL), the combined organic extracts were washed with water (4 x 50 
mL) and brine (50 mL), then dried over magnesium sulfate. The solvent was evaporated under 
reduced pressure to yield the crude product as a brown solid, which was then purified by flash 
column chromatography (hexane/ethyl acetate, 70:30) to give acetonitrile 285 as a reddish 
solid (1.059 g, 46%): m.p. 82-84 
o
C (lit.
9
 81-82.5 
o
C); vmax/cm
-1
 (KBr) 2941, 2360, 2249, 
1602, 1542, 1463, 1410, 1301, 1144; δH (400 MHz, CDCl3) 3.83 [2H, s, CH2], 3.89 [3H, s, 
CH3], 7.13 [1H, dd, J 7.9, 4.7, C-H5], 7.22 [1H, s, C-H2], 7.92 [1H, dd, J 7.9, 1.5, C-H4], 8.40 
[1H, dd, J 4.7, 1.5, C-H6]; δC (75 MHz, CDCl3) 14.5 (CH2, CH2CN), 31.3 (CH3, NCH3), 101.5 
(C, aromatic C), 115.8 (CH, aromatic CH), 117.8 (C, CN), 118.8 (C, aromatic C), 126.6 (CH, 
aromatic CH), 127.5 (CH, aromatic CH), 143.8 (CH, aromatic CH), 147.9 (C, aromatic C); 
m/z (ES+) 172.1 [M+H]
+
 (100%). 
 
3,4,5-Trimethoxybenzoyl chloride (286)
10 
 
To a suspension of 3,4,5-trimethoxybenzoic acid (8.002 g, 37.7 mmol) in 
chloroform (30 mL) was added thionyl chloride (13.7 mL, 189 mmol) in a 
dropwise manner. Upon completion of addition, the mixture was heated to 
reflux for four hours before being cooled to room temperature. The solvent and 
excess thionyl chloride were removed under reduced pressure to yield acyl 
chloride 286 in quantitative yield as a white crystalline solid, which was subsequently used 
without further purification: vmax/cm
-1
 (KBr) 2947, 2836, 1751, 1591, 1503, 1415, 1127. 
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[230] 
 
2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-oxo-3-(3,4,5-
trimethoxyphenyl)propanenitrile (287) 
A solution of LDA (1.8 M, 6.49 mL, 11.7 mmol) in THF (40 mL) 
was cooled to -78 
o
C under a nitrogen atmosphere. Another 
solution of 2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetonitrile 
285 (0.910 g, 5.3 mmol) in THF (5 mL) was then added in a 
dropwise manner and the reaction mixture was stirred for 1 hour, 
with the temperature maintained at -78 
o
C. After 1 hour, 3,4,5-
trimethoxybenzoyl chloride 286 (1.475 g, 6.4 mmol) in THF (10 mL) was added dropwise to 
the reaction mixture, which was then allowed to slowly warm to room temperature under 
stirring over 12 hours. The solvent was removed under reduced pressure, and the residue 
dissolved in ethyl acetate (50 mL), followed by washings with saturated aqueous sodium 
bicarbonate solution (40 mL), water (40 mL) and brine (40 mL). After being dried over 
magnesium sulfate, the solvent was removed under reduced pressure. The crude residue was 
subjected to flash column chromatography (hexane/ethyl acetate, 20:80), yielding pure 
oxopropanenitrile 287 as a yellow solid (0.956 g, 49%): m.p. 80-82 
o
C; vmax/cm
-1
 (KBr) 2940, 
2201, 1684, 1583, 1505, 1461, 1415, 1333, 1127; δH (400 MHz, CDCl3) 3.83 [6H, s, 2 x m-
OCH3], 3.87 [3H, s, p-OCH3], 3.89 [3H, s, NCH3], 5.82 [1H, s, CHα], 7.15 [1H, dd, J 8.0, 4.7, 
C-H5], 7.22 [2H, s, C-H2’,6’], 7.30 [1H, s, C-H2], 8.05 [1H, dd, J 8.0, 1.5, C-H4], 8.38 [1H, dd, 
J 4.7, 1.3, C-H6]; δC (75 MHz, CDCl3) 31.5 (CH3, NCH3), 38.6 (CH, CHCN), 56.4 (2CH3, 2 x 
m-OCH3), 61.0 (CH3, p-OCH3), 102.4 (C, aromatic C), 105.6 (C, aromatic C), 106.8 (2CH, 2 x 
aromatic CH), 116.5 (CH, aromatic CH), 118.0 (C, CN), 127.1 (CH, aromatic CH), 128.3 
(CH, aromatic CH), 128.3 (C, aromatic C), 143.8 (C, aromatic C), 144.2 (CH, aromatic CH), 
147.8 (C, aromatic C), 153.1 (2C, 2 x aromatic C), 187.2 (C, C=O); m/z (ES+) 366.1 [M+H]
+
 
(100%); HRMS (ES+): Exact mass calculated for C20H20N3O4 366.1454. Found 366.1448. 
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[231] 
 
3-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-oxo-2-(3,4,5-
trimethoxyphenyl)propanenitrile (289) 
A solution of LDA (1.8 M, 9.8 mL, 17.7 mmol) in THF (10 mL) 
was then cooled to -78 
o
C under a nitrogen atmosphere. A second 
solution of 3,4,5-trimethoxyphenyl acetonitrile 288 (1.356 g, 6.5 
mmol) in THF (5 mL) was then added in a dropwise manner, with 
the resulting mixture stirred for 1 hour at  -78 
o
C. A suspension of 
1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl chloride 266 
(1.401 g, 7.2 mmol) in THF (25 mL) was slowly added to the reaction mixture over a 20 
minute period. Once the addition was complete, the reaction mixture was warmed to 35 
o
C 
and allowed to stir at this temperature, still under an inert atmosphere, for 12 hours. The 
solvent was evaporated under reduced pressure and the resultant residue was dissolved in 
ethyl acetate (40 mL). The organic phase was washed with a saturated aqueous sodium 
bicarbonate solution (50 mL), water (50 mL) and then brine (50 mL), before being dried over 
magnesium sulfate. The solvent was removed under reduced pressure and the crude residue 
was subjected to flash column chromatography (hexane/ethyl acetate, 30:70) to yield 
oxopropanenitrile 289 as a yellow solid (1.094 g, 46%): m.p. 137-140 
o
C; vmax/cm
-1
 (KBr) 
2933, 2243, 1728, 1643, 1595, 1450, 1130; δH (400 MHz, CDCl3) 3.83 [3H, s, p-OCH3], 3.87 
[6H, s, 2 x m-OCH3], 3.94 [3H, s, NCH3], 5.23 [1H, s, CHα], 6.70 [2H, s, C-H2’6’], 7.28 [1H, 
dd, J 7.9, 4.8, C-H5], 7.97 [1H, s, C-H2], 8.43 [1H, dd, J 4.8, 1.6, C-H6], 8.60 [1H, dd, J 7.9, 
1.6, C-H4]; δC (75 MHz, CDCl3) 32.3 (CH3, NCH3), 47.8 (CH, CHCN), 56.4 (2CH3, 2 x m-
OCH3), 60.9 (CH3, p-OCH3), 105.1 (2CH, 2 x aromatic CH), 111.4 (C, aromatic C), 117.3 (C, 
aromatic C), 119.3 (C, C≡N), 119.4 (CH, aromatic CH), 126.5 (C, aromatic C), 131.2 (CH, 
aromatic CH), 136.0 (CH, aromatic CH), 138.5 (C, aromatic C), 145.4 (CH, aromatic CH), 
148.2 (C, aromatic C), 154.0 (2C, 2 x aromatic C), 182.6 (C, C=O); m/z (ES+) 364.1 [M-H]
-
 
(100%); HRMS (ES+): Exact mass calculated for C20H20N3O4 366.1454. Found 366.1472. 
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7.2.3 Synthesis and derivatisation of 5-aminopyrazole 293 
4-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-
amine (293) 
To a solution of 2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-
oxo-3-(3,4,5-trimethoxyphenyl)propanenitrile 287 (0.806 g, 2.2 
mmol) in absolute alcohol (30 mL), 12 M aqueous HCl (1 mL) 
was slowly added. Hydrazine hydrate (50% aqueous solution, 
0.69 mL, 11.0 mmol) was then added and the resulting mixture 
was heated to reflux for 20 hours. Once the reaction mixture was 
cooled to room temperature, the solvent was removed under reduced pressure. The residue 
was dissolved in ethyl acetate (40 mL) and then washed with saturated aqueous sodium 
bicarbonate solution (30 mL), water (30 mL) and brine (30 mL), before being dried over 
magnesium sulfate. The solvent was evaporated under reduced pressure, and the crude product 
was then purified by flash column chromatography (ethyl acetate/methanol, 90:10) to yield 
pure aminopyrazole 293 as a brown solid (0.586 g, 70 %): m.p. 266-267 
o
C; vmax/cm
-1
 (KBr) 
3357, 3205, 2935, 1579, 1516, 1459, 1410, 1248, 1124; δH (400 MHz, DMSO-d6) 3.37 [6H, 
s, 2 x m-OCH3], 3.59 [3H, s, p-OCH3], 3.86 [3H, s, NCH3], 4.51 [2H, bs, NH2], 6.71 [2H, s, 
C-H2’,6’], 6.97 [1H, dd, J 7.9, 4.7, C-H5], 7.36 [1H, dd, J 7.8, 1.5, C-H4], 7.56 [1H, s, C-H2], 
8.24 [1H, dd, J 4.6, 1.5, C-H6], 11.97 [1H, bs, NH]; δC (75 MHz, DMSO-d6) 30.8 (CH3, 
NCH3), 55.3 (2CH3, 2 x m-OCH3), 60.1 (CH3, p-OCH3), 95.2 (C, broad aromatic C), 103.9 
(2CH, 2 x aromatic CH), 104.4 (C, aromatic C), 115.1 (CH, aromatic CH), 119.5 (C, aromatic 
C), 126.9 (C, broad aromatic C), 128.0 (CH, aromatic CH), 129.2 (CH, aromatic CH), 136.9 
(C, aromatic C), 141.8 (C, broad aromatic C), 142.4 (CH, aromatic CH), 147.5 (C, aromatic 
C), 152.3 (C, broad aromatic C), 152.5 (2C, 2 x aromatic C); m/z (ES+) 380.1 [M+H]
+
 
(100%); HRMS (ES+): Exact mass calculated for C20H22N5O3 380.1723. Found 380.1725. 
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[233] 
 
7.2.3.1 Formation of bicyclic derivatives of 5-aminopyrazole 293 
8-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-7-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-
a][1,3,5]triazine-2,4(1H,3H)-dione (295) 
To a solution of 4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-
(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-amine 293 (0.080 g, 0.21 
mmol) in DCM (10 mL) was added two drops of triethylamine, 
and the resulting mixture was cooled to 0 
o
C in an ice bath. This 
solution was then treated, while stirring, with N-chlorocarbonyl 
isocyanate (0.02 mL, 0.23 mmol). The reaction mixture was 
allowed to warm to room temperature and was stirred for 15 
hours. After careful addition of water (3 mL), the precipitate formed was filtered and 
subsequently washed with water (4 x 5 mL) and ether (2 x 5 mL). The precipitate was 
desiccated at 50 
o
C overnight to give pure pyrazolotriazinedione 295 as a white solid (0.053 g, 
56%): m.p. 301-303 
o
C; vmax/cm
-1
 (KBr) 3516, 2834, 1765, 1703, 1648, 1583, 1549, 1421, 
1332, 1123; δH (400 MHz, DMSO-d6) 3.37 [6H, s, 2 x m-OCH3], 3.61 [3H, s, p-OCH3], 3.88 
[3H, s, NCH3], 6.84 [2H, s, C-H2’,6’], 7.04 [1H, dd, J 7.8, 4.6, C-H5], 7.50 [1H, d, J 7.8, C-H4], 
7.64 [1H, s, C-H2], 8.29 [d, 1H, J 4.5, C-H6], 11.66 [2H, bs, 2 x NH]; δC (75 MHz, DMSO-d6) 
30.9 (CH3, NCH3), 55.2 (2CH3, 2 x m-OCH3), 60.0 (CH3, p-OCH3), 94.2 (C, aromatic C), 
100.4 (C, aromatic C), 104.5 (2CH, 2 x aromatic CH), 115.6 (CH, aromatic CH), 119.9 (C, 
aromatic C), 127.2 (C, aromatic C), 127.6 (CH, aromatic CH), 131.0 (CH, aromatic CH), 
137.9 (C, aromatic C), 140.1 (C, aromatic C), 142.7 (CH, aromatic CH), 144.3 (C, aromatic 
C), 147.6 (C, aromatic C), 148.6 (C, C=O), 152.5 (2C, 2 x aromatic C), 153.4 (C, C=O); m/z 
(ES-) 447.1 [M-H]
-
, (100%); HRMS (ES+): Exact mass calculated for C22H21N6O5 449.1573. 
Found 449.1554. 
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[234] 
 
5,7-Bis(trifluoromethyl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-(3,4,5-
trimethoxyphenyl)pyrazolo[1,5-a]pyrimidine (297) 
To a stirred mixture of 4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-amine 293 (0.080 g, 
0.21 mmol) in acetic acid (10 mL), was added 
hexafluoroacetylacetone (0.60 mL, 4.20 mmol). This mixture was 
then heated to 80 
o
C for 20 hours. After cooling to room 
temperature, the acetic acid and excess hexafluoroacetylacetone 
were removed under reduced pressure, and the residue was 
dissolved in ethyl acetate (30 mL) and then washed with water (20 mL) and brine (20 mL), 
and dried over magnesium sulfate. Evaporation of the solvent under reduced pressure left the 
crude product as a red/brown solid. Purification via flash column chromatography 
(hexane/ethyl acetate, 50:50) gave the pyrimidine 297 as an orange solid (0.062 g, 54%): m.p. 
174-176 
o
C; vmax/cm
-1
 (KBr) 2926, 1590, 1481, 1419, 1271, 1127, 1010; δH (400MHz, CDCl3) 
3.55 [6H, s, 2 x m-OCH3], 3.86 [3H, s, p-OCH3], 4.02 [3H, s, NCH3], 6.96 [1H, dd, J 7.6, 4.6, 
C-H5], 7.04 [2H, s, C-H2’,6’], 7.38 [1H, d, J 7.8, C-H4], 7.46 [1H, s, (CF3)C-CH=C(CF3)], 7.56 
[1H, s, C-H2], 8.35 [1H, bs, C-H4]; δC (125 MHz, CDCl3) 31.6 (CH3, NCH3), 55.9 (2CH3, 2 x 
m-OCH3), 60.9 (CH3, p-OCH3), 102.0 (C, aromatic C), 102.3 (CH, aromatic CH), 106.2 (C, 
aromatic C), 106.3 (2CH, 2 x aromatic CH), 115.9 (CH, aromatic CH), 115.9-122.4 (C, q, J 
275.4, CF3), 117.0-123.5 (C, q, J 275.2, CF3), 119.2 (C, aromatic C), 127.1 (C, aromatic C), 
129.3 (CH, aromatic CH), 129.4 (CH, aromatic CH), 134.6-135.5 (C, q, J 34.7, aromatic C), 
139.3 (C, aromatic C), 143.4 (CH, aromatic CH), 144.5-145.4 (C, q, J 37.8, aromatic C), 
146.7 (C, aromatic C), 148.0 (C, aromatic C), 153.3 (2C, 2 x aromatic C), 156.0 (C, aromatic 
C); m/z (ES+) 552.1 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C25H20N5O3F6 
552.1470. Found 552.1469. 
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[235] 
 
7.2.3.2 Reaction of 5-aminopyrazole 293 with monodentate electrophiles 
2,2,2-Trifluoro-N-(4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-(3,4,5-
trimethoxyphenyl)-1H-pyrazol-3-yl)acetamide (300)  
To a solution of 4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-
(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-amine 293 (0.080 g, 0.21 
mmol) in acetonitrile (10 mL) was added trifluoroacetic 
anhydride (0.04 mL, 0.25 mmol). The reaction mixture was then 
heated to reflux for 28 hours before being left to cool to room 
temperature. Evaporation of the solvent under reduced pressure 
left the crude product as a brown residue. This residue was then 
purified by flash column chromatography (hexane/ethyl acetate, 40:60), yielding 
trifluoroacetamide 300 as a pale yellow solid (0.041 g, 41%): m.p. 230-231 
o
C; vmax/cm
-1
 
(KBr) 3307, 2939, 1714, 1579, 1507, 1464, 1407, 1173, 1129; δH (300 MHz, DMSO-d6) 3.49 
[6H, s, 2 x m-OCH3], 3.69 [3H, s, p-OCH3], 3.92 [3H, s, NCH3], 6.82 [2H, s, C-H2’,6’], 7.05 
(1H, dd, J 7.9, 4.7, C-H5], 7.44 [1H, dd, J 7.9, 1.5, C-H4], 7.54 [1H, s, C-H2], 8.33 [1H, dd, J 
4.6, 1.4, C-H6], 11.23 [1H, bs, NHCOCF3], 13.52 [1H, bs, C=N-NH-C]; δC (75 MHz, DMSO-
d6) 30.8 (CH3, NCH3), 55.4 (2CH3, 2 x m-OCH3), 60.0 (CH3, p-OCH3), 102.8 (C, aromatic C), 
104.0 (2CH, 2 x aromatic CH), 106.5 (C, aromatic C), 106.7 (C, aromatic C), 110.0-121.5 (C, 
q, JF-C 288.4, CF3), 115.3 (CH, aromatic CH), 118.7 (C, aromatic C), 124.5 (C, aromatic C), 
127.8 (CH, aromatic CH), 128.8 (CH, aromatic CH), 137.3 (C, aromatic C), 142.6 (CH, 
aromatic CH), 147.4 (C, aromatic C), 152.7 (2C, 2 x aromatic C), 153.1 (C, aromatic C), 
155.6-157.1 (C, q, JF-C 36.7, C=O); m/z (ES+) 476.1 [M+H]
+
 (100%); HRMS (ES+): Exact 
mass calculated for C22H21N5O4F3 476.1546. Found 476.1540. 
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[236] 
 
1-[5-Amino-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazol-1-yl]ethanone (302) 
To a solution of 4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-
(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-amine 293 (0.080 g, 0.21 
mmol) in acetonitrile (10 mL) was added acetic anhydride (0.021 
mL, 0.22 mmol). The reaction mixture was heated to reflux for 24 
hours before being cooled to room temperature. The solvent and 
excess acetic anhydride was then removed under reduced 
pressure. The crude residue was subjected to flash column 
chromatography (hexane/ethyl acetate, 40:60), yielding the pure acetylated product 302 as a 
pale yellow crystalline solid (0.0547 g, 62%): m.p. 138-140
o
C; vmax/cm
-1
 (KBr) 3435, 2939, 
1702, 1636, 1597, 1577, 1470, 1421, 1380, 1351, 1128;  δH (300MHz, CDCl3) 2.79 [3H, s, 
NCOCH3], 3.48 [6H, s, 2 x m-OCH3], 3.79 [3H, s, p-OCH3], 3.90 [3H, s, NCH3], 5.60 [2H, 
bs, NH2], 6.81 [2H, s, C-H2’,6’], 7.02 [1H, dd, J 7.9, 4.7, C-H5], 7.15 [1H, s, C-H2], 7.62 [1H, 
dd, J 7.9, 1.5, C-H4], 8.35 [1H, dd, J 4.7, 1.4, C-H6]; δC (75 MHz, CDCl3) 23.3 (CH3, 
NCOCH3), 31.3 (CH3, NCH3), 55.7 (2CH3, 2 x m-OCH3), 60.9 (CH3, p-OCH3), 93.9 (C, 
aromatic C), 103.5 (C, aromatic C), 104.9 (2CH, 2 x aromatic CH), 115.9 (CH, aromatic CH), 
119.9 (C, aromatic C), 127.8 (C, aromatic C), 128.5 (2CH, 2 x aromatic CH), 138.5 (C, 
aromatic C), 143.6 (CH, aromatic CH), 147.9 (C, aromatic C), 148.7 (C, aromatic C), 152.9 
(2C, 2 x aromatic C), 153.1 (C, aromatic C), 173.9 (C, C=O); m/z (ES+) 422.2 [M+H]
+
 
(100%); HRMS (ES+): Exact mass calculated for C22H23N5O4 422.1828. Found 422.1812. 
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[237] 
 
5-Amino-N-methyl-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-
trimethoxyphenyl)-1H-pyrazole-1-carbothioamide (304) 
To a solution of 4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-
(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-amine 293 (0.080 g, 0.21 
mmol) in acetonitrile (10 mL) was added methyl isothiocyanate 
(0.016 g, 0.22 mmol). The reaction mixture was heated to reflux 
for 26 hours before being cooled to room temperature. The 
solvent was removed under reduced pressure to give a crude 
brown residue. Subjection to flash column chromatography 
(hexane/ethyl acetate, 50:50) gave pure carbothioamide 304 as a 
white solid (0.044 g, 47%): m.p. 169-171 
o
C; vmax/cm
-1
 (KBr) 3320, 2933, 1626, 1594, 1523, 
1469, 1423, 1361, 1284, 1123; δH (300 MHz, DMSO-d6) 3.16 [3H, bd, J 3.8, NHCH3], 3.37 
[6H, s, 2 x m-OCH3], 3.59 [3H, s, p-OCH3], 3.88 [3H, s, NCH3], 6.90 [2H, s, C-H2’,6’], 7.03 
[1H, dd, J 7.8, 4.6, C-H5], 7.14 [2H, bs, NH2], 7.51 [1H, dd, J 7.8, 1.5, C-H4], 7.60 [1H, s, C-
H2], 8.28 [1H, dd, J 4.6, 1.5, C-H6], 10.15 [1H, bd, J 4.2, NHCH3]; δC (75 MHz, DMSO-d6) 
30.8 (CH3, NCH3), 31.1 (CH3, NHCH3), 55.2 (2CH3, 2 x m-OCH3), 60.0 (CH3, p-OCH3), 92.7 
(C, aromatic C), 102.8 (C, aromatic C), 104.9 (2CH, 2 x aromatic CH), 115.4 (CH, aromatic 
CH), 119.9 (C, aromatic C), 127.5 (C, aromatic C), 127.6 (CH, aromatic CH), 130.3 (CH, 
aromatic CH), 137.7 (C, aromatic C), 142.6 (CH, aromatic CH), 147.7 (C, aromatic C), 148.9 
(C, aromatic C), 150.2 (C, aromatic C), 152.3 (2C, 2 x aromatic C), 175.7 (C, C=S); m/z 
(ES+) 453.1 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C22H25N6O3S 
453.1709. Found 453.1700. 
 
 
 
 
 
Chapter 7 | Experimental 
 
 
[238] 
 
7.2.4 Synthesis and derivatisation of 5-aminopyrazole 312 
5-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-
amine (312) 
To a solution of 3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-
oxo-2-(3,4,5-trimethoxyphenyl)propanenitrile 289 (1.015 g, 2.8 
mmol) in absolute alcohol (30 mL), was added 12 M aqueous 
HCl (1 mL) in a dropwise manner. Hydrazine hydrate (50% 
aqueous solution, 0.87 mL, 13.9 mmol) was then added, and the 
resulting mixture was heated to reflux for 26 hours. Once cooled 
to room temperature, the solvent was evaporated under reduced pressure. The residue was 
dissolved in ethyl actetate (50 mL), then washed successively with saturated aqueous sodium 
bicarbonate solution (40 mL), water (40 mL) and then brine (40 mL), before being dried over 
magnesium sulfate. The solvent was removed under reduced pressure and the crude brown 
residue was subjected to flash column chromatography (ethyl acetate/methanol, 90:10) to 
yield pure aminopyrazole 312 as a light brown solid (0.661 g, 62%): m.p. 135-137 
o
C; 
vmax/cm
-1
 (KBr) 3199, 2931, 1602, 1518, 1470, 1351, 1115; δH (300 MHz, DMSO-d6) 3.53 
[6H, s, 2 x m-OCH3], 3.64 [3H, s, p-OCH3], 3.82 [3H, s, NCH3], 4.68 [2H, bs, NH2], 6.53 
[2H, s, C-H2’6’], 6.98 [1H, dd, J 7.9, 4.6, C-H5], 7.55 [2H, m, C-H2,4], 8.24 [1H, dd, J 4.6, 1.3, 
C-H6], 11.73 [1H, bs, NH]; δC (75 MHz, DMSO-d6) 30.8 (C, NCH3), 55.5 (2C, 2 x m-OCH3), 
60.0 (C, p-OCH3), 94.9 (C, broad aromatic C), 106.1 (2CH, 2 x aromatic CH), 115.5 (CH, 
aromatic CH), 117.9 (C, aromatic C), 125.4 (C, broad aromatic C), 128.2 (CH, aromatic CH), 
128.8 (CH, aromatic CH), 129.4 (C, aromatic C), 135.4 (C, aromatic C), 141.9 (C, broad 
aromatic C), 142.7 (CH, aromatic CH), 147.2 (C, aromatic C), 151.8 (C, aromatic C), 152.7 
(2C, 2 x aromatic C); m/z (ES+) 380.2 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated 
for C20H22N5O3 380.1723. Found 380.1724. 
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[239] 
 
7.2.4.1 Formation of bicyclic derivatives of 5-aminopyrazole 312 
7-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-8-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-
a][1,3,5]triazine-2,4(1H,3H)-dione (313) 
5-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrazol-3-amine 312 (0.100 g, 0.26 mmol) 
was dissolved in DCM (5 mL) containing three drops of 
triethylamine, and the resulting solution was cooled to 0 
o
C in an 
ice bath. This solution was then treated, while stirring, with N-
chlorocarbonyl isocyanate (0.03 mL, 0.29 mmol). The reaction 
mixture was subsequently allowed to warm to room temperature 
and was stirred for 15 hrs. After careful addition of water (3 mL), a solid precipitated, which 
was filtered off and then washed with water (4 x 10 mL), followed by ether (2 x 10 mL). The 
precipitate was desiccated at 50 
o
C overnight to give the desired pyrazolotriazinedione 313 as 
a white solid (0.051 g, 45%): m.p. 284-285 
o
C; vmax/cm
-1
 (KBr) 3215, 3067, 1761, 1713, 1647, 
1586, 1411, 1127; δH (300MHz, DMSO-d6) 3.72 [6H, s, 2 x m-OCH3], 3.74 [3H, s, p-OCH3], 
3.78 [3H, s, NCH3], 6.64 [2H, s, C-H2’,6’], 7.18 [1H, dd, J 7.8, 4.9, C-H5], 7.31 [1H, s, C-H2], 
8.32-8.34 [2H, m, C-H4,6], 11.59 [1H, bs, C=C-NHCO], 11.74 [1H, bs, CONHCO]; δC (75 
MHz, DMSO-d6) 31.0 (CH3, NCH3), 55.8 (2CH3, 2 x m-OCH3), 60.1 (CH3, p-OCH3), 102.0 
(C, aromatic C), 104.8 (C, aromatic C), 107.9 (2CH, 2 x aromatic CH), 116.5 (CH, aromatic 
CH), 118.0 (C, aromatic C), 124.9 (C, aromatic C), 129.5 (CH, aromatic CH), 130.0 (CH, 
aromatic CH), 137.2 (C, aromatic C), 138.1 (C, aromatic C), 143.3 (CH, aromatic CH), 144.1 
(C, aromatic C), 147.2 (C, aromatic C), 148.7 (C, C=O), 149.7 (C, C=O), 153.0 (2C, 2 x 
aromatic C); m/z (ES+) 447.2 [M-H]
-
 (100%); HRMS (ES+): Exact mass calculated for 
C22H21N6O5 449.1573. Found 449.1587. 
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[240] 
 
2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5,7-bis(trifluoromethyl)-3-(3,4,5-
trimethoxyphenyl)pyrazolo[1,5-a]pyrimidine (314) 
To a stirred solution of 5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-amine 312 (0.060 g, 
0.16 mmol) in acetic acid (5 mL), was added 
hexafluoroacetylacetone (0.44 mL, 3.2 mmol). The mixture was 
then heated to 80 
o
C for 22 hours. Once cooled to room 
temperature, the excess solvent was removed under reduced 
pressure. The residue was dissolved in ethyl acetate (20 mL), then 
washed with water (20 mL) and brine (20 mL), before being dried over magnesium sulfate. 
The solvent was removed under reduced pressure and the crude residue was subjected to flash 
column chromatography (hexane/ethyl acetate, 60:40) to yield 314 as an orange solid (0.069 
g, 78%): m.p. 176-178 
o
C; vmax/cm
-1
 (KBr) 2923, 2841, 1586, 1560, 1509, 1279, 1131; δH 
(300MHz, CDCl3) 3.71 [6H, s, 2 x m-OCH3], 3.81 [3H, s, p-OCH3], 3.88 [3H, s, NCH3], 6.82 
[2H, s, C-H2’6’], 7.11 [1H, dd, J 8.0, 4.8, C-H5], 7.33 [1H, s, C-H2], 7.44 [1H, s, CHCCF3], 
8.33-8.38 [2H, m, C-H4,6]; δC (75 MHz, CDCl3) 30.6 (CH3, NCH3), 55.1 (2CH3, 2 x m-OCH3), 
60.0 (CH3, p-OCH3), 100.4 (CH, aromatic CH), 104.3 (C, aromatic C), 106.2 (2CH, 2 x 
aromatic CH), 110.0 (C, aromatic C), 116.2 (CH, aromatic CH), 112.8-123.7 (C, q, JF-C 274.9, 
CF3), 113.8-124.8 (C, q, JF-C 274.6, CF3), 117.8 (C, aromatic C), 124.5 (C, aromatic C), 129.1 
(CH, aromatic CH), 129.7 (CH, aromatic CH), 132.8-134.4 (C, q, JF-C 39.0, aromatic C), 
137.0 (C, aromatic C), 143.0 (CH, aromatic CH), 143.6-145.1 (C, q, JF-C 38.2, aromatic C), 
145.3 (C, aromatic C), 147.0 (C, aromatic C), 151.8 (C, aromatic C), 152.6 (2C, 2 x aromatic 
C); m/z (ES+) 552.2 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C25H20N5O3F6 
552.1470. Found 552.1493. 
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[241] 
 
7.2.4.2 Reaction of 5-aminopyrazole 312 with monodentate electrophiles 
2,2,2-Trifluoro-N-(5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrazol-3-yl)acetamide (315) 
To a solution of 5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-
(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-amine 312 (0.060 g, 0.16 
mmol) in acetonitrile (10 mL), was added trifluoroacetic 
anhydride (0.03 mL, 0.19 mmol). The resulting mixture was 
heated to reflux for 28 hours. Once cooled to room temperature, 
the solvent was evaporated under reduced pressure, and the crude 
brown residue was subjected to flash column chromatography 
(hexane/ethyl acetate, 30:70), yielding trifluoroacetamide 315 as an-off white solid (0.518 g, 
68%): m.p. 129-131 
o
C; vmax/cm
-1
 (KBr) 3215, 3067, 1713, 1603, 1586, 1411; δH (300 MHz, 
DMSO-d6) 3.49 [6H, s, 2 x m-OCH3], 3.66 [3H, s, p-OCH3], 3.91 [3H, s, NCH3], 6.53 [2H, s, 
C-H2’,6’], 7.03 [1H, dd, J 7.9, 4.6, C-H5], 7.32 [1H, d, J 6.5, C-H4], 7.86 [1H, s, C-H2], 8.31 
[1H, d, J 3.5, C-H6], 11.37 [1H, bs, NHCOCF3], 13.30 [1H, bs, C=N-NH-C]; δC (75 MHz, 
DMSO-d6) 31.0 (CH3, NCH3), 55.4 (2CH3, 2 x m-OCH3), 60.0 (CH3, p-OCH3), 102.0 (C, 
aromatic C), 105.8 (2CH, 2 x aromatic CH), 110.2-121.6 (C, q, JF-C 288.0, CF3), 113.9 (C, 
aromatic C), 115.9 (CH, aromatic CH), 117.3 (C, aromatic C), 127.1 (C, aromatic C), 128.2 
(CH, aromatic CH), 129.4 (CH, aromatic CH), 136.2 (C, aromatic C), 143.1 (CH, aromatic 
CH), 147.2 (C, aromatic C), 152.7 (2C, 2 x aromatic C), 152.9 (C, aromatic C), 155.8-157.2 
(C, q, JF-C 36.2, C=O); m/z (ES+) 474.3 [M-H]
-
 (100%); HRMS (ES+): Exact mass calculated 
for C22H21N5O4F3 476.1546. Found 476.1532. 
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[242] 
 
1-(5-Amino-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-
pyrazol-1-yl)ethanone (316) 
To a solution of 5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-
(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-amine 312 (0.060 g, 0.16 
mmol) in acetonitrile (10 mL), was added acetic anhydride (0.016 
mL, 0.17 mmol). The resulting mixture was then heated to reflux 
for 20 hours. Once cooled to room temperature, the solvent was 
removed under reduced pressure. The crude residue was purified 
by flash column chromatography (hexane/ethyl acetate, 50:50) to 
yield acetylated product 316 as an off-white solid (0.048 g, 71%): m.p. 171-172 
o
C; vmax/cm
-1
 
(KBr) 3454, 3358, 2927, 1704, 1624, 1509, 1404, 1124; δH (300MHz, CDCl3) 2.80 [3H, s, 
NCOCH3], 3.79 [3H, s, p-OCH3], 3.79 [6H, s, 2 x m-OCH3], 3.92 [3H, s, NCH3], 5.56 [2H, 
bs, NH2], 6.59 [2H, s, C-H2’,6’], 7.05 [1H, s, C-H2], 7.14 [1H, dd, J 7.9, 4.7, C-H5], 8.36 [1H, 
dd, J 4.7, 1.5, C-H6], 8.47 [1H, dd, J 7.9, 1.6, C-H4]; δC (75 MHz, CDCl3) 23.3 (CH3, 
NCOCH3), 31.4 (CH3, NCH3), 56.2 (CH3, 2 x m-OCH3), 61.0 (CH3, p-OCH3), 101.9 (C, 
aromatic C), 105.9 (C, aromatic C), 107.1 (CH, 2 x aromatic CH), 116.6 (CH, aromatic CH), 
118.8 (C, aromatic C), 127.4 (C, aromatic C), 129.3 (CH, aromatic CH), 130.7 (CH, aromatic 
CH), 137.5 (C, aromatic C), 143.7 (CH, aromatic CH), 147.0 (C, aromatic C), 147.9 (C, 
aromatic C), 148.5 (C, aromatic C), 153.9 (C, 2 x aromatic C), 173.7 (C, C=O); m/z (ES+) 
422.3 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C22H24N5O4 422.1828. Found 
422.1813. 
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[243] 
 
5-Amino-N-methyl-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrazole-1-carbothioamide (317) 
To a solution of 5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-
(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-amine 312  (0.060 g, 0.16 
mmol) in acetonitrile (10 mL), was added methyl isothiocyanate 
(0.014 g, 0.19 mmol). The mixture was heated to reflux for 22 
hours, before then being cooled to room temperature. The solvent 
was evaporated under reduced pressure and the crude residue was 
subjected to flash column chromatography (hexane/ethyl acetate, 
50:50), yielding pure carbothioamide 317 as a white solid (0.055 g, 76%): m.p. 162-164 
o
C; 
vmax/cm
-1
 (KBr) 3378, 2931, 1601, 1523, 1406, 1362, 1129; δH (300 MHz, CDCl3) 3.33 [3H, 
d, J 5.0, NHCH3], 3.78 [6H, s, 2 x m-OCH3], 3.80 [3H, s, p-OCH3], 3.92 [3H, s, NCH3], 6.47 
[2H, bs, NH2], 6.59 [2H, s, C-H2’,6’], 7.08 [1H, s, C-H2], 7.12 [1H, dd, J 7.9, 4.7, C-H5], 8.27 
[1H, dd, J 7.9, 1.6, C-H4], 8.36 [1H, dd, J 4.7, 1.5, C-H6], 9.24 [1H, bd, J 4.7, NHCH3]; δC (75 
MHz, CDCl3) 30.9 (CH3, NHCH3), 31.4 (CH3, NCH3), 56.2 (2CH3, 2 x m-OCH3), 61.0 (CH3, 
p-OCH3), 102.5 (C, aromatic C), 105.4 (C, aromatic C), 107.2 (2CH, 2 x aromatic CH), 116.5 
(CH, aromatic CH), 118.6 (C, aromatic C), 127.6 (C, aromatic C), 129.7 (CH, aromatic CH), 
130.2 (CH, aromatic CH), 137.5 (C, aromatic C), 143.7 (CH, aromatic CH), 145.7 (C, 
aromatic C), 147.8 (C, aromatic C), 148.1 (C, aromatic C), 153.9 (2C, 2 x aromatic C), 176.8 
(C, C=S); m/z (ES+) 453.2 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for 
C22H25N6O3S 453.1709. Found 453.1718. 
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[244] 
 
7.2.5 Synthesis and derivatisation of 5-aminopyrazole 318 
4-(1-Methyl-1H-indol-3-yl)-5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-3-
amine (318) 
To a solution of 2-(1-methyl-1H-indol-3-yl)-3-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)-3-oxopropanenitrile 276 (3.951 g, 
12.0 mmol) in absolute alcohol (100 mL), was carefully added 
12 M aqueous HCl (2 mL) in a dropwise fashion. Hydrazine 
hydrate (50% aqueous solution, 3.74 mL, 60.0 mmol) was then 
added, with the resulting mixture subsequently heated to reflux for 22 hours. Once cooled to 
room temperature, the solvent was evaporated under reduced pressure. The residue was 
dissolved in ethyl acetate (100 mL) and washed with saturated aqueous sodium bicarbonate 
solution (80 mL), water (80 mL) and brine (80 mL), before being dried over magnesium 
sulfate. The solvent was removed under reduced pressure, leaving the crude product as a dark 
brown solid, which was then purified by flash column chromatography (ethyl 
acetate/methanol, 90:10) to yield aminopyrazole 318 as a light brown crystalline solid (2.656 
g, 64%): m.p. 136-139 
o
C; vmax/cm
-1
 (KBr) 3197, 2928, 1611, 1561, 1487, 1405, 1374, 1298; 
H (300 MHz, CD3OD) 3.71 [3H, s, NCH3], 3.77 [3H, s, NCH3], 4.64 [2H, bs, NH2], 6.84-
6.90 [2H, m, C-H5,5’], 7.10 [1H, s, C-H2], 7.11-7.18 [2H, m, C-H6,7], 7.28 [1H, s, C-H2’], 7.35 
[1H, d, J 8.3, C-H4], 7.67 [1H, dd, J 7.9, 1.2, C-H4’], 8.14 [1H, dd, J 4.8, 1.5, C-H6’]; δC (75 
MHz, CD3OD) 31.6 (CH3, NCH3), 32.9 (CH3, NCH3), 99.0 (C, aromatic C), 100.1 (C, 
aromatic C), 101.9 (C, aromatic C), 107.1 (C, aromatic C), 110.4 (CH, aromatic CH), 116.8 
(CH, aromatic CH), 120.1 (CH, aromatic CH), 120.3 (C, aromatic C), 120.9 (CH, aromatic 
CH), 122.7 (CH, aromatic CH), 128.9 (C, aromatic C), 129.5 (CH, aromatic CH), 129.6 (CH, 
aromatic CH), 130.8 (CH, aromatic CH), 138.6 (C, aromatic C), 143.6 (CH, aromatic CH), 
148.4 (C, aromatic C), 150.2 (C, aromatic C); m/z (ES+) 343.2 [M+H]
+
, (100%).    
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[245] 
 
7.2.5.1 Formation of bicyclic derivatives of 5-aminopyrazole 318 
8-(1-Methyl-1H-indol-3-yl)-7-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazolo[1,5-
a][1,3,5]triazine-2,4(1H,3H)-dione (319) 
4-(1-Methyl-1H-indol-3-yl)-5-(1-methyl-1H-pyrrolo[2,3-
b]pyridin-3-yl)-1H-pyrazol-3-amine 318 (0.160 g, 0.47 mmol) 
was dissolved in DCM (15 mL) containing four drops of 
triethylamine, and the resulting solution was cooled to 0 
o
C in 
an ice bath. This solution was then treated, while stirring, with 
N-chlorocarbonyl isocyanate (0.04 mL, 0.52 mmol). The 
reaction mixture was allowed to warm to room temperature and 
stirred for 15 hours. After careful addition of water (5 mL), the precipitate formed was filtered 
off before subsequently being washed with water (4 x 20 mL) and ether (2 x 20 mL). The 
precipitate was desiccated at 50 
o
C overnight to yield pyrazolotriazinedione 319 as a grey 
solid (0.127 g, 66%): m.p. 220-222 
o
C; vmax/cm
-1
 (KBr) 3219, 2818, 1753, 1717, 1604, 1559, 
1447, 1297; H (400 MHz, DMSO-d6) 3.58 [3H, s, NCH3], 3.87 [3H, s, NCH3], 6.94 [1H, t, J 
7.3, C-H5], 7.10 [1H, s, C-H2], 7.13-7.20 [3H, m, C-H5’,6,7], 7.39 [1H, s, C-H2’], 7.51 [1H, d, 
C-H4], 8.29 [1H, dd, J 4.6, 1.6, C-H6’], 8.55 [1H, dd, J 7.9, 1.6, C-H4’], 10.75 [1H, bs, C=C-
NHCO], 11.12 [1H, bs, CONHCO]; δC (150 MHz, DMSO-d6) 30.8 (CH3, NCH3), 32.5 (CH3, 
NCH3), 93.8 (C, aromatic C), 106.1 (C, aromatic C), 109.8 (CH, aromatic CH), 116.3 (CH, 
aromatic CH), 118.1 (C, aromatic C), 118.7 (CH, aromatic CH), 119.8 (CH, aromatic CH), 
121.1 (CH, aromatic CH), 126.8 (C, aromatic C), 129.2 (CH, aromatic CH), 130.2 (CH, 
aromatic CH), 130.3 (CH, aromatic CH), 136.4 (C, aromatic C), 136.7 (C, aromatic C), 143.1 
(CH, aromatic CH), 147.0 (C, aromatic C), 147.1 (C, aromatic C), 150.5 (C, C=O), 162.5 (C, 
C=O); m/z (ES+) 412.1 [M+H]
+
 (30%); HRMS (ES+): Exact mass calculated for C22H18N7O2 
412.1522. Found 412.1531. 
 
 
 
Chapter 7 | Experimental 
 
 
[246] 
 
3-(1-Methyl-1H-indol-3-yl)-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidine (320) 
To a stirred mixture of 4-(1-methyl-1H-indol-3-yl)-5-(1-
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-3-amine 
318 (0.160 g, 0.47 mmol) in acetic acid (15 mL), was added 
hexafluoroacetylacetone (1.31 mL, 9.34 mmol). The resulting 
mixture was heated to 80 
o
C for 20 hours. After cooling to 
room temperature, the acetic acid and excess 
hexafluoroacetylacetone was removed under reduced pressure. The residue was dissolved in 
ethyl acetate (30 mL), then washed with water (2 x 20 mL) and brine (20 mL), before being 
dried over magnesium sulfate. Evaporation of the solvent under reduced pressure yielded the 
crude product as a red/brown solid. Purification via flash column chromatography 
(hexane/ethyl acetate, 60:40) gave the pure pyrimidine product 320 as an orange solid (0.115 
g, 47%): m.p. 234-235 
o
C; vmax/cm
-1
 (KBr) 3118, 2916, 1601, 1559, 1487, 1393, 1274, 1159; 
δH (300 MHz, CDCl3) 3.68 [3H, s, NCH3], 3.93 [3H, s, NCH3], 7.03 [1H, t, J 7.6, C-H5], 7.21-
7.31 [4H, m, C-H2,4,5’,6], 7.37 [2H, s, C-H2’, (CF3)C-CH=C(CF3)], 7.45 [1H, d, J 8.3, C-H7], 
8.40 [1H, dd, J 4.7, 1.5, C-H6’], 8.78 [1H, dd, J 7.9, 1.6, C-H4’]; δC (75 MHz, CDCl3) 31.5 
(CH3, NCH3), 33.2 (CH3, NCH3), 101.1 (CH, C(CF3)CH=C(CF3)), 103.3 (C, aromatic C), 
104.7 (C, aromatic C), 105.7 (C, aromatic C), 109.8 (CH, aromatic CH), 113.9-124.9 (C, q, JF-
C 275.2, CF3), 115.0-125.9 (C, q, JF-C 275.7, CF3), 117.2 (CH, aromatic CH), 119.0 (C, 
aromatic C), 119.6 (CH, aromatic CH), 121.0 (CH, aromatic CH), 122.1 (CH, aromatic CH), 
126.6 (C, aromatic C), 129.4 (CH, aromatic CH), 131.1 (2CH, 2 x aromatic CH), 133.6-135.1 
(C, q, JF-C 38.1, aromatic C), 137.3 (C, aromatic C), 143.8 (CH, aromatic CH), 143.9-145.4 
(C, q, JF-C 37.4, aromatic C), 146.9 (C, aromatic C), 147.9 (C, aromatic C), 153.6 (C, aromatic 
C); m/z (ES+) 515.1 (100%); HRMS (ES+): Exact mass calculated for C25H17N6F6 515.1419. 
Found 515.1425. 
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[247] 
 
7.2.5.2 Reaction of 5-aminopyrazole 318 with monodentate electrophiles 
2,2,2-Trifluoro-N-(4-(1-methyl-1H-indol-3-yl)-5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)-1H-pyrazol-3-yl)acetamide (321) 
To a solution of 4-(1-methyl-1H-indol-3-yl)-5-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-3-amine 318 (0.160 g, 
0.47 mmol) in acetonitrile (15 mL) was added trifluoroacetic 
anhydride (0.08 mL, 0.56 mmol). The reaction mixture was 
then refluxed for 20 hours before being left to cool to room 
temperature. Evaporation of the solvent under reduced pressure 
left the crude product as a brown residue, which was then purified by flash column 
chromatography (hexane/ethyl acetate, 30:70) to yield trifluoroacetamide 321 as a white 
crystalline solid (0.073 g, 35%): m.p. 127-129 
o
C; vmax/cm
-1
 (KBr) 3326, 2922, 1724, 1601, 
1564, 1484, 1299, 1211, 1157; δH (300 MHz, CDCl3) 3.66 [3H, s, NCH3], 3.77 [3H, s, NCH3], 
6.89 [1H, dd, J 7.9, 4.7, C-H5’], 6.97 [1H, s, C-H2], 7.05 [1H, t, J 7.3, C-H5], 7.11 [1H, s, C-
H2’], 7.24-7.39 [2H, m, C-H6,7], 7.37 [1H, d, J 8.2, C-H4], 7.84 [1H, d, J 7.7, C-H4’], 8.23 [1H, 
dd, J 4.6, 1.1, C-H6’], 8.51 [1H, bs, NHCOCF3]; δC (75 MHz, CDCl3) 31.3 (CH3, NCH3), 33.0 
(CH3, NCH3), 102.3 (C, aromatic C), 103.6 (C, aromatic C), 103.9 (C, aromatic C), 109.8 
(CH, aromatic CH), 109.9-121.3 (C, q, JF-C 288.6, CF3), 116.2 (CH, aromatic CH), 117.4 (C, 
aromatic C), 118.2 (C, aromatic C), 119.5 (CH, aromatic CH), 120.1 (CH, aromatic CH), 
122.4 (CH, aromatic CH), 127.0 (C, aromatic C), 128.2 (CH, aromatic CH), 128.3 (CH, 
aromatic CH), 129.1 (CH, aromatic CH), 137.1 (C, aromatic C), 139.9 (C, aromatic C), 143.3 
(CH, aromatic CH), 147.5 (C, aromatic C), 154.0-155.5 (C, q, JF-C 38.0, C=O); m/z (ES+) 
439.1 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C22H18N6OF3 439.1494. 
Found 439.1485. 
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[248] 
 
1-(5-Amino-4-(1-methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-
pyrazol-1-yl)ethanone (322) 
To a solution of 4-(1-methyl-1H-indol-3-yl)-5-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-3-amine 318  (0.160 g, 
0.47 mmol) in acetonitrile (15 mL), was added acetic anhydride 
(0.05 mL, 0.52 mmol). The resulting mixture was heated to 
reflux for 22 hours before being cooled to room temperature. 
The solvent and excess acetic anhydride was then removed 
under reduced pressure. The crude residue was subjected to flash column chromatography 
(hexane/ethyl acetate, 50:50), yielding the pure acetylated product 322 as a white crystalline 
solid (0.126 g, 70%): m.p. 206-207 
o
C; vmax/cm
-1
 (KBr) 3444, 3360, 2929, 1703, 1603, 1558, 
1406, 1385, 1314, 1135; δH (300 MHz, CDCl3) 2.84 [3H, s, COCH3], 3.64 [1H, s, NCH3], 
3.87 [1H, s, NCH3], 5.44 [2H, bs, NH2], 6.99 [1H, s, C-H2], 7.08-7.17 [3H, m, C-H2’,5,5’], 7.30 
[1H, t, J 7.0, C-H6], 7.41-7.45 [2H, m, C-H4,7], 8.35 [1H, dd, J 4.7, 1.5, C-H6’], 8.62 [1H, dd, J 
7.9, 1.6, C-H4’]; δC (75 MHz, CDCl3) 23.3 (CH3, COCH3), 31.3 (CH3, NCH3), 33.1 (CH3, 
NCH3), 93.8 (C, aromatic C), 104.7 (C, aromatic C), 106.2 (C, aromatic C), 109.6 (CH, 
aromatic CH), 116.6 (CH, aromatic CH), 118.9 (C, aromatic C), 119.7 (CH, aromatic CH), 
120.3 (CH, aromatic CH), 122.2 (CH, aromatic CH), 127.5 (C, aromatic C), 128.6 (CH, 
aromatic CH), 129.6 (CH, aromatic CH), 130.8 (CH, aromatic CH), 137.3 (C, aromatic C), 
143.5 (CH, aromatic CH), 147.8 (C, aromatic C), 148.1 (C, aromatic C), 149.9 (C, aromatic 
C), 173.6 (C, C=O); m/z (ES+) 385.4 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated 
for C22H21N6O 385.1777. Found 385.1796. 
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5-Amino-N-methyl-4-(1-methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)-1H-pyrazole-1-carbothioamide (323) 
To a solution of 4-(1-methyl-1H-indol-3-yl)-5-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-3-amine 318 (0.160 g, 
0.47 mmol) in acetonitrile (15 mL), was added methyl 
isothiocyanate (0.038 g, 0.52 mmol). The reaction mixture was 
then heated to reflux for 26 hours before being cooled to room 
temperature. The solvent was removed under reduced pressure 
to give a crude brown residue. Purification was achieved by 
flash column chromatography (hexane/ethyl acetate, 50:50) to yield carbothioamide 323 as a 
white solid (0.062 g, 32%): m.p. 185-186 
o
C; vmax/cm
-1
 (KBr) 3424, 3277, 2930, 1627, 1603, 
1559, 1516, 1485, 1297; δH (300 MHz, CDCl3) 3.34 [3H, bd, J 5.0, NHCH3], 3.64 [3H, s, 
NCH3], 3.86 [3H, s, NCH3], 6.34 [2H, bs, NH2], 7.01 [1H, s, C-H2], 7.07 [1H, s, C-H2’], 7.09-
7.15 [2H, m, C-H5,5’], 7.29 [1H, t, J 7.0, 1.1, C-H6], 7.40-7.44 [2H, m, C-H4,7], 8.34 [1H, dd, J 
4.7, 1.6, C-H6’], 8.43 [1H, dd, J 7.9, 1.6, C-H4’], 9.29 [1H, bd, J 4.6, NHCH3); δC (75 MHz, 
CDCl3) 30.9 (CH3, NHCH3), 31.3 (CH3, NCH3), 33.0 (CH3, NCH3), 94.3 (C, aromatic C), 
104.9 (C, aromatic C), 105.7 (C, aromatic C), 109.5 (CH, aromatic CH), 116.4 (CH, aromatic 
CH), 118.7 (C, aromatic C), 119.7 (CH, aromatic CH), 120.3 (CH, aromatic CH), 122.2 (CH, 
aromatic CH), 127.5 (C, aromatic C), 128.8 (CH, aromatic CH), 130.0 (CH, aromatic CH), 
130.3 (CH, aromatic CH), 137.2 (C, aromatic C), 143.4 (CH, aromatic CH), 147.1 (C, 
aromatic C), 147.7 (C, aromatic C), 149.2 (C, aromatic C), 176.8 (C, C=S); m/z (ES+) 416.2 
[M+H]
+ 
(100%); HRMS (ES+): Exact mass calculated for C22H22N7S 416.1657. Found 
416.1672. 
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7.2.6 Cyclocondensation of oxopropanoate intermediates 
7.2.6.1 Synthesis of pyrazolone 326 
5-(1-Benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrazol-
3(2H)-one (326) 
Camphoric acid (0.162 g, 0.8 mmol) was added to a solution of 
methyl 3-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-(1-
methyl-1H-indol-3-yl)-3-oxopropanoate 273 (0.350 g, 0.8 
mmol) in absolute alcohol (10 mL). Hydrazine hydrate (50% 
aqueous solution, 0.05 mL, 0.8 mmol) was then added 
dropwise to the stirred mixture. Once the addition was 
complete, the mixture was heated to reflux for 2 hours. At this 
point, a further portion of hydrazine hydrate (50% aqueous solution, 0.20 mL, 3.2 mmol) was 
added to the reaction mixture, which was then heated once more to the point of reflux. After 
22 hours, TLC analysis indicated the total consumption of starting material, following which 
the reaction mixture was cooled to room temperature. The solvent was removed under reduced 
pressure and the residue was dissolved in ethyl acetate (30 mL). The organic phase was 
washed successively with 10% aqueous sodium bicarbonate solution (20 mL), water (20 mL) 
and brine (20 mL), before being dried over magnesium sulfate. Once the solvent was removed 
under reduced pressure, the crude product was subjected to flash column chromatography 
(dichloromethane/methanol, 98:2) to yield the pure product 326 as a brown solid (0.175 g, 
52%): m.p. 177-179 
o
C; vmax/cm
-1
 (KBr) 3054, 2932, 1719, 1601, 1567, 1512, 1471, 1302; δH 
(300 MHz, DMSO-d6) 3.75 [3H, s, NCH3], 5.41 [2H, s, CH2Ph], 6.78 [1H, t, J 7.0, C-H5], 
6.99 [1H, dd, J 7.9, 4.7, C-H5’], 7.05-7.10 [4H, m, C-H2,6,2’’,6’’], 7.22-7.25 [4H, m, C-H7,3’’-5’’], 
7.37 [1H, d, J 8.2, C-H4], 7.55 [1H, s, C-H2’], 7.77 [1H, d, J 7.2, C-H4’], 8.21 [1H, dd, J 4.7, 
1.5, C-H6’]; δH (150 MHz, DMSO-d6) 32.4 (CH3, NCH3), 47.1 (CH2, CH2Ph), 105.5 (C, 
aromatic C), 109.4 (CH, aromatic CH), 112.2 (C, aromatic C), 116.0 (CH, aromatic CH), 
117.0 (C, aromatic C), 117.9 (C, aromatic C), 118.6 (CH, aromatic CH), 120.1 (CH, aromatic 
CH), 120.8 (CH, aromatic CH), 126.6 (C, aromatic C), 127.3 (CH, aromatic CH), 128.3 (2CH, 
2 x aromatic CH), 128.4 (CH, aromatic CH), 128.6 (2CH, 2 x aromatic CH), 130.0 (CH, 
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aromatic CH), 135.6 (CH, aromatic CH), 136.2 (C, aromatic C), 136.4 (C, aromatic C), 146.4 
(CH, aromatic CH), 146.6 (C, aromatic C), 147.1 (C, aromatic C), 156.6 (C, C=O); m/z (ES+) 
420.1 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C26H22N5O 420.1824. Found 
420.1833. 
 
7.2.6.2 Synthesis and alkylation of isoxazolone 327 
4-(1-Methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)isoxazol                     
-5(2H)-one (327) 
To a solution of methyl 2-(1-methyl-1H-indol-3-yl)-3-(1-
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-oxopropanoate 267 
(1.205 g,  3.3 mmol) in methanol (30 mL) was added 
hydroxylammonium chloride (1.160 g, 16.7 mmol). The 
resulting mixture was heated to reflux for 14 hours, at which 
time it was cooled to room temperature. The solvent was removed under reduced pressure, 
and the resulting brown residue was treated with water (25 mL), before being extracted with 
ethyl acetate (2 x 30 mL). The combined organic extracts were washed with water (40 mL) 
and brine (40 mL), then dried over magnesium sulfate and evaporated under reduced pressure. 
The crude product was purified by flash column chromatography (hexane/ethyl acetate, 20:80) 
to yield isoxazolone 327 as a light brown solid (0.738 g, 64%): m.p. 138-140 
o
C; vmax/cm
-1
 
(KBr) 3419, 3051, 2927, 1718, 1609, 1551, 1464, 1378; δH (400 MHz, DMSO-d6) 3.76 [3H, s, 
NCH3], 3.82 [3H, s, NCH3], 6.87 [1H, t, J 7.3, C-H5], 7.07-7.15 [3H, m, C-H5’,6,7], 7.46 [1H, s, 
C-H2’], 7.47 [1H, s, C-H2], 7.74 [2H, m, C-H4,4’], 8.31 [1H, dd, J 4.7, 1.4, CH6’]; δC (125 
MHz, DMSO-d6) 31.2 (CH3, NCH3), 32.5 (CH3, NCH3), 101.1 (C, aromatic C), 103.0 (C, 
aromatic C), 109.0 (CH, aromatic CH), 116.8 (CH, aromatic CH), 117.0 (C, aromatic C), 
118.8 (CH, aromatic CH), 119.9 (CH, aromatic CH), 121.2 (CH, aromatic CH), 126.2 (C, 
aromatic C), 129.1 (CH, aromatic CH), 129.5 (CH, aromatic CH), 131.3 (CH, aromatic CH), 
136.5 (C, aromatic C), 143.7 (CH, aromatic CH), 147.2 (C, aromatic C), 156.8 (C, aromatic 
C), 171.9 (C, C=O); m/z (ES+) 345.3 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated 
for C20H17N4O2 345.1352. Found 345.1349.   
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2-Methyl-4-(1-methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)isoxazol-
5(2H)-one (328) 
A solution of 4-(1-Methyl-1H-indol-3-yl)-3-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)isoxazol-5(2H)-one 327 (0.310 g,  
0.90 mmol) in DMF (20 mL) was cooled to 0 
o
C in an ice bath. 
Sodium hydride (0.044 g, 1.1 mmol) was added to the solution 
in a portionwise manner, with the resulting mixture stirred at 0 
o
C for 30 minutes. A solution of iodomethane (0.07 mL, 1.1 mmol) in DMF (5 mL) was 
subsequently added, and the reaction mixture was then allowed warm to room temperature 
over three hours while stirring. Water (20 mL) was carefully added to quench the reaction, and 
the resulting solution was extracted with ethyl acetate (3 x 20 mL). The combined organic 
extracts were washed with water (3 x 25 mL) and brine (25 mL), before being dried over 
magnesium sulfate and evaporated under reduced pressure. The crude product was purified by 
flash column chromatography (hexane/ethyl acetate, 50:50) to give N-methyl isoxazolone 328 
as an off-white solid (0.283 g, 88%): m.p. 109-111 
o
C; vmax/cm
-1
 (KBr) 3053, 2926, 1711, 
1612, 1532, 1469, 1375; δH (400 MHz, CDCl3) 3.24 [3H, s, NCH3], 3.78 [3H, s, NCH3], 3.82 
[3H, s, NCH3], 6.76-6.83 [2H, m, C-H5,6], 7.12-7.17 [2H, m, C-H5’,6,7], 7.46 [1H, s, C-H2’], 
7.47 [1H, s, C-H2], 7.74 [2H, m, C-H4,4’], 8.31 [1H, dd, J 4.7, 1.4, CH6’]; δC (150 MHz, 
CDCl3) 31.7 (CH3, NCH3), 33.0 (CH3, NCH3), 42.5 (CH3, NCH3), 101.5 (C, aromatic C), 
102.9 (C, aromatic C), 109.4 (CH, aromatic CH), 117.5 (CH, aromatic CH), 117.9 (C, 
aromatic C), 119.2 (CH, aromatic CH), 120.9 (CH, aromatic CH), 121.7 (CH, aromatic CH), 
125.3 (C, aromatic C), 129.0 (CH, aromatic CH), 129.6 (CH, aromatic CH), 131.7 (CH, 
aromatic CH), 137.0 (C, aromatic C), 144.0 (CH, aromatic CH), 147.8 (C, aromatic C), 159.3 
(C, aromatic C), 171.4 (C, C=O). m/z (ES+) 359.2 [M+H]
+
 (100%); HRMS (ES+): Exact 
mass calculated for C21H19N4O2 359.1508. Found 359.1517. 
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7.2.6.3 Routes towards aza BIM derivatives containing 6-membered F-rings 
2-Amino-5-(1-methyl-1H-indol-3-yl)-6-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)pyrimidin-4(3H)-one (332) 
 
Sodium metal (0.628 g, 27.3 mmol) was carefully added in a 
portionwise manner over a 30 minute period to dry methanol (20 
mL) under a nitrogen atmosphere. Once the sodium had fully 
reacted, guanidine carbonate (2.463 g, 13.7 mmol) was added to 
the solution, and the resulting mixture was stirred at room 
temperature for 30 minutes. Methyl 2-(1-methyl-1H-indol-3-yl)-
3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-oxopropanoate 267 (0.988 g, 2.7 mmol) was 
then added to the mixture, which was subsequently heated to reflux for 36 hours. Once cooled 
to room temperature, the solvent was removed under reduced pressure and the residue was 
dissolved in water (30 mL). The pH of the strongly basic solution was adjusted to 7 using 2 M 
HCl, and the precipitate formed was filtered and washed with water. The crude brown solid 
was subjected to flash column chromatography (ethyl acetate/methanol, 90:10) to yield 
aminopyrimidinone 332 as a light brown solid (0.424 g, 42%): m.p. 164-166 
o
C; vmax/cm
-1
 
(KBr) 3338, 2927, 1635, 1524, 1460, 1378; δH (300 MHz, DMSO-d6) 3.50 [3H, s, N-CH3], 
3.86 [3H, s, N-CH3], 6.50 [2H, bs, NH2], 6.85-6.89 [2H, m, C-H2,5], 7.02-7.15 [3H, m, C-
H5’,6,7], 7.25 [1H, s, C-H2’], 7.47 [1H, d, J 8.2, C-H4], 8.24 [1H, dd, J 4.6, 1.6, C-H6’], 8.64 
[1H, dd, J 7.9, 1.3, C-H4’], 10.90 [1H, bs, NH]; δC (75 MHz, DMSO-d6) 30.8 (CH3, NCH3), 
32.4 (CH3, NCH3), 103.1 (C, aromatic C), 108.5 (C, aromatic C), 109.5 (CH, aromatic CH), 
111.9 (C, aromatic C), 116.0 (CH, aromatic CH), 118.4 (CH, aromatic CH), 119.3 (C, 
aromatic C), 119.6 (CH, aromatic CH), 120.7 (CH, aromatic CH), 127.1 (C, aromatic C), 
129.7 (CH, aromatic CH), 131.5 (CH, aromatic CH), 131.9 (CH, aromatic CH), 136.6 (C, 
aromatic C), 142.5 (CH, aromatic CH), 146.9 (C, aromatic C), 153.5 (C, aromatic C), 157.4 
(C, aromatic C), 163.0 (C, C=O); m/z (ES+) 371.1 [M+H]
+
 (100%); HRMS (ES+): Exact 
mass calculated for C21H19N6O 371.1620. Found 371.1613. 
 
 
Chapter 7 | Experimental 
 
 
[254] 
 
2-Amino-5,6-bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4(3H)-one (337) 
 
Sodium metal (0.204 g, 8.9 mmol) was added portionwise over 20 
minutes to dry methanol (15 mL) under a nitrogen atmosphere. 
Upon complete reaction of the metal, guanidine carbonate (0.798 g, 
4.4 mmol) was added to the solution, and the resulting mixture was 
stirred at room temperature for 30 minutes. Methyl 2,3-bis(1-
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-oxopropanoate 281 
(0.161 g, 0.44 mmol) was added to the mixture, which was then heated to reflux for 48 hours. 
At this point, TLC evidence indicated the presence of predominantly starting material in the 
reaction mixture. Upon workup, spectroscopic analysis indicated that desired pyrimidinone 
337 had not been formed.  
 
7.2.7 Synthesis of novel aza ICZs 
7.2.7.1 Synthesis of aza ICZ 239 containing 6-membered F-ring 
6-Amino-13,14-dimethyl-13,14-dihydropyrido[3',2':4,5]pyrrolo[2,3-a]pyrimido[4,5-
c]carbazol-8(7H)-one (239) 
To a solution of 2-amino-5-(1-methyl-1H-indol-3-yl)-6-(1-
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4(3H)-one 332 
(0.080 g, 0.22 mmol) in a mixture of acetonitrile (120 mL) and 
methanol (80 mL) was added a spatula tip of iodine. The 
resulting mixture was then irradiated by means of a medium 
pressure mercury lamp for 18 hours. Once cooled to room 
temperature, the solvent was removed under reduced pressure. The crude residue was then 
dissolved in ethyl acetate (60 mL), before being washed with saturated aqueous sodium 
thiosulfate (50 mL), water (50 mL) and brine (50 mL). After being dried over magnesium 
sulfate, the solvent was evaporated under reduced pressure and the residue was subjected to 
flash column chromatography (ethyl acetate/methanol, 99:1) to yield aza ICZ 239 as an off-
white solid (0.041 g, 51%): m.p. 289-292 
o
C; vmax/cm
-1
 (KBr) 3426, 2923, 1654, 1601, 1566, 
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1394, 1084; δH (300 MHz, DMSO-d6) 4.22 [3H, s, N-CH3], 4.34 [3H, s, N-CH3], 6.46 [2H, bs, 
NH2], 7.23 [1H, t, J 7.6, aromatic C-H10], 7.38 [1H, dd, J 7.7, 4.8, aromatic C-H3], 7.49 [1H, t, 
J 7.7, aromatic C-H11], 7.66 [1H, d, J 8.1, aromatic C-H12], 8.54 [1H, dd, J 4.8, 1.7, aromatic 
C-H2], 9.26 [1H, dd, J 7.7, 1.7, aromatic C-H4], 9.71 [1H, d, J 8.2, aromatic C-H9], 11.00 [1H, 
bs, NH]; δC (75 MHz, DMSO-d6) 34.4 (CH3, NCH3), 36.9 (CH3, NCH3), 105.2 (C, aromatic 
C), 110.2 (CH, aromatic CH), 112.8 (C, aromatic C), 116.6 (CH, aromatic CH), 117.2 (C, 
aromatic C), 118.9 (CH, aromatic CH), 120.0 (C, aromatic C), 123.7 (C, aromatic C), 125.4 
(CH, aromatic CH), 125.8 (C, aromatic C), 127.3 (CH, aromatic CH), 131.1 (CH, aromatic 
CH), 132.0 (C, aromatic C), 143.8 (C, aromatic C), 144.7 (CH, aromatic CH), 147.2 (C, 
aromatic C), 151.8 (C, aromatic C), 152.6 (C, aromatic C), 162.0 (C, C=O); m/z (ES+) 369.4 
[M+H]
+
 (20%); HRMS (ES+): Exact mass calculated for C21H17N6O 369.1464. Found 
369.1462. 
 
7.2.7.2 Route towards monoazaindolyl maleimide precursors 
2-(1-Methyl-1H-indol-3-yl)acetic acid (350)
11
 
A stirred suspension of sodium hydride (60 wt.% oil dispersion, 6.002 g, 
150.1 mmol) in THF (150 mL) was cooled to 0 
o
C in an ice bath. A 
solution of indole-3-acetic acid 261 (5.250 g, 30.0 mmol) in THF (50 mL) 
was then added. Following stirring for 30 minutes at 0 
o
C, a solution of 
iodomethane (6.23 mL, 100.1 mmol) in THF (30 mL) was added to the 
reaction mixture in a dropwise manner. The mixture was allowed to warm slowly to room 
temperature and stirred for 16 hours. Methanol (5 mL) was then cautiously added to the 
mixture, followed by water (100 mL), in order to quench the reaction. Ether (100 mL) was 
added to the resulting clear yellow solution, after which the phases were separated. The 
aqueous phase was then acidified to pH 2 using 6M aqueous HCl and extracted with DCM (3 
x 100 mL). The combined DCM extracts were dried over magnesium sulfate and concentrated 
to a volume of roughly 50 mL. Hexane was then added until a brownish solid precipitated out 
of solution. The crude solid was recrystallised from ethanol to give acetic acid 350 as a light 
brown solid (4.784 g, 84%): m.p. 126-128 
o
C (lit.
11
 127-129 
o
C); vmax/cm
-1
 (KBr) 2930, 2676, 
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1698, 1547, 1474, 1412, 1305; δH (300 MHz, DMSO-d6) 3.64 [2H, s, CH2COOH], 3.75 [3H, 
s, NCH3], 7.03 [1H, t, J 7.5, C-H5], 7.15 [1H, t, J 7.6, C-H6], 7.21 [1H, s, C-H2], 7.40 [1H, d, J 
8.2, C-H7], 7.52 [1H, d, J 7.8, C-H4], 12.17 (1H, bs, COOH]; δC (75 MHz, DMSO-d6) 30.7 
(CH2, CH2COOH), 32.2 (CH3, NCH3), 106.9 (C, aromatic C), 109.5 (CH, aromatic CH), 
118.5 (CH, aromatic CH), 118.7 (CH, aromatic CH), 121.1 (CH, aromatic CH), 127.5 (C, 
aromatic C), 128.2 (CH, aromatic CH), 136.5 (C, aromatic C), 173.0 (C, C=O). m/z (ES+) 
190.4 [M+H]
+
 (100%). 
 
3-(1-Methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)furan                         
-2,5-dione (355) 
A solution of 1-methyl-1H-pyrrolo[2,3-b]pyridine 277 (1.808 g, 
13.7 mmol) in diethyl ether (80 mL) was cooled to 0 
o
C in an 
ice bath. Oxalyl chloride (1.39 mL, 16.4 mmol) was then added 
in a dropwise manner over a period of 20 minutes. The resulting 
mixture was stirred for 3 hours, whilst being allowed to slowly 
return to room temperature in that time. The solvent and excess oxalyl chloride was removed 
under reduced pressure and the solid residue was dissolved in DCM (60 mL). This was then 
added to a stirred solution containing 2-(1-methyl-1H-indol-3-yl)acetic acid 350 (2.592 g, 
13.7 mmol) and triethylamine (3.82 mL, 27.4 mmol) in DCM (30 mL). The reaction mixture 
was stirred at room temperature for 14 hours, after which time the solvent was removed under 
reduced pressure. The dark red residue was subjected to flash column chromatography 
(hexane/ethyl acetate, 70:30), yielding maleic anhydride 355 as a red solid (1.796 g, 37%): 
m.p. 222-224 
o
C; vmax/cm
-1
 (KBr) 2919, 1819, 1747, 1523, 1371, 1254; δH (300 MHz, CDCl3) 
3.91 [3H, s, NCH3], 3.94 [3H, s, NCH3], 6.75 [1H, dd, J 8.0, 4.7, C-H5’], 6.77-6.79 [2H, m, C-
H5,6], 7.13-7.19 [1H, m, C-H7], 7.30 [1H, dd, J 8.0, 1.5, C-H4’], 7.34 [1H, d, J 8.3, C-H4], 7.85 
[1H, s, C-H2], 7.86 [1H, s, C-H2’], 8.25 [1H, dd, J 4.7, 1.5, C-H6’]; δC (75 MHz, CDCl3) 31.9 
(CH3, NCH3), 33.6 (CH3, NCH3), 103.6 (C, aromatic C), 104.8 (C, aromatic C), 109.9 (CH, 
aromatic CH), 116.5 (CH, aromatic CH), 118.6 (C, aromatic C), 120.9 (CH, aromatic CH), 
122.3 (CH, aromatic CH), 123.0 (CH, aromatic CH), 125.5 (C, aromatic C), 126.4 (C, 
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aromatic C), 128.1 (C, aromatic C), 130.5 (CH, aromatic CH), 133.6 (CH, aromatic CH), 
134.0 (CH, aromatic CH), 137.0 (C, aromatic C), 144.0 (CH, aromatic CH), 147.8 (C, 
aromatic C), 166.6 (C, C=O), 166.8 (C, C=O); m/z (ES+) 358.1 [M+H]
+
 (100%); HRMS 
(ES+): Exact mass calculated for C21H16N3O3 358.1192. Found 358.1185. 
 
3-(1-Methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole              
-2,5-dione (357)
12 
To a stirred solution of 3-(1-methyl-1H-indol-3-yl)-4-(1-
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)furan-2,5-dione 355 
(0.801 g, 2.2 mmol) in DMF (10 mL) was added 1,1,1,3,3,3-
hexamethyldisilazane (4.70 mL, 22.4 mmol), followed by 
methanol (0.45 mL, 11.2 mmol). The mixture was then stirred 
at room temperature for 24 hours. Water (100 mL) was added 
to the reaction mixture, which was then subsequently extracted with ethyl acetate (3 x 50 mL). 
The combined organic extracts were washed with water (4 x 100 mL) and brine (100 mL), 
then dried over magnesium sulfate. The solvent was removed under reduced pressure and the 
crude residue was subjected to flash column chromatography (hexane/ethyl acetate, 50:50) to 
yield pure maleimide 357 as a bright red solid (0.709 g, 88%): m.p. 238-239 
o
C; vmax/cm
-1
 
(KBr) 3221, 3049, 1754, 1712, 1593, 1530, 1334, 1231; δH (300 MHz, CDCl3) 3.85 [3H, s, 
NCH3], 3.93 [3H, s, NCH3], 6.68 [1H, dd, J 8.0, 4.7, C-H5’], 6.73 [1H, t, J 7.5, C-H5], 6.81 
[1H, d, J 7.7, C-H7], 7.10 [1H, t, J 7.7, C-H6], 7.23 [1H, dd, J 8.0, 1.6, C-H4’], 7.29 [1H, d, J 
8.3, C-H4], 7.74 [1H, s, C-H2], 7.82 [1H, s, C-H2’], 8.23 [1H, dd, J 4.7, 1.5, C-H6’], 8.35 [1H, 
bs, NH]; δC (75 MHz, CDCl3) 31.8 (CH3, NCH3), 33.4 (CH3, NCH3), 104.2 (C, aromatic C), 
105.3 (C, aromatic C), 109.5 (CH, aromatic CH), 116.1 (CH, aromatic CH), 118.9 (C, 
aromatic C), 120.3 (CH, aromatic CH), 122.0 (CH, aromatic CH), 122.4 (CH, aromatic CH), 
125.9 (C, aromatic C), 126.5 (C, aromatic C), 128.1 (C, aromatic C), 130.4 (CH, aromatic 
CH), 132.7 (CH, aromatic CH), 133.0 (CH, aromatic CH), 136.9 (C, aromatic C), 143.4 (CH, 
aromatic CH), 147.7 (C, aromatic C), 172.3 (C, C=O), 172.4 (C, C=O). m/z (ES+) 357.2 
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[M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C21H17N4O2 357.1352. Found 
357.1349. 
 
1-Hydroxy-3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-
pyrrole-2,5-dione (356) 
To a solution of 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)furan-2,5-dione 355 (0.200 g, 0.56 
mmol) in dry pyridine (5 mL) was added hydroxylammonium 
chloride (0.389 g, 5.6 mmol). The resulting mixture was heated 
to reflux for 14 hours before being cooled to room temperature. 
The solvent was removed under reduced pressure and the 
residue was dissolved in ethyl acetate (50 mL), before being washed with water (4 x 50 mL) 
and brine (50 mL), then dried over magnesium sulfate. The solvent was again removed under 
reduced pressure and the crude residue was subjected to flash column chromatography 
(hexane/ethyl acetate, 50:50), yielding hydroxymaleimide 356 as a red solid (0.147 g, 71%): 
m.p. 214-216 
o
C; vmax/cm
-1
 (KBr) 3423, 2919, 1771, 1714, 1530, 1473, 1371, 1102; δH (300 
MHz, CDCl3) 3.82 [3H, s, NCH3], 3.96 [3H, s, NCH3], 6.64-6.72 [3H, m, C-H5,5’,6], 7.06 [1H, 
t, J 7.1, C-H7], 7.22 [1H, dd, J 8.0, 1.5, C-H4’], 7.26 [1H, d, J 8.3, C-H4], 7.74 [1H, s, C-H2], 
7.75 [1H, s, C-H2’], 8.22 [1H, dd, J 4.8, 1.4, C-H6’]; δC (75 MHz, CDCl3) 32.3 (CH3, NCH3), 
33.4 (CH3, NCH3), 104.3 (C, aromatic C), 105.2 (C, aromatic C), 109.6 (CH, aromatic CH), 
116.1 (CH, aromatic CH), 119.4 (C, aromatic C), 120.5 (CH, aromatic CH), 122.0 (CH, 
aromatic CH), 122.6 (CH, aromatic CH), 125.2 (C, aromatic C), 125.7 (C, aromatic C), 127.9 
(C, aromatic C), 131.1 (CH, aromatic CH), 133.1 (CH, aromatic CH), 133.2 (CH, aromatic 
CH), 136.9 (C, aromatic C), 143.0 (CH, aromatic CH), 147.0 (C, aromatic C), 169.1 (C, 
C=O), 169.2 (C, C=O). m/z (ES+) 373.1 [M+H]
+
 (100%); HRMS (ES+): Exact mass 
calculated for C21H17N4O3 373.1302. Found 373.1301. 
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7.2.7.3 Route towards bis(7-azaindol-3-yl)maleimide precursors 
Potassium 2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-oxoacetate (359) 
A solution of 2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-oxoacetic acid 
278 (1.003 g, 4.9 mmol) in ethanol (15 mL) was treated with potassium 
hydroxide (0.324 g, 4.9 mmol). The subsequent mixture was left to stir at 
room temperature for 4 hours before the solvent was removed under 
reduced pressure. The residue was desiccated at 50 
o
C overnight to yield 
potassium oxoacetate 359 as a white solid (1.193 g, 100%): m.p. 294-296 
o
C (decomp.); 
vmax/cm
-1
 (KBr) 3411, 3177, 1647, 1606, 1526, 1456, 1412, 1342; δH (300 MHz, DMSO-d6) 
3.86 [3H, s, NCH3], 7.24 [1H, dd, J 7.8, 4.7, C-H5], 8.32-8.34 [2H, m, C-H2,6], 8.46 [1H, dd, J 
7.8, 1.4, C-H4]; δC (75 MHz, DMSO-d6) 31.2 (CH3, NCH3), 111.5 (C, aromatic C), 117.7 
(CH, aromatic CH), 118.4 (C, aromatic C), 129.5 (CH, aromatic CH), 138.7 (CH, aromatic 
CH), 143.4 (CH, aromatic CH), 147.8 (C, aromatic C), 169.1 (C, C=O), 192.8 (C, C=O); m/z 
(ES+) 205.4 [M+H2-K]
+
 (100%). 
 
3,4-Bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)furan-2,5-dione (358) 
A mixture of 2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic 
acid 279 (0.603 g, 3.2 mmol), potassium 2-(1-methyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)-2-oxoacetate 359 (0.764 g, 3.2 
mmol) and acetic anhydride (30 mL) was heated to 130 
o
C for 4 
hours. After being cooled to room temperature, the solvent was 
evaporated under reduced pressure. The ensuing residue was dissolved in ethyl acetate (80 
mL) before being washed with saturated aqueous sodium bicarbonate (2 x 50 mL), water (50 
mL) and brine (50 mL). The organic phase was then dried over magnesium sulfate and 
evaporated under reduced pressure, yielding a deep red residue. This residue was subjected to 
flash column chromatography (hexane/ethyl acetate, 40:60) to yield maleic anhydride 358 as a 
dark red solid (0.503 g, 45%): m.p. 237-238 
o
C; vmax/cm
-1
 (KBr) 2921, 1816, 1745, 1527, 
1461, 1256, 1113; δH (300 MHz, CDCl3) 3.90 [6H, s, 2 x NCH3], 6.68 [2H, dd, J 8.0, 4.7, C-
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H5,5’], 7.10 [2H, dd, J 8.0, 1.5, C-H4,4’], 7.87 [2H, s, C-H2,2’], 8.20 [2H, dd, J 4.7, 1.5, C-H6,6’]; 
δC (75 MHz, CDCl3) 31.9 (2CH3, 2 x NCH3), 103.1 (2C, 2 x aromatic C), 116.7 (2CH, 2 x 
aromatic CH), 118.1 (2C, 2 x aromatic C), 127.4 (2C, 2 x aromatic C), 130.3 (2CH, 2 x 
aromatic CH), 133.9 (2CH, 2 x aromatic CH), 144.2 (2CH, 2 x aromatic CH), 147.9 (2C, 2 x 
aromatic C), 166.3 (2C, 2 x C=O); m/z (ES+) 359.3 [M+H]
+
 (100%); HRMS (ES+): Exact 
mass calculated for C20H15N4O3 359.1144. Found 359.1141. 
 
3,4-Bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-2,5-dione (361)
12 
To a stirred solution of 3,4-bis(1-methyl-1H-pyrrolo[2,3-
b]pyridin-3-yl)furan-2,5-dione 358 (0.403 g, 1.12 mmol) in 
DMF (5 mL) was added 1,1,1,3,3,3-hexamethyldisilazane (2.36 
mL, 11.2 mmol), followed by methanol (0.23 mL, 5.6 mmol). 
The reaction mixture was then stirred at room temperature for 
24 hours. Water (50 mL) was added to the reaction mixture, 
which was subsequently extracted with ethyl acetate (3 x 30 mL). The combined organic 
extracts were washed with water (4 x 100 mL) and brine (100 mL), and then dried over 
magnesium sulfate. The solvent was removed under reduced pressure and the crude residue 
was subjected to flash column chromatography (hexane/ethyl acetate, 20:80), yielding pure 
maleimide 361 as an orange-red solid (0.368 g, 92%): m.p. 260-262 
o
C (decomp.); vmax/cm
-1
 
(KBr) 2929, 2728, 1716, 1530, 1465, 1336, 1301; δH (300 MHz, DMSO-d6) 3.86 [6H, s, 2 x 
NCH3], 6.74 [2H, dd, J 8.0, 4.7, C-H5,5’], 7.06 [2H, dd, J 8.0, 1.5, C-H4,4’], 8.00 [2H, s, C-
H2,2’], 8.15 [2H, dd, J 4.6, 1.5, C-H6,6’], 11.03 [1H, bs, NH]; δC (75 MHz, DMSO-d6) 31.2 
(2CH3, 2 x NCH3), 102.8 (2C, 2 x aromatic C), 115.9 (2CH, 2 x aromatic CH), 117.8 (2C, 2 x 
aromatic C), 126.9 (2C, 2 x aromatic C), 129.1 (2CH, 2 x aromatic CH), 133.2 (2CH, 2 x 
aromatic CH), 143.1 (2CH, 2 x aromatic CH), 147.3 (2C, 2 x aromatic C), 172.5 (2C, 2 x 
C=O); m/z (ES+) 358.4 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for 
C20H16N5O2 358.1304. Found 358.1290. 
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1-Hydroxy-3,4-bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-2,5-dione (360) 
To a solution of 3,4-bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)furan-2,5-dione 358 (0.201g, 0.56 mmol) in dry pyridine (5 
mL) was added hydroxylammonium chloride (0.392 g, 5.6 
mmol). The resulting mixture was heated to reflux for 16 hours 
before being cooled to room temperature. The solvent was 
removed under reduced pressure and the residue was dissolved 
in ethyl acetate (50 mL), before being washed with water (3 x 50 mL) and brine (50 mL), then 
dried over magnesium sulfate. The solvent was again removed under reduced pressure and the 
crude residue was subjected to flash column chromatography (hexane/ethyl acetate, 30:70), 
yielding pure hydroxymaleimide 360 as a red solid (0.124 g, 59%): m.p. 235-237 
o
C; vmax/cm
-
1
 (KBr) 3378, 2924, 2853, 1716, 1594, 1532, 1466, 1109; δH (300 MHz, DMSO-d6) 3.95 [6H, 
s, 2 x NCH3], 6.83 [2H, dd, J 8.0, 4.6, C-H5,5’], 7.13 [2H, dd, J 8.0, 1.6, C-H4,4’], 8.12 [2H, s, 
C-H2,2’], 8.24 [2H, dd, J 4.6, 1.5, C-H6,6’], 10.57 [1H, bs, OH]; δC (75 MHz, DMSO-d6) 31.3 
(2CH3, 2 x NCH3), 102.7 (2C, 2 x aromatic C), 116.0 (2CH, 2 x aromatic CH), 117.7 (2C, 2 x 
aromatic C), 123.7 (2C, 2 x aromatic C), 129.2 (2CH, 2 x aromatic CH), 133.4 (2CH, 2 x 
aromatic CH), 143.2 (2CH, 2 x aromatic CH), 147.3 (2C, 2 x aromatic C), 167.9 (2C, 2 x 
C=O); m/z (ES+) 374.3 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for 
C20H16N5O3 374.1253. Found 374.1254. 
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7.2.7.4 Synthesis and derivatisation of monoaza ICZs 
12,13-Dimethyl-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H)-dione (364) 
A spatula tip of iodine was added to a stirred solution of 3-(1-
methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)-1H-pyrrole-2,5-dione 357 (0.100 g, 0.28 mmol) in 
acetonitrile (300 mL). The resulting mixture was then irradiated 
using a medium pressure mercury lamp, in the presence of air, 
for 15 hours, at which point TLC analysis confirmed complete 
consumption of starting material. A solution of saturated aqueous sodium thiosulfate (100 mL) 
was subsequently added to the reaction mixture, resulting in the formation of a yellow 
precipitate. The biphasic mixture was stirred for 20 minutes at room temperature before the 
precipitate was filtered off, washed with water and desiccated overnight at 50 
o
C to yield pure 
aza ICZ 364 as a yellow solid (0.081 g, 81%): m.p. >300 
o
C; vmax/cm
-1
 (KBr) 3436, 1718, 
1571, 1470, 1322, 750; δH (300 MHz, DMSO-d6) 4.25 [3H, s, NCH3], 4.31 [3H, s, NCH3], 
7.29-7.36 [2H, m, C-H3,9], 7.60 [1H, t, J 7.5, C-H10], 7.74 [1H, d, J 8.2, C-H11], 8.60 [1H, dd, 
J 4.8, 1.7, C-H2], 9.00 [1H, d, J 7.8, C-H8], 9.17 [1H, dd, J 7.8, 1.6, C-H4], 11.05 [1H, bs, 
NH]; δC (150 MHz, DMSO-d6, 47 
o
C) 34.9 (CH3, NCH3), 36.9 (CH3, NCH3), 110.7 (CH, 
aromatic CH), 114.0 (C, aromatic C), 115.2 (C, aromatic C), 116.9 (CH, aromatic CH), 118.6 
(C, aromatic C), 120.3 (C, aromatic C), 120.3 (C, aromatic C), 120.7 (CH, aromatic CH), 
121.1 (C, aromatic C), 124.4 (CH, aromatic CH), 127.5 (CH, aromatic CH), 130.6 (C, 
aromatic C), 131.7 (C, aromatic C), 132.5 (CH, aromatic CH), 143.7 (C, aromatic C), 147.4 
(CH, aromatic CH), 153.2 (C, aromatic C), 170.5 (C, C=O), 170.5 (C, C=O). m/z (ES+) 355.3 
[M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C21H15N4O2 355.1195. Found 
355.1185. 
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tert-Butyl 12,13-dimethyl-5,7-dioxo-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-
a]pyrrolo[3,4-c]carbazole-6(7H)-carboxylate (368) 
To a suspension of 12,13-dimethyl-12,13-dihydro-5H-
pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-
dione 364 (0.080 g, 0.23 mmol) in acetonitrile (30 mL) was 
added di-tert-butyl dicarbonate (0.110 g, 0.51 mmol), followed 
by DMAP (0.003 g, 0.02 mmol, 10 mol.%). The resulting 
mixture was stirred at room temperature for 1 hour, before the 
solvent and excess anhydride was evaporated under reduced 
pressure. The crude product was initially washed with an aliquot of water (100 mL) containing 
0.5 mL of 2M aqueous HCl, before further copious water washes. Following overnight 
desiccation at 50 
o
C, pure Boc-protected aza ICZ 368 was afforded as a bright yellow solid 
(0.101 g, 97%): m.p. >300 
o
C (decomp.); vmax/cm
-1
 (KBr) 2982, 1791, 1748, 1568, 1477, 
1294; δH (400 MHz, CDCl3) 1.73 [9H, s, C(CH3)3], 4.30 [3H, s, NCH3], 4.41 [3H, s, NCH3], 
7.36 [1H, dd, J 7.9, 4.8, C-H3], 7.38 [1H, t, J 7.5, C-H9], 7.55 [1H, d, J 8.2, C-H11], 7.64 [1H, 
t, J 7.6, C-H10], 8.66 [1H, dd, J 4.8, 1.6, C-H2], 9.23 [1H, d, J 8.0, C-H8], 9.46 [1H, dd, J 7.9, 
1.6, C-H4]; δC (125 MHz, CDCl3) 28.1 (3CH3, C(CH3)3), 35.4 (CH3, NCH3), 37.3 (CH3, 
NCH3), 84.7 (C, C(CH3)3), 110.0 (CH, aromatic CH), 115.2 (C, aromatic C), 116.8 (C, 
aromatic C), 117.5 (CH, aromatic CH), 119.3 (C, aromatic C), 119.4 (C, aromatic C), 120.3 
(C, aromatic C), 121.7 (CH, aromatic CH), 122.1 (C, aromatic C), 125.8 (CH, aromatic CH), 
128.1 (CH, aromatic CH), 131.8 (C, aromatic C), 133.1 (C, aromatic C), 133.9 (CH, aromatic 
CH), 144.6 (C, aromatic C), 147.4 (C, aromatic C), 147.8 (CH, aromatic CH), 154.4 (C, 
C=O), 165.3 (C, C=O), 165.6 (C, C=O); m/z (ES+) 455.3 [M+H]
+
 (60%); HRMS (ES+): 
Exact mass calculated for C26H23N4O4 455.1719. Found 455.1714. 
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6-Hydroxy-12,13-dimethyl-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H)-dione (363) 
Method A: 
Hydroxylammonium chloride (0.061 g, 0.88 mmol) was added to 
a suspension of tert-butyl 12,13-dimethyl-5,7-dioxo-12,13-
dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-6(7H)-carboxylate 368 (0.080 g, 0.18 mmol) in 
pyridine (25 mL). The resulting mixture was stirred at 80 
o
C for 
10 hours, before cooling to room temperature. Water (120 mL) 
was added to the reaction mixture, causing the precipitation of an orange solid, which was 
subsequently filtered off and washed with copious amounts of water. Recrystallisation of the 
crude orange product from absolute ethanol gave pure hydroxymaleimide 363 as a bright 
yellow solid (0.063 g, 94%): m.p. >300 
o
C; vmax/cm
-1
 (KBr) 2928, 2738, 1706, 1575, 1474, 
1006; δH (300 MHz, DMSO-d6) 4.28 [3H, s, NCH3], 4.33 [3H, s, NCH3], 7.27-7.35 [2H, m, C-
H3,9], 7.62 [1H, t, J 7.8, C-H10], 7.77 [1H, d, J 8.4, C-H11], 8.62 [1H, dd, J 4.6, 1.5, C-H2], 
8.98 [1H, d, J 7.8, C-H8], 9.16 [1H, d, J 7.8, C-H4], 10.91 [1H, bs, OH]; δC (150 MHz, 
DMSO-d6, 47 
o
C) 34.9 (CH3, NCH3), 36.9 (CH3, NCH3), 110.8 (CH, aromatic CH), 113.9 (C, 
aromatic C), 115.4 (C, aromatic C), 116.0 (C, aromatic C), 116.0 (C, aromatic C), 116.9 (CH, 
aromatic CH), 118.8 (C, aromatic C), 120.8 (CH, aromatic CH), 120.9 (C, aromatic C), 124.3 
(CH, aromatic CH), 127.7 (CH, aromatic CH), 130.6 (C, aromatic C), 131.7 (C, aromatic C), 
132.4 (CH, aromatic CH), 143.8 (C, aromatic C), 147.6 (CH, aromatic CH), 153.3 (C, 
aromatic C), 165.8 (C, C=O), 165.9 (C, C=O). m/z (ES+) 371.1 [M+H]
+
 (100%); HRMS 
(ES+): Exact mass calculated for C21H15N4O3 371.1144. Found 371.1138. 
Method B:  
Sodium hydroxide (0.423 g, 10.6 mmol) was added to a suspension of 12,13-dimethyl-12,13-
dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 364 (0.075 
g, 0.21 mmol) in water (20 mL). The resulting mixture was heated to reflux for 8 hours, before 
being allowed cool to room temperature. The basic solution was acidified to pH 2 by 
treatment with 2 M aqueous HCl in a dropwise manner, resulting in the formation of a yellow 
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precipitate. Following filtration, water washes and desiccation overnight at 50 
o
C, anhydride 
362 was isolated as a yellow solid (0.063 g, 84%), and used without further purification or full 
characterisation: m.p. >300 
o
C; vmax/cm
-1
 (KBr) 2919, 1819, 1747, 1524, 1254, 1104; m/z 
(ES+) 356.2 [M+H]
+
 (20%). Hydroxylammonium chloride (0.049 g, 0.70 mmol) was added to 
a stirred suspension of anhydride 362 (0.050 g, 0.14 mmol) in pyridine (20 mL). The resulting 
mixture was heated to reflux for 12 hours before being cooled to room temperature and diluted 
with water (100 mL). The resulting precipitate was filtered off and washed with copious 
amounts of water. Recrystallisation from absolute alcohol afforded hydroxymaleimide 363 as 
a yellow solid (0.046 g, 88%). 
Method C: 
To a stirred solution of 1-hydroxy-3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-
b]pyridin-3-yl)-1H-pyrrole-2,5-dione 356 (0.080 g, 0.21 mmol) in acetonitrile (150 mL) was 
added a spatula tip of iodine. The resulting mixture was subsequently irradiated using a 
medium pressure mercury lamp for 16 hours. Following cooling to room temperature and 
removal of the solvent under reduced pressure, spectroscopic analysis indicated that desired 
aza ICZ 363 had not formed, and the crude mixture comprised predominantly of starting 
material, hydroxymalemide 356. 
Method D: 
A mixture of 1-hydroxy-3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-
yl)-1H-pyrrole-2,5-dione 356 (0.025 g, 0.07 mmol) and palladium(II) trifluoroacetate (0.109 
g, 0.33 mmol) in DMF (5 mL) was heated to 90 
o
C for 12 hours. The reaction mixture was 
cooled to room temperature, diluted with ethyl acetate (30 mL) and washed with 1M aqueous 
HCl (60 mL) before being filtered through celite. The solvent was evaporated under reduced 
pressure to leave a crude brown residue. Spectroscopic analysis indicated that aromatisation 
towards aza ICZ 363 had not been achieved, and only hydroxymaleimide starting material 356 
was present. 
 
 
Chapter 7 | Experimental 
 
 
[266] 
 
7-Amino-13,14-dimethyl-13,14-dihydropyrido[3',2':4,5]pyrrolo[2,3-a]pyrimido[4,5-
c]carbazole-6,8(5H,7H)-dione (369) 
To a suspension of 6-hydroxy-12,13-dimethyl-12,13-dihydro-5H-
pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-
dione 363 (0.050 g, 0.14 mmol) in a mixture of DMSO (8 mL) and 
pyridine (0.5 mL), DMAP (0.070 g, 0.57 mmol) was added. The 
resulting mixture was stirred for 15 minutes at room temperature, 
before para-toluenesulfonyl chloride (0.086 g, 0.45 mmol) was 
added. The yellow reaction mixture was then stirred at room temperature for 2 hours, until 
water (100 mL) was added. The yellow precipitate was filtered off, washed with water and 
desiccated overnight at    50 
o
C, at which point it was suspended in ethanol (30 mL). Under 
stirring, hydrazine hydrate (50% aqueous solution, 0.09 mL, 1.5 
mmol) was added to the mixture, which was then heated to reflux 
for 14 hours. Once cooled to room temperature, the solvent was 
removed under reduced pressure. Spectroscopic analysis indicated 
the presence of not only pyrimidinone 369, but also its regioisomer 
370. Separation of the two regioisomers was undertaken using 
preparative HPLC, however, sufficient purification was not achieved to allow for full 
characterisation of either aza ICZ.  
 
7.2.7.5 Synthesis and derivatisation of bisaza ICZs 
12,13-Dimethyl-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-5,7(6H)-dione (371) 
3,4-Bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-
2,5-dione 361 (0.100 g, 0.28 mmol) was dissolved in acetonitrile 
(300 mL), with a spatula tip of iodine then added to the stirred 
solution. The resulting mixture was irradiated using a medium 
pressure mercury lamp for 16 hours, after which time it was 
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cooled to room temperature. A saturated aqueous sodium thiosulfate solution (100 mL) was 
added to the reaction mixture, leading to the precipitation of a yellow solid. After being stirred 
at room temperature for 20 minutes, the precipitate was filtered off, washed with water and 
desiccated at 50 
o
C overnight to yield pure aza ICZ 371 as a bright yellow solid (0.088 g, 
88%): m.p. >300 
o
C; vmax/cm
-1
 (KBr) 3143, 3033, 2755, 1721, 1572, 1469, 1287; δH (400 
MHz, DMSO-d6) 4.43 [6H, s, 2 x NCH3], 7.41 [2H, dd, J 7.8, 4.7, C-H3,9], 8.67 [2H, dd, J 4.7, 
1.6, C-H2,10], 9.25 [2H, dd, J 7.8, 1.6, C-H4,8], 11.03 [1H, bs, NH]; δC (150 MHz, DMSO-d6) 
34.9 (2CH3, 2 x NCH3), 113.8 (2C, 2 x aromatic C), 115.7 (2C, 2 x aromatic C), 117.2 (2CH, 
2 x aromatic CH), 120.9 (2C, 2 x aromatic C), 130.6 (2C, 2 x aromatic C), 133.0 (2CH, 2 x 
aromatic CH), 147.9 (2CH, 2 x aromatic CH), 152.8 (2C, 2 x aromatic C), 170.7 (2C, 2 x 
C=O); m/z (ES+) 356.2 [M+H]
+
 (20%); HRMS (ES+): Exact mass calculated for C20H14N5O2 
356.1147. Found 356.1133. 
 
tert-Butyl 12,13-dimethyl-5,7-dioxo-12,13-dihydro-5H-pyrido[2,3-
b]pyrido[3',2':4,5]pyrrolo[3,2-g]pyrrolo[3,4-e]indole-6(7H)-carboxylate (372) 
To a suspension of 12,13-dimethyl-12,13-dihydro-5H-
pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-g]pyrrolo[3,4-e]indole-
5,7(6H)-dione 371 (0.085 g, 0.24 mmol) in acetonitrile (50 mL) 
was added di-tert-butyl dicarbonate (0.115 g, 0.53 mmol) 
followed by DMAP (0.003 g, 0.02 mmol, 10 mol.%). The 
resulting mixture was stirred for 90 minutes at room temperature, 
before the solvent and excess anhydride was removed under 
reduced pressure. The crude product was then washed with an aliquot of water (100 mL) 
containing 0.5 mL of 2M aqueous HCl, followed by further copious washes with water. 
Desiccation at 50 
o
C overnight afforded Boc-protected maleimide 372 as a yellow solid (0.103 
g, 94%): m.p. 290-292 
o
C (decomp.); vmax/cm
-1
 (KBr) 2980, 1790, 1748, 1569, 1473, 1364, 
1291; δH (400 MHz, CDCl3) 1.73 [9H, s, C(CH3)3], 4.48 [6H, s, 2 x NCH3], 7.36 [2H, dd, J 
7.8, 4.8, C-H3,9], 8.67 [2H, dd, J 4.8, 1.7, C-H2,10], 9.44 [2H, dd, J 7.9, 1.7, C-H4,8]; δC (125 
MHz, CDCl3) 28.1 (3CH3, C(CH3)3), 35.4 (2CH3, 2 x NCH3), 85.0 (C, C(CH3)3), 114.7 (2C, 2 
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x aromatic C), 117.2 (2C, 2 x aromatic C), 117.7 (2CH, 2 x aromatic CH), 119.5 (2C, 2 x 
aromatic C), 131.5 (2C, 2 x aromatic C), 134.0 (2CH, 2 x aromatic CH), 147.2 (2C, 2 x 
aromatic C), 148.2 (2CH, 2 x aromatic CH), 153.8 (C, C=O), 165.4 (2C, 2 x C=O); m/z (ES+) 
456.3 [M+H]
+
 (100%); HRMS (ES+): Exact mass calculated for C25H22N5O4 456.1688. Found 
456.1682. 
 
6-Hydroxy-12,13-dimethyl-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-5,7(6H)-dione (373) 
To a stirred suspension of tert-butyl 12,13-dimethyl-5,7-dioxo-
12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-6(7H)-carboxylate 372 (0.090 g, 0.20 
mmol) in pyridine (20 mL) was added hydroxylammonium 
chloride (0.069 g, 0.99 mmol). The resulting mixture was heated 
at 80 
o
C for 14 hours before being cooled to room temperature. 
Water (150 mL) was added to the reaction mixture, and the resulting precipitate was filtered 
and washed with copious amounts of water. The crude product was recrystallised from 
absolute alcohol, yielding pure hydroxymaleimide 373 as a yellow solid (0.068 g, 93%): m.p. 
>300 
o
C; vmax/cm
-1
 (KBr) 3159, 2925, 1717, 1574, 1367, 1287; δH (400 MHz, DMSO-d6) 4.40 
[3H, s, NCH3], 4.42 [3H, s, NCH3], 7.37 [1H, q, J 7.8, 4.7, C-H3], 7.38 [1H, dd, J 7.8, 4.8, C-
H9], 8.65 [1H, dd, J 4.7, 1.7, C-H2], 8.66 [1H, dd, J 4.7, 1.6, C-H10], 9.18 [1H, dd, C-H4], 9.21 
[1H, dd, C-H8], 11.17 [1H, bs OH]; δC (150 MHz, DMSO-d6, 47 
o
C) 34.6 (2CH3, 2 x NCH3), 
113.5 (C, aromatic C), 113.7 (C, aromatic C), 115.7 (C, aromatic C), 115.9 (C, aromatic C), 
116.4 (C, aromatic C), 117.1 (2CH, 2 x aromatic CH), 120.7 (C, aromatic C), 130.5 (2C, 2 x 
aromatic C), 132.6 (2CH, 2 x aromatic CH), 148.0 (2CH, 2 x aromatic CH), 152.8 (C, 
aromatic C), 152.9 (2C, 2 x aromatic C), 165.7 (2C, 2 x C=O); m/z (ES+) 372.1 [M+H]
+
 
(68%); HRMS (ES+): Exact mass calculated for C20H14N5O3 372.1097. Found 372.1087. 
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7-Amino-13,14-dimethyl-13,14-dihydropyrido[3',2':4,5]pyrrolo[3,2-
f]pyrido[3',2':4,5]pyrrolo[2,3-h]quinazoline-6,8(5H,7H)-dione (374) 
DMAP (0.034 g, 0.28 mmol) was added, at room temperature, to 
a mixture of 6-hydroxy-12,13-dimethyl-12,13-dihydro-5H-
pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-g]pyrrolo[3,4-e]indole-
5,7(6H)-dione 373 (0.025 g, 0.07 mmol) in DMSO (10 mL) and 
pyridine (2.5 mL). Following stirring for 15 minutes, para-
toluenesulfonyl chloride (0.042 g, 0.22 mmol) was added, with 
the resulting mixture then stirred for 2 hours at room temperature. Water (80 mL) was added 
to the reaction mixture, and the resulting yellow precipitate was filtered, washed with water 
and desiccated overnight at 50 
o
C. This precipitate was suspended in ethanol (20 mL), and 
hydrazine hydrate (50% aqueous solution, 0.06 mL, 1 mmol) was added. The stirred reaction 
mixture was heated to reflux for 16 hours before being cooled to room temperature. The 
solvent was removed under reduced pressure, and the crude yellow precipitate was subjected 
to flash column chromatography (dichloromethane/methanol, 95:5), yielding desired product 
374 as an off-white solid (0.013 g, 48%). Due to solubility issues with 374 it was not possible 
to obtain a fully characterised 
13
C spectrum - this shall be a focus of future investigation: m.p. 
>300 
o
C; vmax/cm
-1
 (KBr) 3309, 2924, 1722, 1659, 1579, 1448; δH (600 MHz, DMSO-d6) 4.36 
[3H, s, NCH3], 4.40 [3H, s, NCH3], 4.46 [2H, s, NH2], 7.34 [1H, dd, J 7.8, 4.6, C-H3], 7.46 
[1H, dd, J 7.8, 4.7, C-H10], 8.59 [1H, d, J 4.5, C-H2], 8.63 [1H, d, J 4.6, C-H11], 9.14 [1H, d, J 
7.7, C-H4], 9.93 [1H, d, J 7.6, C-H9], 11.97 [1H, bs, NHCO]; m/z (ES+) 386.2 [M+H]
+
 (40%); 
HRMS (ES+): Exact mass calculated for C20H16N7O2 386.1365. Found 386.1355.   
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7.3 Protocol for biological evaluation 
7.3.1 NCI-60 experimental methodology 
The reported experimental methodology involves initial growth of the tumour cell lines in 
RPMI 1640 medium containing 5% foetal bovine serum and 2 mM L-glutamine.
13
 For a 
typical screening experiment, cells are inoculated into 96 well microtiter plates in 100 µL of 
medium at plating densities ranging from 5,000 to 40,000 cells/well, depending on the 
doubling time of individual cell lines. After cell inoculation, the microtiter plates are 
incubated at 37 °C, 5% CO2, 95% air and 100% relative humidity for 24 hours prior to 
addition of candidate compounds. 
After 24 hours, two plates of each cell line are fixed in situ with trichloroacetic acid (TCA), to 
represent a measurement of the cell population for each cell line at the time of drug addition 
(Tz). Candidate compounds are dissolved in DMSO at 400-fold the desired final maximum 
test concentration and stored frozen prior to use. Initial single dose screening is carried out at a 
concentration of 10 µM, with the second phase of testing involving the examination of five 
different drug concentrations. 
Following drug addition, the plates are incubated for an additional 48 hours at 37 °C, 5% CO2, 
95% air, and 100% relative humidity. For adherent cells, the assay is terminated by the 
addition of cold TCA. Cells are fixed in situ by the gentle addition of 50 µL of cold 50% (w/v) 
TCA and incubated for 60 minutes at 4 °C. Sulforhodamine B (SRB) solution (100 µL) at 
0.4% (w/v) in 1% acetic acid is added to each well, and plates are incubated for 10 minutes at 
room temperature. Absorbance is read on an automated plate reader at a wavelength of 515 
nm, and using seven absorbance measurements (time zero (Tz), control growth (C), and test 
growth in the presence of drug at the five concentration levels (Ti)), the percentage growth is 
calculated at each of the drug concentration levels. The response parameters GI50 
(concentration required for 50% inhibition of growth) and LC50 (concentration required for 
50% cell death) are extracted from concentration-response curves by linear interpolation, 
while TGI (total growth inhibition) is read as the x-axis intercept from the five different drug 
concentrations.
13 
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7.3.2 COMPARE analysis 
The use of the COMPARE algorithm towards the mechanistic investigation of cell growth 
inhibition consists of calculating the linear correlation coefficient between the data over the 
cell lines tested for a particular compound and all sets of data in the NCI database to be 
searched.
14
 The calculation of the correlation coefficient involves three steps: (i) choosing the 
seed (the pattern of interest), (ii) choosing the parameters and (iii) choosing the database.  
In running a COMPARE calculation via the Developmental Therapeutics Program (DTP) 
branch of the NCI website, a number of key parameters can be modified in order to allow for 
more efficient or user-relevant analyses. For example, the data set used as the seed for the 
calculation can comprise any of the growth inhibition measurements for a particular 
compound, such as the GI50, TGI or LC50. There are a number of different databases within 
the NCI that can be used to perform a COMPARE calculation, such as standard 
chemotherapeutic agents or synthetic compounds, and it is possible to return only 
corresponding data sets with a minimum correlation threshold against the seed. It is also 
possible to specify a minimum number of cell lines with which to run the calculation, rather 
than using the entire 60 cell panel.
14
 For COMPARE calculations run in this project, either 
standard agents or synthetic compounds were chosen as the target set. Minimum correlation 
was set at 0.4, minimum count of common cell lines was set at 40, and minimum standard 
deviation was set at 0.05. 
 
7.3.3 Topoisomerase I assay experimental methodology 
The human topo I assay kit was purchased from Inspiralis, Norwich Bioincubator, Norwich 
Research Park, Colney, Norwich, UK. The kit contained: (i) dilution buffer (10 mM Tris.HCl 
(pH 7.5), 1 mM DTT, 1 mM EDTA, 100 mM NaCl, 50% (v/v) glycerol and 100 µg/mL 
albumin); (ii) 10x assay buffer (20 mM Tris.HCl (pH 7.5), 200 mM NaCl, 0.25 mM EDTA, 
5% (v/v) glycerol, 50 µg/mL albumin); (iii) supercoiled pBR322 DNA in 0.01% Tris.HCl and 
0.03% EDTA; (iv) topo I enzyme (human expressed in baculovirus supplied at a minimum 
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concentration of 10 U per 1 µL) in 0.6% (w/v) Tris.HCl (pH 7.9), 0.015% (w/v) DTT, 0.03% 
(w/v) EDTA, 50% (w/v) glycerol and 0.01% BSA.  
Increasing concentrations of the various aza ICZs were assayed on a cleavage assay adapted 
from the Inspiralis technical data sheet supplied with the kit and the protocol of Marminon et 
al.
15
 The activity each aza ICZ was compared to that of camptothecin 37 (20 µM and 50 µM), 
positive control (water) and DNA control (no topo I added). 
A pBR322 stock containing sufficient material for the assay was prepared in the following 
ratio: 1 µg (1 µL) pBR322, 3 µL assay buffer and 17 µL deionised water. An aliquot of 21 µL 
of this stock was added to each eppendorf containing 3 µL of each concentration to be tested, 
along with the controls. This material was incubated for 30 minutes at 37 
o
C to insure binding 
equilibrium before the addition of topo I. An aliquot of 6 µL human topo I (minimum 6 U) 
was added to each eppendorf, bringing the final assay volume to 30 µL, and incubated for a 
further 30 minutes at 37 
o
C. The cleavage reactions were then stopped by the addition of SDS 
and proteinase K to a final concentration of 0.25% and 250 µg/mL, and incubated for 30 min 
at 50 
o
C. To assess topo I induced cleavage, 12 µL of loading buffer was added to each 
sample, and an aliquot of 20 µL of each sample was loaded onto a 1% agarose gel containing 
20 µL Safe View stain (NBS Biologicals, Cambridgeshire, England) per 100 mL gel. The gel 
was run at 20 Volts for 4 hours at room temperature to separate the DNA. The gels were 
viewed under UV light using a DNR Bio-Imaging System and photographed using 
GelCapture software. To compare and quantify the intensity of the cleavage bands produced, 
the image was inverted and analysed using GelQuant software (v. 1.7.8). 
 
7.3.4 Topoisomerase II assay experimental methodology 
The decatenation assay kit was obtained from Inspiralis (Norwich, UK) and comprised of the 
following: (i) 10x assay buffer containing 50 mM Tris.HCl (pH 7.5), 125 mM NaCl, 10 mM 
MgCl2, 5 mM DTT and 100 µg/mL albumin; (ii) dilution buffer containing 50 mM Tris.HCl 
(pH 7.5), 100 mM NaCl, 1 mM DTT, 0.5 mM EDTA, 50% (v/v) glycerol, 50 µg/ml albumin;        
(iii) ATP 30 mM; (iv) kDNA (100 ng/µL); (v) 10 U/µL human topo II in dilution buffer; (vi) 
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5x stop buffer containing 2.5% SDS, 15% Ficoll-400, 0.05% bromophenol blue, 0.05% xylene 
cyanol and 25 mM EDTA. Tris-acetate-EDTA buffer (supplied as 10x buffer) and agarose 
were obtained from Sigma Life Sciences (Dublin, Ireland). 
The topo II decatenation assay protocol involved initial incubation of each inhibitor candidate 
(100 µM) along with a stock solution containing water, ATP, assay buffer, kDNA obtained 
from the mitochondrial DNA of Crithidia fasciculate, and topo II, at 37 
o
C for 1 hour. 
Following addition of stop buffer, agarose DNA gel electrophoresis was run at 50 V for 2 
hours using a Consort EV243 power pack, to determine the relative amounts of decatenated 
DNA bands obtained in each compound lane. Positive (water), as well as negative controls 
(ellipticine) were incorporated in order to validate the results of each run. The resulting gels 
were viewed under UV light using a DNR Bio-Imaging System and photographed using 
GelCapture software. 
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[i] 
 
4-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-amine 
(293) 
 
 
 
Appendices 
 
 
[ii] 
 
8-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-7-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-
a][1,3,5]triazine-2,4(1H,3H)-dione (295) 
 
 
Appendices 
 
 
[iii] 
 
5,7-Bis(trifluoromethyl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-(3,4,5-
trimethoxyphenyl)pyrazolo[1,5-a]pyrimidine (297) 
 
 
Appendices 
 
 
[iv] 
 
1-[5-Amino-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-
1-yl]ethanone (302) 
 
 
Appendices 
 
 
[v] 
 
5-Amino-N-methyl-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazole-1-carbothioamide (304) 
 
 
Appendices 
 
 
[vi] 
 
5-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-amine 
(312) 
 
 
 
Appendices 
 
 
[vii] 
 
7-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-8-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-
a][1,3,5]triazine-2,4(1H,3H)-dione (313) 
 
 
Appendices 
 
 
[viii] 
 
2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5,7-bis(trifluoromethyl)-3-(3,4,5-
trimethoxyphenyl)pyrazolo[1,5-a]pyrimidine (314) 
 
 
Appendices 
 
 
[ix] 
 
1-(5-Amino-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrazol-
1-yl)ethanone (316) 
 
 
Appendices 
 
 
[x] 
 
5-Amino-N-methyl-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-
pyrazole-1-carbothioamide (317) 
 
 
Appendices 
 
 
[xi] 
 
4-(1-Methyl-1H-indol-3-yl)-5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-3-amine 
(318) 
 
 
 
Appendices 
 
 
[xii] 
 
8-(1-Methyl-1H-indol-3-yl)-7-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazolo[1,5-
a][1,3,5]triazine-2,4(1H,3H)-dione (319) 
 
 
Appendices 
 
 
[xiii] 
 
3-(1-Methyl-1H-indol-3-yl)-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidine (320) 
 
 
Appendices 
 
 
[xiv] 
 
1-(5-Amino-4-(1-methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrazol-
1-yl)ethanone (322) 
 
 
Appendices 
 
 
[xv] 
 
5-Amino-N-methyl-4-(1-methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-
pyrazole-1-carbothioamide (323) 
 
 
Appendices 
 
 
[xvi] 
 
5-(1-Benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrazol-3(2H)-one 
(326) 
 
 
Appendices 
 
 
[xvii] 
 
4-(1-Methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)isoxazol-5(2H)-one (327) 
 
 
 
 
Appendices 
 
 
[xviii] 
 
2-Methyl-4-(1-methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)isoxazol-5(2H)-
one (328) 
 
 
 
Appendices 
 
 
[xix] 
 
2-Amino-5-(1-methyl-1H-indol-3-yl)-6-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-
4(3H)-one (332) 
 
 
Appendices 
 
 
[xx] 
 
1-Hydroxy-3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-
2,5-dione (356) 
 
 
 
Appendices 
 
 
[xxi] 
 
3-(1-Methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-2,5-dione 
(357) 
 
 
 
Appendices 
 
 
[xxii] 
 
3,4-Bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-2,5-dione (361) 
 
 
 
 
Appendices 
 
 
[xxiii] 
 
6-Amino-13,14-dimethyl-13,14-dihydropyrido[3',2':4,5]pyrrolo[2,3-a]pyrimido[4,5-c]carbazol-
8(7H)-one (239) 
 
 
 
Appendices 
 
 
[xxiv] 
 
12,13-Dimethyl-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-c]carbazole-
5,7(6H)-dione (364) 
 
 
 
Appendices 
 
 
[xxv] 
 
6-Hydroxy-12,13-dimethyl-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H)-dione (363) 
 
 
 
Appendices 
 
 
[xxvi] 
 
tert-Butyl 12,13-dimethyl-5,7-dioxo-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-6(7H)-carboxylate (368) 
 
 
Appendices 
 
 
[xxvii] 
 
12,13-Dimethyl-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-g]pyrrolo[3,4-
e]indole-5,7(6H)-dione (371) 
 
 
 
Appendices 
 
 
[xxviii] 
 
tert-Butyl 12,13-dimethyl-5,7-dioxo-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-6(7H)-carboxylate (372) 
 
 
Appendices 
 
 
[xxix] 
 
6-Hydroxy-12,13-dimethyl-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-5,7(6H)-dione (373) 
 
 
Appendices 
 
 
[xxx] 
 
4-(1-Methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)isoxazol-5(2H)-one (327) 
 
 
 
 
 
 
 
 
 
Appendices 
 
 
[xxxi] 
 
4-(1-Methyl-1H-indol-3-yl)-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)isoxazol-5(2H)-one (327) 
 
 
 
 
Appendices 
 
 
[xxxii] 
 
3-(1-Methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-2,5-dione 
(357) 
 
 
 
 
 
 
 
 
 
Appendices 
 
 
[xxxiii] 
 
3-(1-Methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-2,5-dione 
(357) 
 
 
 
Appendices 
 
 
[xxxiv] 
 
3,4-Bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-2,5-dione (361) 
 
 
 
 
 
 
 
 
 
Appendices 
 
 
[xxxv] 
 
3,4-Bis(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrrole-2,5-dione (361) 
 
 
 
 
Appendices 
 
 
[xxxvi] 
 
12,13-Dimethyl-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-c]carbazole-
5,7(6H)-dione (364) 
 
 
 
 
 
 
 
Appendices 
 
 
[xxxvii] 
 
12,13-Dimethyl-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-c]carbazole-
5,7(6H)-dione (364) 
 
 
 
Appendices 
 
 
[xxxviii] 
 
6-Hydroxy-12,13-dimethyl-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H)-dione (363) 
 
 
 
 
 
 
 
Appendices 
 
 
[xxxix] 
 
6-Hydroxy-12,13-dimethyl-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H)-dione (363) 
 
 
 
Appendices 
 
 
[xl] 
 
tert-Butyl 12,13-dimethyl-5,7-dioxo-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-6(7H)-carboxylate (368) 
 
 
 
 
 
 
Appendices 
 
 
[xli] 
 
tert-Butyl 12,13-dimethyl-5,7-dioxo-12,13-dihydro-5H-pyrido[3',2':4,5]pyrrolo[2,3-a]pyrrolo[3,4-
c]carbazole-6(7H)-carboxylate (368) 
 
 
Appendices 
 
 
[xlii] 
 
12,13-Dimethyl-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-g]pyrrolo[3,4-
e]indole-5,7(6H)-dione (371) 
 
 
 
 
 
 
 
Appendices 
 
 
[xliii] 
 
12,13-Dimethyl-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-g]pyrrolo[3,4-
e]indole-5,7(6H)-dione (371) 
 
 
 
Appendices 
 
 
[xliv] 
 
tert-Butyl 12,13-dimethyl-5,7-dioxo-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-6(7H)-carboxylate (372) 
 
 
 
 
 
 
Appendices 
 
 
[xlv] 
 
tert-Butyl 12,13-dimethyl-5,7-dioxo-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-6(7H)-carboxylate (372) 
 
 
Appendices 
 
 
[xlvi] 
 
6-Hydroxy-12,13-dimethyl-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-5,7(6H)-dione (373) 
 
 
 
 
 
 
 
Appendices 
 
 
[xlvii] 
 
6-Hydroxy-12,13-dimethyl-12,13-dihydro-5H-pyrido[2,3-b]pyrido[3',2':4,5]pyrrolo[3,2-
g]pyrrolo[3,4-e]indole-5,7(6H)-dione (373) 
 
 
 
